

# US Patent & Trademark Office

## Patent Public Search | Text View

United States Patent Application Publication

20250257359

Kind Code

A1

Publication Date

August 14, 2025

Inventor(s)

Page; John et al.

### MUSK-TARGETING OLIGONUCLEOTIDES

#### Abstract

The present disclosure provides, among other things, MuSK-targeting oligonucleotide compositions that alter the splicing of MuSK transcripts through exon skipping, and methods of treating diseases with said compositions.

**Inventors:** Page; John (Providence, RI), Valat; Anne (Cambridge, MA), Agrawal; Sudhir (Shrewsbury, MA), Brown; Duncan (Berkeley, CA)

**Applicant:** Bolden Therapeutics, Inc. (Providence, RI)

**Family ID:** 87349235

**Appl. No.:** 18/730084

**Filed (or PCT Filed):** January 20, 2023

**PCT No.:** PCT/US23/11286

#### Related U.S. Application Data

us-provisional-application US 63301416 20220120

#### Publication Classification

**Int. Cl.:** C12N15/113 (20100101)

**U.S. Cl.:**

**CPC** C12N15/1138 (20130101); C12Y207/10001 (20130101); C12N2310/14 (20130101); C12N2310/313 (20130101); C12N2310/321 (20130101); C12N2320/33 (20130101)

#### Background/Summary

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a National Phase entry of International Application No. PCT/US23/11286, filed Jan. 20, 2023, which claims the benefit of U.S.

## BACKGROUND

[0002] Neurodegenerative diseases represent a major public health challenge, expected to impact one in five people in their lifetimes. Alzheimer's disease (AD) is the most common cause of age-related dementia. There is a critical and urgent need for therapeutics to prevent and treat AD and other neurodegenerative conditions.

[0003] Skeletal muscle has the ability to regenerate after injury. Muscle regeneration is dependent upon resident stem cells, referred to as muscle satellite cells. In mature muscle tissue, satellite cells constitute a small, scattered population of mitotically and physiologically quiescent cells. Satellite cells are also implicated in normal muscle growth and maintenance throughout life, indicating that they could be exploited to treat muscle wasting conditions.

[0004] Skeletal muscle makes up about 35% of body weight and is essential for metabolism, locomotion, and breathing, which highlights its importance in human health. Muscle wasting reduces mobility, metabolism, and quality of life for the majority of cancer patients, elderly patients, and many others with no history of neuromuscular dysfunction. In addition, muscular dystrophies are an often fatal group of genetic diseases leading to severe muscle loss, including Duchenne Muscular Dystrophy which affects children.

[0005] Neurogenesis and muscle regeneration are dependent on neural stem cells (NSCs) and muscle satellite cells. A roadblock to development of treatments of neurodegeneration and muscle wasting is that the signaling that regulates neural stem cells and satellite cells and their regeneration is poorly understood. Accordingly, there is a need for compositions and methods for promoting neurogenesis and muscle regeneration.

## SUMMARY

[0006] Among other things, the present disclosure provides an insight that presence and/or activity of a particular form(s) of the muscle-specific tyrosine kinase (MuSK) protein, specifically lacking a functional Ig3 domain, may achieve or contribute to beneficial biological events including, for example, neurogenesis and/or muscle regeneration.

[0007] The present disclosure provides certain technologies for enhancing neurogenesis, including in particular in adult humans. In some embodiments, technologies provided herein may be useful in medicine, including specifically treatment of diseases, disorders or conditions associated with neurodegeneration, or otherwise with low or reduced neuronal activity (e.g., neuronal activity in an adult hippocampus and/or in subventricular zone(s)). For example, in some embodiments, technologies provided herein may be useful in the treatment of one or more of Alzheimer's Disease (AD), Parkinson's disease, dementia (e.g., Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (e.g., chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (e.g., traumatic and/or anoxic brain injury), and Huntington's disease.

[0008] Bone morphogenetic protein (BMP) signaling regulates at least two important NSC decision points: 1) quiescence, where proliferating stem cells exit the cell cycle and return to replenish a reserve pool that can supply fresh stem cells; and: 2) differentiation into mature progeny (Mira et al., 2010). The present disclosure contemplates that manipulating the BMP pathway in NSCs is an attractive target for regulating neurogenesis in the adult brain. Additionally, BMP signaling regulates skeletal muscle stem cell activity in both normal and pathological states. The present disclosure provides technologies for increasing level and/or activity of MuSK form(s) that functionally participate in neurogenesis and/or muscle regeneration, including, in some embodiments, by reducing alternative splicing that would otherwise generate MuSK form(s) that do not so participate. In some embodiments, such increase is in a relevant tissue such as muscle. Alternatively or additionally, in some embodiments, such increase is in a tissues such as a brain tissue (e.g., hippocampal and/or subventricular) and/or lung tissue.

[0009] Among other things, the present disclosure provides an insight that presence and/or activity of a particular form(s) of the muscle-specific tyrosine kinase (MuSK) protein, specifically lacking a functional Ig3 domain, may achieve or contribute to neurogenesis in adult humans, or otherwise provide neurological

benefit(s). The MuSK transcript can be alternatively spliced, including to generate at least one form (i.e.,  $\Delta$ Ig3-MuSK) that lacks the Ig3 domain. The present disclosure appreciates that increasing presence and/or level of  $\Delta$ Ig3-MuSK, and/or of other functional form(s) in which its Ig3 domain is altered (e.g., mutated, blocked, etc.) or removed, may provide benefits as described herein.

[0010] In some embodiments, the present disclosure provides technologies for increasing level and/or activity of one or more forms of MuSK whose Ig3 domain is altered (e.g., mutated, blocked, removed, etc.) for example so that it fails to effectively participate in interaction(s) with BMP. In some embodiments, the present disclosure provides technologies for reducing Ig3.sup.+ MuSK, for example by reducing level and/or activity of one or more forms of MuSK whose Ig3 domain effectively participates in interaction(s) with BMP.

[0011] In some embodiments, an agent that targets the MuSK Ig3 domain, as described herein (e.g., a MuSK-targeting oligonucleotide), so that level and/or activity of a MuSK/BMP complex is reduced is useful in contexts of neurogenesis and/or muscle regeneration and/or of muscle growth.

[0012] In some embodiments, provided agent(s) may enhance muscle growth. In some embodiments, muscle growth occurs in uninjured tissue. In some embodiments, muscle growth occurs in injured tissue. In some embodiments, enhanced and/or increased muscle growth is determined by a decrease in satellite cell number and/or increase in muscle fiber size. In this regard, muscle growth can be characterized by a decrease in satellite cell number and/or increase in muscle fiber size, which is indicative of satellite cells differentiating and fusing into/augmenting existing muscle fibers and forming new muscle fibers.

[0013] Embodiments of the present invention provide methods of enhancing neurogenesis and/or muscle regeneration and/or growth, for example in a subject in need thereof, by administering a composition that downregulates MuSK Ig3 domain protein expression, MuSK Ig3 domain gene expression, and/or MuSK Ig3 activation of BMP signaling, thereby upregulating muscle satellite cells which results in enhancement of muscle regeneration and/or growth. In some embodiments, such a composition can comprise and/or deliver a MuSK-targeting oligonucleotide (e.g., a MuSK Ig3-targeting exon-skipping oligonucleotide).

[0014] In some embodiments, enhancing neurogenesis is used in the context of treating a disease or disorder associated with reduced Adult Hippocampal Neurogenesis (AHN). As AHN occurs throughout life in humans and is dramatically reduced in AD (Moreno-Jimenez et al., 2019; Steiner et al., 2019), the present disclosure provides compositions and methods for promoting AHN, enhancing cognitive function and combating neurodegeneration (e.g., Alzheimer's disease).

[0015] In some embodiments, enhancing neurogenesis is used in the context of treating a disease or disorder associated with reduced Subventricular Zone Neurogenesis. As NSCs reside in the subventricular zone (SVZ) lining the lateral ventricles and generate astrocytes and oligodendrocytes that support the existing circuitry as well as neurons in the olfactory bulb that are critical for olfactory discrimination. The present disclosure provides compositions and methods for compensating for the degeneration of neurons in the SVZ through enhancing endogenous neurogenesis. In some embodiments, the present disclosure provides compositions and methods for treating diseases specifically associated with striatal neurogenesis such as Parkinson's disease (which could benefit both from increasing AHN and striatal neurogenesis in the SVZ: Pitcher et al. 2012; Sterling et al. 2013) and Huntington's disease (Sassone et al., 2018). In some embodiments, the present disclosure provides compositions and methods for treating other diseases including addiction (e.g., chronic cocaine use and lifelong cigarette smoking).

[0016] In some embodiments, a subject of interest can be at risk of, or afflicted with, a disease or disorder including, but not limited to, neuromuscular dysfunction, neurodegenerative disorder, cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting. Alternatively or additionally, in some embodiments, a subject of interest can be at risk of, or afflicted with a disease or disorder associated with lung damage, including, for example, idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), pneumonia, and/or certain infections, including viral infections including coronaviral infections such as COVID19.

[0017] Exemplary neuromuscular dysfunctions or disorders that can be treated by technologies of the present invention include, but are not limited to, Becker muscular dystrophy, Congenital muscular dystrophy, Distal muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Myotonic muscular dystrophy, and Oculo-pharyngeal muscular dystrophy.

[0018] In some embodiments, enhancing muscle growth is used in the context of treating a disease or disorder associated with muscle atrophy or muscle wasting. Muscle atrophy or muscle wasting may be observed in connection with various diseases and conditions described herein, such as neuromuscular disorders, or direct or indirectly caused by prolonged inactivity, bed rest, hospitalization, aging, malnutrition, cancer cachexia, chronic inflammatory diseases, etc. Example chronic inflammatory diseases include rheumatoid arthritis, chronic heart failure, and chronic obstructive pulmonary disease (COPD). [0019] Duration of hospitalization and type and severity of the illness can affect the extent of muscle wasting in a subject, and muscle wasting is common in patients suffering from sepsis, organ failure, hyperglycemia, and diseases associated with chronic and systemic inflammation or oxidative stress. Additionally, hospitalization requiring complete immobilization/bed rest contributes significantly to muscle wasting.

[0020] Additional disorders associated with muscle atrophy/wasting include disorders associated with decreased mobility, such as rheumatoid arthritis, osteoarthritis, and injury. (2016 Powers, Scott K., et al. *Medicine and science in sports and exercise* 48(11): 2307). Thus, in some embodiments, the present disclosure provides therapies for preventing/treating muscle wasting or muscle atrophy related to or as a result of a number of diseases or conditions described herein.

[0021] In some embodiments, methods of the present invention can also be used when a subject is in need of enhanced muscle regeneration and muscle growth following surgery, trauma and/or prolonged immobilization (e.g., from bed-rest or casting). As muscle stem cell activity is known to decrease with age, methods of the present invention can also be used to prevent or reverse sarcopenia in patients that are otherwise healthy and could lead to significant improvements in quality of life and autonomy.

[0022] Embodiments of the present invention also provide methods of preventing or treating neurodegenerative diseases (e.g., AD) and/or muscle fibrosis, e.g., in a subject in need thereof, by administering a composition that downregulates the MuSK Ig3 domain protein expression, the MuSK Ig3 domain gene expression, and/or the MuSK Ig3 activation of BMP signaling. The composition can comprise, e.g., a MuSK-targeting oligonucleotide (e.g., a MuSK Ig3-targeting exon-skipping oligonucleotide). The subject can be at risk of, or afflicted with, various neurodegenerative diseases, such as Alzheimer's Disease (AD), Parkinson's disease, dementia (e.g., Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (e.g., chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy; Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (e.g., traumatic and/or anoxic brain injury), and Huntington's disease or muscle fibrosis resulting from a disease or condition including, but not limited to, trauma, heritable disease, muscle disorder and aging. The trauma can result from, for example, radiation treatment, crush injury, laceration, and amputation. The heritable disease or muscle disorder include, but are not limited to, Congenital Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy; Amyotrophic Lateral Sclerosis (ALS), and age-associated sarcopenia.

[0023] The present invention features, inter alia, an oligonucleotide composition comprising plurality of oligonucleotides, the oligonucleotide composition being characterized in that, when it is contacted with a MuSK transcript in a transcript splicing system, relative amounts of transcripts that do and do not include Ig3 domain-encoding sequences are altered as compared with such relative amounts observed under reference conditions selected from the group consisting of absence of the composition, presence of a reference composition, and combinations thereof.

[0024] In some embodiments, the oligonucleotides mediate skipping of at least one exon of the MuSK gene. In some embodiments, the exon skipping lowers levels of mRNAs encoding MuSK protein form that participate in BMP signaling compared with levels observed absent the exon skipping. In some embodiments, the MuSK protein form participating in BMP signaling is or comprises a MuSK protein form that forms a MuSK/BMP complex.

[0025] In some embodiments, the exon skipping reduces the level and/or activity of a MuSK/BMP complex. In some embodiments, at least one skipped exon is selected from the group consisting of exons 3, 4, 6, and 7. In some embodiments, the relative amounts are amounts of transcripts including exons 6 and 7 relative to those lacking exons 6 and 7. In some embodiments, relative amounts are amounts of transcripts including exons 3 and 4 relative to those lacking exons 6 and 7.

[0026] In some embodiments, the alteration comprises skipping one or more of exons 6 and 7 of MuSK. In some embodiments, the alteration comprises skipping one or more of exons 3 and 4 of MuSK. In some embodiments, the alteration comprises skipping one or more of exons 6 and 7 of MuSK, but skipping none of exons 3 and 4 of MuSK.

[0027] In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 6 and 7 is decreased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is decreased, or both. In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 is decreased or level of MuSK protein forms including sequences encoded by exons 3 and 4 is decreased, or both. In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 6 and 7 is increased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is increased, or both. In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 is increased or level of MuSK protein forms including sequences encoded by exons 3 and 4 is increased, or both. In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 remains substantially unchanged and level of MuSK transcripts including exons 6 and 7 is decreased. In some embodiments, MuSK splicing is altered in that level of MuSK protein forms including sequences encoded by exons 3 and 4 remains substantially unchanged and level of MuSK protein forms including sequences encoded by exons 6 and 7 is decreased. In some embodiments, MuSK splicing is altered in that total level of MuSK transcripts remained substantially unchanged and level of MuSK transcripts including exons 6 and 7 is decreased.

[illegible]



MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is about 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2, or 1:0.1, 1:0.05, 1:0.01, 1:0.001, or 1:0001. In some embodiments, after contact with one or more exon-skipping oligonucleotides as described herein, ratio of MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is between about 1:0.9 and 1:0.8, 1:0.8 and 1:0.7, 1:0.7 and 1:0.6, 1:0.6 and 1:0.5, 1:0.5 and 1:0.4, 1:0.4 and 1:0.3, 1:0.3 and 1:0.2, 1:0.2 and 1:0.1, 1:0.1 and 1:0.05, 1:0.05 and 1:0.01, 1:0.01 and 1:0.001, or 1:0.001 and 1:0001. In some embodiments, after contact with one or more exon-skipping oligonucleotides as described herein, ratio of MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is between about 1:0.9 and 1:0.5.

[0032] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 2 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

[0033] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 3 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both. In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 4 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

[0034] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 5 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both. In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 10 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

[0035] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0036] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 70% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0037] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 80% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0038] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 90% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0039] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 30%.

[0040] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including

sequences encoded by exons 3 and 4, or both, decreases by less than 20%. In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 10%. In some embodiments, the base sequence of the oligonucleotide comprises a sequence having no more than 5 mismatches from a 18-25 base long portion of the MuSK gene or its complement.

[0041] In some embodiments, the oligonucleotides correspond to positions 83776-83800 and on 83854-83878 of the MuSK gene sequence represented in SEQ ID NO: 77.

[0042] In some embodiments, the oligonucleotides described herein target a region on the MuSK genomic sequence within a region defined by nucleotides 83841-83905 and 83962-84032 on the MuSK gene sequence represented in SEQ ID NO: 77.

[0043] In some embodiments, oligonucleotides target a region on the MuSK genomic sequence within or comprising at least a portion of sequence

ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT  
GACTCAAGAC (region 1, SEQ ID: 126). In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to no more than 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to at least 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 15-30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 16 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 17 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 26 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 27 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 28 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 29 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 30 consecutive bases of region 1, SEQ ID: 126.



[0044] In some embodiments, oligonucleotides target a region on the MuSK genomic sequence within or comprising at least a portion of sequence  
GGGGAGAAGTTCAGTACTGCCAAGGCTGCAGCCACCATCAGCATAGCAGGTAGG  
ATGCCCCTTCACATTTG (region 2, SEQ ID: 211). In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to no more than 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to at least 15 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 15-30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 15 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 16 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 17 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 18 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 19 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 20 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 21 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 22 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 23 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 24 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 25 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 26 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 27 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 28 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 29 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 30 consecutive bases of region 2, SEQ ID: 211.

[0045] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a sequence within or comprising at least a portion of  
ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT  
GACTCAAGAC (region 1, SEQ ID: 126). In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 95% identical to a portion of region 1 (SEQ ID: 126) that includes at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region



bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 26 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 27 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 28 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 29 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 30 consecutive bases of region 1, SEQ ID: 126.

[0048] In some embodiments, an oligonucleotide has a length of 30 bases. In some embodiments, an oligonucleotide has a length of 29 bases. In some embodiments, an oligonucleotide has a length of 28 bases. In some embodiments, an oligonucleotide has a length of 27 bases. In some embodiments, an oligonucleotide has a length of 26 bases. In some embodiments, the oligonucleotide has a length of 25 bases. In some embodiments, the oligonucleotide has a length of 24 bases. In some embodiments, the oligonucleotide has a length of 23 bases. In some embodiments, the oligonucleotide has a length of 22 bases. In some embodiments, the oligonucleotide has a length of 21 bases. In some embodiments, the oligonucleotide has a length of 20 bases. In some embodiments, the oligonucleotide has a length of 19 bases. In some embodiments, the oligonucleotide has a length of 18 bases. In some embodiments, the oligonucleotide has a length of 17 bases. In some embodiments, the oligonucleotide has a length of 16 bases. In some embodiments, the oligonucleotide has a length of 15 bases.

[0049] In some embodiments, the oligonucleotide has a length of less than about 50 bases. In some embodiments, the oligonucleotide has a length of less than about 40 bases. In some embodiments, the oligonucleotide has a length of less than about 30 bases. In some embodiments, the oligonucleotide has a length of more than about 10 bases. In some embodiments, the oligonucleotide has a length of more than about 15 bases. In some embodiments, the oligonucleotide has a length of more than about 20 bases. In some embodiments, the base sequence of the oligonucleotide comprises from 5' to 3":

TABLE-US-00001 SEQ ID Oligo ID 5' to 3' Sequence 1 Bld1

GCTAGGGTGGTCTTTTAGAAATGCA 2 Bld2 GGTCAGCTAGGGTGGTCTTTTAGA 3 Bld3  
CTGCAGGAAATGGTCAAGCTAGGGT 4 Bld4 GAAGTGGTGAGTGACGCTCCTGCAG 5 Bld5  
GTTAGGAAGACAGAAGTGGTGAGTG 6 Bld6 ATCCTGGCAAAAAGTGTAGGAAGA 7 Bld7  
GTGGGATTCAGGAGCCCGCAGGATC 8 Bld8 GGTGACATTGTGGGATTCAGGAGCC 9 Bld9  
GGAGCCAAAGGTGACATTGTGGGAT 10 Bld10 GGTCACAAAGGAGCCAAAGGTGACA 11 Bld11  
ACAGTGCAGGGTCACAAAGGAGCCA 12 Bld12 CTGTTGCTGTACAGTGCAGGGTCAC 13 Bld13  
GGGACAGGAATGCCTGTTGCTGTAC 14 Bld14 CAGGTGATGGTGGGGACAGGAATGC 15 Bld15  
CCGTTTTCAATCCAGGTGATGGTGG 16 Bld16 TGACACTCACAGCATTTCCGTTTTTC 17 Bld17  
AAGTCCCCACACACATGACACTCAC 18 Bld18 GGTCTTCCCCAGACAAGTCCCCACA 19 Bld19  
ACTATGTCAGTAGATTTGAAGGGAA 20 Bld20 TCCCACTATACTATGTCAGTAGATT 21 Bld21  
TCAGTCAAGGATTTCCCACTATACT 22 Bld22 AAAAGAACTCAGTCAAGGATTTCCC 23 Bld23  
GTAAAGGAAAATAAAAGAACTCAGT 24 Bld24 AACCTGACAGAGTAAAGGAAAATAA 25 Bld25  
GGACCCAGAAGAAACCTGACAGAGT 26 Bld26 CACTCTCTTGAATGGACCCAGAAGA 27 Bld27  
CACTCGGTCTTTCACACTCTCTTGA 28 Bld28 GTCTTGAGTCAATCACTCGGTCTTT 29 Bld29  
GATAAACAGCTGCAGTCTTGAGTCA 30 Bld30 AGTCCTGGCTTGGTGATAAACAGCT 31 Bld31

ATGTGTTAGTGGTGGTGGTGTAT 32 Bld32 GTAGCTGATGTGTAGAGTCTTG 33 Bld33  
 TGCTTATTGGTAGCTATGCATGTGT 34 Bld34 ACTTCTCCCCATGCTTATTGGTAGC 35 Bld35  
 CCTTGGCAGTACTGAACTTCTCCCC 36 Bld36 CCTGCTATGCTGATGGTGGCTGCAG 37 Bld37  
 GGGCATCCTACCTGCTATGCTGATG 38 Bld38 GCAAATGTGAAGGGGGCATCCTACCT 127 Bld51  
 TTGAATGGACCCAGAAGAAA 128 Bld52 CTTGAATGGACCCAGAAGAA 129 Bld53  
 TCTTGAATGGACCCAGAAGA 130 Bld54 CTCTTGAATGGACCCAGAAG 131 Bld55  
 TCTCTTGAATGGACCCAGAA 132 Bld56 CTCTCTTGAATGGACCCAGA 133 Bld57  
 ACTCTCTTGAATGGACCCAG 134 Bld58 CACTCTCTTGAATGGACCCA 135 Bld59  
 AACTCTCTTGAATGGACCC 136 Bld60 CACACTCTCTTGAATGGACC 137 Bld61  
 TCACACTCTCTTGAATGGAC 138 Bld62 TTCACACTCTCTTGAATGGA 139 Bld63  
 TTTCACACTCTCTTGAATGG 140 Bld64 CTTTCACACTCTCTTGAATG 141 Bld65  
 TCTTTCACACTCTCTTGAAT 142 Bld66 GTCTTTCACACTCTCTTGAA 159 Bld25-1  
 CCAGAAGAAACCTGACAGAGTAAAG 160 Bld25-2 ACCCAGAAGAAACCTGACAGAGTAA 161  
 Bld25-3 ATGGACCCAGAAGAAACCTGACAGA 162 Bld25-4  
 GAATGGACCCAGAAGAAACCTGACA 163 Bld25-5 CTTGAATGGACCCAGAAGAAACCTG 164  
 Bld26-1 CTCTTGAATGGACCCAGAAGAAACC 165 Bld26-2  
 CTCTCTTGAATGGACCCAGAAGAAA 166 Bld26-3 CACACTCTCTTGAATGGACCCAGAA 167  
 Bld26-4 TTCACACTCTCTTGAATGGACCCAG 177 Bld25-A ACCCAGAAGAAACCTGACAGAGT  
 178 Bld25-B CCAGAAGAAACCTGACAGAGT 179 Bld25-C GGACCCAGAAGAAACCTGACAGA  
 180 Bld25-D ACCCAGAAGAAACCTGACAGA 181 Bld25-E GGACCCAGAAGAAACCTGACA 182  
 Bld25-5-A GAATGGACCCAGAAGAAACCTGA 183 Bld25-5-B ATGGACCCAGAAGAAACCTGA  
 184 Bld25-5-C TTGAATGGACCCAGAAGAAACCT 185 Bld25-5-D  
 GAATGGACCCAGAAGAAACCT 186 Bld25-5-E TTGAATGGACCCAGAAGAAAC 187 Bld26-2-A  
 CTCTTGAATGGACCCAGAAGAAA 188 Bld26-2-B CTTGAATGGACCCAGAAGAAA 189 Bld26-2-  
 C CTCTCTTGAATGGACCCAGAAGA 190 Bld26-2-D CTCTCTTGAATGGACCCAGAA 191 Bld26-B  
 CTCTTGAATGGACCCAGAAGA 192 Bld26-C CACTCTCTTGAATGGACCCAGAA, or 193 Bld26-  
 D CACTCTCTTGAATGGACCCAG

[0050] In some embodiments, the oligonucleotide is complementary to a nucleotide sequence that is at least 90% identical to any one of SEQ ID NOs: 39-76 and 212-253.

[0051] In some embodiments, the oligonucleotides comprise one or more types of base modifications, sugar modification, and internucleotidic linkage modifications. In some embodiments, the oligonucleotides comprise non-natural sugar moieties, or non-natural internucleotidic linkages, or both.

[0052] In some embodiments, the oligonucleotides comprise internucleotidic linkage modifications. In some embodiments, the internucleotidic linkages of the oligonucleotide comprises natural phosphate, phosphorothioate, or phosphodithioate linkages. In some embodiments, each internucleotidic linkages of the oligonucleotide is a phosphorothioate linkage. In some embodiments, each internucleotidic linkage of the oligonucleotide is a natural phosphate linkage. In some embodiments, oligonucleotide comprises at least one natural phosphate linkage and at least one phosphodithioate linkage. In some embodiments, at least 50%, 60%, 70%, 80%, 90%, 94%, or 95% of internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 50%, 60%, 70%, 80%, 90%, 94%, or 95% of internucleotidic linkages of an oligonucleotide are natural phosphate linkages.

[0053] In some embodiments, the oligonucleotides comprise sugar modification. In some embodiments, the modified sugar moiety has a 2'-modification. In some embodiments, the modified sugar moiety comprises a bicyclic sugar modification. In some embodiments, the modified sugar moiety comprises a 2'-modification, wherein a 2'-modification is 2'-OR<sub>sup.1</sub>, wherein R<sub>sup.1</sub> is optionally substituted C<sub>sub.1-6</sub> alkyl. In some embodiments, the modified sugar moiety comprises a 2'-modification, wherein a 2'-modification is 2'-MOE. In some embodiments, the modified sugar moiety comprises a 2'-modification, wherein a 2'-modification is 2'-OMe. In some embodiments, each sugar of the oligonucleotide is a 2'-MOE modified sugar. In some embodiments, an oligonucleotide comprises 2'-OH sugar (RNA sugar). In some embodiments, an oligonucleotide comprise 2'-H sugar (DNA sugar). In some embodiments, an oligonucleotide comprises 2'-MOE sugar. In some embodiments, an oligonucleotide comprises 2'-OMe sugar. In some embodiments, an oligonucleotide comprises 2'-MOE, 2'-OMe, 2'-OH, 2'-H sugar, or any combination thereof. In some embodiments, an oligonucleotide comprises at least one 2'-MOE sugar and

at least one 2'-OH sugar (RNA sugar). In some embodiments, an oligonucleotide comprises at least one 2'-MOE sugar and at least one 2'-H sugar (DNA sugar).

[0054] In some embodiments, the oligonucleotide has the structure from 5' to 3' of:

TABLE-US-00002	SEQ- Oligo ID	ID	Oligonucleotide	structure,	5'	to	3'	78	Bld1	G*C*T														
*A	*G	*G	*G	*T	*G	*T	*C	*T	*T	*A	*G	*A	*A	*A	*T	*G	*C	*A	79	Bld2	G*G*T			
*C	*A	*A	*G	*C	*T	*A	*G	*G	*T	*C	*T	*T	*T	*T	*A	*G	*A	80	Bld3	C*T*G				
*C	*A	*G	*G	*A	*A	*A	*T	*G	*G	*T	*C	*A	*A	*G	*C	*T	*A	*G	*G	*G	*T	81	Bld4	G*A*A
*G	*T	*G	*G	*T	*G	*A	*G	*T	*G	*A	*C	*G	*C	*T	*C	*C	*T	*G	*C	*A	*G	82	Bld5	G*T*T
*A	*G	*G	*A	*A	*G	*A	*C	*A	*G	*A	*A	*G	*T	*G	*G	*T	*G	*A	*G	*T	*G	83	Bld6	A*T*C
*C	*T	*G	*G	*C	*A	*A	*A	*A	*A	*C	*T	*G	*T	*T	*A	*G	*G	*A	*A	*G	*A	84	Bld7	G*T*G
*G	*G	*A	*T	*T	*C	*A	*G	*G	*A	*G	*C	*C	*G	*C	*A	*G	*G	*A	*T	*C	85	Bld8	G*G*T	
*G	*A	*C	*A	*T	*T	*G	*T	*G	*G	*G	*A	*T	*T	*C	*A	*G	*G	*A	*G	*C	*C	86	Bld9	G*G*A
*G	*C	*C	*A	*A	*A	*G	*G	*T	*G	*A	*C	*A	*T	*T	*G	*T	*G	*G	*A	*T	87	Bld10	G*G*T	
*C	*A	*C	*A	*A	*A	*G	*G	*A	*G	*C	*C	*A	*A	*A	*G	*G	*T	*G	*A	*C	*A	88	Bld11	A*C*A
*G	*T	*G	*C	*A	*G	*G	*G	*T	*C	*A	*C	*A	*A	*A	*G	*G	*A	*G	*C	*C	*A	89	Bld12	C*T*G
*T	*T	*G	*C	*T	*G	*T	*A	*C	*A	*G	*T	*G	*C	*A	*G	*G	*G	*T	*C	*A	*C	90	Bld13	G*G*G
*A	*C	*A	*G	*G	*A	*A	*T	*G	*C	*C	*T	*G	*T	*T	*G	*C	*T	*G	*T	*A	*C	91	Bld14	C*A*G
*G	*T	*G	*A	*T	*G	*G	*T	*G	*G	*G	*A	*C	*A	*A	*G	*G	*A	*A	*T	*G	*C	92	Bld15	C*C*G
*T	*T	*T	*T	*C	*A	*A	*T	*C	*C	*A	*G	*T	*G	*A	*T	*G	*G	*T	*G	*T	*G	93	Bld16	T*G*A
*C	*A	*C	*T	*C	*A	*C	*A	*G	*C	*A	*T	*T	*T	*C	*C	*G	*T	*T	*T	*T	*C	94	Bld17	A*A*G
*T	*C	*C	*C	*C	*A	*C	*A	*C	*A	*C	*A	*T	*G	*A	*C	*A	*C	*T	*C	*A	*C	95	Bld18	G*G*T
*C	*T	*T	*C	*C	*C	*C	*A	*G	*A	*C	*A	*A	*G	*T	*C	*C	*C	*C	*A	*C	*C	96	Bld19	A*C*T
*A	*T	*G	*T	*C	*A	*G	*T	*A	*G	*A	*T	*T	*T	*G	*A	*A	*G	*G	*G	*A	*A	97	Bld20	T*C*C
*C	*A	*C	*T	*A	*T	*A	*C	*T	*A	*T	*G	*T	*C	*A	*G	*T	*A	*G	*A	*T	*T	98	Bld21	T*C*A
*G	*T	*C	*A	*A	*G	*G	*A	*T	*T	*T	*C	*C	*C	*A	*C	*T	*A	*T	*A	*C	*T	99	Bld22	A*A*A
*A	*G	*A	*A	*C	*T	*C	*A	*G	*T	*C	*A	*A	*G	*G	*A	*T	*T	*T	*C	*C	*C	100	Bld23	G*T*A
*A	*A	*G	*G	*A	*A	*A	*A	*T	*A	*A	*A	*A	*G	*A	*A	*C	*T	*C	*A	*G	*T	101	Bld24	A*A*C
*C	*T	*G	*A	*C	*A	*G	*A	*G	*T	*A	*A	*A	*G	*G	*A	*A	*A	*A	*T	*A	*A	102	Bld25	G*G*A
*C	*C	*C	*A	*G	*A	*A	*G	*A	*A	*A	*C	*C	*T	*G	*A	*C	*A	*G	*A	*G	*T	103	Bld26	C*A*C
*T	*C	*T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*A	*G	*A	*A	*G	*A	104	Bld27	C*A*C
*T	*C	*G	*G	*T	*C	*T	*T	*T	*C	*A	*C	*A	*C	*T	*C	*T	*C	*T	*T	*G	*A	105	Bld28	G*T*C
*T	*T	*G	*A	*G	*T	*C	*A	*A	*T	*C	*A	*C	*T	*C	*G	*G	*T	*C	*T	*T	*T	106	Bld29	G*A*T
*A	*A	*A	*C	*A	*G	*C	*T	*G	*C	*A	*G	*T	*C	*T	*T	*G	*A	*G	*T	*C	*A	107	Bld30	A*G*T
*C	*C	*T	*G	*G	*C	*T	*T	*G	*G	*T	*G	*A	*T	*A	*A	*A	*C	*A	*G	*C	*T	108	Bld31	A*T*G
*T	*G	*T	*A	*G	*A	*G	*T	*C	*C	*T	*G	*G	*A	*G	*C	*T	*T	*G	*G	*A	*T	109	Bld32	G*T*A
*G	*C	*T	*A	*T	*G	*C	*A	*T	*G	*T	*G	*T	*A	*G	*A	*G	*T	*C	*C	*T	*G	110	Bld33	T*G*C
*T	*T	*A	*T	*T	*G	*G	*T	*A	*G	*C	*T	*A	*T	*G	*C	*A	*T	*G	*T	*G	*T	111	Bld34	A*C*T
*T	*C	*T	*C	*C	*C	*C	*A	*T	*G	*C	*T	*T	*A	*T	*T	*G	*G	*T	*A	*G	*C	112	Bld35	C*C*T
*T	*G	*G	*C	*A	*G	*T	*A	*C	*T	*G	*A	*A	*C	*T	*T	*C	*T	*C	*C	*C	*C	113	Bld36	C*C*T
*G	*C	*T	*A	*T	*G	*C	*T	*G	*T	*G	*A	*T	*G	*G	*A	*G	*C	*T	*G	*C	*A	114	Bld37	G*G*G
*C	*A	*T	*C	*C	*T	*A	*C	*C	*T	*G	*C	*T	*A	*T	*G	*C	*T	*G	*A	*T	*G	115	Bld38	G*C*A
*A	*A	*T	*G	*T	*G	*A	*A	*G	*G	*G	*G	*C	*A	*T	*C	*C	*T	*A	*C	*C	*T	143	Bld51	
T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*A	*G	*A	*A	*G	*A	*A	*A	*A	*A	144	Bld52	
C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*A	*G	*A	*A	*G	*A	*A	*A	*A	145	Bld53	
T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*A	*G	*A	*A	*G	*A	*A	*A	146	Bld54	
C	*T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*A	*G	*A	*A	*G	*A	*A	147	Bld55	
T	*C	*T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*A	*G	*A	*A	*A	*A	148	Bld56	
C	*T	*C	*T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*A	*G	*A	*A	*A	149	Bld57	
A	*C	*T	*C	*T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*A	*G	*A	*A	150	Bld58	
C	*A	*C	*T	*C	*T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*A	*A	*A	151	Bld59	
A	*C	*A	*C	*T	*C	*T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*C	*C	152	Bld60	
C	*A	*C	*A	*C	*T	*C	*T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	*C	153	Bld61	
T	*C	*A	*C	*A	*C	*T	*C	*T	*C	*T	*T	*G	*A	*A	*T	*G	*G	*A	*C	*C	*C	154	Bld62	

T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A 155 Bld63  
T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*G\*A\*A\*T\*G\*G 156 Bld64 C\*T\*T\*  
\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G 157 Bld65  
T\*C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T 158 Bld66  
G\*T\*C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A 168 Bld25-1  
C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T\*A\*A\*A\*G\* 169 Bld25-2  
A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T\*A\*A\* 170 Bld25-3  
A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\* 171 Bld25-4  
G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\* 172 Bld25-5  
C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\* 173 Bld26-1  
C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\* 174 Bld26-2  
C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\* 175 Bld26-3  
C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\* 176 Bld26-4  
T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\* 194 Bld25-A  
A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T 195 Bld25-B  
C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T 196 Bld25-C  
G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A 197 Bld25-D  
A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A 198 Bld25-E  
G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A 199 Bld25-5-A  
G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A 200 Bld25-5-B  
A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A 201 Bld25-5-C  
T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T 202 Bld25-5-D  
G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T 203 Bld25-5-E  
T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C 204 Bld26-2-A  
C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A 205 Bld26-2-B  
C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A 206 Bld26-2-C  
C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A 207 Bld26-2-D  
C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A 208 Bld26-B  
C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A 209 Bld26-C  
C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A, or 210 Bld26-D  
C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G. wherein \* represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

[0055] In some embodiments, an oligonucleotide composition comprising a mixture of two or more oligonucleotides according to any one of the embodiments.

[0056] In some embodiments, the composition comprises oligonucleotides that targets regions of the MuSK gene that correspond to positions 83776-83800 and on 83854-83878 of SEQ ID NO: 77.

[0057] In some embodiments, a pharmaceutical composition comprises a therapeutically effective amount of an oligonucleotide, and at least one pharmaceutically acceptable inactive ingredient selected from pharmaceutically acceptable diluents, pharmaceutically acceptable excipients, and pharmaceutically acceptable carriers, wherein the oligonucleotide is an oligonucleotide of any one of the embodiments.

[0058] In some embodiments, the oligonucleotides are formulated a nanocarrier. In some embodiments, the oligonucleotides are formulated in lipid nano-particles (LNPs). In some embodiments, the oligonucleotides are covalently conjugated to an additional moiety selected from lipids (for example, cholesterol), peptides, aptamers, antibodies, and sugars (for example, N-acetylgalactosamine (GalNAc). In some embodiments, the oligonucleotides are covalently conjugated to N-acetylgalactosamine (GalNAc).

[0059] In another aspect, the disclosure features, a method of altering relative amounts of MuSK spliced transcripts, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of previous embodiments.

[0060] In some embodiments, the disclosure features the alteration of MuSK spliced transcripts being characterized in that, the ratio of MuSK transcripts containing Ig3 domain-encoding sequences to MuSK transcription containing no Ig3 domain-encoding sequences is increased. In some embodiments, the alteration of MuSK spliced transcripts being characterized in that, the ratio of MuSK transcripts containing Ig3 domain-encoding sequences to MuSK transcription containing no Ig3 domain-encoding sequences

decreases. In some embodiments, the alteration of MuSK spliced transcripts being characterized in that, MuSK transcripts containing Ig3 domain-encoding sequences decreases and level of total MuSK transcripts remains substantially the same.

[0061] In some embodiments, the alteration of MuSK spliced transcripts is characterized in that, the level of MuSK transcripts including exons 6 and 7 decreases or level of MuSK protein forms including sequences encoded by exons 6 and 7 decreases, or both.

[0062] In some embodiments, the alteration of MuSK spliced transcripts being characterized in that, level of MuSK transcripts including exons 6 and 7 is increased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is increased, or both. In some embodiments, the alteration of MuSK spliced transcripts is characterized in that, the level of MuSK transcripts including exons 3 and 4 decreases or level of MuSK protein forms including sequences encoded by exons 3 and 4 decreases, or both. In some embodiments, the alteration of MuSK spliced transcripts is characterized in that, the level of MuSK transcripts including exons 3 and 4 is increased or level of MuSK protein forms including sequences encoded by exons 3 and 4 is increased, or both.

[0063] In some embodiments, the alteration of MuSK spliced transcripts being characterized in that, the level of MuSK transcripts including exons 3 and 4 remains substantially the same, or level of MuSK protein forms including sequences encoded by exons 3 and 4 remains substantially the same, or both. In some embodiments, the alteration of MuSK spliced transcripts is characterized that, the level of MuSK transcripts including exons 3 and 4 remains substantially the same, or level of MuSK protein forms including sequences encoded by exons 3 and 4 remains substantially the same, or both; and level of MuSK transcripts including exons 6 and 7 decreases or level of MuSK protein forms including sequences encoded by exons 6 and 7 decreases, or both.

[0064] In another aspect, the disclosure features, a method of treating a subject suffering from one or more features of neurodegenerative diseases, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0065] In another aspect, the disclosure features, a method of increasing neurogenesis, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0066] In another aspect, the disclosure features, a method of treating a subject suffering from one or more features of neuromuscular dysfunction or a muscular dystrophy, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0067] In another aspect, the disclosure features, a method of increasing muscle regeneration and/or muscle growth, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0068] In another aspect, the disclosure features, a method of treating muscle fibrosis, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0069] In some embodiments, the subject is at risk of, or afflicted with, a disease or disorder selected from the group consisting of: neuromuscular dysfunction, neurodegenerative disorder, cardiac disorder, and diseases characterized by muscle wasting. In some embodiments, the neurodegenerative disorder is selected from the group consisting of Alzheimer's Disease (AD), Parkinson's disease, dementia (e.g., Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (e.g., chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (e.g., traumatic and/or anoxic brain injury), and Huntington's disease. In some embodiments, the neurodegenerative disease is Alzheimer's Disease (AD).

[0070] In some embodiments, the neuromuscular dysfunction is a muscular dystrophy selected from the group consisting of: Becker, Congenital, Distal, Duchenne, Emery-Dreifuss, Facioscapulohumeral, Limb-girdle, Myotonic, and Oculo-pharyngeal muscular dystrophy. In another aspect, the disclosure features,

[0071] In some embodiments, the cardiac disorder is myocardial infarction or cardiomyopathy. In some

embodiments, the subject is in need of enhanced muscle regeneration and/or growth following a condition selected from the group consisting of: surgery, trauma and prolonged immobilization. In some embodiments, the prolonged immobilization results from bed-rest or casting. In some embodiments, the subject is at risk of, or afflicted with, sarcopenia. In some embodiments, the subject is at risk of, or afflicted with, muscle fibrosis resulting from a disease or condition selected from the group consisting of: trauma, heritable disease, muscle disorder, and aging. In some embodiments, the trauma is the result of a condition selected from the group consisting of: radiation treatment, crush injury, laceration, and amputation.

[0072] In some embodiments, the heritable disease or muscle disorder selected from the group consisting of: Congenital Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy: Amyotrophic Lateral Sclerosis (ALS), and age-associated sarcopenia.

[0073] In some embodiments, the composition is delivered to the CNS. In some embodiments, the composition is delivered to the cerebrospinal fluid. In some embodiments, the composition is delivered to the muscle. In some embodiments, the composition is delivered to the liver. In some embodiments, the composition can be formulated for systemic or localized administration. In some embodiments, the composition is formulated for delivery by a route selected from intravenous injection, intravenous infusion, intramuscular injection, intrathecal administration, oral administration, buccal administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration.

[0074] In some embodiments, the composition is formulated for delivery by intramuscular administration. In some embodiments, the composition is formulated for delivery by intravenous administration. In some embodiments, the composition is formulated for delivery by oral administration.

---

## Description

### BRIEF DESCRIPTION OF THE DRAWING

[0075] For the purpose of illustration, certain embodiments of the present invention are shown in the drawings described below. Like numerals in the drawings indicate like elements throughout. It should be understood, however, that the invention is not limited to the precise arrangements, dimensions, and instruments shown. In the drawings:

[0076] FIG. 1 is a schematic representation of an interaction between BMP and Ig3 domain of MuSK and its implications in BMP signaling and neurogenesis and cognition.

[0077] FIG. 2 is a schematic representation of the full-length and MuSK $\Delta$ Ig3 transcripts and encoded proteins and exemplary primer design to selectively detect total MuSK and full-length MuSK transcripts.

[0078] FIG. 3 shows relative MuSK expression measured by qPCR using Taqman or SYBR green technology in LHCN-M2 cells.

[0079] FIG. 4 is a schematic representation of "region 1" and "region 2" of exon 7 of MuSK transcript.

[0080] FIG. 5 shows an alignment of the ASOs Bld1-Bld18 on the genetic sequence of MuSK.

[0081] FIG. 6 shows microscopic acquisitions of LHCN-M2 24 h after being transfected with the ASOs Bld1-Bld4, Bld6, Bld7, Bld9, Bld11, Bld12, Bld13, Bld14, Bld15, Bld16, Bld17, and untreated control at 100 nM (scale 100 nm).

[0082] FIG. 7 shows relative MuSK expression measured by qPCR of LHCN-M2 cells transfected with ASOs Bld1-Bld18 at 50 and 100 nM. Panel A shows total MuSK expression (i.e., of MuSK34, a primer spanning exon/exon junction 3-4) and Panel B shows expression of MuSK exons 6-7 (i.e., using MuSK67, a primer spanning exon/exon junction 6-7). All samples are normalized to the housekeeping genes GAPDH and YWHAZ and to controls.

[0083] FIG. 8 shows alignment of the ASOs Bld1-Bld18 on the genetic sequence of MuSK and their effect on MuSK expression. Green: no effect or increase in MuSK expression (MuSK expression comprised between 90 and 300% of the untreated condition). Orange: moderate decrease in MuSK expression (MuSK expression comprised between 40 and 70% of the untreated condition). Red: high decrease in MuSK expression (MuSK expression below 40% of the untreated condition). Red areas indicate regions important for the expression of MuSK where ASOs induced a decrease of MuSK67>80%.

[0084] FIG. 9 shows an alignment of the ASOs Bld19-Bld38 on the genetic sequence of MuSK.

[0085] FIG. 10 shows microscopic acquisitions of LHCN-M2 24 h after being transfected with the ASOs



Bld 19-22, Bld29-34, and untreated control at 100 nM (scale 100 nm).

[0086] FIG. 11 shows relative MuSK expression measured by qPCR of LHCN-M2 cells transfected with ASOs (control, Bld19-Bld28) at 50 and 100 nM. Panel A shows MuSK34 expression and panel B shows MuSK67 expression. All samples are normalized to the housekeeping genes GAPDH and YWHAZ and to controls.

[0087] FIG. 12 shows the alignment of the ASOs Bld19-Bld38 on the genetic sequences and their effect on MuSK expression. Green: no effect or increase in MuSK expression (MuSK expression comprised between 90 and 300% of the untreated condition). Orange: moderate decrease in MuSK expression (MuSK expression comprised between 40 and 70% of the untreated condition). Red: high decrease in MuSK expression (MuSK expression below 40% of the untreated condition). Red areas indicate regions important for the expression of MuSK where ASOs induced a decrease of MuSK67 > 80%. Purple areas indicate regions that can be targeted to selectively inhibit MuSK67 expression (with lower effect on other exons).

[0088] FIG. 13 shows relative MuSK expression in response to various doses of ASOs (Bld25 (panel A), Bld26 (panel B), Bld27 (panel C), Bld28 (panel D), Bld35 (panel E), Bld38 (panel F)). MuSK34 (in blue) and MuSK67 (in red) expressions were measured by qPCR and normalized to housekeeping genes and to the controls. The estimated IC is indicated on each graph. The 5 tested doses were 2.5, 5, 25, 125, and 400 nM.

[0089] FIG. 14 shows relative MuSK expression in response to various doses of ASOs (Bld25 (panel A), Bld26 (panel B)). MuSK34 (in blue) and MuSK67 (in red) expressions were measured by qPCR and normalized to housekeeping genes and to the controls. The 4 tested doses were 5, 7.5, 12.5 and 25 nM.

[0090] FIG. 15 shows relative MuSK expression in response to combination of ASOs Bld25 and Bld26 at 12.5 nM final concentration compared to an untreated control. MuSK34 (in blue) and MuSK67 (in red) expressions were measured by qPCR and normalized to housekeeping genes and to controls.

[0091] FIG. 16 shows migration of PCR products from exon 3 to exon 9 on gel electrophoresis. cDNA of ASO-treated cells (Bld25, i.e., “hu7-10 or Bld26, i.e., “hu73”) was amplified by PCR and deposited on gel electrophoresis to be migrated (panel A). Predicted products are presented in panel B and panel B’.

[0092] FIG. 17 shows an alignment of sequences of various target portion of “region 1”. ASOs Bld25, Bld26, and Bld51-Bld66 target various portions of “region 1.”

[0093] FIG. 18 shows the relative change of gene expression of total MuSK (MuSK34) and MuSK containing Ig3 domain (MuSK67) for ASOs Bld51-Bld66 at a concentration of 12.5 nM (Panel A) and at a concentration of 100 nM (Panel B).

[0094] FIG. 19 shows an alignment of ASOs Bld25-1, Bld25-2, Bld25, Bld25-3, Bld25-4, Bld25-5, Bld26-1, Bld26-2, Bld26, Bld26-3, Bld26-4, Bld27, Bld28, Bld35, Bld 38 on various target portions of “region 1” and “region 2” of exon 7 of human MuSK.

[0095] FIG. 20 shows MuSK gene expression analyzed in qPCR. Panel A shows relative gene expression of MuSKIg3 (MuSK67) and Panel B shows relative gene expression of total MuSK (MuSK34).

[0096] FIG. 21 shows MuSK gene expression from only the ASOs which showed relative expression of MuSK67 of less than 50% and total MuSK (MuSK34) of greater than 60% compared to the control. Panel A shows relative gene expression of MuSKIg3 (MuSK67) and Panel B shows relative gene expression of total MuSK (MuSK34).

[0097] FIG. 22 shows a comparison of Bld25-5 to Bld25 after transfection with ASO for 24 hours (Panels A and B) and 48 hours (Panels C and D).

[0098] FIG. 23 shows an alignment of ASOs Bld25, Bld25-A, Bld25-B, Bld25-C, Bld25-D, Bld25-E, Bld25-5, Bld25-5-A, Bld25-5-B, Bld25-5-C, Bld25-5-D, Bld25-5-E, Bld26-2, Bld26-2-A, Bld26-2-B, Bld26-2-C, Bld26-2-D, Bld26, Bld26-B, Bld26-C, Bld26-D, on various target portions of “region 1” of exon 7 of human MuSK.

[0099] FIG. 24 shows relative gene expression (MuSK34 and MuSK67) for ASOs Bld25-A, Bld25-B, Bld25-C, Bld25-D, and Bld25-E.

[0100] FIG. 25 shows relative gene expression (MuSK34 and MuSK67) for ASOs Bld25-5-A, Bld25-5-B, Bld25-5-C, Bld25-5-D, and Bld25-5-E.

[0101] FIG. 26 shows a graphical representation of the 3 variants of MuSK RNA. Full length and  $\Delta$ Ig3 indicate the lengths of the full-length sequence and the sequence comprising a deletion of exon 6, 7,

respectively, amplified by PCR from exon 3 to exon 9.

[0102] FIG. 27 shows the gel migration of pcr products from cells treated with Bld25 and Bld25-5 and intensity of bands from Bld25 and Bld25-5 products.

[0103] FIG. 28 shows that the sequence of the band lower band positioned, where  $\Delta 6,7$  variant 1 (687 bases) was expected, was indeed the sequence of this splice variant.

[0104] FIG. 29 shows images of HCN-M2 cells being treated for 48 h with 10 nM of siRNA against MuSK and were then stained for MuSK protein on days 2, 3, 4, and 5 following siRNA treatment.

## DEFINITIONS

[0105] For convenience, the meaning of some terms and phrases used in the specification, examples, and appended claims, are provided below. Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below.

[0106] These definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims.

[0107] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification shall prevail.

[0108] About or Approximately: The term “about” or “approximately”, when used herein in reference to a value, refers to a value that is similar, in context to the referenced value. In general, those skilled in the art, familiar with the context, will appreciate the relevant degree of variance encompassed by “about” in that context. For example, in some embodiments, the term “about” may encompass a range of values that within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the referred value.

[0109] Administration: As used herein, the term “administration” typically refers to the administration of a composition to a subject or system, for example to achieve delivery of an agent (e.g., an agonizing agent) that is, or is included in or otherwise delivered by, the composition. Those of ordinary skill in the art will be aware of a variety of routes that may, in appropriate circumstances, be utilized for administration to a subject, for example a human. For example, in some embodiments, administration may be ocular, oral, buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e.g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc. In some embodiments, an agent (e.g., an agonizing agent) is delivered to the central nervous system (CNS), e.g., delivered via intracerebroventricular administration. In some embodiments, administration may involve only a single dose. In some embodiments, administration may involve application of a fixed number of doses. In some embodiments, administration may involve dosing that is intermittent (e.g., a plurality of doses separated in time) and/or periodic (e.g., individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (e.g., perfusion) for at least a selected period of time.

[0110] Agent: In general, the term “agent”, as used herein, may be used to refer to a compound or entity of any chemical class including, for example, a polypeptide, nucleic acid, saccharide, lipid, small molecule, metal, or combination or complex thereof. In appropriate circumstances, as will be clear from context to those skilled in the art, the term may be utilized to refer to an entity that is or comprises a cell or organism, or a fraction, extract, or component thereof. Alternatively or additionally, as context will make clear, the term may be used to refer to a natural product in that it is found in and/or is obtained from nature. In some instances, again as will be clear from context, the term may be used to refer to one or more entities that is man-made in that it is designed, engineered, and/or produced through action of the hand of man and/or is not found in nature. In some embodiments, an agent may be utilized in isolated or pure form: in some embodiments, an agent may be utilized in crude form. In some embodiments, potential agents may be provided as collections or libraries, for example that may be screened to identify or characterize active agents within them. In some cases, the term “agent” may refer to a compound or entity that is or comprises a polymer: in some cases, the term may refer to a compound or entity that comprises one or more polymeric moieties. In some embodiments, the term “agent” may refer to a compound or entity that is not

a polymer and/or is substantially free of any polymer and/or of one or more particular polymeric moieties. In some embodiments, the term may refer to a compound or entity that lacks or is substantially free of any polymeric moiety.

[0111] Agonist: Those skilled in the art will appreciate that the term “agonist” may be used to refer to an agent (i.e., an “agonizing agent”), condition, or event whose presence, level, degree, type, or form correlates with increased level or activity of another agent (i.e., the agonized agent or the target agent). In general, an agonist may be or include an agent of any chemical class including, for example, small molecules, polypeptides, nucleic acids, carbohydrates, lipids, metals, and/or any other entity that shows the relevant activating activity: In some embodiments, an agonist may be direct (in which case it exerts its influence directly upon its target): in some embodiments, an agonist may be indirect (in which case it exerts its influence by other than binding to its target: e.g., by interacting with a regulator of the target, so that level or activity of the target is altered). In some embodiments, an agonist is a binding agent that is a protein (e.g., an antibody) or a nucleic acid (e.g., an antisense oligonucleotide) that binds a target (e.g., a protein or nucleic acid) so that level, form, and/or activity of the target is altered. In some embodiments, the altered level, form and/or activity is an increased level of altered protein expressed from the target nucleic acid sequence. Those skilled in the art, reading the present disclosure, will appreciate that, in some embodiments, an agonizing agent may bind to (and potentially agonize) a binding target, which binding causes an increase in level or activity of a further agonized target. To give a specific example, in some embodiments, an agonizing agent that binds to a nucleic acid target may alter level and/or activity of that target, and in some specific embodiments may agonize an activity of that nucleic acid target (e.g., by increasing its modification, splicing, 5' cap formation, and/or 3' end formation, transport, and/or translation, etc, so that a level of a desired product—e.g., mRNA, is increased) and/or may agonize a downstream target, such as a polypeptide encoded by such nucleic acid target. To give one particular such example, in some embodiments, an agonizing agent may be or comprise an oligonucleotide that binds to a primary transcript and alters its splicing pattern so that level and/or activity of a particular spliced form (e.g., mature mRNA) is increased, which may, in turn achieved increased level of a product (e.g., a polypeptide) that is or is encoded by such particular spliced form.

[0112] Antagonist: Those skilled in the art will appreciate that the term “antagonist”, as used herein, may be used to refer to an agent (i.e., an “antagonizing agent”), condition, or event whose presence, level, degree, type, or form correlates with decreased level or activity of another agent (i.e., the inhibited agent, or target). In general, an antagonist may be or include an agent of any chemical class including, for example, small molecules, polypeptides, nucleic acids, carbohydrates, lipids, metals, and/or any other entity that shows the relevant inhibitory activity. In some embodiments, an antagonist may be direct (in which case it exerts its influence directly upon its target): in some embodiments, an antagonist may be indirect (in which case it exerts its influence by other than binding to its target: e.g., by interacting with a regulator of the target, so that level or activity of the target is altered). In some embodiments, an antagonist is binding agent that is a protein (e.g., an antibody) or a nucleic acid (e.g., an antisense oligonucleotide) that binds a target (e.g., a protein or nucleic acid) so that the level, form, and/or activity of the target is altered. In some embodiments, the altered level, form and/or activity is a decreased level of altered protein expressed from the target nucleic acid sequence. Those skilled in the art, reading the present disclosure, will appreciate that, in some embodiments, an antagonizing agent may bind to (and potentially antagonize) a binding target, which binding causes a decrease in level or activity of a further antagonized target. To give a specific example, in some embodiments, an antagonizing agent that binds to a nucleic acid target may alter level and/or activity of that target, and in some specific embodiments may antagonize an activity of that nucleic acid target (e.g., by decreasing its modification, splicing, 5' cap formation, and/or 3' end formation, transport, and/or translation, etc, so that a level of an undesired product—e.g., mRNA, is suppressed) and/or may antagonize a downstream target, such as a polypeptide encoded by such nucleic acid target. To give one particular such example, in some embodiment, an antagonizing agent may be or comprise an oligonucleotide that binds to a primary transcript and alters its splicing pattern so that level and/or activity of a particular spliced form (e.g., mature mRNA) is suppressed, which may, in turn achieved decreased level of a product (e.g., a polypeptide) that is or is encoded by such particular spliced form.

[0113] Antibody agent: As used herein, the term “antibody agent” refers to an agent that specifically binds

to a particular antigen (e.g., that may be or comprise an epitope of a protein of interest—e.g., a MuSK protein). In some embodiments, the term encompasses any polypeptide or polypeptide complex that includes immunoglobulin structural elements sufficient to confer specific binding. Exemplary antibody agents include, but are not limited to monoclonal antibodies or polyclonal antibodies. In some embodiments, an antibody agent may include one or more constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, an antibody agent may include one or more sequence elements are humanized, primatized, chimeric, etc., as is known in the art. In many embodiments, the term “antibody agent” is used to refer to one or more of the art-known or developed constructs or formats for utilizing antibody structural and functional features in alternative presentation. For example, embodiments, an antibody agent utilized in accordance with the present invention is in a format selected from, but not limited to, intact IgA, IgG, IgE or IgM antibodies: bi- or multi-specific antibodies (e.g., Zybodies®, etc): antibody fragments such as Fab fragments, Fab’ fragments, F(ab)2 fragments, Fd’ fragments, Fd fragments, and isolated CDRs or sets thereof: single chain Fvs: polypeptide-Fc fusions: single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof): cameloid antibodies: masked antibodies (e.g., Probodies®): Small Modular ImmunoPharmaceuticals (“SMIPs™”); single chain or Tandem diabodies (TandAb®): VHHs: Anticalins®; Nanobodies R; minibodies: BiTE®s: ankyrin repeat proteins or DARPINs®; Avimers R: DARTs: TCR-like antibodies; Adnectins®; Affilins®; Trans-Bodies®; Affibodies®; TrimerX®; MicroProteins: Fynomers®, Centyrins®, and KALBITOR®s. In some embodiments, an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally. In some embodiments, an antibody may contain a covalent modification (e.g., attachment of a glycan, a payload [e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc], or other pendant group [e.g., poly-ethylene glycol, etc.]. In many embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those skilled in the art as a complementarity determining region (CDR): in some embodiments an antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (e.g., at least one heavy chain CDR and/or at least one light chain CDR) that is substantially identical to one found in a reference antibody. In some embodiments an included CDR is substantially identical to a reference CDR in that it is either identical in sequence or contains between 1-5 amino acid substitutions as compared with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes structural elements recognized by those skilled in the art as an immunoglobulin variable domain. In some embodiments, an antibody agent is a polypeptide protein having a binding domain which is homologous or largely homologous to an immunoglobulin-binding domain.

[0114] Antibody: As used herein, the term “antibody” refers to an immunoglobulin or a derivative thereof containing an immunoglobulin domain capable of binding to an antigen (e.g., that may be or comprise an epitope of a protein of interest—e.g., a MuSK protein). The antibody can be of any species, e.g., human, rodent, rabbit, goat, chicken, etc. The antibody may be a member of any immunoglobulin class, including

any of the human classes: IgG, IgM, IgA, IgD, and IgE, or subclasses thereof such as IgG1, IgG2, etc. In various embodiments of the invention the antibody is a fragment such as an Fab', F(ab)2, scFv (single-chain variable) or other fragment that retains an antigen binding site, or a recombinantly produced scFv fragment, including recombinantly produced fragments. See, e.g., Allen, T., *Nature Reviews Cancer*, Vol. 2, 750-765, 2002, and references therein. The antibody can be monovalent, bivalent or multivalent. The antibody may be a chimeric or "humanized" antibody in which, for example, a variable domain of rodent origin is fused to a constant domain of human origin, thus retaining the specificity of the rodent antibody. The domain of human origin need not originate directly from a human in the sense that it is first synthesized in a human being. Instead, "human" domains may be generated in rodents whose genome incorporates human immunoglobulin genes. See, e.g., Vaughan, et al., (1998), *Nature Biotechnology*, 16:535-539. The antibody may be partially or completely humanized. An antibody may be polyclonal or monoclonal, though for purposes of the present invention monoclonal antibodies are generally preferred. Methods for producing antibodies that specifically bind to virtually any molecule of interest are known in the art. For example, monoclonal or polyclonal antibodies can be purified from blood or ascites fluid of an animal that produces the antibody (e.g., following natural exposure to or immunization with the molecule or an antigenic fragment thereof), can be produced using recombinant techniques in cell culture or transgenic organisms, or can be made at least in part by chemical synthesis. In some embodiments, the antibody can act as an antagonist, e.g., by binding to a target antigen, resulting in a decreased level or activity of said antigen. In some embodiments, the antibody can act as an agonist, e.g., by binding to a target antigen, resulting in an increased level or activity of said antigen.

[0115] Antisense: The term "antisense" is used herein to refer to a nucleic acid whose nucleotide sequence is complementary to part or all of a sequence found in a coding strand nucleic acid. Typically, a "coding strand" nucleic acid is one whose sequence includes part or all of an open reading frame or other stretch of residues that encodes part or all of a polypeptide. In some embodiments, the term "antisense" may particularly be used herein in reference to an oligonucleotide that binds specifically to a coding strand (i.e., to a target sequence within such coding strand). In some embodiments, a coding strand may include both coding and non-coding sequences (e.g., to give but one example, may be a transcript, such as a primary transcript, that includes both intron and exon sequences). Those skilled in the art, reading the present disclosure, will appreciate that, in some embodiments, an oligonucleotide may be considered or referred to as an "antisense" oligonucleotide when some or all of its sequence is complementary to non-coding portion(s) of its target strand. In some embodiments, an antisense oligonucleotide binds to coding sequences in a target sense strand: in some embodiments, an antisense oligonucleotide binds to non-coding sequences in a target coding strand. In some embodiments, an antisense oligonucleotide binds to both coding and non-coding sequences in a target coding strand. In some embodiments, an antisense oligonucleotide is characterized in that, when bound to its target sequence in a coding strand (e.g., a transcript), it alters post-transcriptional processing (e.g., one or more of modification, splicing, 5' cap formation, and/or 3' end formation, transport, and/or translation) of such coding strand. In some particular embodiments, an antisense oligonucleotide alters splicing of its target coding strand. Alternatively or additionally, in some embodiments, an antisense-coding strand complex is or can be degraded, e.g., by RNase H.

[0116] Approximately: As used herein, the terms "approximately" or "about" in reference to a number are generally taken to include numbers that fall within a range of 5%, 10%, 15%, or 20% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value).

[0117] Binding agent: In general, the term "binding agent" is used herein to refer to any entity that binds to a target of interest as described herein. In many embodiments, a binding agent of interest is one that binds specifically with its target in that it discriminates its target from other potential binding partners in a particular interaction context. In general, a binding agent may be or comprise an entity of any chemical class (e.g., polymer, non-polymer, small molecule, polypeptide, carbohydrate, lipid, nucleic acid, etc). In some embodiments, a binding agent is a single chemical entity. In some embodiments, a binding agent is a complex of two or more discrete chemical entities associated with one another under relevant conditions by non-covalent interactions. For example, those skilled in the art will appreciate that in some embodiments, a binding agent may comprise a "generic" binding moiety (e.g., one of

biotin/avidin/streptavidin and/or a class-specific antibody) and a “specific” binding moiety (e.g., an antibody or aptamers with a particular molecular target) that is linked to the partner of the generic binding moiety. In some embodiments, such an approach can permit modular assembly of multiple binding agents through linkage of different specific binding moieties with the same generic binding moiety partner. In some embodiments, binding agents are or comprise polypeptides (including, e.g., antibodies or antibody fragments). In some embodiments, binding agents are or comprise small molecules. In some embodiments, binding agents are or comprise nucleic acids (e.g., antisense oligonucleotides). In some embodiments, binding agents are aptamers. In some embodiments, binding agents are polymers: in some embodiments, binding agents are not polymers. In some embodiments, binding agents are non-polymeric in that they lack polymeric moieties. In some embodiments, binding agents are or comprise carbohydrates. In some embodiments, binding agents are or comprise lectins. In some embodiments, binding agents are or comprise peptidomimetics. In some embodiments, binding agents are or comprise scaffold proteins. In some embodiments, binding agents are or comprise mimotopes. In some embodiments, binding agents are or comprise stapled peptides. In certain embodiments, binding agents are or comprise nucleic acids, such as DNA or RNA (e.g., antisense oligonucleotides).

[0118] Complementary: As used herein, in accordance with its art-accepted meaning, “complementary” refers to the capacity for precise pairing between particular bases, nucleosides, nucleotides or nucleic acids. For example, adenine (A) and uridine (U) are complementary; adenine (A) and thymidine (T) are complementary; and guanine (G) and cytosine (C), are complementary and are referred to in the art as Watson-Crick base pairings. If a nucleotide at a certain position of a first nucleic acid sequence is complementary to a nucleotide located opposite in a second nucleic acid sequence when the strands are aligned in anti-parallel orientation, the nucleotides form a complementary base pair, and the nucleic acids are complementary at that position. The percent complementarity of a first nucleic acid to a second nucleic acid may be evaluated by aligning them in antiparallel orientation for maximum complementarity over a window of evaluation, determining the total number of nt in both strands that form complementary base pairs within the window; dividing by the total number of nt within the window; and multiplying by 100. For example, AAAAAAAAA and TTTGTTAT are 75% complementary since there are 12 nt in complementary base pairs out of a total of 16 nt. When computing the number of complementary nt needed to achieve a particular % complementarity; fractions are rounded to the nearest whole number. A position occupied by non-complementary nucleotides constitutes a mismatch, i.e., the position is occupied by a non-complementary base pair. In certain embodiments a window of evaluation has the length described herein for duplex portions or target portions. Complementary sequences include base-pairing of a polynucleotide comprising a first nucleotide sequence to a polynucleotide comprising a second nucleotide sequence over the entire length of both nucleotide sequences (if the same length) or over the entire length of the shorter sequence (if different lengths). Such sequences can be referred to as “perfectly complementary.” (100% complementarity) with respect to each other herein. Nucleic acids that are at least 70% complementary over a window of evaluation are considered “substantially complementary” over that window: In certain embodiments complementary nucleic acids are at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% complementary over the window of evaluation. Where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences may be perfectly complementary or they may comprise one or more unmatched bases upon hybridization, e.g., up to about 5%, 10%, 15%, 20%, or 25% unmatched bases upon hybridization, e.g., 1, 2, 3, 4, 5, or 6 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while retaining the ability to hybridize under the conditions most relevant to their intended use. It should be understood that where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs are not regarded as mismatches or unpaired nucleotides with regard to the determination of percent complementarity: For example, the two strands of a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is perfectly complementary to the shorter oligonucleotide and a 2 nucleotide overhang, may be referred to as “perfectly complementary” herein. “Complementary” sequences, as used herein may include one or more non-Watson-Crick base pairs and/or base pairs formed from non-natural and other modified nucleotides, in so far as the requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not

limited to, G: U Wobble or Hoogsteen base pairing. Those of ordinary skill in the art are aware that guanine, cytosine, adenine, and uracil can be replaced by other bases without substantially altering the base pairing properties of a polynucleotide comprising a nucleotide bearing such bases, according to the so-called “wobble” rules (see, e.g., Murphy, FV IV & V Ramakrishnan, V., Nature Structural and Molecular Biology 11:1251-1252 (2004)). For example, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Thus, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of an Inhibitory RNA described herein by a nucleotide containing, for example, inosine. It will be understood that the terms “complementary”, “perfectly complementary”, and “substantially complementary.” can be used with respect to the base matching between any two nucleic acids, e.g., the base matching between the sense strand and the antisense strand of a double stranded nucleic acid, or portion thereof. “Hybridize”, as used herein, refers to the interaction between two nucleic acid sequences (which in some embodiments may be part of the same nucleic acid molecule and in other embodiments may be or include part(s) of different nucleic acid molecules) comprising or consisting of complementary portions such that a duplex structure (i.e., an intramolecular or intermolecular duplex) is formed that is stable under the particular conditions of interest, as will be understood by the ordinary skilled artisan.

[0119] **Comprising:** The term “comprising” means that other elements can also be present in addition to the defined elements presented. The use of “comprising” indicates inclusion rather than limitation.

[0120] **Consisting of:** The term “consisting of” refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment. As used herein the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.

[0121] **Combination therapy:** As used herein, the term “combination therapy” refers to those situations in which a subject is simultaneously exposed to two or more therapeutic regimens (e.g., two or more therapeutic agents). In some embodiments, the two or more regimens may be administered simultaneously: in some embodiments, such regimens may be administered sequentially (e.g., all “doses” of a first regimen are administered prior to administration of any doses of a second regimen); in some embodiments, such agents are administered in overlapping dosing regimens. In some embodiments, “administration” of combination therapy may involve administration of one or more agent(s) or modality(ies) to a subject receiving the other agent(s) or modality(ies) in the combination. For clarity, combination therapy does not require that individual agents be administered together in a single composition (or even necessarily at the same time), although in some embodiments, two or more agents, or active moieties thereof, may be administered together in a combination composition, or even in a combination compound (e.g., as part of a single chemical complex or covalent entity).

[0122] **Comparable:** As used herein, the term “comparable” refers to two or more agents, entities, situations, sets of conditions, etc., that may not be identical to one another but that are sufficiently similar to permit comparison there between so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied.

[0123] **Domain:** The term “domain” as used herein refers to a section or portion of an entity: In some embodiments, a “domain” is associated with a particular structural and/or functional feature of the entity so that, when the domain is physically separated from the rest of its parent entity, it substantially or entirely retains the particular structural and/or functional feature. Alternatively or additionally, a domain may be or include a portion of an entity that, when separated from that (parent) entity and linked with a

different (recipient) entity, substantially retains and/or imparts on the recipient entity one or more structural and/or functional features that characterized it in the parent entity. In some embodiments, a domain is a section or portion of a molecule (e.g., a small molecule, carbohydrate, lipid, nucleic acid, or polypeptide). In some embodiments, a domain is a section of a polypeptide (e.g., the Ig3 domain of a MuSK protein): in some such embodiments, a domain is characterized by a particular structural element (e.g., a particular amino acid sequence or sequence motif,  $\alpha$ -helix character,  $\beta$ -sheet character, coiled-coil character, random coil character, etc.), and/or by a particular functional feature (e.g., binding activity, enzymatic activity, folding activity, signaling activity, etc.).

[0124] Dosing regimen: Those skilled in the art will appreciate that the term “dosing regimen” may be used to refer to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which is separated in time from other doses. In some embodiments, individual doses are separated from one another by a time period of the same length: in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (i.e., is a therapeutic dosing regimen).

[0125] Expression: As used herein, “expression” of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5' cap formation, and/or 3' end formation); (3) transport of an RNA transcript (e.g., from nucleus to cytoplasm; and/or (4) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.

[0126] Isolated or Partially Purified: The term “isolated” or “partially purified” as used herein refers, in the case of a nucleic acid or polypeptide, to a nucleic acid or polypeptide separated from at least one other component (e.g., nucleic acid or polypeptide) that is present with the nucleic acid or polypeptide as found in its natural source and/or that would be present with the nucleic acid or polypeptide when expressed by a cell, or secreted in the case of secreted polypeptides. A chemically synthesized nucleic acid or polypeptide or one synthesized using in vitro transcription/translation is considered “isolated.” The terms “purified” or “substantially purified” refer to an isolated nucleic acid or polypeptide that is at least 95% by weight the subject nucleic acid or polypeptide, including, for example, at least 96%, at least 97%, at least 98%, at least 99% or more. In some embodiments, the antibody, antigen-binding portion thereof, or chimeric antigen receptor (CAR) described herein is isolated. In some embodiments, the antibody, antibody reagent, antigen-binding portion thereof, or CAR described herein is purified.

[0127] Engineered: As used herein, “engineered” refers to the aspect of having been manipulated by the hand of man. For example, an antibody, antibody reagent, antigen-binding portion thereof, CAR or bispecific antibody is considered to be “engineered” when the sequence of the antibody, antibody reagent, antigen-binding portion thereof, CAR or bispecific antibody is manipulated by the hand of man to differ from the sequence of an antibody as it exists in nature. As is common practice and is understood by those in the art, progeny and copies of an engineered polynucleotide and/or polypeptide are typically still referred to as “engineered” even though the actual manipulation was performed on a prior entity.

[0128] Fragment: A “fragment” of a material or entity as described herein has a structure that includes a discrete portion of the whole, but lacks one or more moieties found in the whole. In some embodiments, a fragment consists of such a discrete portion. In some embodiments, a fragment consists of or comprises a characteristic structural element or moiety found in the whole. In some embodiments, a polymer fragment comprises or consists of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more monomeric units (e.g., residues)



as found in the whole polymer. In some embodiments, a polymer fragment comprises or consists of at least about 5%, 10%, 15%, 20%, 25%, 30%, 25%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the monomeric units (e.g., residues) found in the whole polymer. The whole material or entity may in some embodiments be referred to as the “parent” of the fragment.

[0129] Gene: As used herein, the term “gene” refers to a DNA sequence in a chromosome that codes for a product (e.g., an RNA product and/or a polypeptide product). In some embodiments, a gene includes coding sequence (i.e., sequence that encodes a particular product); in some embodiments, a gene includes non-coding sequence. In some particular embodiments, a gene may include both coding (e.g., exonic) and non-coding (e.g., intronic) sequences. In some embodiments, a gene may include one or more regulatory elements that, for example, may control or impact one or more aspects of gene expression (e.g., cell-type-specific expression, inducible expression, etc.).

[0130] Gene product or expression product: As used herein, the term “gene product” or “expression product” generally refers to an RNA transcribed from the gene (pre- and/or post-processing) or a polypeptide (pre- and/or post-modification) encoded by an RNA transcribed from the gene. In some embodiments, a gene product may be or comprise a particular processed form of an RNA transcript (e.g., a particular edited form, a particular splice form, a particular capped form, etc.).

[0131] Homology: As used herein, the term “homology” refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% similar.

[0132] Identity: As used herein, the term “identity” refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “substantially identical” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. Calculation of the percent identity of two nucleic acid or polypeptide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of a reference sequence. The nucleotides at corresponding positions are then compared. When a position in the first sequence is occupied by the same residue (e.g., nucleotide or amino acid) as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), which has been incorporated into the ALIGN program (version 2.0). In some exemplary embodiments, nucleic acid sequence comparisons made with the ALIGN program use a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.

[0133] Improve, “increase”, “inhibit” or “reduce”: As used herein, the terms “improve”, “increase”, “inhibit”, “reduce”, or grammatical equivalents thereof, indicate values that are relative to a baseline or other reference measurement. In some embodiments, an appropriate reference measurement may be or comprise a measurement in a particular system (e.g., in a single individual, a single cell, or cell population) under otherwise comparable conditions absent presence of (e.g., prior to and/or after) a particular agent or treatment, or in presence of an appropriate reference agent (e.g., a positive control agent

or a negative control agent). In some embodiments, an appropriate reference measurement may be or comprise a measurement in comparable system known or expected to respond in a particular way, in presence of the relevant agent or treatment. Those skilled in the art will appreciate that an “improvement”, “increase”, “reduction”, etc typically refers to a statistically significant change. Moreover, those skilled in the art will understand from context what magnitude of change may be relevant. For example, in some embodiments, a change may be a “fold” change—i.e., so that a “changed” value represents a 1.1, 1.2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50 or more (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1), e.g., 1.5, 1.6, 1.7, 1.8, etc.)-fold difference relative to the relevant reference. Alternatively or additionally, in some embodiments, a “change” may be a “percentage” change, so that a “changed” value represents a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% increase or decrease, including all integers and decimal points in between), relative to the relevant reference.

[0134] Linked: As used herein, the term “linked”, when used with respect to two or more moieties, means that the moieties are physically associated or connected with one another to form a molecular structure that is sufficiently stable so that the moieties remain associated under the conditions in which the linkage is formed and, preferably, under the conditions in which the new molecular structure is used, e.g., physiological conditions. In certain preferred embodiments of the invention the linkage is a covalent linkage. In other embodiments the linkage is noncovalent. Moieties may be linked either directly or indirectly. When two moieties are directly linked, they are either covalently bonded to one another or are in sufficiently close proximity such that intermolecular forces between the two moieties maintain their association. When two moieties are indirectly linked, they are each linked either covalently or noncovalently to a third moiety, which maintains the association between the two moieties. In general, when two moieties are referred to as being linked by a “linker” or “linking moiety” or “linking portion”, the linkage between the two linked moieties is indirect, and typically each of the linked moieties is covalently bonded to the linker. The linker can be any suitable moiety that reacts with the two moieties to be linked within a reasonable period of time, under conditions consistent with stability of the moieties (which may be protected as appropriate, depending upon the conditions), and in sufficient amount, to produce a reasonable yield.

[0135] Internucleotidic linkage: As used herein, the phrase “internucleotidic linkage” refers generally to the phosphorus-containing linkage between nucleotide units of an oligonucleotide, and is interchangeable with “inter-sugar linkage” and “phosphorus atom bridge,” as used above and herein. In some embodiments, an internucleotidic linkage is a phosphodiester linkage, as found in naturally occurring DNA and RNA molecules. In some embodiments, an internucleotidic linkage is a “modified internucleotidic linkage” wherein each oxygen atom of the phosphodiester linkage is optionally and independently replaced by an organic or inorganic moiety. In some embodiments, such an organic or inorganic moiety is selected from but not limited to  $=S$ ,  $=Se$ ,  $=NR'$ ,  $-SR'$ ,  $-SeR'$ ,  $-N(R')$ .sub.2,  $B(R')$ .sub.3,  $-S-$ ,  $-Se-$ , and  $-N(R')-$ , wherein each  $R'$  is independently as defined and described below. In some embodiments, an internucleotidic linkage is a phosphotriester linkage, phosphorothioate diester linkage ##STR00001##

or modified phosphorothioate triester linkage. It is understood by a person of ordinary skill in the art that the internucleotidic linkage may exist as an anion or cation at a given pH due to the existence of acid or base moieties in the linkage. In some embodiments, an internucleotide linkage may be a chiral linkage.

[0136] Long-term Administration: As used herein, the term “long-term” administration means that the therapeutic agent or drug is administered for a period of at least 12 weeks. This includes that the therapeutic agent or drug is administered such that it is effective over, or for, a period of at least 12 weeks and does not necessarily imply that the administration itself takes place for 12 weeks, e.g., if sustained release compositions or long acting therapeutic agent or drug is used. Thus, the subject is treated for a period of at least 12 weeks. In many cases, long-term administration is for at least 4, 5, 6, 7, 8, 9 months or more, or for at least 1, 2, 3, 5, 7 or 10 years, or more.

[0137] Moiety: Those skilled in the art will appreciate that a “moiety” is a defined chemical group or entity with a particular structure and/or activity, as described herein.

[0138] Nanoparticle: As used herein, the term “nanoparticle” refers to a particle having a diameter of less

than 1000 nanometers (nm). In some embodiments, a nanoparticle has a diameter of less than 300 nm, as defined by the National Science Foundation. In some embodiments, a nanoparticle has a diameter of less than 100 nm as defined by the National Institutes of Health. In some embodiments, nanoparticles are micelles in that they comprise an enclosed compartment, separated from the bulk solution by a micellar membrane, typically comprised of amphiphilic entities which surround and enclose a space or compartment (e.g., to define a lumen). In some embodiments, a micellar membrane is comprised of at least one polymer, such as for example a biocompatible and/or biodegradable polymer.

[0139] Nucleic acid: As used herein, in its broadest sense, refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. As will be clear from context, in some embodiments, “nucleic acid” refers to an individual nucleic acid residue (e.g., a nucleotide and/or nucleoside); in some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising individual nucleic acid residues. In some embodiments, a “nucleic acid” is or comprises RNA; in some embodiments, a “nucleic acid” is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone. For example, in some embodiments, a nucleic acid is, comprises, or consists of one or more “peptide nucleic acids”, which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention. Alternatively or additionally, in some embodiments, a nucleic acid has one or more phosphorothioate and/or 5'-N-phosphoramidite linkages rather than phosphodiester bonds. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxy guanosine, and deoxycytidine). In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0 (6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, a nucleic acid comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or protein. In some embodiments, a nucleic acid includes one or more introns. In some embodiments, nucleic acids are prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), reproduction in a recombinant cell or system, and chemical synthesis. In some embodiments, a nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long. In some embodiments, a nucleic acid is partly or wholly single stranded: in some embodiments, a nucleic acid is partly or wholly double stranded. In some embodiments a nucleic acid has a nucleotide sequence comprising at least one element that encodes, or is the complement of a sequence that encodes, a polypeptide. In some embodiments, a nucleic acid has enzymatic activity.

[0140] Oligonucleotide: As used herein, the term “oligonucleotide” refers to a polymer or oligomer of nucleotide monomers, containing any combination of nucleobases, modified nucleobases, sugars, modified sugars, phosphate bridges, or modified phosphorus atom bridges (also referred to herein as “internucleotidic linkage”, defined further herein). Oligonucleotides can be single-stranded or double-stranded. A single-stranded oligonucleotide can have double-stranded regions and a double-stranded oligonucleotide can have single-stranded regions. Example oligonucleotides include, but are not limited to structural genes, genes including control and termination regions, self-replicating systems such as viral or plasmid DNA, single-stranded and double-stranded siRNAs and other RNA interference reagents (RNAi agents or iRNA agents), shRNA, antisense oligonucleotides, ribozymes, microRNAs, microRNA mimics, supermirs, aptamers, antimirs, antagomirs, U1 adaptors, triplex-forming oligonucleotides, G-quadruplex

oligonucleotides, RNA activators, immunostimulatory oligonucleotides, and decoy oligonucleotides. Double-stranded and single-stranded oligonucleotides that are effective in inducing RNA interference are also referred to as siRNA, RNAi agent, or iRNA agent, herein. In some embodiments, these RNA interference inducing oligonucleotides associate with a cytoplasmic multi-protein complex known as RNAi-induced silencing complex (RISC). In many embodiments, single-stranded and double-stranded RNAi agents are sufficiently long that they can be cleaved by an endogenous molecule, e.g., by Dicer, to produce smaller oligonucleotides that can enter the RISC machinery and participate in RISC mediated cleavage of a target sequence, e.g. a target mRNA.

[0141] Operably linked: As used herein, the term “operably linked” refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control element “operably linked” to a functional element is associated in such a way that expression and/or activity of the functional element is achieved under conditions compatible with the control element. In some embodiments, “operably linked” control elements (e.g., promoters, enhancers, etc.) are contiguous (e.g., covalently linked) with the coding elements of interest: in some embodiments, control elements act in trans- or cis- with the coding functional element of interest.

[0142] Patient: As used herein, the term “patient” refers to any organism to which a provided composition (e.g., an agonizing agent such as an ASO) is or may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and/or humans). In some embodiments, a patient is a human. In some embodiments, a patient is suffering from or susceptible to one or more disorders or conditions. In some embodiments, a patient displays one or more symptoms of a disorder or condition. In some embodiments, a patient has been diagnosed with one or more disorders or conditions. In some embodiments, the disorder or condition is Alzheimer's disease or other disease characterized by neurodegeneration. In some embodiments, the disorder or condition is muscular dystrophy or other disease characterized by neuromuscular dysfunction. In some embodiments, the patient is receiving or has received certain therapy to diagnose and/or to treat a disease, disorder, or condition.

[0143] Pharmaceutical composition: As used herein, the term “pharmaceutical composition” refers to an active agent (e.g., MuSK-targeting oligonucleotide), formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue: parenteral administration, for example, by subcutaneous, intramuscular, intravenous, intraperitoneal, intrathecal, intravenous, intraventricular or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation: topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin, lungs, or oral cavity: intravaginally or intrarectally, for example, as a pessary, cream, or foam: sublingually: ocularly: transdermally: or nasally, pulmonary, and to other mucosal surfaces.

[0144] Pharmaceutically acceptable: As used herein, the phrase “pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0145] Pharmaceutically acceptable carrier: As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato

starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.

[0146] Pharmaceutically acceptable salt: The term “pharmaceutically acceptable salt”, as used herein, refers to salts of such compounds that are appropriate for use in pharmaceutical contexts, i.e., salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 66:1-19 (1977). In some embodiments, pharmaceutically acceptable salt include, but are not limited to, nontoxic acid addition salts, which are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, a provided compound comprises one or more acidic groups. e.g., an oligonucleotide, and a pharmaceutically acceptable salt is an alkali, alkaline earth metal, or ammonium (e.g., an ammonium salt of N(R)<sub>3</sub>, wherein each R is independently defined and described in the present disclosure) salt. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, a pharmaceutically acceptable salt is a sodium salt. In some embodiments, a pharmaceutically acceptable salt is a potassium salt. In some embodiments, a pharmaceutically acceptable salt is a calcium salt. In some embodiments, pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate. In some embodiments, a provided compound comprises more than one acid groups, for example, an oligonucleotide may comprise two or more acidic groups (e.g., in natural phosphate linkages and/or modified internucleotidic linkages). In some embodiments, a pharmaceutically acceptable salt, or generally a salt, of such a compound comprises two or more cations, which can be the same or different. In some embodiments, in a pharmaceutically acceptable salt (or generally, a salt), all ionizable hydrogen (e.g., in an aqueous solution with a pK<sub>a</sub> no more than about 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2; in some embodiments, no more than about 7; in some embodiments, no more than about 6; in some embodiments, no more than about 5; in some embodiments, no more than about 4; in some embodiments, no more than about 3) in the acidic groups are replaced with cations. In some embodiments, each internucleotidic linkage, e.g., phosphate group, independently exists in its salt form (e.g., if sodium salt, —O—P(O)(ONa)—O—). In some embodiments, a pharmaceutically acceptable salt is a sodium salt of an oligonucleotide. In some embodiments, a pharmaceutically acceptable salt is a sodium salt of an oligonucleotide, wherein each acidic phosphate and modified phosphate group, if any, exists as a salt form (all sodium salt).

[0147] Polypeptide: As used herein, the term “polypeptide,” which is interchangeably used herein with the term “protein,” refers to a polymer of at least three amino acid residues. In some embodiments, a polypeptide comprises one or more, or all, natural amino acids. In some embodiments, a polypeptide comprises one or more, or all non-natural amino acids. In some embodiments, a polypeptide comprises

one or more, or all, D-amino acids. In some embodiments, a polypeptide comprises one or more, or all, L-amino acids. In some embodiments, a polypeptide comprises one or more pendant groups or other modifications, e.g., modifying or attached to one or more amino acid side chains, at the polypeptide's N-terminus, at the polypeptide's C-terminus, or any combination thereof. In some embodiments, a polypeptide comprises one or more modifications such as acetylation, amidation, aminoethylation, biotinylation, carbamylation, carbonylation, citrullination, deamidation, deimination, eliminylation, glycosylation, lipidation, methylation, pegylation, phosphorylation, sumoylation, or combinations thereof. In some embodiments, a polypeptide may participate in one or more intra- or inter-molecular disulfide bonds. In some embodiments, a polypeptide may be cyclic, and/or may comprise a cyclic portion. In some embodiments, a polypeptide is not cyclic and/or does not comprise any cyclic portion. In some embodiments, a polypeptide is linear. In some embodiments, a polypeptide may comprise a stapled polypeptide. In some embodiments, a polypeptide participates in non-covalent complex formation by non-covalent or covalent association with one or more other polypeptides (e.g., as in an antibody). In some embodiments, a polypeptide has an amino acid sequence that occurs in nature. In some embodiments, a polypeptide has an amino acid sequence that does not occur in nature. In some embodiments, a polypeptide has an amino acid sequence that is engineered in that it is designed and/or produced through action of the hand of man. In some embodiments, the term "polypeptide" may be appended to a name of a reference polypeptide, activity, or structure: in such instances it is used herein to refer to polypeptides that share the relevant activity or structure and thus can be considered to be members of the same class or family of polypeptides. For each such class, the present specification provides and/or those skilled in the art will be aware of exemplary polypeptides within the class whose amino acid sequences and/or functions are known: in some embodiments, such exemplary polypeptides are reference polypeptides for the polypeptide class or family. In some embodiments, a member of a polypeptide class or family shows significant sequence homology or identity with, shares a common sequence motif (e.g., a characteristic sequence element) with, and/or shares a common activity (in some embodiments at a comparable level or within a designated range) with a reference polypeptide of the class: in some embodiments with all polypeptides within the class). For example, in some embodiments, a member polypeptide shows an overall degree of sequence homology or identity with a reference polypeptide that is at least about 30-40%, and is often greater than about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more and/or includes at least one region (e.g., a conserved region that may in some embodiments comprise a characteristic sequence element) that shows very high sequence identity: often greater than 90% or even 95%, 96%, 97%, 98%, or 99%. Such a conserved region usually encompasses at least 3-4 and often up to 20 or more amino acids: in some embodiments, a conserved region encompasses at least one stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids. In some embodiments, a useful polypeptide may comprise a fragment of a parent polypeptide. In some embodiments, a useful polypeptide as may comprise a plurality of fragments, each of which is found in the same parent polypeptide in a different spatial arrangement relative to one another than is found in the polypeptide of interest (e.g., fragments that are directly linked in the parent may be spatially separated in the polypeptide of interest or vice versa, and/or fragments may be present in a different order in the polypeptide of interest than in the parent), so that the polypeptide of interest is a derivative of its parent polypeptide. In some embodiments, the polypeptide described herein (or a nucleic acid encoding such a polypeptide) can be a functional fragment of one of the amino acid sequences described herein. As used herein, a "functional fragment" is a fragment or segment of a peptide which retains at least 50% of the wildtype reference polypeptide's activity according to the assays described below herein. A functional fragment can comprise conservative substitutions of the sequences disclosed herein. In some embodiments, the polypeptide described herein can be a variant of a sequence described herein. In some embodiments, the variant is a conservatively modified variant. Conservative substitution variants can be obtained by mutations of native nucleotide sequences, for example. A "variant," as referred to herein, is a polypeptide substantially homologous to a native or reference polypeptide, but which has an amino acid sequence different from that of the native or reference polypeptide because of one or a plurality of deletions, insertions or substitutions. Variant polypeptide-encoding DNA sequences encompass sequences that comprise one or more additions, deletions, or substitutions of nucleotides when compared to a native or reference DNA sequence, but that encode a variant protein or fragment thereof that retains activity. A

wide variety of PCR-based site-specific mutagenesis approaches are known in the art and can be applied by the ordinarily skilled artisan. In the various embodiments described herein, it is further contemplated that variants (naturally occurring or otherwise), alleles, homologs, conservatively modified variants, and/or conservative substitution variants of any of the particular polypeptides described are encompassed. As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid and retains the desired activity of the polypeptide. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles consistent with the disclosure.

[0148] Prevent or prevention: as used herein when used in connection with the occurrence of a disease, disorder, and/or condition, refers to reducing the risk of developing the disease, disorder and/or condition and/or to delaying onset of one or more characteristics or symptoms of the disease, disorder or condition. Prevention may be considered complete when onset of a disease, disorder or condition has been delayed for a predefined period of time.

[0149] Recombinant: As used herein, the term “recombinant” is intended to refer to polypeptides that are designed, engineered, prepared, expressed, created, manufactured, and/or or isolated by recombinant means, such as polypeptides expressed using a recombinant expression vector transfected into a host cell: polypeptides isolated from a recombinant, combinatorial human polypeptide library: polypeptides isolated from an animal (e.g., a mouse, rabbit, sheep, fish, etc.) that is transgenic for or otherwise has been manipulated to express a gene or genes, or gene components that encode and/or direct expression of the polypeptide or one or more component(s), portion(s), element(s), or domain(s) thereof; and/or polypeptides prepared, expressed, created or isolated by any other means that involves splicing or ligating selected nucleic acid sequence elements to one another, chemically synthesizing selected sequence elements, and/or otherwise generating a nucleic acid that encodes and/or directs expression of the polypeptide or one or more component(s), portion(s), element(s), or domain(s) thereof. In some embodiments, one or more of such selected sequence elements is found in nature. In some embodiments, one or more of such selected sequence elements is designed in silico. In some embodiments, one or more such selected sequence elements results from mutagenesis (e.g., in vivo or in vitro) of a known sequence element, e.g., from a natural or synthetic source such as, for example, in the germline of a source organism of interest (e.g., of a human, a mouse, etc.).

[0150] Small molecule: As used herein, the term “small molecule” means a low molecular weight organic and/or inorganic compound. In general, a “small molecule” is a molecule that is less than about 5 kilodaltons (KD) in size. In some embodiments, a small molecule is less than about 4 kD, 3 kD, about 2 kD, or about 1 kD. In some embodiments, the small molecule is less than about 800 daltons (D), about 600 D, about 500 D, about 400 D, about 300 D, about 200 D, or about 100 D. In some embodiments, a small molecule is less than about 2000 g/mol, less than about 1500 g/mol, less than about 1000 g/mol, less than about 800 g/mol, or less than about 500 g/mol. In some embodiments, a small molecule is not a polymer. In some embodiments, a small molecule does not include a polymeric moiety. In some embodiments, a small molecule is not and/or does not comprise a protein or polypeptide (e.g., is not an oligopeptide or peptide). In some embodiments, a small molecule is not and/or does not comprise a polynucleotide (e.g., is not an oligonucleotide). In some embodiments, a small molecule is not and/or does not comprise a polysaccharide: for example, in some embodiments, a small molecule is not a glycoprotein, proteoglycan, glycolipid, etc.). In some embodiments, a small molecule is not a lipid. In some embodiments, a small molecule is a modulating agent (e.g., is an inhibiting agent or an activating agent). In some embodiments, a small molecule is biologically active. In some embodiments, a small molecule is detectable (e.g., comprises at least one detectable moiety). In some embodiments, a small molecule is a therapeutic agent. Those of ordinary skill in the art, reading the present disclosure, will appreciate that certain small molecule compounds described herein may be provided and/or utilized in any of a variety of forms such as, for example, crystal forms, salt forms, protected forms, pro-drug forms, ester forms, isomeric forms (e.g., optical and/or structural isomers), isotopic forms, etc. Those of skill in the art will appreciate that certain small molecule compounds have structures that can exist in one or more stereoisomeric forms. In some embodiments, such a small molecule may be utilized in accordance with the present disclosure in the form

of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers: in some embodiments, such a small molecule may be utilized in accordance with the present disclosure in a racemic mixture form. Those of skill in the art will appreciate that certain small molecule compounds have structures that can exist in one or more tautomeric forms. In some embodiments, such a small molecule may be utilized in accordance with the present disclosure in the form of an individual tautomer, or in a form that interconverts between tautomeric forms. Those of skill in the art will appreciate that certain small molecule compounds have structures that permit isotopic substitution (e.g., <sup>2</sup>H or <sup>3</sup>H for H; <sup>11</sup>C, <sup>13</sup>C or <sup>14</sup>C for <sup>12</sup>C; <sup>13</sup>N or <sup>15</sup>N for <sup>14</sup>N; <sup>17</sup>O or <sup>18</sup>O for <sup>16</sup>O; <sup>36</sup>Cl for <sup>35</sup>Cl; <sup>18</sup>F for <sup>19</sup>F; <sup>131</sup>I for <sup>127</sup>I; etc). In some embodiments, such a small molecule may be utilized in accordance with the present disclosure in one or more isotopically modified forms, or mixtures thereof. In some embodiments, reference to a particular small molecule compound may relate to a specific form of that compound. In some embodiments, a particular small molecule compound may be provided and/or utilized in a salt form (e.g., in an acid-addition or base-addition salt form, depending on the compound): in some such embodiments, the salt form may be a pharmaceutically acceptable salt form. In some embodiments, where a small molecule compound is one that exists or is found in nature, that compound may be provided and/or utilized in accordance in the present disclosure in a form different from that in which it exists or is found in nature. Those of ordinary skill in the art will appreciate that, in some embodiments, a preparation of a particular small molecule compound that contains an absolute or relative amount of the compound, or of a particular form thereof, that is different from the absolute or relative (with respect to another component of the preparation including, for example, another form of the compound) amount of the compound or form that is present in a reference preparation of interest (e.g., in a primary sample from a source of interest such as a biological or environmental source) is distinct from the compound as it exists in the reference preparation or source. Thus, in some embodiments, for example, a preparation of a single stereoisomer of a small molecule compound may be considered to be a different form of the compound than a racemic mixture of the compound: a particular salt of a small molecule compound may be considered to be a different form from another salt form of the compound; a preparation that contains only a form of the compound that contains one conformational isomer ((Z) or (E)) of a double bond may be considered to be a different form of the compound from one that contains the other conformational isomer ((E) or (Z)) of the double bond: a preparation in which one or more atoms is a different isotope than is present in a reference preparation may be considered to be a different form: etc.

[0151] Specific binding: As used herein, the term “specific binding” refers to an ability to discriminate between possible binding partners in the environment in which binding is to occur. A binding agent that interacts with one particular target when other potential targets are present is said to “bind specifically” to the target (e.g., a target amino acid or nucleic acid sequence on a target protein/gene of interest) with which it interacts. In some embodiments, specific binding is assessed by detecting or determining degree of association between the binding agent and its partner: in some embodiments, specific binding is assessed by detecting or determining degree of dissociation of a binding agent-partner complex: in some embodiments, specific binding is assessed by detecting or determining ability of the binding agent to compete an alternative interaction between its partner and another entity. In some embodiments, specific binding is assessed by performing such detections or determinations across a range of concentrations.

[0152] Specificity: As is known in the art, “specificity” is a measure of the ability of a particular ligand to distinguish its binding partner from other potential binding partners.

[0153] Subject: As used herein, the term “subject” refers an organism, typically a mammal (e.g., a human, in some embodiments including prenatal human forms). In some embodiments, a subject is suffering from a relevant disease, disorder or condition (e.g., Alzheimer's disease (AD), muscular dystrophy or other disease characterized by neurodegeneration or neuromuscular dysfunction). In some embodiments, a subject is susceptible to a disease, disorder, or condition. In some embodiments, a subject displays one or more symptoms or characteristics of a disease, disorder or condition. In some embodiments, a subject does not display any symptom or characteristic of a disease, disorder, or condition. In some embodiments, a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition. In some embodiments, a subject is a patient. In some embodiments, a subject is an individual to whom diagnosis and/or therapy is and/or has been administered.



[0154] Substantially: As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[0155] Substantial identity: as used herein refers to a comparison between amino acid or nucleic acid sequences. As will be appreciated by those of ordinary skill in the art, two sequences are generally considered to be “substantially identical” if they contain identical residues in corresponding positions. As is well known in this art, amino acid or nucleic acid sequences may be compared using any of a variety of algorithms, including those available in commercial computer programs such as BLASTN for nucleotide sequences and BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences. Exemplary such programs are described in Altschul et al., Basic local alignment search tool, J. Mol. Biol., 215 (3): 403-410, 1990; Altschul et al., Methods in Enzymology: Altschul et al., Nucleic Acids Res. 25:3389-3402, 1997; Baxevanis et al., Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener, et al, (eds.), Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol. 132), Humana Press, 1999. In addition to identifying identical sequences, the programs mentioned above typically provide an indication of the degree of identity. In some embodiments, two sequences are considered to be substantially identical if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are identical over a relevant stretch of residues. In some embodiments, the relevant stretch is a complete sequence. In some embodiments, the relevant stretch is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more residues.

[0156] Suffering from: An individual who is “suffering from” a disease, disorder, and/or condition (e.g., muscular dystrophy or other disease characterized by neuromuscular dysfunction) has been diagnosed with and/or displays one or more symptoms of a disease, disorder, and/or condition.

[0157] Susceptible to: An individual who is “susceptible to” a disease, disorder, and/or condition (e.g., Alzheimer's disease (AD), muscular dystrophy or other disease characterized by neurodegeneration or neuromuscular dysfunction) is one who has a higher risk of developing the disease, disorder, and/or condition than does a member of the general public. In some embodiments, an individual who is susceptible to a disease, disorder and/or condition may not have been diagnosed with the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may not exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.

[0158] Symptoms are reduced: According to the present invention, “symptoms are reduced” when one or more symptoms of a particular disease, disorder or condition (e.g., Alzheimer's disease (AD), muscular dystrophy or other disease characterized by neurodegeneration or neuromuscular dysfunction) is reduced in magnitude (e.g., intensity, severity, etc.) and/or frequency. For purposes of clarity, a delay in the onset of a particular symptom is considered one form of reducing the frequency of that symptom.

[0159] Target gene: A “target gene”, as used herein, refers to a gene whose expression is to be modulated, e.g., through modifying splice activity (e.g., by inducing exon-skipping). As used herein, the term “target portion” or “target region” refers to a contiguous portion of the nucleotide sequence of a target gene. In some embodiments, a target portion or target region is one or more exons within the target gene sequence. A target portion may be from about 8-36 nucleotides in length, e.g., about 10-20 or about 15-30 nucleotides in length. A target portion length may have specific value or subrange within the aforementioned ranges. For example, in certain embodiments a target portion may be between about 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-

23, 19-22, 19-21, 19-20, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length.

[0160] Therapeutic agent: As used herein, the phrase “therapeutic agent” refers to any agent that, when administered to a subject, has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and/or reduce incidence of one or more symptoms or features of a disease, disorder, and/or condition (e.g., one or more symptoms or features of Alzheimer's disease (AD), muscular dystrophy or other disease characterized by neurodegeneration or neuromuscular dysfunction).

[0161] Therapeutically effective amount: As used herein, the term “therapeutically effective amount” means an amount of a substance (e.g., a therapeutic agent, composition, and/or formulation) that elicits a desired biological response when administered as part of a therapeutic dosing regimen. In some embodiments, a therapeutically effective amount of a substance is an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the disease, disorder, and/or condition. As will be appreciated by those of ordinary skill in this art, the effective amount of a substance may vary depending on such factors as the desired biological endpoint, the substance to be delivered, the target cell or tissue, etc. It will be appreciated that there will be many ways known in the art to determine the effective amount for a given application. For example, the pharmacological methods for dosage determination may be used in the therapeutic context. In the context of therapeutic or prophylactic applications, the amount of a composition administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. For example, the effective amount of compound in a formulation to treat a disease, disorder, and/or condition is the amount that alleviates, ameliorates, relieves, inhibits, prevents, delays onset of, reduces severity of and/or reduces incidence of one or more symptoms or features of the disease, disorder, and/or condition. As used herein, the terms “effective amount” and “therapeutically-effective amount” include an amount sufficient to prevent or ameliorate a manifestation of disease or medical condition, such as Alzheimer's disease (AD), Parkinson's disease, or another disease characterized by neurodegeneration, reduced mobility, metabolism, and quality of life resulting from muscle wasting in cancer patients, elderly patients, and many others with no history of neuromuscular dysfunction, in addition to muscular dystrophies such as Becker, Congenital, Distal, Duchenne, Emery-Dreifuss, Facioscapulohumeral, Limb-girdle, Myotonic. Oculopharyngeal Muscular Dystrophy: It will be appreciated that there will be many ways known in the art to determine the effective amount for a given application. For example, the pharmacological methods for dosage determination may be used in the therapeutic context. In the context of therapeutic or prophylactic applications, the amount of a composition administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. The compositions can also be administered in combination with one or more additional therapeutic compounds. In some embodiments, a therapeutically effective amount is administered in a single dose: in some embodiments, multiple unit doses are required to deliver a therapeutically effective amount.

[0162] Treating: As used herein, the term “treating” refers to providing treatment. i.e., providing any type of medical or surgical management of a subject. The treatment can be provided in order to reverse, alleviate, inhibit the progression of, prevent or reduce the likelihood of a disease, disorder, or condition, or in order to reverse, alleviate, inhibit or prevent the progression of, prevent or reduce the likelihood of one or more symptoms or manifestations of a disease, disorder or condition. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of the deficit, stabilized (i.e., not worsening) state of a muscular dystrophy, delay or slowing of muscle wasting, and an increased lifespan as compared to that expected in the absence of treatment. Treating can include administering an agent to the subject following the development of one or more symptoms or manifestations indicative of Alzheimer's disease (AD), muscular dystrophy or other disease characterized

by neurodegeneration or neuromuscular dysfunction, e.g., in order to reverse, alleviate, reduce the severity of, and/or inhibit or prevent the progression of the condition and/or to reverse, alleviate, reduce the severity of, and/or inhibit or one or more symptoms or manifestations of the condition. A composition of the disclosure can be administered to a subject who has developed Alzheimer's disease, muscular dystrophy or other disease characterized by neurodegeneration, neuromuscular dysfunction or is at increased risk of developing such a disorder relative to a member of the general population. A composition of the disclosure can be administered prophylactically, i.e., before development of any symptom or manifestation of the condition. Typically in this case the subject will be at risk of developing the condition.

[0163] Variant: As used herein in the context of molecules, e.g., nucleic acids (e.g., ASOs), proteins, or small molecules, the term “variant” refers to a molecule that shows significant structural identity with a reference molecule but differs structurally from the reference molecule, e.g., in the presence or absence or in the level of one or more chemical moieties as compared to the reference entity. In some embodiments, a variant also differs functionally from its reference molecule. In general, whether a particular molecule is properly considered to be a “variant” of a reference molecule is based on its degree of structural identity with the reference molecule. As will be appreciated by those skilled in the art, any biological or chemical reference molecule has certain characteristic structural elements. A variant, by definition, is a distinct molecule that shares one or more such characteristic structural elements but differs in at least one aspect from the reference molecule. To give but a few examples, a polypeptide may have a characteristic sequence element comprised of a plurality of amino acids having designated positions relative to one another in linear or three-dimensional space and/or contributing to a particular structural motif and/or biological function: a nucleic acid may have a characteristic sequence element comprised of a plurality of nucleotide residues having designated positions relative to one another in linear or three-dimensional space. In some embodiments, a variant polypeptide or nucleic acid may differ from a reference polypeptide or nucleic acid as a result of one or more differences in amino acid or nucleotide sequence and/or one or more differences in chemical moieties (e.g., carbohydrates, lipids, phosphate groups) that are covalently components of the polypeptide or nucleic acid (e.g., that are attached to the polypeptide or nucleic acid backbone). In some embodiments, a variant polypeptide or nucleic acid shows an overall sequence identity with a reference polypeptide or nucleic acid that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 99%. In some embodiments, a variant polypeptide or nucleic acid does not share at least one characteristic sequence element with a reference polypeptide or nucleic acid. In some embodiments, a reference polypeptide or nucleic acid has one or more biological activities. In some embodiments, a variant polypeptide or nucleic acid shares one or more of the biological activities of the reference polypeptide or nucleic acid. In some embodiments, a variant polypeptide or nucleic acid lacks one or more of the biological activities of the reference polypeptide or nucleic acid. In some embodiments, a variant polypeptide or nucleic acid shows a reduced level of one or more biological activities as compared to the reference polypeptide or nucleic acid. In some embodiments, a polypeptide or nucleic acid of interest is considered to be a “variant” of a reference polypeptide or nucleic acid if it has an amino acid or nucleotide sequence that is identical to that of the reference but for a small number of sequence alterations at particular positions. Typically, fewer than about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, or about 2% of the residues in a variant are substituted, inserted, or deleted, as compared to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 substituted residues as compared to a reference. Often, a variant polypeptide or nucleic acid comprises a very small number (e.g., fewer than about 5, about 4, about 3, about 2, or about 1) number of substituted, inserted, or deleted, functional residues (i.e., residues that participate in a particular biological activity) relative to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises not more than about 5, about 4, about 3, about 2, or about 1 addition or deletion, and, in some embodiments, comprises no additions or deletions, as compared to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and commonly fewer than about 5, about 4, about 3, or about 2 additions or deletions as compared to the reference. In some embodiments, a reference polypeptide or nucleic acid is one found in nature. In some embodiments, a reference polypeptide or nucleic acid is a human polypeptide or nucleic acid.

[0164] Vector: As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “expression vectors”. Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference for any purpose.

#### DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

##### Neurogenesis

[0165] Neurogenesis occurs in distinct regions of the adult mammalian brain. Neural stem cells (NSCs) are the endogenous source of new neurons and are active throughout life in virtually all mammals, including humans (Eriksson et al., 1998; Ernst et al., 2014; Moreno-Jiménez et al., 2019; Spalding et al., 2013). Extensive work in rodent models shows that neurogenesis supports learning and memory, sensory functions, and mood regulation (Enwere et al., 2004; Gage, 2019; Imayoshi et al., 2008; Zhang et al., 2008b). NSCs reside in two neurogenic niches: the subgranular zone (SGZ) in the dentate gyrus of the hippocampus and the subventricular zone (SVZ) lining the lateral ventricles. NSCs in the SVZ generate astrocytes and oligodendrocytes that support the existing circuitry as well as neurons in the olfactory bulb that are critical for olfactory discrimination. NSCs in the dentate gyrus give rise to granule neurons important for learning and memory. The majority of NSCs in the human brain are located in the hippocampus. Most hippocampal NSCs reside in a state of dormancy, termed quiescence. For neurogenesis to occur, quiescent NSCs must become activated in response to extrinsic or intrinsic cues. Newly born neurons functionally integrate into the local circuitry within the hippocampus and contribute to cognitive functions. The capacity of quiescent NSCs to activate declines during healthy and pathological aging and this loss precedes the decline in cognition (Enwere et al. 2004; Giachino et al. 2014; Capilla-Gonzalez et al. 2014).

[0166] Recent work indicates that endogenous or exogenous NSCs may be a valuable source of new neurons for the millions of individuals suffering from cognitive decline or brain injury. Activation of endogenous NSCs through exercise, re-feeding, or young blood improves age-related cognitive impairments in mice (Brandhorst et al., 2015; van Praag et al., 2005; Villeda et al., 2011, 2014). Accumulation of negative signals that degrade the neurogenic niche may contribute to reduction in newborn neurons in aging and AD. However, it has been difficult to harness the neurogenic potential of NSCs due to the lack of a specific therapeutic target that has the ability to overcome inhibitory signals. The present disclosure appreciates that recent mechanistic studies suggest that BMP signaling may represent a promising pathway to target in the context of AD and other diseases characterized by neurodegeneration. BMPs negatively regulate activation of NSCs (Mira et al., 2010) and are upregulated in AD and APP transgenic mice (Crews et al., 2010). The present disclosure provides technologies to specifically modulate BMP signaling in the neurogenic niche.

##### Adult Hippocampal Neurogenesis

[0167] Adult Hippocampal Neurogenesis (AHN) is critical for normal learning and memory: AHN is abundant in healthy aged humans but is reduced from the earliest stages of Alzheimer's Disease (AD). AHN occurs throughout life in humans and is dramatically reduced in AD (Moreno-Jimenez et al., 2019; Steiner et al., 2019). Work in animal models has underscored the role of AHN in improving cognition in the face of AD pathology. Thus, restoring AHN may be an attractive target for an AD therapy:

Interventions that promote adult hippocampal neurogenesis could enhance cognitive function and combat neurodegeneration.

[0168] AHN is critical for learning and memory. Newborn dentate granule cells are hyperexcitable and exhibit robust synaptic plasticity. Thus, dysregulation of the quiescent state and/or a failure to integrate into the mature circuitry are thought to contribute to the age-associated decline in neurogenesis and cognitive performance in aging and dementia.

[0169] AHN in Humans. Although AHN has been established in rodents and other species for decades, the existence of this process in human has been controversial until quite recently. Reports using BrdU incorporation (Eriksson et al., 1998), <sup>14</sup>C dating (Ernst et al., 2014; Spalding et al., 2013) and markers of immature neuron (Boldrini et al., 2018; Moreno-Jiménez et al., 2019; Tobin et al., 2019) have provided independent lines of support from multiple labs supporting human AHN. Mathematical modeling of radiocarbon birth dating data yielded estimates that in humans 35% of hippocampal neurons are replaced by newborn neurons during adulthood at a rate of 1.75% per year (Spalding et al., 2013). On the other hand, another recent report using markers for immature neurons failed to detect significant levels of AHN in adult humans (Sorrells et al., 2018). In depth comparison of these reports have revealed several methodological and sample differences that seem likely to explain the failure to detect adult neurogenesis in the Sorrells et al., paper (Kempermann et al., 2018; Lucassen et al., 2019).

[0170] AHN and Alzheimer's Disease. Alzheimer's Disease is a devastating disorder. It is progressive, fatal and has an enormous societal and economic cost. 5.8 million Americans are living with AD. By 2050 this number is projected to rise to 14M. In 2019, AD and other dementias cost the nation \$290 billion. By 2050, these costs could rise as high as \$1.1 trillion. There are no effective treatments. There have been several recent high profile drug trials. Almost all of these trails have been based upon the 'amyloid hypothesis'. There is an enormous unmet need for innovative and effective therapies for AD. Alzheimer's Disease devastates the hippocampus, a brain region necessary for encoding memories. The hippocampus is one of the two sites of adult neurogenesis in the brain. A large number of animal studies have shown that these adult-born neurons are necessary for learning and memory. A recent crucial study provided convincing evidence for robust neurogenesis in the adult human brain. Importantly, the level of adult neurogenesis in AD brain is greatly diminished compared to age-matched controls. (See E. P. Moreno-Jimenez et al. Nature Med. <https://doi.org/10.1038/s41591-019-0375-9>; 2019; See also related Editorial in Nature 567:433; 28 Mar. 2019). Thus, promoting adult neurogenesis is emerging as a highly attractive target in treating AD.

[0171] The hippocampus is one of the earliest and most affected brain regions in AD and its atrophy is a hallmark of disease progression (Allison et al., 2019). Moreover, work in both rodents and humans has demonstrated that hippocampal-dependent learning is impaired in the Alzheimer's setting (Crews et al., 2010). Notably, AHN levels in AD patients are only 30% of those observed in age-matched controls (Moreno-Jiménez et al., 2019). Critically, a recent mouse study using genetically diverse AD mouse models showed that the total number of hippocampal neurons (NeuN+cells) correlates with cognition (Neuner Neuron 2019). Finally, a recent study has shown that exercise-mediated rescue of pathology in AD mice requires AHN, and that AHN ablation alone exacerbates cognitive defects in these mice (Choi et al., 2018). Thus, strategies to compensate for the degeneration of hippocampal neurons through enhancing endogenous neurogenesis have the potential to open a new pathway for treating Alzheimer's disease.

[0172] Other diseases associated with impaired AHN include e.g., diseases and disorders associated with progressive memory loss, such as Frontotemporal Dementia (Terrerros-Roncal et al., 2019), stroke (Lindvall et al., 2015). Impaired AHN is also associated with psychiatric disorders such as major depressive disorder (MDD), bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), substance-related and addictive disorders (Yun et al., 2016), and other diseases such as Temporal-Lobe Epilepsy (Cook et al., 1992), Hippocampal Sclerosis (Tai et al. 2018), Niemann Pick Type C (Hong et al., 2015), and Diabetes-mediated hippocampal neuronal loss (Ho et al, 2013; Gold et al., 2007).

#### Subventricular Zone Neurogenesis

[0173] In addition to the hippocampus (i.e., the subgranular zone (SGZ) in the dentate gyrus of the hippocampus), NSCs reside in the subventricular zone (SVZ) lining the lateral ventricles. NSCs in the SVZ generate astrocytes and oligodendrocytes that support the existing circuitry as well as neurons in the olfactory bulb that are critical for olfactory discrimination. Recent evidence suggests that SVZ NSCs can

give rise to terminally differentiated neurons in the striatum in response to ischemic stroke or neurodegenerative diseases (Arvidsson et al. 2002; Parent et al. 2002; Thored et al. 2006; Ernst et al. 2014).

[0174] The present disclosure recognizes that strategies to compensate for the degeneration of neurons in the SVZ through enhancing endogenous neurogenesis have the potential to open a new pathway for treating diseases specifically associated with striatal neurogenesis such as Parkinson's disease (which could benefit both from increasing AHN and striatal neurogenesis in the SVZ: Pitcher et al. 2012; Sterling et al. 2013) and Huntington's disease (Sassone et al., 2018). Other diseases including addiction (e.g., chronic cocaine use and lifelong cigarette smoking) are also associated with reduced striatal volume (Barros-Loscertales et al. 2011; Das et al., 2012) and have the potential to be treated through enhancing endogenous neurogenesis in the SVZ.

#### MuSK and Neurogenesis

[0175] MuSK is a receptor tyrosine kinase comprised extracellularly of three Ig and one CRD/Fz domain and an intracellular tyrosine domain (TK: FIG. 1). The best understood function of MuSK is at the neuromuscular junction (NMJ) where agrin-LRP4 binding to the Ig1 domain triggers MuSK TK activity and synapse differentiation (Kim et al., 2008; Zhang et al., 2008a).

[0176] The MuSK-BMP Pathway. The brain harbors neural stem cells (NSCs) that generate neurons and glial cells throughout life (Moreno-Jiménez et al., 2019; Steiner et al., 2019). BMPs regulate at least two important NSC decision points: 1) quiescence, where proliferating stem cells exit the cell cycle and return to replenish a reserve pool that can supply fresh stem cells; and: 2) differentiation into mature progeny (Mira et al., 2010). The present disclosure contemplates that manipulating the BMP pathway in NSCs is an attractive target for regulating neurogenesis in the adult brain.

[0177] It was recently discovered that MuSK is also a BMP co-receptor that binds BMP and its receptors ALK3 and 6, upregulates BMP signaling and shapes the composition of the transcriptional response in myogenic cells (Yilmaz et al., 2016). This BMP signaling pathway neither regulates nor requires MuSK TK activity nor is it activated by agrin-LRP4. Importantly, the MuSK Ig3 domain is necessary for high affinity BMP binding but is dispensable for agrin-LRP4 TK activation. Moreover, the Ig3 domain is endogenously alternatively spliced, including in the brain (Garcia-Osta et al., 2006; Hesser et al., 1999). Since BMP signaling induces NSC quiescence and can inhibit integration of newborn neurons we have found that restraining BMP drive by reducing MuSK-BMP signaling could increase neurogenesis (FIG. 1).

[0178] Yilmaz et al. 2016 discloses that the 'Ig3' domain of MuSK is required for high affinity binding of BMPs. The major species of MuSK expressed endogenously is full length. This Ig3 domain can be alternatively spliced endogenously, creating an isoform termed "Δg3MuSK". This splicing entails the coordinated removal of exons 6 and 7 from the MuSK pre-mRNA.

[0179] Exemplary amino acid sequences of human and mouse MuSK Ig3 domains (i.e., of MuSK Ig3 domain polypeptides) are as set out below:

TABLE-US-00003 MuSK HUMAN\_Ig3\_Domain: (SEQ ID NO: 116)

ARILRAPESHNVTFGSFVTLHCTATGIPVPTITWIENGNAVSSGSIQES

VKDRVIDSRLQLFITKPGLYTCIATNKHGEKFSTAKAAATIS MuSK MOUSE Ig3 Domain

(SEQ ID NO: 117) ARILRAPESHNVTFGSFVTLRCTAIGIPVPTISWIENGNAVSSGSIQES

VKDRVIDSRLQLFITKPGLYTCIATNKHGEKFSTAKAAATVS

[0180] Among other things, the present disclosure provides compositions such as MuSK-targeting oligonucleotides that regulate MuSK alternative splicing as a strategy for increasing AHN in AD.

#### MuSK and Muscle Regeneration and/or Growth

[0181] Satellite cells account for about 5% of muscle nuclei and are distributed along mature, multinucleated myofibers, usually in a state of quiescence. When muscle is injured, satellite cells usually proliferate before either returning to quiescence or differentiating. Upon differentiation, satellite cells become committed myoblasts that fuse into myotubes, eventually forming mature myofibers in a process termed myogenesis. Bone morphogenetic protein (BMP) signaling regulates satellite cell dynamics and muscle regeneration both in vivo and in vitro by modulating transcriptional outputs. BMP signaling is not detectable in quiescent satellite cells, it is upregulated in proliferating satellite cells, and it is downregulated during differentiation. However, mediators regulating the balance between satellite cell proliferation and differentiation are unknown.

[0182] Muscle-Specific Kinase (MuSK), also known as Muscle-Associated Receptor Tyrosine Kinase, is a transmembrane protein that was first recognized for its essential role in the formation and maintenance of the neuromuscular junction (NMJ). MuSK has three extracellular Immunoglobulin (Ig)-like domains and a cysteine-rich frizzled (CRD/Fz) domain, as well as an intracellular tyrosine kinase (TK) domain. The Ig1, TK and potentially the CRD/Fz domains are required for NMJ formation and maintenance. The Ig1 and TK domains are essential for agrin-LRP4 signaling directing synaptic differentiation. For this reason, global deletion MuSK mice are neo-natal lethal. Two isoforms of MuSK that exist in vivo are: full-length (FL) MuSK and a naturally-occurring splice variant that lacks the Ig3 domain ( $\Delta$ Ig3-MuSK). FL MuSK mRNA levels are 10 $\times$  higher than mRNA of  $\Delta$ Ig3-MuSK but the two are expressed coordinately.

[0183] Among other things, the present disclosure provides compositions such as MuSK-targeting oligonucleotides that regulate MuSK alternative splicing as a strategy for increasing muscle regeneration.

[0184] MuSK is activated by a nerve-derived proteoglycan called agrin. Agrin has been characterized for its role in the development of the neuromuscular junction during embryogenesis. Agrin is named based on its involvement in the aggregation of acetylcholine receptors during synaptogenesis. In humans, this protein is encoded by the AGRN gene. The agrin protein has nine domains homologous to protease inhibitors.

[0185] MuSK is expressed in muscle and is upregulated during muscle regeneration. Data suggest that MuSK is implicated in BMP signaling in myogenesis. MuSK can act as a BMP co-receptor that binds BMP2, BMP4, and BMP7 as well as the Type I BMP receptors ALK3 and ALK6. See, for example, Yilmaz et al., *Sci. Signal.* 9:ra87, doi: 10.1126/scisignal.aaf0890, 2016, incorporated herein by reference. The Ig3 domain of MuSK is required for high-affinity binding to BMP. MuSK upregulates BMP signaling as measured by BMP4-dependent phosphorylation of SMAD1/5/8. Importantly, MuSK-BMP signaling shapes the magnitude and composition of BMP-induced transcriptome in myoblasts and myotubes and this role is independent of any MuSK tyrosine kinase activity. MuSK is a BMP co-receptor that potentiates BMP signaling and regulates myogenic factors, such as myogenic factor 5 (Myf5), in immortalized myogenic cells.

[0186] Activated satellite cells express MuSK protein and disruption of MuSK-BMP signaling alters satellite cell proliferation in regenerating muscle in vivo. Additionally, previous studies have suggested the role of the MuSK-BMP pathway in satellite cells and muscle regeneration and that targeting MuSK-BMP pathway enhances muscle growth (see e.g., PCT Publication No. WO 2021/076883, which is incorporated by reference herein).

#### MuSK-Targeting Oligonucleotides

[0187] As described herein, a strategy for regulating the MuSK-BMP pathway includes MuSK-targeting oligonucleotides (e.g., MuSK Ig3 targeting oligonucleotides). Specifically, the disclosure provides, among other things, oligonucleotides and compositions thereof that target regions spanning exon 6 and/or exon 7 of MuSK to induce exon-skipping of exon 6 and/or exon 7. Such alternative splicing activity leads to an increased expression of  $\Delta$ Ig3-MuSK.

[0188] The present disclosure also describes regions within the MuSK transcript at or near exon 6 and/or exon 7 that are particularly useful as target sequences for oligonucleotides in inducing exon skipping of exon 6 and/or exon 7, thereby generating and  $\Delta$ Ig3-MuSK transcripts.

[0189] In some embodiments, the present disclosure also provides specific oligonucleotides and combinations thereof that induce alternative splicing activity of MuSK and generate  $\Delta$ Ig3-MuSK transcripts.

[0190] In addition, the present disclosure provides compositions comprising one or more MuSK-targeting oligonucleotides that induce exon skipping of MuSK exons 6 and/or 7, and can be administered to a subject in a therapeutically effective amount to increase neurogenesis and/or muscle regeneration in the subject.

[0191] The disclosure includes compositions and methods related to one or more nucleotide sequences that are, comprise, or encode an oligonucleotide that binds to and inhibits expression of messenger RNA (mRNA) produced by a target gene (e.g., MuSK). Oligonucleotides can be single stranded (e.g., an antisense oligonucleotide) or double stranded nucleic acid. In some embodiments, an oligonucleotide comprises a double stranded RNA duplex such as microRNA (miRNA) or small interfering RNA (siRNA). In some embodiments, an oligonucleotide is an siRNA or miRNA, or a vector comprising a nucleotide

sequence encoding an siRNA or miRNA. In some embodiments, an oligonucleotide is an antisense oligonucleotide (ASO), or a vector comprising a nucleotide sequence encoding an ASO.

[0192] In some embodiments, an oligonucleotide is capable of inhibiting expression of the full-length MuSK sequence comprises three extracellular Immunoglobulin (Ig)-like domains (Ig1, Ig2, and Ig3), a cysteine-rich frizzled (CRD/Fz) domain, as well as an intracellular tyrosine kinase (TK) domain.

[0193] As described herein, the oligonucleotides may target the MuSK sequence of human MuSK or one or more non-human species, e.g., a non-human primate MuSK, e.g., *Macaca fascicularis* MuSK (Gene ID 102127677), or e.g., *chlorocebus sabaeus* (Gene ID: 103219025), or murine MuSK (Gene ID: 18198). In some embodiments, a MuSK-targeting oligonucleotide comprises an antisense strand that is complementary to a target portion that is identical in the human and/or murine MuSK transcripts. In some embodiments, an oligonucleotide comprises a sequence that is complementary to a target portion of a human MuSK transcript that differs by 1, 2, or 3 nucleotides from a sequence in a murine or human MuSK transcript. It will be appreciated that an oligonucleotide that alters splicing of human MuSK may also alter splicing (i.e., induce exon skipping) of non-primate MuSK, e.g., rat or mouse MuSK, particularly if conserved regions of MuSK transcript are targeted.

[0194] The amino acid and nucleotide sequences of human MuSK are known in the art and can be found in publicly available databases, for example, the National Center for Biotechnology Information (NCBI) Reference Sequence (RefSeq) database, where the genomic nucleotide sequence is listed under RefSeq accession numbers NG\_016016.2 (SEQ ID NO: 77) and forms of the mRNA/protein sequences are listed under NM\_005592.4/NP\_005583.1 (muscle, skeletal receptor tyrosine-protein kinase isoform 1), NM\_001166280.2/NP\_001159752.1 (muscle, skeletal receptor tyrosine-protein kinase isoform 2), NM\_001166281.2/NP\_001159753.1 (muscle, skeletal receptor tyrosine-protein kinase isoform 3) and NM\_001369398.1/NP\_001356327.1 (muscle, skeletal receptor tyrosine-protein kinase isoform 4). See [www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=Details Search&Term=4593](http://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=Details Search&Term=4593), which is incorporated herein by reference.

[0195] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a target portion of a MuSK transcript, e.g., MuSK mRNA (e.g., complementary to a nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a target portion of SEQ ID NO: 77, e.g., Bld25/hu7-10 (SEQ ID NO: 63), Bld26/hu73 (SEQ ID NO: 64), etc.). In some embodiments, the target portion comprises a region that corresponds to positions 83776-83800 and/or 83854-83878 of SEQ ID No: 77 or a corresponding region of a different version of the genomic sequence MuSK. The target portion may be 15-30 nucleotides long, e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides long, although shorter and longer target portions are also contemplated.

[0196] In some embodiments, a target portion of a MuSK transcript, e.g., MuSK mRNA, comprises a sequence of ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT GACTCAAGAC (region 1, SEQ ID: 126), or a region within or a portion thereof. In some embodiments, a target portion comprises a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 10 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a





comprises a sequence that is identical to 12 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 13 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 14 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 15 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 16 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 17 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 18 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 19 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 20 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 21 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 22 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 23 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 24 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 25 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 26 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 27 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 28 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 29 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 30 consecutive bases of region 2, SEQ ID: 211.

[0200] In some embodiments, the target portion comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the sequences listed below in Table 1.

TABLE-US-00004 TABLE 1 Region SEQ Description ID 5' to 3' Sequence Exon 6 39  
TGCATTTCTAAAAGACCACCCTAGC Exon 6 40 TCTAAAAGACCACCCTAGCTTGACC Exon 6  
41 ACCCTAGCTTGACCATTTCTGTCAG Exon 6 42 CTGCAGGAGCGTCACTCACCCTTC  
Exon 6 43 CACTCACCCTTCTGTCTTCTAAC Exon 6 44  
TCTTCTAACAGTTTTTGCCAGGAT Exon 6 45 GATCCTGCGGGCTCCTGAATCCCAC Exon 6  
46 GGCTCCTGAATCCCACAATGTCACC Exon 6 47 ATCCCACAATGTCACCTTTGGCTCC  
Exon 6 48 TGTCACCTTTGGCTCCTTTGTGACC Exon 6 49  
TGGCTCCTTTGTGACCCTGCACTGT Exon 6 50 GTGACCCTGCACTGTACAGCAACAG Exon  
6 51 GTACAGCAACAGGCATTCCTGTCCC Exon 6 52 GCATTCCTGTCCCCACCATCACCTG  
Exon 6 53 CCACCATCACCTGGATTGAAAACGG Exon 6 54  
GAAAACGGAAATGCTGTGAGTGTCA Exon 6 55 GTGAGTGTGATGTGTGTGGGGACTT Exon  
6 56 TGTGGGGACTTGTCTGGGGAAGACC Exon 7 57 TTCCCTTCAAATCTACTGACATAGT  
Exon 7 58 AATCTACTGACATAGTATAGTGGA Exon 7 59  
AGTATAGTGGGAAATCCTTGACTGA Exon 7 60 GGGAAATCCTTGACTGAGTTCTTTT Exon 7  
61 ACTGAGTTCTTTTATTTCTCTTAC Exon 7 62 TTATTTCTCTTACTCTGTCAGGTT Exon 7  
63 ACTCTGTCAGGTTTCTTCTGGGTCC Exon 7 64 TCTTCTGGGTCCATTCAAGAGAGTG  
Exon 7 65 TCAAGAGAGTGTGAAAGACCGAGTG Exon 7 66  
AAAGACCGAGTGATTGACTCAAGAC Exon 7 67 TGAATCAAGACTGCAGCTGTTTATC Exon  
7 68 AGCTGTTTATCACCAAGCCAGGACT Exon 7 69 ATCACCAAGCCAGGACTCTACACAT  
Exon 7 70 CAGGACTCTACACATGCATAGCTAC Exon 7 71  
ACACATGCATAGCTACCAATAAGCA Exon 7 72 GCTACCAATAAGCATGGGGAGAAGT Exon 7  
73 GGGGAGAAGTTCAGTACTGCCAAGG Exon 7 74 CTGCAGCCACCATCAGCATAGCAGG  
Exon 7 75 CATCAGCATAGCAGGTAGGATGCC Exon 7 76  
AGGTAGGATGCCCTTCACATTTGC Exon 7 212 TTTCTTCTGGGTCCATTCAA Exon 7 213  
TTCTTCTGGGTCCATTCAAG Exon 7 214 TCTTCTGGGTCCATTCAAGA Exon 7 215  
CTTCTGGGTCCATTCAAGAG Exon 7 216 TTCTGGGTCCATTCAAGAGA Exon 7 217

TCTGGTCCATTCAAGAGAGAG Exon 7 218 CTGGGTCCATTCAAGAGAGT Exon 7 219  
 TGGGTCCATTCAAGAGAGTGT Exon 7 220 GGGTCCATTCAAGAGAGTGT Exon 7 221  
 GGTCCATTCAAGAGAGTGTG Exon 7 222 GTCCATTCAAGAGAGTGTGA Exon 7 223  
 TCCATTCAAGAGAGTGTGAA Exon 7 224 CCATTCAAGAGAGTGTGAAA Exon 7 225  
 CATTCAAGAGAGTGTGAAAG Exon 7 226 ATTCAAGAGAGTGTGAAAGA Exon 7 227  
 TTCAAGAGAGTGTGAAAGAC Exon 7 228 CTTTACTCTGTCAGGTTTCTTCTGG Exon 7 229  
 TTTACTCTGTCAGGTTTCTTCTGGGT Exon 7 230 TCTGTCAGGTTTCTTCTGGGTCCAT Exon 7  
 231 TGTCAGGTTTCTTCTGGGTCCATTTC Exon 7 232 CAGGTTTCTTCTGGGTCCATTCAAG  
 Exon 7 233 GGTTTCTTCTGGGTCCATTCAAGAG Exon 7 234  
 TTTCTTCTGGGTCCATTCAAGAGAG Exon 7 235 TTCTGGGTCCATTCAAGAGAGTGTG Exon  
 7 236 CTGGGTCCATTCAAGAGAGTGTGAA Exon 7 237 ACTCTGTCAGGTTTCTTCTGGGT  
 Exon 7 238 ACTCTGTCAGGTTTCTTCTGG Exon 7 239 TCTGTCAGGTTTCTTCTGGGTCC  
 Exon 7 240 TCTGTCAGGTTTCTTCTGGGT Exon 7 241 TGTCAGGTTTCTTCTGGGTCC Exon  
 7 242 TCAGGTTTCTTCTGGGTCCATTTC Exon 7 243 TCAGGTTTCTTCTGGGTCCAT Exon 7 244  
 AGGTTTCTTCTGGGTCCATTCAA Exon 7 245 AGGTTTCTTCTGGGTCCATTTC Exon 7 246  
 GTTCTTCTGGGTCCATTCAA Exon 7 247 TTTCTTCTGGGTCCATTCAAGAG Exon 7 248  
 TTTCTTCTGGGTCCATTCAAG Exon 7 249 TCTTCTGGGTCCATTCAAGAGAG Exon 7 250  
 TTCTGGGTCCATTCAAGAGAG Exon 7 251 TCTTCTGGGTCCATTCAAGAG Exon 7 252  
 TTCTGGGTCCATTCAAGAGAGTG Exon 7 253 CTGGGTCCATTCAAGAGAGTG

[0201] Administration of MuSK-targeting oligonucleotide(s) as described herein can reduce the level of full-length MuSK transcript or full-length MuSK protein in a subject or in a biological sample (e.g., a blood, serum or plasma sample, or a sample comprising hepatocytes) compared to a level before the administration of the composition. In some embodiments, the level of full-length MuSK transcript or full-length MuSK protein is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90%, relative to a level before the administration.

[0202] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a target portion of a MuSK transcript, e.g., MuSK mRNA. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a target portion of a MuSK transcript, e.g., MuSK mRNA.

[0203] In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT GACTCAAGAC (region 1, SEQ ID: 126) that includes at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 95% identical to a portion of SEQ ID: 126 that includes at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 10 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that









Bld25-4 GATGGACCCAGAAGAAACCTGACA 163 Bld25-5  
 CTTGAATGGACCCAGAAGAAACCTG 164 Bld26-1 CTCTTGAATGGACCCAGAAGAAACC 165  
 Bld26-2 CTCTCTTGAATGGACCCAGAAGAAA 166 Bld26-3  
 CACTCTCTTGAATGGACCCAGAA 167 Bld26-4 TTCACACTCTCTTGAATGGACCCAG 177  
 Bld25-A ACCCAGAAGAAACCTGACAGAGT 178 Bld25-B CCAGAAGAAACCTGACAGAGT 179  
 Bld25-C GGACCCAGAAGAAACCTGACAGA 180 Bld25-D ACCCAGAAGAAACCTGACAGA 181  
 Bld25-E GGACCCAGAAGAAACCTGACA 182 Bld25-5-A GAATGGACCCAGAAGAAACCTGA 183  
 Bld25-5-B ATGGACCCAGAAGAAACCTGA 184 Bld25-5-C TTGAATGGACCCAGAAGAAACCT  
 185 Bld25-5-D GAATGGACCCAGAAGAAACCT 186 Bld25-5-E TTGAATGGACCCAGAAGAAAC  
 187 Bld26-2-A CTCTTGAATGGACCCAGAAGAAA 188 Bld26-2-B  
 CTTGAATGGACCCAGAAGAAA 189 Bld26-2-C CTCTCTTGAATGGACCCAGAAGA 190 Bld26-2-D  
 CTCTCTTGAATGGACCCAGAA 191 Bld26-B CTCTTGAATGGACCCAGAAGA 192 Bld26-C  
 CACTCTCTTGAATGGACCCAGAA 193 Bld26-D CACTCTCTTGAATGGACCCAG

[0211] In some embodiments, an oligonucleotide has a sequence that differs from that explicitly set forth in Table 2, for example by substitution of one or more residues, or types of residues, with an alternative residue or residue type—e.g., an analog or otherwise corresponding residue type. For example, in some embodiments, one or more “T” residues (or all “T” residues) of a sequence presented in Table 2 is a “U” residue or analog thereof.

[0212] In some embodiments, an oligonucleotide comprises mismatch(es) with the target. The base pair may be ranked on the basis of their propensity to promote dissociation or melting (e.g., on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual pair basis, though next neighbour or similar analysis can also be used). In terms of promoting dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over G:C (I=inosine).

[0213] In some embodiments, an oligonucleotide can include one or more (e.g., 2, 3, 4, or 5) nucleotides on the 3' and/or 5' end that is not complementary to the target sequence.

#### Chemical Structures of MuSK-Targeting Oligonucleotides

[0214] Synthetic oligonucleotides provide useful molecular tools in a wide variety of applications. For example, oligonucleotides are useful in therapeutic, diagnostic, research, and new nanomaterials applications. The use of naturally occurring nucleic acids (e.g., unmodified DNA or RNA) is limited, for example, by their susceptibility to endo- and exo-nucleases. As such, various synthetic counterparts have been developed to circumvent these shortcomings. These include synthetic oligonucleotides that contain chemical modification, e.g., base modifications, sugar modifications, backbone modifications, etc., which, among other things, render these molecules less susceptible to degradation and improve other properties of oligonucleotides.

[0215] Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages, and patterns thereof), and/or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages), and/or patterns thereof), can have significant impact on properties, e.g., stability, splicing-altering capabilities, etc. In some embodiments, oligonucleotide properties can be adjusted by optimizing chemical modifications (modifications of base, sugar, and/or internucleotidic linkage) and/or stereochemistry (pattern of backbone chiral centers).

[0216] In some embodiments, the present disclosure demonstrates that oligonucleotide compositions comprising oligonucleotides with controlled structural elements, e.g., controlled chemical modification, provide unexpected properties, including but not limited to those described herein. In some embodiments, provided compositions comprising oligonucleotides having chemical modifications (e.g., base modifications, sugar modification, internucleotidic linkage modifications, etc.) have improved properties, such as improved splicing-altering capabilities, or improved protein binding profile, and/or improved delivery, etc. Particularly, in some embodiments, the present disclosure provides compositions and methods for altering splicing of transcripts (e.g., MuSK transcripts). In some embodiments, the present disclosure provides compositions and methods for improving splicing of transcripts. In some embodiments, altered transcript splicing by provided compositions and methods include production of products having desired and/or improved biological functions, and/or knockdown of undesired product by,



e.g., modifying splicing products so that undesired biological functions can be suppressed or removed. [0217] In some embodiments, a splicing product is mRNA. In some embodiments, alteration comprises skipping one or more exons. In some embodiments, splicing of a transcript is improved in that exon skipping increases levels of mRNA and proteins that have improved beneficial activities compared with absence of exon skipping.

[0218] In some embodiments, splicing of a transcript is improved in that exon skipping lowers levels of mRNA and proteins that have undesired activities compared with absence of exon skipping. In some embodiments, a target is knocked down through exon skipping which, by skipping one or more exons, causes premature stop codon and/or frameshift mutations.

[0219] In some embodiments, an oligonucleotide of the disclosure includes one or more natural nucleobase and/or one or more modified nucleobases derived from a natural nucleobase. Examples include, but are not limited to, uracil, thymine, adenine, cytosine, and guanine having their respective amino groups protected by acyl protecting groups, 2-fluorouracil, 2-fluorocytosine, 5-bromouracil, 5-iodouracil, 2,6-diaminopurine, azacytosine, pyrimidine analogs such as pseudoisocytosine and pseudouracil and other modified nucleobases such as 8-substituted purines, xanthine, or hypoxanthine (the latter two being the natural degradation products).

[0220] Modified nucleobases also include expanded-size nucleobases in which one or more aryl rings, such as phenyl rings, have been added.

[0221] In some embodiments, modified nucleobases are of any one of the following structures, optionally substituted:

##STR00002##

[0222] In some embodiments, a modified nucleobase is unsubstituted. In some embodiments, a modified nucleobase is substituted. In some embodiments, a modified nucleobase is substituted such that it contains, e.g., heteroatoms, alkyl groups, or linking moieties connected to fluorescent moieties, biotin or avidin moieties, or other protein or peptides. In some embodiments, a modified nucleobase is a “universal base” that is not a nucleobase in the most classical sense, but that functions similarly to a nucleobase. One representative example of such a universal base is 3-nitropyrrole.

[0223] In some embodiments, an oligonucleotide described herein includes nucleosides that incorporate modified nucleobases and/or nucleobases covalently bound to modified sugars. Some examples of nucleosides that incorporate modified nucleobases include 4-acetylcytidine; 5-(carboxyhydroxymethyl) uridine; 2'-O-methylcytidine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxy methylaminomethyluridine; dihydrouridine; 2'-O-methylpseudouridine; beta,D-galactosylqueosine; 2'-O-methylguanosine; N.sup.6-isopentenyladenosine; 1-methyladenosine; 1-methylpseudouridine; 1-methylguanosine; 1-methylinosine; 2,2-dimethylguanosine; 2-methyladenosine; 2-methylguanosine; N.sup.7-methylguanosine; 3-methyl-cytidine; 5-methylcytidine; 5-hydroxymethylcytidine; 5-methylcytosine, 5-formylcytosine; 5-carboxylcytosine; N.sup.6-methyladenosine; 7-methylguanosine; 5-methylaminoethyluridine; 5-methoxyaminomethyl-2-thiouridine; beta, D-mannosylqueosine; 5-methoxy carbonylmethyluridine; 5-methoxyuridine; 2-methylthio-N.sup.6-isopentenyladenosine; N-((9-beta, D-ribofuranosyl-2-methylthiopurine-6-yl) carbamoyl) threonine; N-((9-beta,D-ribofuranosylpurine-6-yl)-N-methylcarbamoyl) threonine; uridine-5-oxyacetic acid methylester; uridine-5-oxyacetic acid (v); pseudouridine; queosine; 2-thiocytidine; 5-methyl-2-thiouridine; 2-thiouridine; 4-thiouridine; 5-methyluridine; 2'-O-methyl-5-methyluridine; and 2'-O-methyluridine.

[0224] In some embodiments, nucleosides include 6'-modified bicyclic nucleoside analogs that have either (R) or (S)-chirality at the 6'-position and include the analogs described in U.S. Pat. No. 7,399,845. In other embodiments, nucleosides include 5'-modified bicyclic nucleoside analogs that have either (R) or (S)-chirality at the 5'-position and include the analogs described in U.S. Publ. No. 20070287831. In some embodiments, a nucleobase or modified nucleobase is 5-bromouracil, 5-iodouracil, or 2,6-diaminopurine. In some embodiments, a nucleobase or modified nucleobase is modified by substitution with a fluorescent moiety.

[0225] In some embodiments, an oligonucleotide described herein includes one or more modified nucleotides wherein a phosphate group or linkage phosphorus in the nucleotides are linked to various positions of a sugar or modified sugar. As non-limiting examples, the phosphate group or linkage phosphorus can be linked to the 2', 3', 4' or 5' hydroxyl moiety of a sugar or modified sugar. Nucleotides

that incorporate modified nucleobases as described herein are also contemplated in this context.

[0226] Other modified sugars can also be incorporated within an oligonucleotide molecule. In some embodiments, a modified sugar contains one or more substituents at the 2' position including one of the following: —F; —CF<sub>3</sub>, —CN, —N<sub>3</sub>, —NO, —NO<sub>2</sub>, —OR', —SR', or —N(R')<sub>2</sub>, wherein each R' is independently as defined above and described herein: —O—(C<sub>1-10</sub> alkyl), —S(C<sub>1-10</sub> alkyl), —NH—(C<sub>1-10</sub> alkyl), or —N(C<sub>1-10</sub> alkyl)<sub>2</sub>; —O—(C<sub>2-10</sub> alkenyl), —S—(C<sub>2-10</sub> alkenyl), —NH—(C<sub>2-10</sub> alkenyl), or —N(C<sub>2-10</sub> alkenyl)<sub>2</sub>; —O—(C<sub>2-10</sub> alkynyl), —S—(C<sub>2-10</sub> alkynyl), —NH—(C<sub>2-10</sub> alkynyl), or —N(C<sub>2-10</sub> alkynyl)<sub>2</sub>; or —O—(C<sub>1-10</sub> alkylene)-O—(C<sub>1-10</sub> alkyl), —O—(C<sub>1-10</sub> alkylene)-NH—(C<sub>1-10</sub> alkyl) or —O—(C<sub>1-10</sub> alkylene)-NH—(C<sub>1-10</sub> alkyl)<sub>2</sub>, —NH—(C<sub>1-10</sub> alkylene)-O—(C<sub>1-10</sub> alkyl), or —N(C<sub>1-10</sub> alkyl)-(C<sub>1-10</sub> alkylene)-O—(C<sub>1-10</sub> alkyl), or salt thereof, wherein the alkyl, alkylene, alkenyl and alkynyl may be substituted or unsubstituted. Examples of substituents include, and are not limited to, —O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, and —O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub> or salt thereof, wherein n is from 1 to about 10, —OCH<sub>2</sub>CH<sub>2</sub>OMe (MOE) or salt thereof, —OCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub> (DMAOE) or salt thereof, —OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub> (DMAEOE) or salt thereof.

[0227] In some embodiments, the 2'-OH of a ribose is replaced with a substituent including one of the following: —H, —F; —CF<sub>3</sub>, —CN, —N<sub>3</sub>, —NO, —NO<sub>2</sub>, —OR', —SR', or —N(R')<sub>2</sub>, wherein each R' is independently as defined above and described herein: —O—(C<sub>1-10</sub> alkyl), —S(C<sub>1-10</sub> alkyl), —NH—(C<sub>1-10</sub> alkyl), or —N(C<sub>1-10</sub> alkyl)<sub>2</sub>; —O—(C<sub>2-10</sub> alkenyl), —S(C<sub>2-10</sub> alkenyl), —NH—(C<sub>2-10</sub> alkenyl), or —N(C<sub>2-10</sub> alkenyl)<sub>2</sub>; —O—(C<sub>2-10</sub> alkynyl), —S—(C<sub>2-10</sub> alkynyl), —NH—(C<sub>2-10</sub> alkynyl), or —N(C<sub>2-10</sub> alkynyl)<sub>2</sub>; or —O—(C<sub>1-10</sub> alkylene)-O—(C<sub>1-10</sub> alkyl), —O—(C<sub>1-10</sub> alkylene)-NH—(C<sub>1-10</sub> alkyl) or —O—(C<sub>1-10</sub> alkylene)-NH(C<sub>1-10</sub> alkyl)<sub>2</sub>, —NH—(C<sub>1-10</sub> alkylene)-O—(C<sub>1-10</sub> alkyl), or —N(C<sub>1-10</sub> alkyl)-(C<sub>1-10</sub> alkylene)-O—(C<sub>1-10</sub> alkyl), wherein the alkyl, alkylene, alkenyl and alkynyl may be substituted or unsubstituted. In some embodiments, the 2'-OH is replaced with —H (deoxyribose). In some embodiments, the 2'-OH is replaced with —F. In some embodiments, the 2'-OH is replaced with —OR'. In some embodiments, the 2'-OH is replaced with —OMe. In some embodiments, the 2'-OH is replaced with —OCH<sub>2</sub>CH<sub>2</sub>OMe (MOE).

[0228] Modified sugars also include locked nucleic acids (LNAs). In some embodiments, the locked nucleic acid has the structure indicated below. A locked nucleic acid of the structure below is indicated, wherein Ba represents a nucleobase or modified nucleobase as described herein, and wherein R<sub>2s</sub> is —OCH<sub>2</sub>C4'—

##STR00003##

[0229] In some embodiments, each sugar of the oligonucleotide is or comprises a modified sugar moiety. In some embodiments, each sugar of the oligonucleotide is or comprises a 2'-MOE modified sugar. In some embodiments, each sugar of the oligonucleotide is or comprises a 2'-OMe modified sugar. In some embodiments, each sugar of the oligonucleotide is or comprises a 2'-OH modified sugar. In some embodiments, each sugar of the oligonucleotide is or comprises a 2'-H modified sugar.

[0230] In some embodiments, the present disclosure provides an oligonucleotide comprising 2'-MOE modified sugar, 2'-OMe modified sugar, 2'-OH modified sugar, 2'-H modified sugar, or combinations thereof. In some embodiments, a provided oligonucleotide comprises at least one 2'-MOE sugar and at least one 2'-OH sugar (RNA sugar). In some embodiments, a provided oligonucleotide comprises at least one 2'-MOE sugar and at least one 2'-H sugar (DNA sugar).

[0231] In some embodiments, the present invention provides an oligonucleotide comprising one or more modified internucleotidic linkages independently having the structure of formula I:

##STR00004## [0232] wherein: [0233] P\* is an asymmetric phosphorus atom and is either Rp or Sp configuration; [0234] W is O, S or Se; [0235] each of X, Y and Z is independently—O—, —S—, —N(L-R<sub>1</sub>)—, or L;

[0236] L is a covalent bond or an optionally substituted, linear or branched C.sub.1-C.sub.10 alkylene, wherein one or more methylene units of L are optionally and independently replaced by an optionally substituted C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6 alkenylene,  $\text{—C}\equiv\text{C—}$ ,  $\text{—C(R')}_2\text{—}$ ,  $\text{—Cy—}$ ,  $\text{—O—}$ ,  $\text{—S—}$ ,  $\text{—S—S—}$ ,  $\text{—N(R')—}$ ,  $\text{—C(O)—}$ ,  $\text{—C(S)—}$ ,  $\text{—C(NR')—}$ ,  $\text{—C(O)N(R')—}$ ,  $\text{—N(R')C(O)N(R')—}$ ,  $\text{—N(R')C(O)—}$ ,  $\text{—N(R')C(O)O—}$ ,  $\text{—OC(O)N(R')—}$ ,  $\text{—S(O)—}$ ,  $\text{—S(O)}_2\text{—}$ ,  $\text{—S(O)}_2\text{N(R')—}$ ,  $\text{—N(R')S(O)}_2\text{—}$ ,  $\text{—SC(O)—}$ ,  $\text{—C(O)S—}$ ,  $\text{—OC(O)—}$ , or  $\text{—C(O)O—}$ ;

[0237] R.sub.1 is halogen, R, or an optionally substituted C.sub.1-C.sub.50 aliphatic wherein one or more methylene units are optionally and independently replaced by an optionally substituted C.sub.1-C.sub.6 alkylene, C.sub.1-C.sub.6 alkenylene,  $\text{—C}\equiv\text{C—}$ ,  $\text{—C(R')}_2\text{—}$ ,  $\text{—Cy—}$ ,  $\text{—O—}$ ,  $\text{—S—}$ ,  $\text{—S—S—}$ ,  $\text{—N(R')—}$ ,  $\text{—C(O)—}$ ,  $\text{—C(S)—}$ ,  $\text{—C(NR')—}$ ,  $\text{—C(O)N(R')—}$ ,  $\text{—N(R')C(O)N(R')—}$ ,  $\text{—N(R')C(O)—}$ ,  $\text{—N(R')C(O)O—}$ ,  $\text{—OC(O)N(R')—}$ ,  $\text{—S(O)—}$ ,  $\text{—S(O)}_2\text{—}$ ,  $\text{—S(O)}_2\text{N(R')—}$ ,  $\text{—N(R')S(O)}_2\text{—}$ ,  $\text{—SC(O)—}$ ,  $\text{—C(O)S—}$ ,  $\text{—OC(O)—}$ , or  $\text{—C(O)O—}$ ; [0238] each R' is independently-R,  $\text{—C(O)R}$ ,  $\text{—CO}_2\text{R}$ , or  $\text{—SO}_2\text{R}$ , or: [0239] two R' on the same nitrogen are taken together with their intervening atoms to form an optionally substituted heterocyclic or heteroaryl ring, or [0240] two R' on the same carbon are taken together with their intervening atoms to form an optionally substituted aryl, carbocyclic, heterocyclic, or heteroaryl ring: [0241]  $\text{—Cy—}$  is an optionally substituted bivalent ring selected from phenylene, carbocyclylene, arylene, heteroarylene, or heterocyclylene: [0242] each R is independently hydrogen, or an optionally substituted group selected from C.sub.1-C.sub.6 aliphatic, phenyl, carbocyclyl, aryl, heteroaryl, or heterocyclyl; and [0243] each

##STR00005##

independently represents a connection to a nucleoside.

[0244] In some embodiments, the internucleotidic linkage having the structure of formula I is

##STR00006## ##STR00007##

[0245] In some embodiments, an oligonucleotide comprises both non-natural internucleotidic linkage as described herein and natural phosphate linkage. In some embodiments, each internucleotidic linkages of the oligonucleotide is a non-natural internucleotidic linkage. In some embodiments, each internucleotidic linkages of the oligonucleotide is a chiral internucleotidic linkage. In some embodiments, each internucleotidic linkages of the oligonucleotide is a phosphorothioate linkage

##STR00008##

[0246] In some embodiments, each internucleotidic linkages of an oligonucleotide is a natural phosphate linkage. In some embodiments, an oligonucleotide comprises at least one natural phosphate linkage and at least one phosphodithioate linkage. In some embodiments, at least 50% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 60% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 70% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 80% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 90% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 94% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 95% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages.

[0247] In some embodiments, at least 50% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 60% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 70% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 80% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 90% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 94% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 95% internucleotidic linkages of an oligonucleotide are natural phosphate linkages.

[0248] Among other things, the present disclosure provides oligonucleotides of various designs, which may comprises various nucleobases and patterns thereof, sugars and patterns thereof, internucleotidic linkages and patterns thereof, and/or additional chemical moieties and patterns thereof as described in the present disclosure. In some embodiments, provided oligonucleotides can downregulate the MuSK Ig3 domain protein expression, the MuSK Ig3 domain gene expression, and/or the MuSK Ig3 activation of

BMP signaling level, thereby increasing adult hippocampal neurogenesis (AHN) and improving cognition in AD. In some embodiments, provided oligonucleotides can downregulate the MuSK Ig3 domain protein expression, the MuSK Ig3 domain gene expression, and/or the MuSK Ig3 activation of BMP signaling level, thereby increasing muscle regeneration. In some embodiments, provided oligonucleotides can direct a decrease in the expression, level and/or activity of MuSK Ig3 domain and/or one or more of its products in a cell of a subject or patient. In some embodiments, provided oligonucleotides can direct a decrease in the expression, level and/or activity of MuSK Ig3 domain and/or one or more of its products in a cell of a subject or patient, while the expression, level, and/or activity of all forms of MuSK remains substantially the same. In some embodiments, a cell normally expresses or produces protein encoded by MuSK Ig3 domain. In some embodiments, provided MuSK-targeting oligonucleotides can direct a decrease in the expression, level and/or activity of MuSK Ig3 domain gene or a gene product and have a base sequence which consists of, comprises, or comprises a portion (e.g., a span of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more contiguous bases) of the base sequence of an oligonucleotide disclosed herein, wherein each T can be independently substituted with U and vice versa, and the oligonucleotide comprises at least one non-naturally-occurring modification of a base, sugar and/or internucleotidic linkage.

[0249] As described herein, the naturally highly abundant full length MuSK harbors the BMP-binding Ig3 domain and potentiates BMP signaling and thus restrains neurogenesis. In contrast,  $\Delta$ Ig3-MuSK has lower BMP signaling and promotes AHN and improves cognition. In some embodiments, the present disclosure provides exon-skipping MuSK-targeting oligonucleotides that switch MuSK from the AHN restraining full length MuSK to AHN permissive  $\Delta$ Ig3-MuSK splice form.

[0250] As described herein, the highly abundant full length MuSK harbors the BMP-binding Ig3 domain and potentiates BMP signaling and affects muscle regeneration. In contrast,  $\Delta$ Ig3-MuSK has lower BMP signaling and promotes muscle regeneration and/or prevents muscle fibrosis. In some embodiments, the present disclosure provides exon-skipping MuSK-targeting oligonucleotides that switch MuSK from the full length MuSK to the muscle-promoting  $\Delta$ Ig3-MuSK splice form.

[0251] In some embodiments, one or more skipped exons are selected from exon 6 and/or 7 of the MuSK gene. In some embodiments, exon 6 of MuSK is skipped. In some embodiments, exon 7 of MuSK is skipped. In some embodiments, both exons 6 and 7 of MuSK are skipped.

[0252] In some embodiments, a MuSK-targeting oligonucleotide described herein can provide exon-skipping of exon 6 and/or 7, but does not provide exon-skipping of exon 3 and/or 4.

[0253] In some embodiments, a MuSK-targeting oligonucleotide described herein can provide exon-skipping of exon 6 and/or 7 at a greater level than it provides exon-skipping of exon 3 and/or 4.

[0254] In some embodiments, a MuSK-targeting oligonucleotide described herein provides exon-skipping such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0255] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0256] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 70% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0257] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 80% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0258] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts

such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 90% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0259] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 30%.

[0260] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 20%.

[0261] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 10%.

[0262] In various embodiments, an active compound is an oligonucleotide that directs skipping of one or more exons in a MuSK gene. In various embodiments, an active compound is an oligonucleotide that directs skipping of multiple exons in a MuSK gene. In some embodiments, an active compound is an oligonucleotide that directs skipping of exon 6, exon 7, or both in a MuSK gene. In some embodiments, an active compound is an oligonucleotide that directs skipping of exon 6 in a MuSK gene. In some embodiments, an active compound is an oligonucleotide that directs skipping of exon 7 in a MuSK gene. In some embodiments, an active compound is an oligonucleotide that directs skipping of exons 6 and 7 in a MuSK gene. In some embodiments, a plurality of oligonucleotides may be used together. In some such embodiments, two or more different exon skipping oligonucleotides (e.g., at least one that directs skipping of exon 6 and one that directs skipping of exon 7) may be used in combination. Alternatively or additionally, in some embodiments, at least one exon skipping oligonucleotide may be used in combination with at least one degrading oligonucleotide (e.g., that targets a transcript for RNase H degradation) which, for example, may target MuSK transcript(s) that include a functional Ig3 domain, or portion thereof.

[0263] In some embodiments, oligonucleotides are provided and/or utilized in salt forms. In some embodiments, oligonucleotides are provided as salts comprising negatively-charged internucleotidic linkages (e.g., phosphorothioate internucleotidic linkages, natural phosphate linkages, etc.) existing as their salt forms. In some embodiments, oligonucleotides are provided as pharmaceutically acceptable salts. In some embodiments, oligonucleotides are provided as metal salts. In some embodiments, oligonucleotides are provided as sodium salts. In some embodiments, oligonucleotides are provided as metal salts, e.g., sodium salts, wherein each negatively-charged internucleotidic linkage is independently in a salt form (e.g., for sodium salts,  $\text{—O—P(O)(SNa)—O—}$  for a phosphorothioate internucleotidic linkage,  $\text{—O—P(O)(ONa)—O—}$  for a natural phosphate linkage, etc.).

[0264] In some embodiments, individual oligonucleotides within a composition may be considered to be of the same constitution and/or structure even though, within such composition (e.g., a liquid composition), particular such oligonucleotides might be in different salt form(s) (and may be dissolved and the oligonucleotide chain may exist as an anion form when, e.g., in a liquid composition) at a particular moment in time. For example, those skilled in the art will appreciate that, at a given pH, individual internucleotidic linkages along an oligonucleotide chain may be in an acid (H) form, or in one of a plurality of possible salt forms (e.g., a sodium salt, or a salt of a different cation, depending on which ions might be present in the preparation or composition), and will understand that, so long as their acid forms (e.g., replacing all cations, if any, with H<sup>+</sup>) are of the same constitution and/or structure, such individual oligonucleotides may properly be considered to be of the same constitution and/or structure.

[0265] In some embodiments, an oligonucleotide composition comprises two or more oligonucleotides. In

some embodiments, an oligonucleotide composition comprises two or more pluralities of oligonucleotides, wherein each plurality is independently a plurality of oligonucleotides as described herein. For example, in some embodiments, each plurality independently shares a same base sequence and the same internucleotidic linkages. In some embodiments, at least two pluralities or each plurality independently targets the same exon(s) of the same transcript (e.g., exons 6 and/or 7 of MuSK). In some embodiments, at least two pluralities or each plurality independently targets different exons of the same transcript (e.g., exons 3, 4, 6, and/or 7 of MuSK). In some embodiments, at least two pluralities or each plurality independently targets a different transcript of the same or different nucleic acids. In some embodiments, at least two pluralities or each plurality independently targets transcripts of a different gene. In some embodiments, at least two pluralities or each plurality independently targets different regions on the MuSK transcript. Among other things, such compositions may be utilized to target two or more targets, in some embodiments, simultaneously and in the same system.

#### Characterization of MuSK-Targeting Oligonucleotides

[0266] MuSK-targeting oligonucleotides provided herein may be identified, assessed and/or characterized for one or more their physical/chemical properties and/or biological activities. Those skilled in the art will be aware of a variety of approaches, including particular assays, that may be utilized for such identification, assessment, and/or characterization.

[0267] In some embodiments, a MuSK-targeting oligonucleotide as described herein is characterized in that, for example, the MuSK-targeting oligonucleotide, when contacted with a cell expressing MuSK, will increase the level or activity of MuSK  $\Delta$ Ig3 mRNA and/or protein, e.g., relative to another MuSK form or other appropriate reference. In some embodiments, achieving such increase may be considered to represent “agonizing” MuSK  $\Delta$ Ig3.

[0268] In some embodiments, a MuSK-targeting oligonucleotide is characterized by its ability to alter splicing activity of MuSK pre-mRNA in a cell. For example, a cell may be transfected with a MuSK-targeting oligonucleotide, and after a period of incubation, expression of an alternative form of processed form of a MuSK RNA transcript (e.g., where exons 6 and 7 have been skipped), can be measured by RT-PCR. For example, the efficiency of MuSK exon skipping in cultured cells greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 95%.

[0269] In some aspects, a MuSK-targeting oligonucleotide increases of MuSK  $\Delta$ Ig3 mRNA. In some aspects, a MuSK-targeting oligonucleotide alters splicing of MuSK pre-mRNA. In some aspects, a MuSK-targeting oligonucleotide promotes the skipping of exon 6 and/or exon 7.

[0270] Modulation of expression of MuSK  $\Delta$ Ig3 can be measured in a bodily fluid of a subject treated with MuSK MR-targeting oligonucleotide, which may or may not contain cells: tissue: or organ of the animal. Methods of obtaining samples for analysis, such as body fluids (e.g., sputum, serum, CSF), tissues (e.g., biopsy), or organs, and methods of preparation of the samples to allow for analysis are well known to those skilled in the art. The effects of treatment on a subject can be assessed by measuring biomarkers associated with the target gene expression in one or more biological fluids, tissues or organs, collected from an animal contacted with one or more compositions described in this application.

[0271] In some embodiments, an increase in MuSK  $\Delta$ Ig3 mRNA means that the intracellular level of MuSK  $\Delta$ Ig3 mRNA is higher than a reference level, such as the level of MuSK  $\Delta$ Ig3 mRNA in a control (for example in a subject that is not being administered an MuSK-targeting oligonucleotide). An increase in intracellular MuSK  $\Delta$ Ig3 mRNA can be measured as an increase in the level of MuSK  $\Delta$ Ig3 protein and/or mRNA produced. In some embodiments, an increase in MuSK  $\Delta$ Ig3 mRNA can be determined by e.g., methods as described below in the examples, and/or by assay techniques such as RNA solution hybridization, nuclease protection, Northern hybridization, reverse transcription, gene expression monitoring with a microarray, antibody binding, enzyme linked immunosorbent assay (ELISA), nucleic acid sequencing, Western blotting, radioimmunoassay (RIA), other immunoassays, fluorescence activated cell analysis (FACS), or any other technique or combination of techniques that can detect the presence of MuSK  $\Delta$ Ig3 mRNA or protein (e.g., in a subject or a sample obtained from a subject).

[0272] In some embodiments, by comparing the level of MuSK  $\Delta$ Ig3 mRNA in a sample obtained from a subject receiving a MuSK-targeting oligonucleotide treatment to a level of MuSK  $\Delta$ Ig3 mRNA in a subject not treated with a MuSK-targeting oligonucleotide, the extent to which the MuSK-targeting oligonucleotide treatment increased MuSK  $\Delta$ Ig3 mRNA can be determined. In some embodiments, the

reference level of MuSKΔIg3 mRNA is obtained from the same subject prior to receiving MuSK-targeting oligonucleotide treatment. In some embodiments, the reference level of MuSK ΔIg3 mRNA is a range determined by a population of subjects not receiving MuSK-targeting oligonucleotide treatment. In some embodiments, the level of full-length MuSK mRNA is compared to the level of MuSK ΔIg3 mRNA. In some embodiments, the ratio of the MuSK ΔIg3 mRNA to a full length MuSK mRNA (e.g., MuSK mRNA without exons 6 and 7) in a subject receiving a MuSK-targeting oligonucleotide treatment, for example, greater than 1 fold, 1.5-5 fold, 5-10 fold, 10-50 fold, 50-100 fold, about 1.1-, 1.2-, 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-fold or more higher than a reference ratio.

[0273] In some embodiments, an increased level of MuSK ΔIg3 mRNA is, for example, greater than 1 fold, 1.5-5 fold, 5-10 fold, 10-50 fold, 50-100 fold, about 1.1-, 1.2-, 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-fold or more higher than a reference value.

[0274] In some embodiments, the increase of MuSK ΔIg3 mRNA in a subject can be indicated by the increase of MuSK ΔIg3 protein as compared to a reference level. In some embodiments, the reference level of MuSK ΔIg3 protein is the MuSK ΔIg3 protein level obtained from a subject having or at risk of having e.g., AD or a disease characterized by neurodegeneration. In some embodiments, the reference level of MuSK ΔIg3 protein is the MuSK ΔIg3 protein level obtained from a subject having or at risk of having e.g., neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting prior to treatment.

Methods whereby bodily fluids, organs or tissues are contacted with an effective amount of one or more compositions described herein are also contemplated. Bodily fluids, organs or tissues can be contacted with one or more compositions comprising MuSK-targeting oligonucleotides, resulting in expression of MuSK ΔIg3 and modulation of MuSK expression in the cells of bodily fluids, organs or tissues. An effective amount of can be determined by monitoring the effect on functional MuSK ΔIg3 protein expression of MuSK-targeting oligonucleotides that are administered to a subject or contacted to a cell.

[0275] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells, (e.g., comprising NSCs and/or neural progenitor cells (MPCs)), increases the number of cells that are in an activated state (e.g., active proliferation). Cells within a population can be assessed for whether they are in an activated state by known methods in the art, including e.g., an EdU assay, where EdU+ cycling cells are compared with total cell counts. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising NSCs, decreases the number of quiescent NSCs in the population and/or increases the number of activated NSCs.

[0276] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells, (e.g., comprising satellite cells (SCs), myoblasts, myogenic progenitor cells (MPCs)), increases the number of cells that are in an activated state (e.g., active proliferation). Cells within a population can be assessed for whether they are in an activated state by known methods in the art, including e.g., an EdU assay, where EdU+cycling cells are compared with total cell counts. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising satellite cells, decreases the number of quiescent satellite cells in the population and/or increases the number of activated satellite cells.

[0277] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising NSCs and/or NPCs, increases the number of cells expressing genes associated with early neurons (e.g., Dex) and/or decreases the number of cells expressing genes associated with mature neurons (e.g., Map2), astrocytes (e.g., GFAP and S100b), and/or oligodendrocytes (e.g., CNPase and O4). In some embodiments, a MuSK-targeting oligonucleotide, when administered to a population of cells comprising NSCs and/or NPCs, increases the level of expression of genes associated with early neurons (e.g., Dex) and/or decreases the level of expression of genes associated with mature neurons (e.g., Map2), astrocytes (e.g., GFAP and S100b), and/or oligodendrocytes (e.g., CNPase and O4) in the population of cells.

[0278] In some embodiments, a population of cells comprises NSCs that have been induced to be NSCs (e.g., from stem cells such as embryonic stems cells or pluripotent stem cells).

[0279] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising SCs, MPCs, and/or myoblasts, increases the

number of cells expressing genes or myogenic factors (e.g., Pax7, MyoD, myogenin, and MERGE) and/or decreases the number of cells expressing genes associated with the MuSK-BMP signaling pathway (e.g., RGS4, Msx2, Myf5, Ptx3, Id1). In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising satellite cells and/or myoblasts, increases the level of expression of genes associated with myogenic factors (e.g., Pax7, MyoD, myogenin, and MERGE) and/or decreases the level of expression of genes associated with the MuSK-BMP signaling pathway (e.g., RGS4, Msx2, Myf5, Ptx3, Id1) in the population of cells.

[0280] In some embodiments, a population of cells comprises satellite cells and/or myoblasts that have been induced to be satellite cells and/or myoblasts (e.g., from stem cells such as embryonic stem cells or pluripotent stem cells).

[0281] In some embodiments, a population of cells is obtained from a healthy subject. In some embodiments, a population of cells is obtained from a subject having or at risk of having e.g., AD or a disease characterized by neurodegeneration or a subject suffering from a disease or disorder such as a neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting.

[0282] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when contacted with a population of cells from a subject, increases neurogenesis in a subject. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same is contacted with the population of cells in vivo, for example, by injection into a subject. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same is contacted with the population of cells ex vivo by obtaining a population of cells from a subject, and neurogenesis is increased when the treated cells are re-introduced into the subject.

[0283] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when contacted with a population of cells from a subject, increases muscle regeneration and/or growth in a subject. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same is contacted with the population of cells in vivo, for example, by injection into a subject. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same is contacted with the population of cells ex vivo by obtaining a population of cells from a subject, and muscle regeneration is increased when the treated cells are re-introduced into the subject.

[0284] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a subject, will increase neurogenesis and/or growth, and/or improve cognition. Examples of methods to assess these biological effects are detailed, e.g., in the below examples.

[0285] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a subject, will increase muscle regeneration and/or growth, and/or neuromuscular function, and/or myogenesis. Examples of methods to assess these biological effects are detailed, e.g., in the below examples.

#### Production of MuSK-Targeting Oligonucleotides

[0286] A MuSK-targeting oligonucleotide described herein can be synthesized by standard methods known in the art, e.g., by use of an automated synthesizer. Following chemical synthesis (e.g., solid-phase synthesis using phosphoramidite method), oligonucleotide molecules can be deprotected, annealed to ds molecules, and purified (e.g., by gel electrophoresis or HPLC). Protocols for preparation of MuSK-targeting oligonucleotide oligonucleotides are known in the art.

[0287] In some embodiments, the present disclosure provides technologies for preparing chirally controlled oligonucleotides and compositions thereof. In some embodiments, the present disclosure provides technologies for preparing stereopure oligonucleotides and compositions thereof. In some embodiments, provided oligonucleotides and compositions thereof are of high purity. In some embodiments, oligonucleotides of the present disclosure are at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% stereochemically pure at linkage phosphorus of chiral internucleotidic linkages. In some embodiments, oligonucleotides of the present disclosure are prepared stereoselectively and are substantially free of stereoisomers. In some embodiments, in provided compositions comprising a plurality of oligonucleotides which share the same base sequence of the same pattern of chiral linkage phosphorus stereochemistry (e.g., comprising one or more of Rp and/or Sp, wherein each chiral linkage phosphorus is independently Rp or Sp), at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of all



oligonucleotides in the composition that share the same base sequence as oligonucleotides of the plurality share the same pattern of chiral linkage phosphorus stereochemistry or are oligonucleotides of the plurality. In some embodiments, in provided compositions comprising a plurality of oligonucleotides which share the same base sequence of the same pattern of chiral linkage phosphorus stereochemistry, at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of all oligonucleotides in the composition that share the same constitution as oligonucleotides of the plurality share the same pattern of chiral linkage phosphorus stereochemistry or are oligonucleotides of the plurality.

[0288] MuSK-targeting oligonucleotides can also be formed within a cell by transcription of RNA from an expression construct introduced into the cell (see, e.g., Yu et al., Proc. Natl. Acad. Sci. USA 2002:99:6047-6052). An expression construct for in vivo production of oligonucleotide molecules can include one or more antisense encoding sequences operably linked to elements necessary for the proper transcription of the antisense encoding sequence(s), including, e.g., promoter elements and transcription termination signals. Preferred promoters for use in such expression constructs include the polymerase-III HI-RNA promoter (see, e.g., Brummelkamp et al., Science 2002; 296:550-553) and the U6 polymerase-III promoter (see, e.g., Sui et al., Proc. Natl. Acad. Sci. USA 2002; Paul et al., Nature Biotechnol. 2002; 20:505-508; and Yu et al., Proc. Natl. Acad. Sci. USA 2002 99:6047-6052). A MuSK-targeting oligonucleotide expression construct can further comprise one or more vector sequences that facilitate the cloning of the expression construct. Standard vectors that can be used include, e.g., pSilencer 2.0-U6 vector (Ambion Inc., Austin, Tex.).

#### Pharmaceutical Compositions

[0289] The present disclosure provides pharmaceutical compositions that comprise and/or deliver MuSK-targeting oligonucleotides as described herein. The present disclosure also provides pharmaceutical compositions that are or comprise cell populations that have been exposed to MuSK-targeting oligonucleotides as described herein.

[0290] For example, in some embodiments, a provided pharmaceutical composition may comprise and/or deliver MuSK-targeting oligonucleotides that, when administered, achieves an increase in level and/or activity of a MuSK polypeptide (e.g., a MuSK  $\Delta$ Ig3 polypeptide, or another MuSK variant polypeptide with disrupted Ig3) that lacks an Ig3 domain functional for interaction with BMP. Alternatively or additionally, in some embodiments, a provided pharmaceutical composition may comprise and/or deliver a population of cells that has been exposed to a MuSK-targeting oligonucleotide, so that neuronal cell number and/or activity is increased in the population.

[0291] In many embodiments, a pharmaceutical composition will be or comprise an active agent (e.g., a MuSK-targeting oligonucleotide as described herein or a precursor thereof) in combination with one or more pharmaceutically acceptable excipients. Those skilled in the art will appreciate that components of a particular pharmaceutical composition may be influenced by route of administration of the pharmaceutical composition.

[0292] The compositions of the disclosure can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington, The Science and Practice of Pharmacy, (20th ed. 2000).

[0293] Compositions of the present invention can be prepared and administered in a wide variety of oral, parenteral, and topical dosage forms. Thus, the compositions of the present invention can be administered by injection (e.g. intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally). Also, the compositions described herein can be administered by inhalation, for example, intranasally. Additionally, the composition of the present invention can be administered transdermally. It is also envisioned that multiple routes of administration (e.g., intramuscular, oral, transdermal) can be used to administer the compositions of the invention.

[0294] In some embodiments, a pharmaceutical composition as described herein may be formulated for delivery by a route selected from intravenous injection, intrathecal administration, oral administration, buccal administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration. In some embodiments, a pharmaceutical composition may be formulated for delivery by intrathecal administration. In some embodiments, a pharmaceutical composition may be formulated for delivery by intravenous administration. In some embodiments, a pharmaceutical composition may be formulated for delivery by oral administration.

[0295] In certain embodiments, oligonucleotides and compositions are delivered to the CNS. In certain embodiments, oligonucleotides and compositions are delivered to the cerebrospinal fluid. In certain embodiments, oligonucleotides and compositions are administered to the brain parenchyma. In certain embodiments, oligonucleotides and compositions are delivered to an animal/subject by intrathecal administration, or intracerebroventricular administration. Broad distribution of oligonucleotides and compositions, described herein, within the central nervous system may be achieved with intraparenchymal administration, intrathecal administration, or intracerebroventricular administration.

[0296] In certain embodiments, parenteral administration is by injection, by, e.g., a syringe, a pump, etc. In certain embodiments, the injection is a bolus injection. In certain embodiments, the injection is administered directly to a tissue, such as striatum, caudate, cortex, hippocampus and cerebellum.

[0297] In certain embodiments, methods of specifically localizing a pharmaceutical agent, such as by bolus injection, decreases median effective concentration (EC<sub>50</sub>) by a factor of 20, 25, 30, 35, 40, 45 or 50. In certain embodiments, the pharmaceutical agent in an antisense compound as further described herein. In certain embodiments, the targeted tissue is brain tissue. In certain embodiments the targeted tissue is hippocampus tissue. In certain embodiments, decreasing EC<sub>50</sub> is desirable because it reduces the dose required to achieve a pharmacological result in a patient in need thereof.

[0298] In certain embodiments, an antisense oligonucleotide is delivered by injection or infusion once every month, every two months, every 90 days, every 3 months, every 6 months, twice a year or once a year.

[0299] In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of an active compound into preparations which can be used pharmaceutically: The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.

[0300] Pharmaceutical preparations for oral use can be obtained by combining an active compound with solid excipients, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol: cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethyl-cellulose (CMC), and/or polyvinylpyrrolidone (PVP: povidone). If desired, disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0301] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol (PEG), and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dye-stuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0302] Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin, and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, an active compound may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols (PEGs). In addition, stabilizers may be added.

[0303] In some embodiments, the pharmaceutical composition is a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop or an ear drop.

[0304] Depending on the specific conditions being treated, pharmaceutical composition of the present disclosure may be formulated into liquid or solid dosage forms and administered systemically or locally. The pharmaceutical composition may be delivered, for example, in a timed- or sustained-low release form as is known to those skilled in the art. Techniques for formulation and administration may be found in Remington, The Science and Practice of Pharmacy (20th ed. 2000). Suitable routes may include oral, buccal, by inhalation spray, sublingual, rectal, transdermal, vaginal, transmucosal, nasal or intestinal administration: parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intra-articular, intra-sternal, intra-synovial, intra-

hepatic, intralesional, intracranial, intraperitoneal, intranasal, or intraocular injections or other modes of delivery.

[0305] For injection, the pharmaceutical composition of the disclosure may be formulated and diluted in aqueous solutions, such as in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0306] Use of pharmaceutically acceptable inert carriers to formulate the compositions herein disclosed for the practice of the disclosure into dosages suitable for systemic administration is within the scope of the disclosure. With proper choice of carrier and suitable manufacturing practice, the compositions of the present disclosure, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection.

[0307] In some embodiments, compositions as described herein can be formulated using pharmaceutically acceptable carriers available in the art into dosages suitable for oral administration. Such carriers enable the compounds of the disclosure to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject (e.g., patient) to be treated.

[0308] For nasal or inhalation delivery, one or more solubilizing, diluting, or dispersing substances such as, saline, preservatives, such as benzyl alcohol, absorption promoters, and fluorocarbons, may be employed.

[0309] In some embodiments, a provided composition may comprise and/or deliver a precursor of an active agent, wherein the precursor becomes or releases active therapeutic agent upon administration. In some embodiments, for example, a precursor may be or comprise a prodrug of a small molecule agonizing agent, or a nucleic acid that encodes a protein agonizing agent, etc.

[0310] In some particular embodiments, a provided pharmaceutical composition comprises or delivers a therapeutically effective amount (e.g., an amount that is effective when administered according to an established protocol) of a provided oligonucleotide (which may, as described herein, be provided in a pharmaceutically acceptable salt form, e.g., as a sodium salt, ammonium salt, etc.); in some embodiments, such a provided pharmaceutical composition includes a relevant oligonucleotide and at least one pharmaceutically acceptable inactive ingredient selected from pharmaceutically acceptable diluents, pharmaceutically acceptable excipients, and pharmaceutically acceptable carriers. In some embodiments, a salt form of a provided oligonucleotide comprises two or more cations, for example, in some embodiments, up to the number of negatively charged acidic groups (e.g., phosphate, phosphorothioate, etc.) in an oligonucleotide.

[0311] Pharmaceutically acceptable salts are generally well known to those of ordinary skill in the art, and may include, by way of example but not limitation, acetate, benzenesulfonate, besylate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, carnsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, or teoate. Other pharmaceutically acceptable salts may be found in, for example, Remington, The Science and Practice of Pharmacy (20th ed. 2000). Preferred pharmaceutically acceptable salts include, for example, acetate, benzoate, bromide, carbonate, citrate, gluconate, hydrobromide, hydrochloride, maleate, mesylate, napsylate, pamoate (embonate), phosphate, salicylate, succinate, sulfate, or tartrate.

[0312] As appreciated by a person having ordinary skill in the art, oligonucleotides may be formulated as a number of salts for, e.g., pharmaceutical uses. In some embodiments, a salt is a metal cation salt and/or ammonium salt. In some embodiments, a salt is a metal cation salt of an oligonucleotide. In some embodiments, a salt is an ammonium salt of an oligonucleotide. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, a salt is a sodium salt of an oligonucleotide. In some embodiments, pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed with counterions such as hydroxide, carboxylate, sulfate, phosphate, nitrate, sulfonate, phosphorothioate, etc. that may be within provided oligonucleotides. As appreciated by a person having ordinary skill in the art, a

salt of an oligonucleotide may contain more than one cations, e.g., sodium ions, as there may be more than one anions within an oligonucleotide.

[0313] In some embodiments, provided oligonucleotides, and compositions thereof, may be effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.01 to about 1000 mg, from about 0.5 to about 100 mg, from about 1 to about 50 mg per day, and from about 5 to about 100 mg per day are examples of dosages that may be used. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.

[0314] In some embodiments, the present disclosure provides technologies (e.g., compositions, methods, etc.) for combination therapy, for example, with other therapeutic agents and/or medical procedures. In some embodiments, provided oligonucleotides and/or compositions may be used together with one or more other therapeutic agents. In some embodiments, provided compositions comprise provided oligonucleotides, and one or more other therapeutic agents. In some embodiments, the one or more other therapeutic agents may have one or more different targets, and/or one or more different mechanisms toward targets, when compared to provided oligonucleotides in the composition. In some embodiments, a therapeutic agent is an oligonucleotide. In some embodiments, a therapeutic agent is a small molecule drug. In some embodiments, a therapeutic agent is a protein. In some embodiments, a therapeutic agent is an antibody. A number of a therapeutic agent may be utilized in accordance with the present disclosure. In some embodiments, provided oligonucleotides or compositions thereof are administered prior to, concurrently with, or subsequent to one or more other therapeutic agents and/or medical procedures. In some embodiments, provided oligonucleotides or compositions thereof are administered concurrently with one or more other therapeutic agents and/or medical procedures. In some embodiments, provided oligonucleotides or compositions thereof are administered prior to one or more other therapeutic agents and/or medical procedures. In some embodiments, provided oligonucleotides or compositions thereof are administered subsequent to one or more other therapeutic agents and/or medical procedures. In some embodiments, provide compositions comprise one or more other therapeutic agents.

#### Production of Pharmaceutical Compositions

[0315] For preparing pharmaceutical compositions from the compositions of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substance that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

[0316] In powders, the carrier is a finely divided solid in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

[0317] The powders and tablets preferably contain from 5% to 70% of the therapeutic agent. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active therapeutic agent with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0318] For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

[0319] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

[0320] When parenteral application is needed or desired, particularly suitable admixtures for compositions of the invention are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories. In particular, carriers for parenteral

administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like. Ampoules are convenient unit dosages. The compositions of the invention can also be incorporated into liposomes or administered via transdermal pumps or patches. Pharmaceutical admixtures suitable for use in the present invention include those described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309, which is herein incorporated by reference.

[0321] Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

[0322] Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

[0323] The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

[0324] The quantity of active component in a unit dose preparation may be varied or adjusted according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

#### Patient Populations

[0325] In some embodiments, an appropriate patient or population is one suffering from and/or susceptible to a disease, disorder or a condition associated with neurodegeneration (e.g., AD) or that otherwise would benefit from increased neurogenesis. In some embodiments, an appropriate patient or population is one suffering from and/or susceptible to a disease, disorder such as neuromuscular dysfunction, a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting or that otherwise would benefit from increased muscle regeneration).

[0326] In some embodiments, such neurodegenerative disease, disorder, or condition is one or more of Alzheimer's Disease (AD), Parkinson's disease, dementia (e.g., Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (e.g., chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (e.g., traumatic and/or anoxic brain injury), and Huntington's disease.

[0327] In some embodiments, population may additionally or alternatively be suffering from and/or susceptible to a disease or disorder of the lung. In some embodiments, such a disease or disorder is one or more of idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), pneumonia, and lung complications due to viral infections.

[0328] In some embodiments, an appropriate patient or population is model organisms. In some embodiments, an appropriate patient or population is humans. In some embodiments, a human has an age in a range of from about 0 months to about 6 months old, from about 6 to about 12 months old, from about 6 to about 18 months old, from about 18 to about 36 months old, from about 1 to about 5 years old, from about 5 to about 10 years old, from about 10 to about 15 years old, from about 15 to about 20 years old, from about 20 to about 25 years old, from about 25 to about 30 years old, from about 30 to about 35 years old, from about 35 to about 40 years old, from about 40 to about 45 years old, from about 45 to about 50 years old, from about 50 to about 55 years old, from about 55 to about 60 years old, from about 60 to about 65 years old, from about 65 to about 70 years old, from about 70 to about 75 years old, from about 75 to about 80 years old, from about 80 to about 85 years old, from about 85 to about 90 years old, from about 90 to about 95 years old or from about 95 to about 100 years old.

[0329] In some embodiments, a human is a human infant. In some embodiments, a human is a human

toddler. In some embodiments, a human is a human child. In some embodiments, a human is a human adult. In yet other embodiments, a human is an elderly human.

[0330] In some embodiments, an appropriate patient or population may be characterized by one or more criterion such as age group, gender, genetic background, preexisting clinical conditions, prior exposure to therapy.

[0331] In some embodiments, an appropriate patient or population is one suffering from e.g., neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting. In some embodiments, an appropriate patient or population is one suffering that has received surgery or experienced injury, trauma and/or prolonged immobilization (e.g., from bed-rest or casting). In some embodiments, an appropriate patient or population is one suffering from sarcopenia. In some embodiments, an appropriate patient or population is one suffering from or at risk of muscle fibrosis resulting from a disease or condition including, but not limited to, trauma, heritable disease, muscle disorder, and aging. Trauma can result from, for example, radiation treatment, crush injury, laceration, and amputation. In some embodiments, an appropriate patient or population is one suffering from or at risk of heritable disease associated with muscle fibrosis such as Congenital Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy; Amyotrophic Lateral Sclerosis (ALS), age-associated sarcopenia, Distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Myotonic muscular dystrophy, and Oculo-pharyngeal muscular dystrophy.

[0332] In some embodiments, an appropriate patient or population maybe defined by those in accordance with the screening tools for diseases or disorders associated with Alzheimer's disease. In some embodiments, an appropriate patient or population maybe defined by those in accordance with the screening tools for other diseases characterized by neurodegeneration, e.g., Parkinson's disease, dementia (e.g., Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (e.g., chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (e.g., traumatic and/or anoxic brain injury), and Huntington's disease.

[0333] In some embodiments, an appropriate patient or population maybe defined by those in accordance with the screening tools for diseases or disorders associated with muscle fibrosis and/or muscle wasting. In some embodiments, an appropriate patient or population may be defined by those in accordance with the screening tools and methods for diagnosing a disease associated with muscle fibrosis and/or muscle wasting.

[0334] In some embodiments, an appropriate patient or population may be defined according to the results obtained in structural imaging (e.g., magnetic resonance imaging (MRI), computed tomography (CT), ultrasound etc.). In some embodiments, an appropriate patient or population may be defined according to the results of cognitive tests. In some embodiments, an appropriate patient or population may be defined according to the results of neurological tests. In some embodiments, the cognitive tests involve one or more tests of Motor Screening Task (MOT), Reaction Time (RTI), Paired Associates Learning (PAL), Spatial Working Memory (SWM), Pattern Recognition Memory (PRM), Delayed Matching to Sample (DMS), Rapid Visual Information Processing (RVP). Rapid Visual Information Processing (RVP), Delayed Matching to Sample (DMS), Match to Sample Visual Search (MTS). In some embodiments, an appropriate patient or population may be defined according to the results of assessments such as measuring muscle enzymes, EMG, muscle biopsy, genetic testing, heart testing (e.g., ECG), assessments of strength and respiratory function.

#### Administration

[0335] Those skilled in the art will appreciate that, in some embodiments, dosage administered to a subject, particularly a human, may vary, for example depending on the particular therapeutic and/or formulation employed, the method of administration, the dosing regimen, one or more characteristics of the particular subject being treated, etc. In some embodiments, a clinician skilled in the art will determine the therapeutically effective amount of a therapeutic to be administered to a human or other subject in order to treat or prevent a particular medical condition. The precise amount of the therapeutic required to be therapeutically effective will depend upon numerous factors, e.g., such as the specific activity of the

therapeutic, and the route of administration, in addition to many subject-specific considerations, which are within those of skill in the art.

[0336] In some embodiments, administration may be ocular, oral, buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e.g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc.

[0337] Those skilled in the art, reading the present disclosure will appreciate that, in some embodiments, it may be desirable to achieve delivery of a MuSK-targeting oligonucleotide composition to muscle.

Alternatively or additionally, in some embodiments, it may be desirable to achieve delivery of a MuSK-targeting oligonucleotide composition to the CNS (e.g., the brain, such as the hippocampus and/or the subventricular region) and/or to the lung.

[0338] In some embodiments, a MuSK-targeting oligonucleotide composition is delivered via systemic delivery and/or local delivery to muscle (e.g., via intramuscular injection).

[0339] In some embodiments, a MuSK-targeting oligonucleotide composition is administered using a viral vector to effectively deliver a MuSK-targeting oligonucleotide composition in the form of a nucleic acid payload. In some embodiments, a viral vector targets certain cell types (e.g., myoblasts, myocytes, myotubes, satellite cells and myofibers). AAV1, AAV6, and AAV9 vectors have been used to target different muscle cell types (See, for example, Arnett et al., *Mol Ther Methods Clin Dev.* 1. pii: 14038, 2014 and Riaz et al., *Skeletal Muscle* 5 (37).sub.2015).

[0340] Those skilled in the art, reading the present disclosure will appreciate that, in some embodiments, it may be desirable to achieve delivery of a MuSK-targeting oligonucleotide composition to the CNS, and, in some embodiments to the brain.

[0341] In some embodiments systemic administration achieves delivery to CNS (e.g., brain e.g., hippocampus and/or subventricular zone). In some embodiments, an agent (e.g., an agonizing agent or MuSK-targeting oligonucleotide) is delivered to the central nervous system (CNS), via intracerebroventricular administration.

[0342] Additionally, certain viral vectors are known to selectively target neurons, and to effectively deliver genetic payloads to the brain. For example, AAV2/1 vectors have been established to effectively deliver nucleic acid payloads (e.g., gene therapy, encoded RNAs, etc) to neuronal cells in the hippocampus. See, for example, Hammond et al *PLOS One* 12:e0188830, 2017; Guggenhuber et al *PLOS One* 5:e15707, 2010; Lawlor et al *Mol. Neurodeg.* 2:11, 2007). Analogously, certain AAV vectors (e.g., AAV2/1 and/or AAV4 vectors) have been established to target and effectively deliver nucleic acid payloads to certain cells in the subventricular zone cells. See, for example, Liu et al *Gene Ther* 12:1503, 2005; Bockstael et al *Hum Gene Therap* 23:doi.org/10.1089/hum.2011.216, 2012).

[0343] For subjects suffering from or susceptible to a disease, disorder or condition associated with neurodegeneration, administration that achieves delivery to the CNS, e.g., to the brain (e.g., to the hippocampus and/or the subventricular region) may be desirable.

[0344] In some embodiments, effective delivery may be achieved by systemic administration of a composition as described herein. Alternatively or additionally, in some embodiments, effective delivery may be achieved by local administration to the CNS and/or to the brain, for example by intrathecal and/or intracavitary (e.g., intracerebroventricular) delivery.

[0345] Technologies for local administration to the CNS and/or to the brain have been developed and demonstrated to be effective, for example, for various protein therapeutics (see, for example Calias et al., *Pharmacol. & Therap.* 144:122, 2014), for small molecules (see, for example, Dodou *Pharm. J.* 289:501, 2012), for cell compositions (see, for example, Eftekharzadeh et al., *Iran J Basic Med Sci* 18:520, 2015); and nucleic acid therapeutics (see, for example, Otsuka et al, *J. Neurotrauma* 28:1063, 2011: see also prescribing information for onasemnogene abeparvovec-xioi [sold under the brand name Zolgensma™] and that for nusinersen [sold under the brand name Spinraza™]).

[0346] Those skilled in the art will be aware that intrathecal delivery may be particularly effective to achieve delivery to the hippocampus, including for cellular, protein, and nucleic acid therapeutics.

[0347] Systemic administration technologies (including, e.g., oral, parenteral, mucosal, etc) are well established for a wide variety of agents. Systemic administration that achieves CNS and/or brain delivery,

in some embodiments, may depend on ability to cross the blood brain barrier (BBB).

[0348] Certain active agents and/or delivery systems are known to cross the BBB. Recent technologies have been shown to achieve CNS and/or brain delivery even of agents, such as oligonucleotides, that had historically been considered to be particularly challenging in that regard. To give but one example, Min et al. *Angew Chem Int Ed Engl* doi: 10.1002/anie.201914751, 2020, incorporated herein by reference, describes glucose-coated polymeric nanocarriers that transport oligonucleotides across the BBB.

[0349] It has also been reported that incorporation of certain particular chemistries into oligonucleotide therapeutics can facilitate their travel across the BBB. For example, Khorkova et al (*Nature Biotech* 35:249, 2017, incorporated herein by reference) have described that: [0350] “2'-modified phosphorothioate oligonucleotides . . . may be particularly adaptable for CNS disorders, given their long half-life, with effects in the brain lasting up to 6 months following a single injection. In another type of sugar moiety modification, locked nucleic acids (LNAs), a bridge is introduced that connects the 2' oxygen and 4' carbon. This modification substantially elevates the melting temperature of the LNA-DNA and LNA-RNA hybrids, thus allowing the creation of shorter ODN-based compounds with increased bioavailability and reduced manufacturing costs. A recently proposed tricyclo-DNA, a conformationally constrained oligonucleotide analog, has three additional C-atoms between C (5') and C (3') of the sugar (FIG. 2). This modification increases stability, hydrophobicity and RNA affinity, and improves tissue uptake and BBB permeability”.

(Citations Omitted).

[0351] For subjects suffering from or susceptible to a disease or disorder such as idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), pneumonia, and lung complications due to viral infections, administration that achieves delivery to the lungs may be desirable.

[0352] In some embodiments, oligonucleotides (e.g., antisense oligonucleotides) are developed to enhance their delivery to target site(s). As described in the art, oligonucleotide is covalently or non-covalently bound to additional chemical moieties (e.g., a carrier or ligand) to enhance the delivery. See Thomas C. Roberts et al. *Nature Reviews Drug Discovery* volume 19, pages 673-694 (2020), the entirety of which is incorporated herein by reference).

[0353] As appreciated by those skilled in the art, various technologies of bioconjugation can be utilized to enhance the delivery oligonucleotides to target site(s). For example, oligonucleotides can be covalently conjugated to lipids (e.g., cholesterol that facilitates interactions with lipoprotein particles in the circulation), peptides (for cell targeting and/or cell penetration), aptamers, antibodies and sugars (e.g., N-acetyl galactosamine to enhance safer delivery to the target site (See Verma, *Ann Indian Acad Neurol*. 2018 21 (1): 3-8. doi: 10.4103/aian.AIAN\_298\_17), N-acetylgalactosamine (GalNAc)).

[0354] As appreciated by those skilled in the art, lipid conjugates include, e.g., oligonucleotides bound to Cholesterol,  $\alpha$ -tocopherol (vitamin E), long-chain (>C.sub.18) fatty acids, lipoprotein particles (for example, HDL and LDL), etc.

[0355] As appreciated by those skilled in the art, conjugation of N-acetylgalactosamine (GalNAc) can enhance the uptake of oligonucleotides into target sites (e.g., hepatocytes).

[0356] As appreciated by those skilled in the art, antibody and aptamer conjugates can be used to enhance oligonucleotide delivery. Various receptors have been successfully targeted for oligonucleotide delivery, including, e.g., the HIV gp160 protein, HER2, CD7 (T cell marker), CD71 (transferrin receptor, highly expressed in cardiac and skeletal muscle) and TMEFF2. Similarly, oligonucleotides have also been conjugated with antibodies against CD44 (a neural stem cell marker), EPHA2 and EGFR193. Additionally, aptamers can be conjugated to oligonucleotide to enhance its delivery.

[0357] As appreciated by those skilled in the art, various nanocarriers can be used to enhance oligonucleotide delivery. For example, oligonucleotide can form non-covalent complex with cationic polymers (for example, polyethylenimine), dendrimers, CPPs (for example, MPG-8, PepFect6, RVG-9R228, and Xentry-KALA229) and inorganic methods (for example, calcium phosphate nanoparticles).

[0358] As appreciated by those skilled in the art, various lipoplexes and liposomes (e.g., lipid nanoparticles (LNPs)) can be used to enhance oligonucleotide delivery.

[0359] In some embodiments, a MuSK-targeting oligonucleotide is modified to form a bioconjugate (e.g., conjugated with sugar, peptide, antibody, aptamer, lipid, etc.) to enhance its delivery to target site(s). In some embodiments, a MuSK-targeting oligonucleotide is formulated as lipoplexes and liposomes (e.g.,



lipid nano-particles (LNPs)) to enhance its delivery to target site(s).

[0360] Certain technologies have been developed to improve the efficiency of cellular delivery of ASOs to target site, e.g., muscle. For example, aminoglycosides (AGs) are shown to improve the delivery of antisense phosphorodiamidate morpholino oligomer (PMO) both in vitro and in vivo (See Wang, et al., *Mol Ther Nucleic Acids*. 2019; 16: 663-674, doi: 10.1016/j. omt.2019.04.023). Short cell-penetrating peptides (CPPs) that can be either directly attached to oligonucleotides through covalent linkages or through the formation of noncovalent nanoparticle complexes can facilitate cellular uptake (See McClorey et al.: *Biomedicine* 2018, 6 (2), 51). ASO fatty acid conjugates are also reported to enhance the functional uptake of antisense oligonucleotide (ASO) in the muscle (See Prakash et al.: *Nucleic Acids Research*, 47, 2019, 6029-6044).

[0361] Those skilled in the art will be familiar with eteplirsen (ExonDys 51), an approved treatment for Duchenne muscular dystrophy (DMD), which is a third-generation phosphorodiamidate morpholino ASO.

[0362] Eteplirsen, sold under the brand name Exondys 51™, (Sarepta Therapeutics) causes exon 51 to be spliced out in pre-mRNA, restoring the reading frame in the 13% of patients with amenable frame-shifting mutations (See Crudele et al. *Human Molecular Genetics*, Volume 28, Issue R1, pp. R102-R107, 2019).

[0363] Eteplirsen is administered via intravenous infusion over 35 to 60 minutes. In particular, its recommended dosage is 30 mg/kg body weight weekly. In a single-dose vial, the pharmaceutical composition is formulated as a 100 mg/2 ml or 500 mg/mL (50 mg/mL) solution.

[0364] Those skilled in the art will further be familiar with other delivery systems used with oligonucleotide therapeutics. For example, the first approved RNAi oligonucleotide therapeutic, Patisiran (Onpattro), which is developed by Alnylam Pharma for treatment for TTR (hereditary transthyretin amyloidosis, polyneuropathy), utilizes a nanoparticle delivery system (i.e., lipid nano-particles, LNP formulation); it also includes co-treatment with steroids and antihistamines.

[0365] Patisiran is administered via intravenous infusion. In particular, for patients weighing less than 100 kg, its recommended dosage is 0.3 mg/kg once every 3 weeks. For patients weighing 100 kg or more, the recommended dosage is 30 mg once every 3 weeks.

[0366] Other approved oligonucleotide therapeutics are typically administered via intravenous infusion to various organs, e.g., eyes, liver, skeletal muscle, spinal cord, etc.

[0367] In some embodiments, an oligonucleotide therapeutic as described herein may be administered intravenously. In some such embodiments, such oligonucleotide therapeutic may be administered according to a regimen reasonably comparable to that used for eteplirsen [sold under the brand name Exondys 51™]. In some such embodiments, such oligonucleotide therapeutic may be administered according to a regimen reasonably comparable to that used for Patisiran [sold under the brand name Onpattro].

[0368] In some embodiments a lower dose of an MuSK-targeting oligonucleotide oligonucleotide as described herein is 12 mg. In some embodiments, a total of 5 mg to 60 mg per dose of MuSK-targeting oligonucleotide is administered to a subject. In some embodiments, a total of 12 mg to 48 mg per dose of MuSK-targeting oligonucleotide is administered to a subject. In some aspects, a total of 12 mg to 36 mg per dose of MuSK-targeting oligonucleotide is administered to a subject. In some aspects, a total of 12 mg per dose of MuSK-targeting oligonucleotide is administered to a subject.

[0369] Those skilled in the art will be familiar with nusinersen [sold under the brand name Spinraza™], an antisense oligonucleotide therapeutic that targets the survival motor neuron-2 (SMN2)-directed gene transcript and is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. Spinraza is administered intrathecally: In particular, its recommended dosage is 12 mg/5 ml (2.4 mg/mL) in a single-dose vial per administration, according to a regiment that involves four loading doses: the first three of which are administered at 14-day intervals, and the fourth of which is administered 30 days after the 3rd dose: a maintenance dose is administered once every 4 months thereafter. It is recommended that platelet count, coagulation laboratory testing, and quantitative spot urine protein testing is done at baseline, and prior to each dose.

[0370] In some embodiments, an oligonucleotide therapeutic as described herein may be administered intrathecally. In some such embodiments, such oligonucleotide therapeutic may be administered according to a regimen reasonably comparable to that used for nusinersen [sold under the brand name Spinraza™].

[0371] In some embodiments, an oligonucleotide therapeutic as described herein may be administered

intrathecally. In some such embodiments, such oligonucleotide therapeutic may be administered according to a regimen reasonably comparable to that used for nusinersen [sold under the brand name Spinraza™]. [0372] An oligonucleotide therapeutic as described herein may be administered according to any of the dosing regimens described herein.

#### Cell Therapy

[0373] In light of the ability of MuSK-targeting oligonucleotide compositions, as described herein, to promote neurogenesis (e.g., in cell populations that are or comprise neural progenitor cells), those skilled in the art reading the present disclosure will appreciate that, among other things, the present disclosure provides technologies for enhancing level of neural cells present in a cell population. That is, contacting an original cell population with a MuSK-targeting oligonucleotide composition as described herein can generate a resulting population with an increased level and/or percentage of neural cells as compared with that in the original population: administration of such MuSK-targeting oligonucleotide composition as described herein can achieve such increase.

[0374] Additionally, MuSK-targeting oligonucleotide compositions, as described herein, promote muscle regeneration (e.g., in cell populations that are or comprise SCs, MPCs, and/or myoblasts), and those skilled in the art reading the present disclosure will appreciate that, among other things, the present disclosure provides technologies for enhancing level of SCs, MPCs, and/or myoblasts present in a cell population. That is, contacting an original cell population with a MuSK-targeting oligonucleotide composition as described herein can generate a resulting population with an increased level and/or percentage of SCs, MPCs, and/or myoblasts as compared with that in the original population: administration of such MuSK-targeting oligonucleotide composition as described herein can achieve such increase.

[0375] In some embodiments, an original cell population may be or comprise NSCs and/or NPCs. In some embodiments, an original cell population may be or comprise SCs, MPCs, and/or myoblasts. In some embodiments, an original cell population is or comprises embryonic stems cells and/or pluripotent stem cells. In some embodiments, embryonic stems cells and/or pluripotent stem cells are or have been differentiated into neural or neural precursor cells, for example using techniques known in the art (see e.g., U.S. Pat. No. 9,631,175). In some embodiments, embryonic stems cells and/or pluripotent stem cells are or have been differentiated into myogenic progenitor cells, for example using techniques known in the art (See e.g., Miyagoe-Suzuki et al . . . , Stem Cells Int. 7824614 2017).

[0376] In some embodiments, as discussed above, administration to a cell population delivers the MuSK-targeting oligonucleotide composition such that it is exposed to (i.e., contacts) a relevant original cell population in vivo (e.g., in a human, and in particular in an adult human, for example into in the brain—e.g., the hippocampus and/or subventricular region of the brain, of such human).

[0377] In some embodiments, as discussed above, administration delivers the MuSK-targeting oligonucleotide composition such that it is exposed to (i.e., contacts) a relevant original cell population in vivo (e.g., in a human, and in particular in an adult human, for example into muscle tissue, of such human).

[0378] In some embodiments, administration in accordance with the present disclosure contacts a MuSK-targeting oligonucleotide composition with a population of cells (e.g., an original population of cells), that for example, may be or comprise neural progenitor cells, SCs, MPCs, and/or myoblasts, ex vivo. For example, in some embodiments, a MuSK-targeting oligonucleotide composition is administered ex vivo (e.g., in vitro) to a population of cells from a subject. In some embodiments, a population of cells obtained from a subject.

[0379] Oligonucleotides that direct exon skipping of MuSK transcript(s) to favor forms that lack functional Ig3, and/or that direct degradation (and/or block translation) of forms that include functional Ig3, may be utilized.

[0380] In some embodiments, a population of cells is contacted with a MuSK-targeting oligonucleotide composition and simultaneously or subsequently stimulated and/or expanded. Alternatively or additionally, a population of cells is enriched and/or selected for cells exhibiting characteristics of activated NSCs (e.g., expression of Dex) or satellite cells or for expression of myogenic factors (e.g., Pax7, MyoD, myogenin, and MERGE) or for decreased/lack of expression of genes associated with the MuSK-BMP signaling pathway (e.g., RGS4, Msx2, Myf5, Ptx3, Id1).

[0381] In some embodiments, a resulting population of cells, achieved by contacting an original population of cells with a MuSK-targeting oligonucleotide composition ex vivo is then administered to a subject. In some embodiments, a resulting population of cells is administered to a subject suffering from or susceptible to a disease or disorder such as a neuromuscular dysfunction, a neurodegenerative disorder (e.g., AD), a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting. In some embodiments, a resulting population of cells is administered to the subject from whom the original population of cells was obtained. In some embodiments, a resulting population of cells is administered to a different subject than the one from which the original population of cells was obtained: in some such embodiments, the original population was obtained from a healthy subject and the resulting population is administered to a subject suffering from or susceptible to a disease or disorder such as a neurodegenerative disorder (e.g., AD), a neuromuscular dysfunction, a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting.

[0382] In some embodiments, administering a population of cells, contacted with a MuSK-targeting oligonucleotide composition effectively treats a disease or disorder such as a neuromuscular dysfunction, a neurodegenerative disorder (e.g., AD), a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting in the subject.

[0383] In some embodiments, a population of stimulated and/or expanded NSCs, SCs, MPCs, and/or myoblasts described herein can be formulated into a cellular therapeutic. In some embodiments, a cellular therapeutic includes a pharmaceutically acceptable carrier, diluent, and/or excipient. Pharmaceutically acceptable carriers described herein, for example, vehicles, adjuvants, excipients, and diluents, are well known and readily available to those skilled in the art. Preferably, the pharmaceutically acceptable carrier is chemically inert to the active agent(s), e.g., a cellular therapeutic, and does not elicit any detrimental side effects or toxicity under the conditions of use.

[0384] In some embodiments, a cellular therapeutic can be formulated for administration by any suitable route, such as, for example, intravenous, intratumoral, intraarterial, intramuscular, intraperitoneal, intrathecal, epidural, and/or subcutaneous administration routes. Preferably, the cellular therapeutic is formulated for a parenteral route of administration. In some embodiments, a cellular therapeutic is administered to a subject via an infusion.

[0385] In some embodiments, a cellular therapeutic suitable for parenteral administration can be an aqueous or non-aqueous, isotonic sterile injection solution, which can contain anti-oxidants, buffers, bacteriostats, and solutes, for example, that render the composition isotonic with the blood of the intended recipient. An aqueous or nonaqueous sterile suspension can contain one or more suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.

[0386] In some embodiments, a single therapeutic cell described herein is capable of expanding and providing a therapeutic benefit. In some embodiments, 10.sup.2 or more, e.g., 10.sup.3 or more, 10.sup.4 or more, 10.sup.5 or more, or 10.sup.8 or more, therapeutic cells are administered as a cellular therapeutic. Alternatively, or additionally 10.sup.12 or less, e.g., 10.sup.11 or less, 10.sup.9 or less, 10.sup.7 or less, or 10.sup.5 or less, therapeutic cells described herein are administered to a subject as a cellular therapeutic. In some embodiments, 10.sup.2-10.sup.5, 10.sup.4-10.sup.7, 10.sup.3-10.sup.9, or 10.sup.5-10.sup.10 therapeutic cells described herein are administered as a cellular therapeutic.

[0387] A dose of a cellular therapeutic described herein can be administered to a subject at one time or in a series of subdoses administered over a suitable period of time, e.g., on a daily, semi-weekly, weekly, bi-weekly, semi-monthly, bi-monthly, semi-annual, or annual basis, as needed. A dosage unit comprising an effective amount of a cellular therapeutic may be administered in a single daily dose, or the total daily dosage may be administered in two, three, four, or more divided doses administered daily, as needed. In some embodiments, a cellular therapeutic is administered in combination with another therapy.

#### Combination Therapy

[0388] In some embodiments, a MuSK-targeting oligonucleotide therapy as described herein is administered in combination with another therapy—e.g., so that a subject is simultaneously or sequentially exposed to both therapies.

[0389] The dosage of the MuSK-targeting oligonucleotide therapy as described herein and the dosage of another therapy administered in combination, as well as the dosing schedule can depend on various

parameters, including, but not limited to, the disease being treated (e.g., a neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder, or a genetic disease characterized by muscle wasting), the subject's general health, and the administering physician's discretion.

[0390] MuSK-targeting oligonucleotide therapy can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concurrently with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of the other therapy, to a subject in need thereof. In various embodiments MuSK-targeting oligonucleotide therapy and the other therapy are administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, 11 hours to 12 hours apart, no more than 24 hours apart or no more than 48 hours apart. In one embodiment, MuSK-targeting oligonucleotide therapy and the other therapy are administered within 3 hours. In another embodiment, MuSK-targeting oligonucleotide therapy and the other therapy are administered at 1 minute to 24 hours apart.

[0391] A synergistic combination of MuSK-targeting oligonucleotide therapy and the other therapy, might allow the use of lower dosages of one or both of these agents and/or less frequent administration of the therapies to a subject suffering from neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder, or genetic diseases characterized by muscle wasting. A synergistic effect might result in the improved efficacy of these agents and/or the reduction of any adverse or unwanted side effects associated with the use of either agent alone.

[0392] In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with a standard of care treatment for a relevant disease, disorder, or condition (e.g., a neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder, or genetic diseases characterized by muscle wasting).

[0393] Therapies for DMD include deflazacort (Emflaza; PTC Therapeutics) eteplirsen (Exondys 51; Sarepta Therapeutics), Ataluren (Translarna; PTC Therapeutics), and glucocorticoids such as prednisone. In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more therapies for DMD.

[0394] Approved therapies for ALS include Radicava, Rilutek, Tiglutik, and Nuedexta. In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more therapies for ALS.

[0395] Approved therapies for cardiomyopathy include but are not limited to angiotensin II-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and spironolactone. In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more therapies for cardiomyopathy.

[0396] In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more therapies that relieves a symptom or characteristic of a relevant disease, disorder or condition, or of a therapy therefor. In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more other therapies that relieves a symptom or characteristic so that the side effects associated with said other therapies are relieved. In some embodiments, the side effect associated with therapy is characterized by one or more of nausea, vomiting, loss of appetite, muscle cramps and spasms, increased frequency of bowel movements, headache, confusion and dizziness, constipation, fatigue, excessive saliva and phlegm, pain, depression, sleep problems, and uncontrolled outbursts of laughing or crying.

[0397] Any therapy which is known to be useful, or which has been used, will be used or is currently being used for the treatment or prevention of neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder, or genetic diseases characterized by muscle wasting, can be used in combination with the MuSK-targeting oligonucleotide therapy in accordance with the invention described herein.

## EXEMPLIFICATION

### Example 1: Design and Screening of MuSK-Targeting Oligonucleotides

[0398] In this Example, human MuSK-targeting oligonucleotides were designed and tested for their ability to induce exon skipping of the MuSK exon 6 and/or exon 7.

## Methods

### A. Cell Types

[0399] The choice of cell type was based on the expression of MuSK and the relevance of the cell type for the study. Two cell types were retained and tested: [0400] 1. HEK293 (ATCC, CRL-1573) is a cell line commonly used in neuroscience studies because of its ability to differentiate to neurogenic lineage (Shaw et al., 2002). [0401] 2. LHCN-M2 (Evercyte, CKHT-040-231-2) is a cell line that was shown to highly express MuSK (19.8NX according to ProteinAtlas). In HEK293, MuSK expression was variable, and sometimes not high enough to be detected with qPCR. In LHCN-M2, MuSK expression was more consistent and detectable. Therefore, LHCN-M2 was chosen.

### B. Cell Culture

[0402] LHCN-M2 were obtained from Evercyte (CKHT-040-231-2) and were cultured according to their protocol.

[0403] The cell vessels were pre-coated with 80 µl/cm<sup>2</sup> of 0.1% porcine gelatin (Sigma-Aldrich, Cat #G1890) in water for at least 4 h in 37° C. and up to one week. Before plating the cells, excess gelatin was removed.

[0404] For detachment, cells were rinsed twice with PBS (Thermofisher, 14190144) and were incubated with Trypsin-EDTA solution (Sigma, T3924-100ML) (room-temperature: 20 µl/cm<sup>2</sup>) for 2 minutes.

[0405] Once the cells are detached, about 160 µl/cm<sup>2</sup> of growth medium was added to the trypsin. Cells were detached by pipetting and diluted at the appropriate density (between 1/2 to 1/6). Final volume of growth medium was 240 µl/cm<sup>2</sup>.

[0406] LHCN-M2 cells were grown in MyoUp medium at 37° C. in a humidified atmosphere with 5% CO<sub>2</sub>. Cells were passaged twice a week when having reached about 30-40% confluence.

#### MyoUp Medium:

[0407] DMEM (Thermofisher Cat #10566016)/M199 (Gibco, Cat #31150022) (4+1) [0408] 15% Fetal bovine serum (FBS) (Hyclone, SH30071.03) [0409] 20 mM Hepes (Sigma Aldrich, Cat #H0887) [0410] 3 µg/ml Zinc sulfate (Sigma, Cat #Z0251) [0411] 1.4 µg/ml Vitamin B12 (Sigma, Cat #V2876) [0412] 0.055 µg/ml Dexamethasone (Sigma Aldrich, Cat #D4902) [0413] 2.5 ng/ml HGF (Merck Millipore, Cat #GF116) [0414] 10 ng/ml bFGF (Peprotech, Cat #100-18C)

### C. ASO Transfection

[0415] ASOs were diluted in cell culture grade water to reach a concentration of 100 UΜ and were preserved at -20° C.

[0416] LHCN-M2 cells were plated in gelatin-coated 6 well plates at 35,000 cells/well in 2.25 mL. After 2 days, cells reached 60% confluency and were ready to be transfected with the ASOs and lipofectamine RNAiMAX (Invitrogen, 13778150) according to the manufacturer's protocol:

TABLE-US-00006

Volume (µL)	Oligos	50 nM	100 nM	final	final
1-	Dilution of Lipofectamine in Opti-MEM	400	Opti-MEM	Lipofectamine	24
2-	Dilution of siRNA in Opti-MEM	400	400	OptiMEM	siRNA
8	of 8	of 50 µM	100 µM	3-	Add siRNA/Opti-MEM in siRNA/Opti-MEM
400	lipo-OptiMEM	Lipo/Opti-MEM	400	4-	Incubate 5 min at RT
5-	Add siRNA-lipo to cells	mix	250 µL	per well	siRNA/Lipo/Opti-MEM

[0417] 24 hours after transfection, cells were rinsed with PBS and the RNA was extracted.

### D. RNA Extraction

[0418] To obtain the best RNA extraction ratio, two kits were tested: Zymo Research Quick-RNA™ Miniprep Kit (cat #50444597) and Qiagen RNeasy Plus Mini Kit (cat #74136).

[0419] Cells were seeded in 6-well plates at a density of 45 000 cells/well. The RNA was extracted 2 days after seeding. The RNA concentration was measured using a nanodrop (Thermofisher, NanoDrop™ 8000 Spectrophotometer) and the results are given in Table 3.

TABLE-US-00007

TABLE 3	Yield of RNA extraction from LHCN-M2 cells with ZYMO or QIAGEN extraction kits.							
ZYMO	QIAGEN	Total	Total (ug)	A260/A280	(ug)	A260/A280	Control1	4.14
1.99	Control1	2.56	2.08	Control2	3.51	1.98	Control2	2.86
1.98	Control3	3.81	2.00	Control3	3.27	1.9		

[0420] With the Zymo kit, a yield of RNA extraction of 3.82 µg/well was obtained, while 2.9 µg/well was obtained with the Qiagen kit. Therefore, the Zymo kit was chosen for the study.

[0421] The Zymo Research Quick-RNA™ Miniprep Kit is used for RNA extraction (cat #50444597).

Zymo Kit Protocol:

[0422] All steps at room temperature and centrifugation at 13,000×g for 30 seconds, unless specified.

[0423] 1. Cells are lysed in 400 µL of RNA Lysis buffer using a cell scraper. [0424] 2. Lysates are vortexed for 20 s to be homogenized and centrifuged for 30 s at 13,000×g to remove the cell debris. [0425] 3. The supernatants are transferred into a Spin-Away™ Filter (yellow) in a Collection Tube and centrifuged to remove the majority of genomic DNA. [0426] 4. 0.5 volume of ethanol (95-100%) is added to the flow-through and well mixed. The samples are transferred into a Zymo-Spin™ IIICG Column (green) in a Collection Tube and centrifuged. [0427] 5. The RNA, attached to the column, is DNase treated. [0428] (D1) Wash the column with 400 µl RNA Wash Buffer and centrifuge. Discard the flow-through. [0429] (D2) In a nuclease-free tube, 5 µl DNase I (1 U/µl) is added to 75 µl DNA Digestion Buffer [0430] and mix. Mixture is directly added into the column matrix. [0431] (D3) The column incubates at room temperature (20-30° C.) for 15 minutes. [0432] 6. 400 µl of RNA Prep Buffer is added to the column and centrifuged. The flow-through is discarded. [0433] 7. 700 µl of RNA Wash Buffer is added to the column and centrifuged. The flow-through is discarded. [0434] 8. 400 µl of RNA Wash Buffer is added to the column and centrifuged for 1 min to ensure complete removal of the wash buffer. Then, the column is transferred into a 1.5 mL nuclease-free tube. [0435] 9. 100 µl of DNase/RNase-Free Water is added directly to the column matrix and centrifuged. [0436] 10. Extracted RNA is usually immediately transcribed to cDNA, or stored at -80° C. if necessary.

cDNA Transcription:

[0437] The reverse transcriptase SuperScript™ IV VILO™ Master Mix from Thermofisher (11756050) is used 4 µL of the enzyme is added to 16 µl of RNA (corresponding to ~550-650 ng).

[0438] According to the manufacturer's protocol, the reverse transcription is obtained by the following steps: [0439] 10 min at 25° C. to anneal the primers [0440] 10 min at 50° C. to perform the reverse transcription [0441] 5 min at 85° C. to inactivate the enzyme

[0442] The cDNA is then diluted by 2 in DNase RNase free water and conserved at -20° C. until the qPCR is done.

[0443] For MuSK analyses, the cDNA was used at this concentration.

[0444] For housekeeping gene analyses, the cDNA was further diluted by 5.

E. qPCR

[0445] Two qPCR technologies were tested, TaqMan and SYBR Green.

[0446] Relative MuSK expression was measured by qPCR using Taqman or SYBR green technology in LHCN-M2 cells. Both gave similar results regarding MuSK inhibition by siRNA (Thermofisher, 4392420) (FIG. 3). However, the Cq, related to the level of detection, was lower with SYBR green than for Taqman-around 22 and 27 respectively for the controls, indicating better detection with SYBR green technology. Since the level of detection is important to discriminate the level of MuSK inhibition between conditions, SYBR Green technology was chosen for the study.

SYBR Green qPCR Protocol:

[0447] To analyze the gene expression, SYBR Green technology was used. Results were normalized to two housekeeping genes (GAPDH and YWHAZ). qPCR was performed in 384-well plates. cDNA was used at 1/2 to analyze MuSK expression and at 1/10 to analyze HKG expressions. Measures were performed in duplicates or triplicates.

[0448] The primer sequences are shown below in Table 4:

TABLE-US-00008 TABLE 4 Gene Forward Reverse MuSK 34 (spanning CCTGCAAGTGAAGATGAAACCTAAA ATGAATCCTCAAGCTCCAGA the exon/exon (SEQ ID NO: 118) (SEQ ID NO: 119) junction 3-4) MuSK 67 (spanning GGCTCCTGAATCCCACAATG GAATGGACCCAGAAGAAACAGCA the exon/exon (SEQ ID NO: 120) (SEQ ID NO: 121) junction 6-7) GAPDH (HKG) CCTCAACGACCACTTTGTCA TTA CTCTTGGAGGCCATGT (SEQ ID NO: 122) (SEQ ID NO: 123) YWHAZ (HKG) CGAAGCTGAAGCAGGAGAAG TTTGTGGGACAGCATGGATG (SEQ ID NO: 124) (SEQ ID NO: 125)

[0449] In each well, 9 µL of the premix [3.5 µL RNase/DNase free water, 5 µL SYBR Green (Biorad, 1725120), 0.5 µL primer at 10 µM] is deposited and 1 µL of the cDNA at the appropriate dilution was

added. After being sealed, the plate was centrifuged, briefly vortexed and centrifuged a second time. The Thermocycler QuantStudio 6 or 7 Pro (Thermofisher) was used to perform the qPCR. The steps are: [0450] 30 s at 95° C. [0451] PCR (X40 cycles): [0452] 3 s at 95° C. [0453] 30 s at 60° C. [0454] Melting curve (step and hold, 4 s): [0455] 20 s at 65° C. [0456] 15 s at 95° C.

#### Design and Screen of Human ASOs

[0457] A first batch of 38 human antisense oligonucleotides (ASOs) were designed and then subsequently produced by Microsynth (Switzerland). The ASO sequences are shown below in Table 5.

TABLE-US-00009	TABLE 5	Oligo ID	SEQ ID	5' to 3' Sequence	Bld1	1
GCTAGGGTGGTCTTTTAGAAATGCA	Bld2	2	GGTCAAGCTAGGGTGGTCTTTTAGA	Bld3	3	
CTGCAGGAAATGGTCAAGCTAGGGT	Bld4	4	GAAGTGGTGAGTGACGCTCCTGCAG	Bld5	5	
GTTAGGAAGACAGAAGTGGTGAGTG	Bld6	6	ATCCTGGCAAAAAGTGTAGGAAGA	Bld7	7	
GTGGGATTCAGGAGCCCGCAGGATC	Bld8	8	GGTGACATTGTGGGATTCAGGAGCC	Bld9	9	
GGAGCCAAAGGTGACATTGTGGGAT	Bld10	10	GGTCACAAAGGAGCCAAAGGTGACA	Bld11	11	
ACAGTGCAGGGTCACAAAGGAGCCA	Bld12	12	CTGTTGCTGTACAGTGCAGGGTCAC	Bld13	13	
GGGACAGGAATGCCTGTTGCTGTAC	Bld14	14	CAGGTGATGGTGGGGACAGGAATGC	Bld15	15	
CCGTTTTCAATCCAGGTGATGGTGG	Bld16	16	TGACACTCACAGCATTTCGGTTTTTC	Bld17	17	
AAGTCCCCACACACATGACACTCAC	Bld18	18	GGTCTTCCCCAGACAAGTCCCCACA	Bld19	19	
ACTATGTCAGTAGATTTGAAGGGAA	Bld20	20	TCCCACTATACTATGTCAGTAGATT	Bld21	21	
TCAGTCAAGGATTTCCCACTATACT	Bld22	22	AAAAGAACTCAGTCAAGGATTTCCC	Bld23	23	
GTAAAGGAAAATAAAAGAACTCAGT	Bld24	24	AACCTGACAGAGTAAAGGAAAATAA	Bld25	25	
GGACCCAGAAGAAACCTGACAGAGT	Bld26	26	CACTCTCTTGAATGGACCCAGAAGA	Bld27	27	
CACTCGGTCTTTCACACTCTCTTGA	Bld28	28	GTCTTGAGTCAATCACTCGGTCTTT	Bld29	29	
GATAAACAGCTGCAGTCTTGAGTCA	Bld30	30	AGTCCTGGCTTGGTGATAAACAGCT	Bld31	31	
ATGTGTAGAGTCCTGGCTTGGTGAT	Bld32	32	GTAGCTATGCATGTGTAGAGTCCTG	Bld33	33	
TGCTTATTGGTAGCTATGCATGTGT	Bld34	34	ACTTCTCCCCATGCTTATTGGTAGC	Bld35	35	
CCTTGGCAGTACTGAACTTCTCCCC	Bld36	36	CCTGCTATGCTGATGGTGGCTGCAG	Bld37	37	
GGGCATCCTACCTGCTATGCTGATG	Bld38	38	GCAAATGTGAAGGGGCATCCTACCT			

[0458] All ASOs Bld1-Bld38 were designed to include 2'-MOE modification on each sugar and where there is a phosphorothioate internucleotidic linkage between each nucleotide. Sequences were designed so that they would avoid activation of RNase H. All ASOs were 25 nucleotides in length. Alignment of ASOs Bld1-Bld38 to the MuSK genomic sequence along regions including exons 6 and 7 is shown in FIG. 4.

#### Antisense Oligonucleotides Targeting Exon6

##### i. Alignment to the Genetic Sequence

[0459] The ASOs were designed to be complementary to regions of the MuSK Exon6 genetic sequence, presented in FIG. 5.

##### ii. Cell Observations

[0460] Cells were plated at 30,000 cells/well in gelatin pre-coated 6-well plates and were transfected 48 h after seeding with ASO at 50 nM and 100 nM. 24 h after transfection, cells were observed (FIG. 4) and the RNA was extracted and analyzed. FIG. 6 shows microscopic acquisitions of LHCN-M2 cells 24 h after being transfected with the ASO at 100 nM (Scale=100 nm). The data of Bld5, Bld8, Bld10, and Bld18 are not shown.

[0461] Some ASOs induced a visible effect to the cells after 24 h: Bld8 (data not shown), Bld5 (data not shown), Bld10 (data not shown), Bld126 and Bld14 appeared to have a negative effect on the cell health. Other ASOs induced small differences. For example, cells transfected with the ASOs Bld11, Bld13, and Bld15 were shorter. Otherwise, cells in the other treatment groups were healthy and similar to the control, including Bld18, the data of which are not shown in FIG. 6 and Bld9.

##### iii. MuSK Expression Analyses

[0462] 24 h after transfection, RNA was extracted and MuSK expression was measured by qPCR. The primers were designed to span either the 3-4 exon/exon junction (named MuSK34) or the 6-7 exon/exon junction (named MuSK67). The MuSK34 primer therefor detects all forms of the MuSK transcript (both the long form (i.e., containing the Ig3 domain and the short form (i.e., MuSKΔIg3)) while the MuSK67 primer detects only the long form of MuSK and not MuSKΔIg3. The primer design rationale is shown in FIG. 2. Results were normalized to two housekeeping genes, YWHAZ and GAPDH, whose stabilities

were assessed using the software BestKeeper and are shown in FIG. 7.

[0463] The qPCR results show that the ASOs Bld7, Bld8, Bld9, Bld11, Bld13, Bld16, Bld15, and Bld18 induced a decrease in the expression of MuSK34 (>75%) and of MuSK67 (>90%). The ASOs Bld13, Bld4, Bld5, Bld6, Bld12 and Bld14 and Bld17 induced a decrease of MuSK34 (between 50-75%) and a higher decrease of MuSK67 (70-85%). The ASOs Bld3 and Bld17 induced slighter effects on MuSK34 and MuSK67 expression (20-50%). Finally, the two ASOs Bld1 and Bld18 induced an increase in the expression of MuSK34 and 67.

[0464] The goal of the screen of ASOs was to identify an ASO that would induce a moderate/important decrease of MuSK67 with no effect on MuSK34 (i.e., would induce an increase in MuSKΔIg3). The results shown in FIG. 7 indicate that the ASOs tested targeting Exon 6 may not be targeting the appropriate region to obtain a good skipping of Exons 6 and 7.

[0465] The results were correlated with the ASO alignment (FIG. 8) in order to identify key regions on the sequence important for MuSK expression. In FIG. 8, Green indicates a slight decrease or an increase in MuSK expression (between 90-300% of the control). Orange indicates a moderate decrease in MuSK expression (MuSK34 between 40 and 70% of the control, MuSK67<45% of the control). Red indicates high decrease in MuSK expression (MuSK34<40% of the control, MuSK67<20% of the control). Red areas indicate key regions for the expression of MuSK where ASOs induced a decrease of MuSK34 by >60% and MuSK67 by >80%.

[0466] The relative expression of MuSK 67 for each of the ASOs Bld1-Bld18 at 50 nM are shown in Table 6 below:

TABLE-US-00010	TABLE 6	Relative Oligo SEQ MuSK	67	ID	ID	NO:	Sequence-(5' to 3').sup.a			
expression.sup.b	ASOs	targeting	exon	6	Bld1	78	G*C*T *A*G*G *G*T*G *G*T*C			
*T*T*T	*T*A*G	*A*A*A	1.0449	*T*G*C	*A	Bld2	79 G*G*T *C*A*A *G*C*T			
*A*G*G	*G*T*G	*G*T*C	*T*T*T	0.4366	*T*A*G	*A	Bld3 80 C*T*G *C*A*G			
*G*A*A	*A*T*G	*G*T*C	*A*A*G	*C*T*A	0.5139	*G*G*G	*T Bld4 81 G*A*A			
*G*T*G	*G*T*G	*A*G*T	*G*A*C	*G*C*T	*C*C*T	0.1545	*G*C*A *G Bld5 82			
G*T*T	*A*G*G	*A*A*G	*A*C*A	*G*A*A	*G*T*G	*G*T*G	0.2419 *A*G*T *G Bld6			
83 A*T*C	*C*T*G	*G*C*A	*A*A*A	*A*C*T	*G*T*T	*A*G*G	0.3612 *A*A*G *A Bld7			
84 G*T*G	*G*G*A	*T*T*C	*A*G*G	*A*G*C	*C*C*G	*C*A*G	0.0180 *G*A*T *C			
Bld8 85	G*G*T	*G*A*C	*A*T*T	*G*T*G	*G*G*A	*T*T*C	*A*G*G 0.0098 *A*G*C *C			
Bld9 86	G*G*A	*G*C*C	*A*A*A	*G*G*T	*G*A*C	*A*T*T	*G*T*G 0.0091 *G*G*A			
*T Bld10	87 G*G*T	*C*A*C	*A*A*A	*G*G*A	*G*C*C	*A*A*A	*G*G*T 0.0099			
*G*A*C	*A	Bld11 88	A*C*A	*G*T*G	*C*A*G	*G*G*T	*C*A*C *A*A*A *G*G*A			
0.0103	*G*C*C	*A	Bld12 89	C*T*G	*T*T*G	*C*T*G	*T*A*C *A*G*T *G*C*A			
*G*G*G	0.0053	*T*C*A	*C	Bld13 90	G*G*G	*A*C*A	*G*G*A *A*T*G *C*C*T			
*G*T*T	*G*C*T	0.0088	*G*T*A	*C	Bld14 91	C*A*G	*G*T*G *A*T*G *G*T*G			
*G*G*G	*A*C*A	*G*G*A	0.0911	*A*T*G	*C	Bld15 92	C*C*G *T*T*T *T*C*A			
*A*T*C	*C*A*G	*G*T*G	*A*T*G	*G*T*G	0.0222	*G	Bld16 93 T*G*A *C*A*C			
*T*C*A	*C*A*G	*C*A*T	*T*T*C	*C*G*T	*T*T*T	0.0558	*C	Bld17 94	A*A*G	
*T*C*C	*C*C*A	*C*A*C	*A*C*A	*T*G*A	*C*A*C	0.6501	*T*C*A	*C	Bld18 95	
G*G*T	*C*T*T	*C*C*C	*C*A*G	*A*C*A	*A*G*T	*C*C*C	1.6763	*C*A*C	*A	.sup.a*

represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar. .sup.ba value of 1.0 represents the level of MuSK67 expression for untreated cells.

#### Antisense Oligonucleotides Targeting Exon7

##### i. Alignment to the Genetic Sequence

[0467] The alignment of the ASOs Bld19-Bld38 on the genetic sequence of Exon7 of MuSK is presented in FIG. 9.

##### ii. Cell Observations

[0468] Cells were plated at 30,000 cells/well in gelatin pre-coated 6-well plates and were transfected 48 h after seeding with ASO at 50 nM and 100 nM. 24 h after transfection, cells were observed (FIG. 10) and the RNA was extracted and analyzed. FIG. 10 shows microscopic acquisitions of LHCN-M2 cells 24 h after being transfected with the ASO at 100 nM (Scale=100 nm).

[0469] After 24 h of transfection, cells looked healthy in all conditions. Cells transfected with the ASOs



Bld19 and Bld30 were shorter than the control, while cells transfected with the ASOs Bld32 and Bld34 were more elongated. Cell transfected with the ASOs Bld23, Bld24, Bld25, Bld26, Bld27, Bld28, Bld35, Bld36, Bld37, Bld38 did not present any significant differences compared to the control (data not shown).

### iii. MuSK Expression Analyses

[0470] 24 h after transfection, RNA was extracted, and MuSK gene expression was analyzed in qPCR (FIG. 11). Methods described for screen of ASOs to Exon6 were used.

[0471] Relative expression of each ASO at 50 nM is shown in Table 7 below:

TABLE-US-00011	TABLE 7	Relative Oligo SEQ	MuSK 67	ID	ID	NO:	Sequence-(5' to 3').sup.a				
expression.sup.b	ASOs	targeting	exon 7	Bld19	96	A*C*T	*A*T*G *T*C*A *G*T*A				
*G*A*T	*T*T*G	*A*A*G	1.1548	*G*G*A	*A	Bld20	97 T*C*C *C*A*C *T*A*T				
*A*C*T	*A*T*G	*T*C*A	*G*T*A	1.7641	*G*A*T	*T	Bld21	98 T*C*A *G*T*C			
*A*A*G	*G*A*T	*T*T*C	*C*C*A	*C*T*A	0.4483	*T*A*C	*T	Bld22	99 A*A*A		
*A*G*A	*A*C*T	*C*A*G	*T*C*A	*A*G*G	*A*T*T	1.0207	*T*C*C	*C	Bld23	100	
G*T*A	*A*A*G	*G*A*A	*A*A*T	*A*A*A	*A*G*A	*A*C*T	1.8924	*C*A*G	*T	Bld24	101
A*A*C	*C*T*G	*A*C*A	*G*A*G	*T*A*A	*A*G*G	*A*A*A	1.1254	*A*T*A	*A	Bld25	102
G*G*A	*C*C*C	*A*G*A	*A*G*A	*A*A*C	*C*T*G	*A*C*A	0.1010				
*G*A*G	*T	Bld26	103	C*A*C	*T*C*T	*C*T*T	*G*A*A	*T*G*G	*A*C*C	*C*A*G	0.1450
A*A*G	*A	Bld27	104	C*A*C	*T*C*G	*G*T*C	*T*T*T	*C*A*C	*A*C*T	*C*T*C	0.1570
*T*T*G	*A	Bld28	105	G*T*C	*T*T*G	*A*G*T	*C*A*A	*T*C*A	*C*T*C		
*G*G*T	0.1024	*C*T*T	*T	Bld29	106	G*A*T	*A*A*A	*C*A*G	*C*T*G	*C*A*G	
*T*C*T	*T*G*A	0.0555	*G*T*C	*A	Bld30	107	A*G*T	*C*C*T	*G*G*C	*T*T*G	
*G*T*G	*A*T*A	*A*A*C	0.1978	*A*G*C	*T	Bld31	108	A*T*G	*T*G*T	*A*G*A	
*G*T*C	*C*T*G	*G*C*T	*T*G*G	0.0871	*T*G*A	*T	Bld32	109	G*T*A	*G*C*T	
*A*T*G	*C*A*T	*G*T*G	*T*A*G*	A*G*T	0.3343	*C*C*T	*G	Bld33	110	T*G*C	
*T*T*A	*T*T*G	*G*T*A	*G*C*T	*A*T*G	*C*A*T	1.0718	*G*T*G	*T	Bld34	111	
A*C*T	*T*C*T	*C*C*C	*C*A*T	*G*C*T	*T*A*T	*T*G*G	0.3860	*T*A*G	*C	Bld35	112
C*C*T	*T*G*G	*C*A*G	*T*A*C	*T*G*A	*A*C*T	*T*C*T	0.3559	*C*C*C	*C	Bld36	113
C*C*T	*G*C*T	*A*T*G	*C*T*G	*A*T*G	*G*T*G	*G*C*T	0.3926	*G*C*A			
*G	Bld37	114	G*G*G	*C*A*T	*C*C*T	*A*C*C	*T*G*C	*T*A*T	*G*C*T	0.4601	
*G*A*T	*G	Bld38	115	G*C*A	*A*A*T	*G*T*G	*A*A*G	*G*G*G	*C*A*T	*C*C*T	0.3908

.sup.a represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar. .sup.ba value of 1.0 represents the level of MuSK67 expression for untreated cells.

[0472] ASOs Bld29 and Bld31 induced a decrease in the expression of MuSK34 (>75%) and of MuSK67 (>90%). ASOs Bld30, Bld32 and Bld34 induced a decrease of MuSK34 (between 40-60%) and a higher decrease of MuSK67 (55-85%). ASO Bld19 induced slighter effects on MuSK34 and MuSK67 expression (<20%). ASOs Bld19, Bld20, Bld24, Bld23 and Bld33 induced an increase in expression of MuSK34 and 67.

[0473] ASOs Bld25, Bld26, Bld27, Bld28, Bld35 and Bld38 induced a decrease of MuSK67>60% at 50 nM and a decrease of MuSK34<40% for both concentrations. Therefore, these ASOs were considered good candidates to be tested at additional doses.

[0474] The alignment of these results to the genetic sequences indicated that one region is key region to regulate the splicing of the exons 6 and 7 without affecting the transcription of the other exons (indicated in purple in FIG. 12).

[0475] The alignment of these results to the MuSK exon7 genetic sequence indicated that some regions may be key regions to regulate the splicing of the exons 6 and 7 without affecting the transcription of the other exons (indicated in purple in FIG. 12). In FIG. 12, green indicates a slight decrease or an increase in MuSK expression (between 90-300% of the control). Orange indicates a moderate decrease in MuSK expression (MuSK34 between 40 and 70% of the control, MuSK67<45% of the control). Red indicates high decrease in MuSK expression. MuSK34<40% of the control, MuSK67<20% of the control Purple and grey areas indicate regions that may be targeted to obtain an efficient skipping of exons 6/7 with lower effect on other exons based on the results shown in FIG. 11 (i.e., the regions targeted by ASOs hu7-10, hu73, hu717, hu730, hu711 and hu7158). These regions "region 1" and "region 2" are shown in FIG. 4.

#### Dose Response of Exemplary ASO Candidates

[0476] The first ASO screen at 50 and 100 nM indicated that Bld25, Bld26, Bld27, Bld28, Bld35 and Bld38 were potential candidates that could induce efficient skipping of exons 6/7 to generate MuSK $\Delta$ Ig3 transcript expression. These ASOs were tested at different concentrations: 2.5, 5, 25, 125 and 400 nM to examine the dose response. Results are shown in FIG. 13 (panels A-F).

[0477] Specifically, FIG. 13 shows relative MuSK expression in response to various doses of the 6 candidate ASOs (Bld25 (A), Bld26 (B), Bld27 (C), Bld28 (D), Bld35 (E), Bld38 (F)). MuSK34 (in blue) and MuSK67 (in red) expression was measured by qPCR and each was normalized to the housekeeping genes and to the values obtained for untreated cells. The estimated IC is indicated on each graph. The 5 tested doses were 2.5, 5, 25, 125, 400 nM.

[0478] The results from the dose response study indicated that ASO Bld35 induced both a decrease of MuSK34 and of MuSK67 of 20-40% and 50-70%, respectively. Therefore, the difference between the expression of MuSK34 and MuSK67 is too low to obtain a high ratio of  $\Delta$ Ig3 MuSK without affecting the transcription of the other exons.

[0479] For the ASOs that Bld25, Bld26, Bld27, Bld28 and Bld38, MuSK34 expression was between 75 and 85% of the control level while MuSK67 was at 50% of the control level, making them potential candidates.

[0480] For ASO Bld38, the inhibition of MuSK67 was limited at 60% of the control level, even at high concentrations (400 nM).

[0481] For ASOs Bld27 and Bld28, a concentration higher than 125 nM induced a decrease in MuSK34 expression >75%.

[0482] For ASOs Bld25 and Bld26, MuSK34 expression reached a plateau of 60% of the control level when the ASO concentration was between 25 and 400 nM, while MuSK67 expression decreased to 10% of the control. These results indicate that ASOs Bld25 and Bld26 result in a targeted decrease in expression of MuSK67, with less of an effect on MuSK34 expression, making them the 2 best candidates of this study. The estimated IC<sub>50</sub> values were 11.5 nM and 11.4 nM for Bld25 and Bld26, respectively.

[0483] A more targeted dose response was performed in this area to refine these results (FIG. 14). These additional data indicated that the IC<sub>50</sub> is actually between 5 and 7.5 nM for both Bld25 and Bld26. With ASO Bld26, MuSK34 expression dropped at the same ASO concentration as MuSK67 (7.5 nM). With ASO Bld25, at a concentration of 7.5 nM, MuSK67 expression decreased by 70% while MuSK34 expression was at 94% of the control. Therefore, Bld25 may be a better candidate than Bld26 to obtain a selective skipping of exons 6 and 7.

[0484] An additional test was done by combining both Bld25 and Bld26 at a final concentration of 12.5 nM. Results are shown in FIG. 15. Specifically, FIG. 19 shows MuSK34 expression in green and MuSK67 expression in red measured by qPCR and normalized to housekeeping genes and to the controls.

[0485] The Bld25/Bld26 mix resulted in MuSK34 expression at a level of 72% of the control level, while MuSK67 expression was at a level of 6% of the control level. Of note, MuSK67 expression was at 8% when inhibited by siRNA (Thermofisher, cat #4392420, Assay Id s224071) against MuSK at 10 nM (data not shown). These results suggest that combining several oligos (e.g., Bld25 and Bld26) may be a good strategy to obtain a selective skipping of exons 6 and 7.

#### Confirmation of Exon Skipping by Gel Migration

[0486] To verify the ASO-induced splicing of the RNA, we amplified the genetic sequence from exon 3 to exon 9 by PCR and the size of the PCR product was measured by migrating it on gel electrophoresis.

[0487] Several forms of MuSK RNA exist naturally in human. 3 variants were identified in the literature (FIG. 26):

[0488] Variant 1, NM\_005592.4 (full length: 972 bp and  $\Delta$ Ig3: 687 bp) [0489] Variant 2, NM\_001166280.2 (full length: 783 bp and  $\Delta$ Ig3: 453 bp) [0490] Variant 3, NM\_001166281.2 (full length: 708 bp and  $\Delta$ Ig3: 423 bp)

[0491] Full length and  $\Delta$ Ig3 indicate the lengths of the full-length sequence and  $\Delta$ Ig3 (6,7) sequence amplified by PCR from exon 3 to exon 9. Compared to variant 1, the exon 8 is missing in variant 2 and variant 3. In addition, a small exon of 30 bases is present only in variant 2. Therefore, skipping exons 6 and 7 would produce 3 additional MuSK RNA forms.

[0492] The sequence of exon3-9 of the cDNA from the dose response presented in FIG. 10 was amplified by PCR in the conditions without or with hu7-10 (Bld25) and hu73 (Bld26) at 5 and 25 nM. Results from

the gel electrophoresis are shown in FIG. 16. In FIG. 16, “Long” (with exon6-7) and “Short” (without exon 6-7, i.e.,  $\Delta$ Ig3) designed synthetic sequences were based on variant 1.

[0493] As shown in FIG. 16, several bands were detected. In the control conditions, major bands were visible at approximately 1 kb, 970b (red arrow), and a double band at 700-750b (green arrows) (see FIG. 16, panel B). In conditions where splicing of the exons 6/7 occurred (confirmed previously by qPCR), major bands were observed at approximately 690b (yellow arrow) and 450b (blue arrow) (FIG. 16, panel B'), and a lighter band at 970b. An additional double band was detected at 600b (orange arrow).

[0494] Based on the sequences presented in FIG. 16 it appears that:

[0495] The red arrow indicated the cDNA of variant 1 full-length (972 bases), while the double bands highlighted by the green arrow correspond to the variant 2 and 3 full-length (738 and 708 bases respectively). This would explain why we observed a small fraction of the red band in the Bld25 at 25 nM condition (see FIG. 16 B') and the fraction of the green band was too light to be detected.

[0496] For the ASO hu7-10 (Bld25) at 25 nM, the yellow band corresponded to  $\Delta$ 6,7 variant 1 (687 bases) and the blue band corresponded to  $\Delta$ 5+,6,7 variant 2 and  $\Delta$ 6,7 variant 3 (453 bases).

[0497] Next the bands were sequenced to confirm these bands correspond to the indicated variants.

## CONCLUSIONS

[0498] This study aimed to find ASOs that would induce the skipping of the exons 6 and 7 in MuSK protein without affecting the other exons. 38 ASOs were designed and manufactured to be tested. LHCN-M2 cell line was chosen for its qPCR detectable MuSK expression.

[0499] In the first screening, we tested each of the 38 ASOs at concentrations of 50 and 100 nM. From this screen, the 6 best candidates in a key region near/on the exon 7 were selected for further testing. These 6 candidates were further tested at different doses: 2.5, 5, 25, 125 and 400 nM. The results indicated that a dose below 25 nM would be enough to obtain the desired splicing without affecting the transcription of the other exons, and that 2 ASOs, Bld25 and Bld26, were better to obtain the desired splicing, while maintaining stability of the expression of the other exons at higher doses. These 2 candidates were tested at additional doses, 5, 7.5, 12.5 and 25 nM. These results indicated that the IC50 would be between 5 and 7.5 nM for both ASOs. Additionally, Bld25 was considered the best candidate since there is a dose (7.5 nM) where we obtained an efficient skipping of exons 6/7 (by 70%) with little effect on the other exons (expression was 94% of the control level).

[0500] Additionally, a combination of these 2 candidates (Bld25 and Bld26) at 12.5 nM was also shown to be efficient in reducing the level of expression of full-length MuSK transcripts by 94% (indicated by MuSK67 in FIG. 15), where the total MuSK expression (indicated by MuSK34 in FIG. 15) was only reduced by 28%. Migration on gel electrophoresis and further sequence confirmed this was due to exon skipping.

Example 2: In Vivo Evaluation of Exon-Skipping Induced by MuSK-Targeting Oligonucleotides

[0501] Preliminary confirmation of activities for oligonucleotides provided herein have been confirmed by testing corresponding murine oligonucleotide sequences in an established mouse model. See, e.g., Renault et al., 2009, the entirety of which is incorporated herein by reference.

[0502] In this experiment, the corresponding murine oligonucleotides are further evaluated in vivo in wild-type mice at ages where AHN has declined. Further evaluations such as pharmacodynamic and safety studies are conducted to establish optimal conditions for ASO-mediated MuSK exon skipping in aging wild type mice.

Experiment #1: Tolerability, Exon Skipping and PK

[0503] ASOs are delivered by intracerebroventricular (ICV) stereotactic injection in 4 doses ranging from 5-100  $\mu$ g, n=6/group. A scrambled ASO (with the same number of bases) will serve as a control.

[0504] Mice are monitored for potential immediate safety signals (e.g. seizures, hindlimb weakness, prolonged lethargy) and animals where these issues do not resolve within the first hours after dosing are euthanized.

[0505] Mice receiving doses that do not show tolerability signals are monitored daily.

[0506] Unfixed brains are harvested at 4 weeks. One-half of the brains are sectioned and analyzed by histology for signs of inflammation or other toxicity by a board-certified veterinary pathologist.

[0507] The hippocampus and cortex from the other half are dissected and further divided for RNA isolation and PK analysis. The level of MuSK alternative splicing (i.e., skipping of exons 6-7) are assessed

by TaqMan assays and gel-based PCR as described in Examples 1-2. For the latter, gel bands are excised and sequenced to confirm correct skipping. The remaining portion for of cortex are used for HPLC quantification of the ASO (PK).

#### Experiment #2. Neurogenesis (Fixed Brains)

[0508] Neurogenesis Group size: To determine the number of animals required to assess increased neurogenesis, a power analysis using G\*Power version 3.1 was performed (Faul et al., 2007). To allow for possible loss of animals during the experiment 6 animals/group are allocated. Analyses is performed using either GraphPad Prism or R.

[0509] In this experiment, ASOs are delivered to a second set of animals with at least three non-toxic doses (as determined in Experiment 1).

[0510] For these animals EdU is delivered from 3 to 4 weeks post-injection. Animals are perfused, fixed and immunohistochemistry is performed against EdU and DCX to assess the numbers of new neurons (EdU+/DCX+ cells).

[0511] Maturation of the newborn cells is assessed by performing a 30-day chase after administration of the EdU and measuring Edu+/NeuN+ cells.

#### Experiment #3. Cognition

[0512] Cognition group size: An analysis using G\*Power 3.1.9.4. (Faul et al., 2007) was performed to determine the group size of cognition experiment. Based on the prior studies, 18 animals per group is sufficient to observe an effect size (d) of 1 (a=0.05: power=0.80).

[0513] Aged wild-type mice are dosed by ICV at 11 months of age and are assessed for cognition at 12 months of age. A single dose is performed to promote AHN as determined from Experiment #2 (18 animals per group).

[0514] The mice are evaluated using tests including Novel Object Location task, a hippocampal-dependent spatial learning task, and a Conditioned Fear and a Y-maze to measure spatial working memory (Gotz and Ittner, 2008), two tasks commonly used to test cognition.

[0515] Pairwise comparisons will be analyzed by using the Student's t test. Experiments with more than two groups will be analyzed using a Bonferroni correction for multiple comparisons.

[0516] Female mice. Efficacy of ASO treatment on promoting neurogenesis using the optimal dose determined above in female mice is also assessed.

[0517] Discussion Experiments 1-3 are designed such that they will relate the dose delivered to safety, PK, level of MuSK splicing, degree of AHN promotion and cognitive improvement.

[0518] A 4 week period of exposure was utilized since this is the time course over which NSCs are born and mature (Babcock et al., 2021). However, additionally studies with longer exposures, with and without repeat dosing will also be performed.

[0519] In addition to the HPLC measurement of ASO in the brain hybridization-based method will also be utilized.

#### Example 3: In Vivo Evaluation of Exon-Skipping Induced by MuSK-Targeting Oligonucleotides in FAD Model

[0520] In this experiment, the corresponding murine oligonucleotides from Example 2 are evaluated in Familial Alzheimer's Disease (FAD) mouse model where plaque burden is well established and tangles are present. This experiments aims to determine whether corresponding murine oligonucleotides and the exon-skipping approach is effective in the hostile, inflammatory milieu along with a high plaque burden and neurofibrillary tangles that characterize the AD brain, and whether corresponding oligonucleotides promote AHN in an FAD mouse model.

[0521] FAD Mouse Model. 3×Tg is used in this experiment, which harbors transgenes for Tau, PSEN1 and APP FAD alleles (Oakley et al., 2006; Kimura and Ohno, 2009; Belfiore et al., 2019). This model has been characterized and develops both amyloid plaques at 6 months and neurofibrillary tangles by 12 months. AHN is decreased as early as 3 months of age and is essentially undetectable by 12 months. We have confirmed a reduction AHN at 6 months in these mice. This decrease in AHN is strongly correlated with the increase in amyloid burden (Rodríguez et al., 2008). Animals are dosed with ASO at 11 months and analyzed at 12 months of age, when AHN and cognitive phenotypes are evident. Female 3×Tg mice are used since they show an earlier and more consistent pathological profile (Belfiore et al., 2019).

[0522] Experimental Approach. The dosing strategy (level, duration) is based on the results from Example

3. Three groups are dosed: scrambled ASO, and two doses of MuSK exon-skipping ASOs. Group sizes will be n=18 in order to assess both AHN and cognition. 6 animals from each group are also treated with EdU once a day for 7 days for neurogenesis analysis. In order to control for potential effects of handling, the remaining animals are injected with saline. Neurogenesis and cognition analyses are performed as described in Example 3. The effects of ASO treatment on AD histopathology is also assessed.

#### Example 4: Formulation and Administration of MuSK-Targeting Oligonucleotides

##### A. Formulation

[0523] In this Example, human MuSK-targeting oligonucleotides as described herein are formulated into suitable forms to enhance the delivery to target site(s) and are administered to human subject via various means.

[0524] In some embodiments, human MuSK-targeting oligonucleotides are formulated into lipid complex, as a homogeneous solution in a single-dose vial. In some embodiments, single-dose vial is 10 mg/5 ml (2 mg/mL).

##### B. Administration

###### 1. Indication

[0525] MuSK-targeting oligonucleotides are indicated for the treatment of the AD in adults.

###### 2. Dosage and Administration

###### 2.1 Dosing Information

[0526] MuSK-targeting oligonucleotides are administered by a healthcare professional.

[0527] MuSK-targeting oligonucleotides are administered via intravenous (IV) infusion. Dosing is based on actual body weight. For patients weighing less than 100 kg, the recommended dosage is 0.3 mg/kg once every 3 weeks. For patients weighing 100 kg or more, the recommended dosage is 30 mg once every 3 weeks.

[0528] Missed Dose: If a dose is missed, administer MuSK-targeting oligonucleotides as soon as possible. If MuSK-targeting oligonucleotides are administered within 3 days of the missed dose, continue dosing according to the patient's original schedule. If MuSK-targeting oligonucleotides are administered more than 3 days after the missed dose, continue dosing every 3 weeks thereafter.

###### 2.2 Preparation

[0529] MuSK-targeting oligonucleotides are filtered and diluted prior to intravenous infusion. The diluted solution for infusion is prepared by a healthcare professional using aseptic technique as follows: [0530] 1. Remove MuSK-targeting oligonucleotides vial from the refrigerator and allow to warm to room temperature. Do not shake or vortex. [0531] 2. Inspect visually for particulate matter and discoloration. Do not use if discoloration or foreign particles are present. [0532] 3. Calculate the required dose of MuSK-targeting oligonucleotides based on the recommended weight-based dosage [see Dosage and Administration (2.1)]. [0533] 4. Withdraw the entire contents of one or more vials into a single sterile syringe. [0534] 5. Filter MuSK-targeting oligonucleotides through a sterile 0.45 micron polyethersulfone (PES) syringe filter into a sterile container. [0535] 6. Withdraw the required volume of filtered MuSK-targeting oligonucleotides from the sterile container using a sterile syringe. [0536] 7. Dilute the required volume of filtered MuSK-targeting oligonucleotides into an infusion bag containing 0.9% Sodium Chloride Injection, USP for a total volume of 200 mL. Use infusion bags that are di(2-ethylhexyl) phthalate-free (DEHPfree). [0537] 8. Gently invert the bag to mix the solution. Do not shake. Do not mix or dilute with other drugs. [0538] 9. Discard any unused portion of MuSK-targeting oligonucleotides. [0539] 10. The diluted solution should be administered immediately after preparation. If not used immediately, store in the infusion bag at room temperature (up to 30° C. [86° F.]) for up to 16 hours (including infusion time). Do not freeze.

###### 2.3 Infusion

[0540] MuSK-targeting oligonucleotides are infused as follows: [0541] 1. Use a dedicated line with an infusion set containing a 1.2 micron polyethersulfone (PES) in-line infusion filter. Use infusion sets and lines that are DEHP-free. [0542] 2. Infuse the diluted solution of MuSK-targeting oligonucleotides intravenously, via an ambulatory infusion pump, over approximately 80 minutes, at an initial infusion rate of approximately 1 mL/min for the first 15 minutes, then increase to approximately 3 mL/min for the remainder of the infusion. [0543] 3. Administer only through a free-flowing venous access line. Monitor the infusion site for possible infiltration during drug administration. Suspected extravasation should be

managed according to local standard practice for non-vesicants. [0544] 4. Observe the patient during the infusion. [0545] 5. After completion of the infusion, flush the intravenous administration set with 0.9% Sodium Chloride Injection, USP to ensure that all ONPATTRO has been administered.

## REFERENCES

[0546] Shaw, G., Morse, S., Ararat, M., & Graham, F. L. (2002). Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. *The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology*, 16(8), 869-871

### Example 5: Design and Screening of 20-Mer MuSK-Targeting Oligonucleotides

[0547] In this Example, additional human MuSK-targeting oligonucleotides were designed based on the lead candidates from Example 1 targeting exon 7 of MuSK. The screen in Example 1 identified 6 lead ASOs that targeted two regions within the MuSK exon 7. Upon further dose response experiments and analysis of the resulting MuSK transcripts, one of these regions was identified as a key region to modulate the splicing of Ig3 domain. This region, or “region 1” corresponds to the core sequence SEQ ID NO: 126 (ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGACTCAAGAC) which is located at positions 83841-83905 of the MuSK transcript (SEQ ID NO: 77) (or corresponding regions within other MuSKvariant sequences). In this Example, additional ASOs are designed to target the region corresponding to SEQ ID NO: 126 (“region 1”) of exon 7 and specifically to include different portions of the sequences of ASOs Bld25 and Bld26. These ASOs were designed to test whether shorter ASOs of 20 nucleotides, rather than 25 nucleotides (as tested in Example 1) would have increased activity.

[0548] The additional oligonucleotides were tested for their ability to induce exon skipping of the MuSK exon 6 and/or exon 7.

### Design of Human ASOs

[0549] Human antisense oligonucleotides (ASOs) were designed as described above and as shown in FIG. 17, and produced by Microsynth (Switzerland). The ASO sequences are shown below in Table 8.

TABLE-US-00012	TABLE 8	Oligo ID	SEQ ID	5' to 3' Sequence	Bld
		127		TTGAATGGACCCAGAAGAAA	Bld51
		128		CTTGAATGGACCCAGAAGAA	Bld53
		129		TCTTGAATGGACCCAGAAGA	Bld54
		130		CTCTTGAATGGACCCAGAAG	Bld55
		131		TCTCTTGAATGGACCCAGAA	Bld56
		132		CTCTCTTGAATGGACCCAGA	Bld57
		133		ACTCTCTTGAATGGACCCAG	Bld58
		134		CACTCTCTTGAATGGACCCA	Bld59
		135		ACACTCTCTTGAATGGACCC	Bld60
		136		CACACTCTCTTGAATGGACC	Bld61
		137		TCACACTCTCTTGAATGGAC	Bld62
		138		TTCACACTCTCTTGAATGGA	Bld63
		139		TTTCACACTCTCTTGAATGG	Bld64
		140		CTTTCACACTCTCTTGAATG	Bld65
		141		TCTTTCACACTCTCTTGAAT	Bld66
		142		GTCTTTCACACTCTCTTGAA	

[0550] All ASOs in Table 8 were designed to include 2'-MOE modification on each sugar and where there is a phosphorothioate internucleotidic linkage between each nucleotide. All ASOs in Table 8 were 20 nucleotides in length.

### Screen of Shorter Antisense Oligonucleotides Targeting Exon7 Region 1

[0551] ASO transfection and cell culture, RNA extraction, cDNA transcription, qPCR were performed according to the methods described in Example 1, unless indicated otherwise.

#### i. Alignment to the Genetic Sequence

[0552] The alignment of the ASOs in Table 8 on the genetic sequence of Exon7 of MuSK is presented in FIG. 17.

#### ii. Cell Observations

[0553] LHCN-M2 cells were plated at 30,000 cells/well in gelatin pre-coated 6-well plates and were transfected 48 h after seeding with ASO at 12.5 nM and 100 nM. 24 h after transfection, cells were observed (data not shown) and the RNA was extracted and analyzed.

[0554] After 24 h of transfection, cells looked healthy in all conditions except for cells treated with ASOs Bld54, Bld55, and Bld56 at the 100 nM dose (data not shown).

#### iii. MuSK Expression Analyses

[0555] 24 h after transfection, RNA was extracted, and MuSK gene expression was analyzed in qPCR. Relative gene expression of total MuSK (MuSK34) and MuSKIg3 domain (MuSK67) is shown in FIG. 18. Methods described for screening of ASOs in Example 1 were used.

[0556] ASOs with the modifications used in this Example are shown in Table 9 below.

TABLE-US-00013 TABLE 9 SEQ Oligo ID ID NO: Sequence-(5' to 3')<sup>a</sup> Bld51 143

T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A Bld52 144

C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A Bld53 145

T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A Bld54 146

C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G Bld55 147

T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A Bld56 148

C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A Bld57 149

A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G Bld58 150

C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A Bld59 151

A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C Bld60 152

C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C Bld61 153

T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C Bld62 154

T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A Bld63 155

T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G Bld64 156

C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G Bld65 157

T\*C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T Bld66 158

G\*T\*C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A<sup>a</sup> represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar. .sup.ba value of 1.0 represents the level of MuSK67 expression for untreated cells.

[0557] Results from the screen showed that these shorter ASOs (20-mers) targeting region 1 of Exon 7 resulted in less potent activity than the ASOs Bld25 and Bld26 (25mers) and had either little/no effect on MuSKdelIg3 level or inhibited levels of total MuSK.

Example 6: Design and Screening of Additional MuSK-Targeting Oligonucleotides Targeting Region 1 of Exon 7

[0558] In this Example, additional human MuSK-targeting oligonucleotides were designed based on the lead candidates from Example 1 targeting region 1 of exon 7 of MuSK SEQ ID NO: 126

(CTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGACTCAAGAC), which is located at positions 83841-83905 of the MuSK transcript (SEQ ID NO: 77) (or corresponding regions within other MuSK variant sequences).

[0559] Sequences were designed to specifically to include different portions of the sequences of ASOs Bld25 and Bld26. Because shortening the length of the ASOs targeting this region was showed less activity, ASOs designed in this Example were produced to be 25 nucleotides in length.

[0560] The additional oligonucleotides were tested for their ability to induce exon skipping of the MuSK exon 6 and/or exon 7.

Design of Human ASOs

[0561] Human antisense oligonucleotides (ASOs) were designed as described above and are shown in FIG. 19. These ASOs were produced by Microsynth (Switzerland). The ASO sequences are shown below in Table 10.

TABLE-US-00014 TABLE 10 Oligo ID SEQ ID 5' to 3' Sequence Bld25-1 159

CCAGAAGAAACCTGACAGAGTAAAG Bld25-2 160 ACCCAGAAGAAACCTGACAGAGTAA

Bld25-3 161 ATGGACCCAGAAGAAACCTGACAGA Bld25-4 162

GAATGGACCCAGAAGAAACCTGACA Bld25-5 163 CTTGAATGGACCCAGAAGAAACCTG

Bld26-1 164 CTCTTGAATGGACCCAGAAGAAACC Bld26-2 165

CTCTCTTGAATGGACCCAGAAGAAA Bld26-3 166 CACACTCTCTTGAATGGACCCAGAA Bld26-

4 167 TTCACACTCTCTTGAATGGACCCAG

[0562] All ASOs in Table 10 were designed to include 2'-MOE modification on each sugar and where there is a phosphorothioate internucleotidic linkage between each nucleotide. All ASOs in Table 10 were 25 nucleotides in length.

Screen of Antisense Oligonucleotides Targeting Exon7 Region 1

[0563] ASO transfection and cell culture, RNA extraction, cDNA transcription, qPCR were performed according to the methods described in Example 1, except as where indicated otherwise.

i. Alignment to the Genetic Sequence

[0564] The alignment of the ASOs in Table 10 on the genetic sequence of Exon7 of MuSK is presented in FIG. 19.

## ii. Cell Observations

[0565] LHCN-M2 cells were plated at 35,000 cells/well in gelatin pre-coated 6-well plates and were transfected 48 h after seeding with ASO at 5 nM, 12.5 nM, 25 nM, 50 nM, and 125 nM. Each of the ASOs in Table 10 were tested with Bld25, Bld26, Bld27, Bld28, Bld35 and Bld38 (leads identified in Example 1). 24 h after transfection, cells were observed (data not shown) and the RNA was extracted and analyzed. [0566] After 24 h of transfection, cells looked healthy in all conditions except for cells treated with ASOs Bld25-3 and Bld25-4 at the 140 nM dose (data not shown).

## iii. MuSK Expression Analyses

[0567] 24 h after transfection, RNA was extracted, and MuSK gene expression was analyzed in qPCR (FIG. 20). Panel A shows relative gene expression of MuSK67 and Panel B shows relative gene expression of total MuSK (MuSK34). The new sequences were compared to Bld25 and Bld26 from Example 1. FIG. 21 shows the same data from only the ASOs which showed relative expression of MuSK67 of less than 50% and total MuSK (MuSK34) of greater than 60% compared to the untreated control.

[0568] FIG. 22 shows a comparison of Bld25-5 to Bld25 after transfection with ASO for 24 hours (Panels A and B) and 48 hours (Panels C and D). Methods described for screen of ASOs in Example 1 were used.

[0569] ASOs with the modifications used in this Example are shown in Table 11 below:

TABLE-US-00015 TABLE 11 Oligo ID SEQ ID NO: Sequence-(5' to 3').sup.a Bld25-1 168

C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T\*A\*A\*A\*G\* Bld25-2 169

A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T\*A\*A\* Bld25-3 170

A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\* Bld25-4 171

G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\* Bld25-5 172

C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G Bld26-1 173

C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\* Bld26-2 174

C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A Bld26-3 175

C\*A\*C\*A\*C\*T\*C\*T\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\* Bld26-4 176

T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G .sup.a\*represents a

phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

TABLE-US-00016 TABLE 12 Potency MuSK 67 (IC in nM) IC50 IC75 Bld25-5 15.6 30.2 Bld25 16.5

30.4 Bld26 17.0 20.8 Bld25-4 18.0 n/a Bld25-3 20.8 34.4 Bld26-2 22.8 n/a Bld26-4 28.8 n/a

TABLE-US-00017 TABLE 13 Selectivity MuSK 34 (IC in nM) IC50 IC75 Bld26-2 n/a n/a Bld25-4 49.7

52.4 Bld26 23.7 24.5 Bld26-4 19.2 69.5 Bld25 13.3 n/a Bld25-5 8.4 30.4 Bld25-3 0.9 15.0

[0570] Table 12 shows the concentration at which there is either 50% (IC50) or 75% (IC75) inhibition in total MuSK67 expression. Table 13 shows the IC10 and IC25 values of MuSK34 (nM) of each ASO, and represents concentration in which there is either 10% (IC10) or 25% (IC25) inhibition in total MuSK expression (MuSK34). ASOs performing exon skipping of exon 6 and/or 7, are expected to show lower IC50/IC75 values of MuSK67 and higher IC10/25 values of MuSK34.

[0571] Results from this screen showed that ASOs Bld25, Bld25-5, Bld26-2, and Bld26 showed the best potency and selectivity (see Tables 12 and 13).

## Confirmation of Exon Skipping by Gel Migration

[0572] To verify the ASO-induced splicing of the RNA, the genetic sequence from exon 3 to exon 9 was amplified by PCR and the size of the PCR product was measured by migrating it on gel electrophoresis.

[0573] Several forms of MuSK RNA exist naturally in human. 3 variants were identified in the literature (FIG. 26):

[0574] Variant 1, NM\_005592.4 (full length: 972 bp and ΔIg3: 687 bp) [0575] Variant 2,

NM\_001166280.2 (full length: 783 bp and ΔIg3: 453 bp) [0576] Variant 3, NM\_001166281.2 (full length:

708 bp and ΔIg3: 423 bp)

[0577] Full length and ΔIg3 indicate the lengths of the full-length sequence and ΔIg3 (6,7) sequence amplified by PCR from exon 3 to exon 9. Compared to variant 1, the exon 8 is missing in variant 2 and variant 3. In addition, a small exon of 30 bases is present only in variant 2. Therefore, skipping exons 6 and 7 would produce 3 additional MuSK RNA forms.

[0578] The sequence of exon3-9 of the cDNA from the dose response presented in this Example was amplified by PCR in the conditions without or with Bld25 and Bld25-5 at 50 nM. Results from the gel



electrophoresis are shown in FIG. 27. In FIG. 27, “4/5/6/7/EWS/8/9” indicates full length variant 1, “4/5/5+/6/7/EWS/9” indicates full length variant 2, and “4/5/6/7/EWS/9” indicates full length variant 3. Similarly, “4/5/EWS/8/9” indicates  $\Delta$ Ig3 (6,7) in variant 1, “4/5/9” indicates A5+/Ig3 (6,7) of variant 2, and indicates the  $\Delta$ Ig3 (6,7) of variant 3.

[0579] As shown in FIG. 27, several bands were detected. In the control conditions, major bands were visible where the full length variants would be expected. In conditions where splicing of the exons 6/7 occurred (confirmed previously by qPCR), major bands were observed at for the spliced versions of the variants.

[0580] Intensity of the bands was also examined. Intensity of bands from Bld25 and Bld25-5 products are also shown above the gel images in FIG. 27. These results show that amount of MuSK PCR product with ASO is about 80-90% of the amount of MuSK PCR product in untreated conditions (controls). Therefore, total MuSK is decreased by only a small amount.

[0581] Next, the bands of pcr products from cells treated with ASO 25-5 were sequenced to confirm these bands correspond to the indicated variants. FIG. 28 shows that the sequence of the band lower band positioned where  $\Delta$ 6,7 variant 1 (687 bases) was indeed the sequence of this splice variant.

Example 7: Design and Screening of Shortened MuSK-Targeting Oligonucleotides Targeting Region 1 of Exon 7

[0582] In this Example, additional human MuSK-targeting oligonucleotides were designed by reducing the size of the lead ASOs identified in Example 1 and Example 6 (Bld25, Bld25-5, Bld26, and Bld26-2).

These ASOs target region 1 of exon 7 of MuSK SEQ ID NO: 126

(ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGACTCAAGAC) which is located at positions 83841-83905 of the MuSK transcript (SEQ ID NO: 77) (or a corresponding regions within other MuSK variant sequences).

[0583] Sequences were designed by shortening the sequences of ASOs Bld25, Bld25-5, Bld26- and Bld26-2 by different amounts. ASOs designed in this Example were produced to be 21 and 23 nucleotides in length.

[0584] These ASOs were then tested for their ability to induce exon skipping of the MuSK exon 6 and/or exon 7.

Design of Human ASOs

[0585] Human antisense oligonucleotides (ASOs) were designed as described above and as shown in FIG. 23. The ASOs were produced by Microsynth (Switzerland). The ASO sequences are shown below in Table 14.

TABLE-US-00018	TABLE	14	Oligo	ID	SEQ	ID	5' to 3' Sequence
							Bld25-A 177
							ACCCAGAAGAAACCTGACAGAGT Bld25-B 178
							CCAGAAGAAACCTGACAGAGT Bld25-C 179
							GGACCCAGAAGAAACCTGACAGA Bld25-D 180
							ACCCAGAAGAAACCTGACAGA Bld25-E 181
							GGACCCAGAAGAAACCTGACA Bld25-5-A 182
							GAATGGACCCAGAAGAAACCTGA Bld25-5-B
							183 ATGGACCCAGAAGAAACCTGA Bld25-5-C 184
							TTGAATGGACCCAGAAGAAACCT Bld25-5-D
							185 GAATGGACCCAGAAGAAACCT Bld25-5-E 186
							TTGAATGGACCCAGAAGAAAC Bld26-2-A
							187 CTCTTGAATGGACCCAGAAGAAA Bld26-2-B 188
							CTTGAATGGACCCAGAAGAAA Bld26-2-C
							189 CTCTCTTGAATGGACCCAGAAGA Bld26-2-D 190
							CTCTCTTGAATGGACCCAGAA Bld26-B
							191 CTCTTGAATGGACCCAGAAGA Bld26-C 192
							CACTCTCTTGAATGGACCCAGAA Bld26-D 193
							CACTCTCTTGAATGGACCCAG

[0586] All ASOs in Table 14 were designed to include 2'-MOE modification on each sugar and where there is a phosphorothioate internucleotidic linkage between each nucleotide. All ASOs in Table 14 were 21 or 23 nucleotides in length.

Screen of 21-Mer and 23-Mer Antisense Oligonucleotides Targeting Exon7 Region 1

[0587] ASO transfection and cell culture, RNA extraction, cDNA transcription, qPCR were performed according to the methods described in Example 1, except as where indicated otherwise.

i. Alignment to the Genetic Sequence

[0588] The alignment of the ASOs in Table 14 on the genetic sequence of Exon7 of MuSK is presented in FIG. 23.

ii. Cell Observations

[0589] LHCN-M2 cells were plated at 35,000 cells/well in gelatin pre-coated 6-well plates and were

transfected 48 h after seeding with ASO at 5 nM, 12.5 nM, 25 nM, 50 nM, and 125 nM. Each of the ASOs in Table 14 were tested in addition to Bld25, Bld25-5, Bld26, and Bld26-2 (leads identified in Examples 1 and 6). 24 h after transfection, cells were observed (data not shown) and the RNA was extracted and analyzed.

[0590] After 24 h of transfection, cells looked healthy in all conditions (data not shown).

### iii. MuSK Expression Analyses

[0591] 24 h after transfection, RNA was extracted, and MuSK gene expression was analyzed in qPCR (FIGS. 24-25).

[0592] ASOs with the modifications used in this Example are shown in Table 15 below.

TABLE-US-00019 TABLE 15 Oligo ID SEQ ID NO: Sequence-(5' to 3').sup.a Bld25-A 194

A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T Bld25-B 195

C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T Bld25-C 196

G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A Bld25-D 197

A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A Bld25-E 198

G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A Bld25-5-A 199

G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A Bld25-5-B 200

A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A Bld25-5-C 201

T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T Bld25-5-D 202

G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T Bld25-5-E 203

T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C Bld26-2-A 204

C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A Bld26-2-B 205

C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A Bld26-2-C 206

C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A Bld26-2-D 207

C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A Bld26-B 208

C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A Bld26-C 209

C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A Bld26-D 210

C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G .sup.a\*represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

[0593] Results from this screen showed that ASOs Bld25-E and Bld25-5-A showed the best activity (see FIG. 24 and FIG. 25). Bld25-E showed MuSK67 maximum correction of 80%, with less of an effect on total MuSK (MuSK34), and an IC50 of MuSK67 of about 21 nM. Bld25-5-A showed MuSK67 maximum correction of 80%, with less of an effect on total MuSK (MuSK34) and an IC50 of MuSK67 about 35 nM. These results indicate that ASOs Bld25-E and Bld25-5-A are additional candidates to effectuate exon6-7 skipping in MuSK and have shorter lengths (21-mer and 23-mer) than the lead ASOs identified from Examples 1 and 6.

### Example 8: Analysis of MuSK Protein

[0594] This Example aims to examine the resulting MuSK protein after treatments with the ASOs described herein.

#### Timing of Effect on MuSK Protein

[0595] In order to examine resulting MuSK protein produced from ASO-treated cells, it is important to understand the relative timing of the effect of targeting MuSK with RNA.

[0596] Length of time from RNA treatment was examined to determine how long after treatment will there be an effect on MuSK protein (i.e., production of MuSKΔIg3).

[0597] In this experiment, LHCN-M2 cells were treated for 48 h with 10 nM of siRNA (Thermofisher, 4392420, assay ID s224071) against MuSK and were then stained for MuSK protein on days 2, 3, 4, and 5 (with MuSK antibodies isolated from patients with a disease involving the natural production of MuSK antibodies followed by goat anti-human (A-2133)) following siRNA treatment. Results for each timepoint in treated and untreated cells are shown in FIG. 29. Results show that in the untreated wells, MuSK protein amount increases while cells start to be confluent. In wells treated with siRNA, MuSK protein amount decreases, especially 5 days after the transfection. Overall, these results show that MuSK protein amount can be modulated, and the best timing to observe an effect is 5 days after modulating the RNA.

[0598] FIG. 29 shows the cells at Day 5 magnified and stained for MuSK (red) (with MuSK antibodies isolated from patients with a disease involving the natural production of MuSK antibodies followed by

goat anti-human (A-2133)) and actin phalloidin (green) (ab 176743 at 1:1000). These results confirm that (i) the MuSK antibody used to stain for MuSK protein works in immunofluorescence, (ii) MuSK protein level increases over time, probably along with cell differentiation, and (iii) MuSK siRNA (“Si-MuSK”) induces a reduction of MuSK protein, especially after 5 days of exposure.

#### Measuring Removal of Ig3 Domain of MuSK

[0599] Since ASOs as described herein are targeting the Ig3 domain and inducing exon skipping (6,7) to produce MuSKΔIg3, there needs to be a way to detect MuSKΔIg3 protein. Timing of the effects of the ASOs/RNA on MuSK protein has been established. An assessment (e.g., Western blot analysis) will be performed. Such an assessment includes assessment of MuSKΔIg3 protein produced from cells treated with ASOs described herein. A MuSK antibody that targets the MuSK cytoplasmic domain will be utilized for identification of MuSKΔIg3 protein. Antibodies are produced and tested using the recombinant MuSK cytoplasmic domain.

[0600] Since human and murine MuSK protein sequences vary, human MuSK controls should be used for assessment (e.g., by Western Blot). Positive controls (i.e., MuSKΔIg3 protein and human FL MuSK protein) are used to confirm the forms of MuSK that are present. Plasmids coding for the different WT and D3 (Ig3) isoforms of MuSK protein are obtained. Cells are transfected with the plasmids and positive control isoforms are expressed and obtained.

[0601] Human MuSK antibodies targeting the cytoplasmic domain of MuSK and human MuSK positive controls (i.e., MuSKΔIg3 protein and human FL MuSK protein) are obtained, and such reagents are used in a assessment (e.g., Western Blot) to characterize the MuSK protein produced from cells treated with ASOs described herein.

#### TABLE-US-00020 I. LISTING OF SEQUENCES Oligonucleotide (SEQ ID NO: 1)

GCTAGGGTGGTCTTTTAGAAATGCA	Oligonucleotide	(SEQ ID NO: 2)
GGTCAAGCTAGGGTGGTCTTTTAGA	Oligonucleotide	(SEQ ID NO: 3)
CTGCAGGAAATGGTCAAGCTAGGGT	Oligonucleotide	(SEQ ID NO: 4)
GAAGTGGTGAGTGACGCTCCTGCAG	Oligonucleotide	(SEQ ID NO: 5)
GTTAGGAAGACAGAAGTGGTGAGTG	Oligonucleotide	(SEQ ID NO: 6)
ATCCTGGCAAAAAGTGTAGGAAGA	Oligonucleotide	(SEQ ID NO: 7)
GTGGGATTCAGGAGCCCGCAGGATC	Oligonucleotide	(SEQ ID NO: 8)
GGTGACATTGTGGGATTCAGGAGCC	Oligonucleotide	(SEQ ID NO: 9)
GGAGCCAAAGGTGACATTGTGGGAT	Oligonucleotide	(SEQ ID NO: 10)
GGTCACAAAGGAGCCAAAGGTGACA	Oligonucleotide	(SEQ ID NO: 11)
ACAGTGCAGGGTCACAAAGGAGCCA	Oligonucleotide	(SEQ ID NO: 12)
CTGTTGCTGTACAGTGCAGGGTCAC	Oligonucleotide	(SEQ ID NO: 13)
GGGACAGGAATGCCTGTTGCTGTAC	Oligonucleotide	(SEQ ID NO: 14)
CAGGTGATGGTGGGGACAGGAATGC	Oligonucleotide	(SEQ ID NO: 15)
CCGTTTTCAATCCAGGTGATGGTGG	Oligonucleotide	(SEQ ID NO: 16)
TGACACTCACAGCATTTCGTTTTTC	Oligonucleotide	(SEQ ID NO: 17)
AAGTCCCCACACACATGACACTCAC	Oligonucleotide	(SEQ ID NO: 18)
GGTCTTCCCCAGACAAGTCCCCACA	Oligonucleotide	(SEQ ID NO: 19)
ACTATGTCAGTAGATTGGAAGGGAA	Oligonucleotide	(SEQ ID NO: 20)
TCCCCTACTACTATGTCAGTAGATT	Oligonucleotide	(SEQ ID NO: 21)
TCAGTCAAGGATTTCCCCTACTACT	Oligonucleotide	(SEQ ID NO: 22)
AAAAGAACTCAGTCAAGGATTTCCC	Oligonucleotide	(SEQ ID NO: 23)
GTAAAGGAAAATAAAAGAACTCAGT	Oligonucleotide	(SEQ ID NO: 24)
AACCTGACAGAGTAAAGGAAAATAA	Oligonucleotide	(SEQ ID NO: 25)
GGACCCAGAAGAAACCTGACAGAGT	Oligonucleotide	(SEQ ID NO: 26)
CACTCTCTTGAATGGACCCAGAAGA	Oligonucleotide	(SEQ ID NO: 27)
CACTCGGTCTTTCACACTCTTGA	Oligonucleotide	(SEQ ID NO: 28)
GTCTTGAGTCAATCACTCGGTCTTT	Oligonucleotide	(SEQ ID NO: 29)
GATAAACAGCTGCAGTCTTGAGTCA	Oligonucleotide	(SEQ ID NO: 30)
AGTCCTGGCTTGGTGATAAACAGCT	Oligonucleotide	(SEQ ID NO: 31)
ATGTGTAGAGTCCTGGCTTGGTGAT	Oligonucleotide	(SEQ ID NO: 32)

GTAGCTATGCTGTGCTG Oligonucleotide (SEQ ID NO: 33)  
 TGCTTATTGGTAGCTATGCATGTGT Oligonucleotide (SEQ ID NO: 34)  
 ACTTCTCCCCATGCTTATTGGTAGC Oligonucleotide (SEQ ID NO: 35)  
 CCTTGGCAGTACTGAACTTCTCCCC Oligonucleotide (SEQ ID NO: 36)  
 CCTGCTATGCTGATGGTGGCTGCAG Oligonucleotide (SEQ ID NO: 37)  
 GGGCATCCTACCTGCTATGCTGATG Oligonucleotide (SEQ ID NO: 38)  
 GCAAATGTGAAGGGGGCATCCTACCT hu6-75; SEQ ID NO: 39  
 TGCATTTCTAAAAGACCACCCTAGC hu6-69; SEQ ID NO: 40  
 TCTAAAAGACCACCCTAGCTTGACC hu6-58; SEQ ID NO: 41  
 ACCCTAGCTTGACCATTTCTGCAG hu6-39; SEQ ID NO: 42  
 CTGCAGGAGCGTCACTCACCCTTC hu6-27; SEQ ID NO: 43  
 CACTCACCCTTCTGTCTTCCTAAC hu6-12; SEQ ID NO: 44  
 TCTTCCTAACAGTTTTTGCCAGGAT hu610; SEQ ID NO: 45  
 GATCCTGCGGGCTCCTGAATCCCAC hu619; SEQ ID NO: 46  
 GGCTCCTGAATCCCACAATGTCACC hu628; SEQ ID NO: 47  
 ATCCCACAATGTCACCTTTGGCTCC hu637; SEQ ID NO: 48  
 TGTCACCTTTGGCTCCTTTGTGACC hu646; SEQ ID NO: 49  
 TGGCTCCTTTGTGACCCTGCACTGT hu656; SEQ ID NO: 50  
 GTGACCCTGCACTGTACAGCAACAG hu669; SEQ ID NO: 51  
 GTACAGCAACAGGCATTCCTGTCCC hu681; SEQ ID NO: 52  
 GCATTCCTGTCCCCACCATCACCTG hu693; SEQ ID NO: 53  
 CCACCATCACCTGGATTGAAAACGG hu6110; SEQ ID NO: 54  
 GAAAACGGAAATGCTGTGAGTGTCA hu6125; SEQ ID NO: 55  
 GTGAGTGTGATGTGTGTGGGGACTT hu6139; SEQ ID NO: 56  
 TGTGGGGACTTGTCTGGGGAAGACC hu7-75; SEQ ID NO: 57  
 TTCCCTTCAAATCTACTGACATAGT hu7-66; SEQ ID NO: 58  
 AATCTACTGACATAGTATAGTGGGA hu7-53; SEQ ID NO: 59  
 AGTATAGTGGGAAATCCTTGACTGA hu7-45; SEQ ID NO: 60  
 GGGAAATCCTTGACTGAGTTCTTTT hu7-33; SEQ ID NO: 61  
 ACTGAGTTCTTTTATTTTCTTTAC hu7-22; SEQ ID NO: 62  
 TTATTTTCCTTTACTCTGTCAGGTT hu7-10; SEQ ID NO: 63  
 ACTCTGTCAGGTTTCTTCTGGGTCC hu73; SEQ ID NO: 64  
 TCTTCTGGGTCCATTCAAGAGAGTG hu717; SEQ ID NO: 65  
 TCAAGAGAGTGTGAAAGACCGAGTG hu730; SEQ ID NO: 66  
 AAAGACCGAGTGATTGACTCAAGAC hu744; SEQ ID NO: 67  
 TGA CTCAAGACTGCAGCTGTTTATC hu758 ; SEQ ID NO: 68  
 AGCTGTTTATCACCAAGCCAGGACT hu766; SEQ ID NO: 69  
 ATCACCAAGCCAGGACTCTACACAT hu776; SEQ ID NO: 70  
 CAGGACTCTACACATGCATAGCTAC hu785; SEQ ID NO: 71  
 ACACATGCATAGCTACCAATAAGCA hu796; SEQ ID NO: 72  
 GCTACCAATAAGCATGGGGAGAAGT hu7111; SEQ ID NO: 73  
 GGGGAGAAGTTCAGTACTGCCAAGG hu7136; SEQ ID NO: 74  
 CTGCAGCCACCATCAGCATAGCAGG hu7146; SEQ ID NO: 75  
 CATCAGCATAGCAGGTAGGATGCCC hu7158; SEQ ID NO: 76  
 AGGTAGGATGCCCCTTCACATTTGC MuSK Genomic Sequence (SEQ ID NO: 77) 1  
 tatacagtca tttatcactt aacatcaggg atatgttctg agaaatgcat ccatagtcca 61 ttttgttatt gtgtgaacat  
 catagagtat acttacagaa accttgatgg tatagccac 121 tgcacaccta ggctgtatgg atagcctatt gcccgtaggc  
 tacaacctg tcagcatgtt 181 actacactga atactgtagg caattgtagc acaatggtac gtatttgtgt atctaaacat 241  
 agaaaacata cagtaaaaat acagtataaa agataaaaat ggtacacctg cattgggcac 301 ttaccatgaa cgaagatttc  
 agcactgaag tttgctctgg gtaagtcagt gagtgagtga 361 tgtgtgaatg tgaaggccta ggacattact gtacactgt  
 gtaaacttta taaatactgt 421 acacttagac tacgctaaat ttatttttaa aatattttc tttctttaat aataaattaa 481  
 ccttagctta ccacaactat tttattttat aaacttttaa aatttgtaat cttttgact 541 cttttgtaat aatactctgt  
 ttgaaacaca aatatattgt acagtatac aaaaatagtt 601 tttctcata tccttaagct ctttctatc ttaaaatttt

tttattttt 11 tttacttttt 661 tttattttt tgtaaacaac taagacaata acacacaata gctttggcct acacagggct 721  
aggatcaaaa catcactgcc tttaacagc ttgtcctact ggaaggctct caggggcaat 781 aacacacatg gagctgcat  
ctcctatggg aacaatgtat tcttctagaa tacctgcctg 841 aggctgtttt acaatcaatt tttattttat tttttttt  
tatgttttta aataagtaca 901 ggggtatacac agtaaaataa taataaaaat atagtacatt aaaaaaacca gcaacatggg 961  
catttattat cattatcaac tattatgtac tctacataat tgtatgtgct tttttattca 1021 aaaagaaaat cattaagaac  
acagcaatat taatatttat tctttttttt agaagaacct 1081 gatttattta ttaattttt ttattatact ttaagttctg  
ggatacatgt gcaaaacgtg 1141 taggtttgtt acacaggtat acatgtgccca tgggtgggtt ctgtatccat caacccatca  
1201 tctacattag gcatttctcc taatgctatc cctcccctag cccccaccc ctgacaggc 1261 cccagtatgt  
gattctcccc tcctgtgtc catgtgttct cattgttagc tcccacttat 1321 gagtgagaac atgtgggtgt tggttttctg  
ttcctgtatt agtttgctga gaatgatgg 1381 ttccagcttc atccatgtcc ctgcaaagga tataaactca ttgttttta  
tggctgcata 1441 gtattccgta gtgtatatgt gccacattt ctttatctag tctatcattg attggcattt 1501 ggggtgggtc  
caagtctttg ccattgtgaa tagtgctgaa ataaacatat atgtgcatgt 1561 gtctttatag tagaatgatt tatagtcctt  
tgggtatata cccagtaatg agattgctgg 1621 gtcaaagtgt atttctggtt ctaatcctg aagaattgcc acactgtctc  
ccacaatggg 1681 tgaactaatt tacactccca caaacaggtgt aaaagcattc ctatttttcc acattctctc 1741  
cagcatcggg tgcttctga cttttaatg attgccactc taacaggcat gagatgggtat 1801 ctcattgtgg tttgatttg  
catttctcta atgaccaata atgatgagct ttatttcata 1861 tgtttgttgg ctgcataaat gtcttattt gagaagtgc  
tgttcataac cttcgccac 1921 ttttgatgg ggttgttgt tttttctg taaattgtt taagttctt gtagattctg 1981  
gatattagcc ctttgcaga tggatagatt gcaaaaattt tctccactc tgtaggtgc 2041 ctgctcactc taatgatag  
tcctttgtc gagcagatgg tcttagttt aattaggctc 2101 catttgtaa tttgactt tgttgccatt gctttgggg  
ttttagtc at gaagtcttg 2161 cccatgccta tgtcctgaat ggtattgcct aggttttct ctagggttt tatggttta 2221  
ggttttacat ttaagtattt aatccatctt gagttaattt ttgtatgaga tataaggaag 2281 ggggccagtt ccagtttcc  
gcatatggct agccagtttt cccaacacca ttattaaat 2341 agggaaatcct ttcctactg ctgtttttg tcaggttgt  
caaagatcag atgggttag 2401 atgtgtggca ttatttctta ggcctctgtt ctgttccatt ggtctatata tctgttttg 2461  
taccagtacc atgctgttt ggcaaaccag gaagaagctg aatccctgaa tataccaata 2521 agaagtctg aaattgaggc  
agtaattaat agcctaccga gcaaaaaaaaa aaaaaaaaaa 2581 aaaaaaatcc aggaccagac ggattcacag  
ccgaattcta ccagaggtag aaagaggagc 2641 tggtagcatt ccttctgaaa ctattccaat caatagaaaa  
agaggggaatc ctctctaact 2701 aattttatga gtccagcatc atcctgatac caaacctgg cagaggcaca accaaaaaca  
2761 gaaaatttca ggccaatc cctgatgaat attgatgtga aaattctcaa taaaatactg 2821 gcaaactgaa  
tccaacagca catcaaaaag cttaccacc acgatcaagt tggcttcatc 2881 cctgggatgc aaggctggtt  
aaacatatgc aatatcaata atgtaacca tcacataaac 2941 agaaccagt acaaaaacca catgattatc tcaatagatg  
cagaaaaggc tttaataaa 3001 atttaacacc ctttatgtc aaaaactctc aataaactag gtattgatgg aacctatga  
3061 aaaaaaatga gctatttatg acaaacaccac agccaatgtc aactgaatg agaaaaagct 3121 ggaagtattc  
ccttgaaaa ctggcacgag acaaggatgc cctctctac cactcgtatt 3181 caacctata ttggaagttc tggccagggc  
aatcaggcaa gagaaagaaa taaagcgtat 3241 tcaaatagga agagagaaaag tcaaattgtc tctgtttgca  
gatgacatga ttgtatatt 3301 agaaaacccc atcatctcag ccccaaatct ccttaagctg ataagcaact tcagcaaagt  
3361 cccaggatac aaatcaatg tgcaagatc acaagattcc tatataccaa taacagacaa 3421 acagagagcc  
aatcatgag tgaactccca tcacaattg ctacaaagag aataaaatac 3481 ctagggaatcc aacttacaag  
ggatatgaag gacctttca aggagaacta caaacactg 3541 ctcaaggga taaaagagga cacaataaa  
tggaaaaaca ttcatgctc atgataggaa 3601 gaatcaatat tgtgaaaatg gctgtactgc ccaaggtaat ttatagattc  
aatgctatcc 3661 ccatcaagct accattgact ttcttcacag aattagaaaa aactacttta aatttcatat 3721  
ggaacaaaa aagagcccat atagccaagg caatcctaag caaaaagaac aaagctggcg 3781 gcatcacact  
acctgactct aaagtctat aatgaactc acgaggccaa agaataaga 3841 agacaccaac acaaagggga  
aaaaatcaaa acaatatggg cattgcaatg gtagagatat 3901 gcacagtata ttatggaaac ccagagaaga  
caaacgtaac acagctttgg gaagatatgg 3961 aattttctc ccaggaggag aggatgatca agctgagaga  
tgtgtgaact gagtggaag 4021 gaggggagta gtattccaag agaagcaaac agtatgagca attcatggag  
gtaggaaagc 4081 tgtatacagg gaaccatcag caggttgtt aataaaggaa gctgaatgag gctgggcaca 4141  
gtagctcag cctgcattcc cagcactttg agaggccgag gtggaatcat cattgaggc 4201 cagcagttg  
agaccagcct gggtaacata gcctgaccac atctctccaa aaaataaaaa 4261 taaattagcc tgctgtagt  
gcagtgcctg tagtctagc tactctgaaa ggatcacttg 4321 agtcaggag gctgagggtg cagtgaagta  
tgattacccc attgcactcc agcctgggca 4381 acagagcaag accctgactc tgaaaaaaaa aaaaaacaaa  
aaacaaaaac aggatcgtaa 4441 aagacaatac taacatacaa caaagcatgc agattccagt aaagcctgtc atattaggca  
4501 gattaggcag gtttaaata attttatgt gatgatgagc ccctaaaggc tttgagcag 4561 gagggactat  
ctgaaaaaag atatagaatg gttaaagacc aagacagaga gaagtacaa 4621 ggactattg gttgataaaa

ctcttaggaa ttggaatggg ctgaatgtgg gagtgggggt 4681 ggggtgagag atggggagga ctgaagctg  
aatagacca gatttctggt ttgagtcggg 4741 gagaggtggg gtgctgaatt cgaaggtcag gacacctata  
cctctgggaa tacagcgatg 4801 gttgcaaaag gcatctggta ttgtccttct gccactgtct taaaagggat tctaaagggg  
4861 ttttctgcc ctgttctc cagccctaca ctgcatcagc ttgagctcag 4921 cagctggctg  
tgtccatcat tgcagccaag tctgagaatt cctgattata cttagagcct 4981 gtggagctgc tgacacaaac agtcattagc  
agacaacctt tttgcaaca agtatgctt 5041 aaaatgtaa ctgtggagcc atttccctg cgttgtccag aaggaacttc  
gtcctgcgtg 5101 agcctggatt aatcatgaga gagctcgtca acattccact ggtacatatt ctactctgg 5161  
ttgccttcag cggaactgag aaacttccaa aagggttggt tgagcaatcg tgtcttctg 5221 ttgtctgtc atgggtgtaa  
agtgtgtgta tatgagatat gaccaagact gatttatagt 5281 atgggtgggt tgggtttac ttgaagaagt aagggtgaaa  
tgtatgatga gggaggaaat 5341 tatatacata agcaattggg tgatggctc tctaccaata tttactccg aagtctgca 5401  
ataaaaggct tagccacata gtgcatgcag agctctgact tctagggcaa aacataagca 5461 tgtacactgc  
aagtatcaa ggtctattt gtttatgca atgtcaaatt tcagggtgg 5521 ctaagtggat gatgacaacc tttcgcac  
agggttgcca ggaatagaat caacccatt 5581 ctcagacatc cagagcattt gcttctgaat aaaaactact tttatttca  
gttttagctt 5641 tgccaaactc ttaataata tttagtgc taaaattgg aaatacagaa agacgtacac 5701 aattgcctg  
tgtaacaaac ccggaagaca atggatttta aataacttg aggctggagt 5761 catgatttg ctggcaaga gactgcaaaa  
gttttttca gagccttgg aatgtaccgg 5821 aaataacacc acctcagggg aaaggaaagc aacttaagaa  
actgacaaac acctgttgca 5881 gtagcaagaa tgtccagtga tatagtttct ggccagtga ttatgaaact gggactagcg  
5941 tattgaaat cagaaagact ggaaagtctg tgattgcaa agtgactaag ggtatcactg 6001 aaatctttt  
ttaaaaagac atgagaaagc agatcgagtg gtatcaatac aagagtttc 6061 aaatttaag ttataccata gagtaaaaag  
agattttgc ttcaggacat gttcaaatta 6121 atcatttcc cttatatta atcaaagcac tgaaacagtt tgtattgtg  
agataaatga 6181 aggtggatc tgtatataga tgcaaatgt atcttagat tttctggtc actaaaaatt 6241 ctggagccat  
aaggtaaaag ttcacatgca aataagatgc gggtttctc acaacaatc 6301 tgatttcaca gatttttg tttcatttg  
ttgcttctt tttccattt tacttgagta 6361 taatggatc ttcaaagta tttaaacatt taatttctaa tgaacttt  
aaggcatcta 6421 cagataaaag agactctaga tctttcaaa cagctaataa tagtcagaaa gacttaacat 6481  
tggcttcaga ttatttaaat acttctgat caaacaacgg atgtccgga agggccacc 6541 tggatgttg aacgtatggg  
ttgtcttaag tattattgt atatttctaa accacgcagt 6601 tacataaaaa tgatagggtt aaatactaaa atacagtctt  
ataaagagca ggacaattga 6661 tttgatgat tcaaataagg attgttgta cacacacaca aaaccccaa aatctctta  
6721 tctgaataag tcttaattta tattctagaa agaattgatt ttcattcca aactttaca 6781 ataaagccct taattcaaat  
gcacactatc tctatttga aaatattgaa atatatggc 6841 atagagataa caaagccaaa caccctgact tttaataaa  
ctaaccagat cattcacca 6901 atttcattc ttataattta ttactacta gaattagggt taaaatcaa aaatttaag 6961  
caatttttc tcagtctatt gtactgtaa atctaaatta gtatgagtt aacatcact 7021 ttgcaaaaa taccatgtct  
aggagaacaa acatttatt actacataca gcagtctga 7081 gaataactaa tatcatgaaa gcataatcct taaaatttta  
aatgtgaag ggtgaggaat 7141 acattggtg aaaagaacca caataaaatt ttattttt cattattatt attattatt 7201  
gagacagagt ctcgttctg tgccaggctg cagtgcagt gtgtgatc agctcactgc 7261 aacctctcc tccagggtc  
aagctatact cctgcctcag actcgcaat acctgggact 7321 acagggtgcaa gccaccacac tcggctaatt ttatattt  
tagtagagac agggttcac 7381 catgtggcc aagatggtc ccatctctg acctcgtgat ctgcctgcct cggcctcca  
7441 aagtgcaggg attacaggca tgagccactg cgccagccat tactactg aaactaata 7501 aatggccca  
cccaaactat ttactatt tctagaaaac tactgtttc cctattctg 7561 gcagacggta ataacaaaa gatgtttta  
gataatatac ttctcctaa gtccttctc 7621 atgaatgcat aaaggaaatt gtacaatat tattagctaa taaattgaca  
tatttaaaat 7681 aacacaaaag tattcagtg attatttct gacttctgc acatattt ttgataaaaa 7741 ttaatatcca  
actttgtaga attaattgt catagtctt attttagtt aattaaggct 7801 actaatgcc aatgataagg ggaagaatca  
ttgtcttct gaatcattc aactagtgt 7861 attttcaat atgaattcag tgccataacc caagtagtag aattcaca  
actgtcatt 7921 atgaaagtag ccaatgtcc actggataat tggcttaact acatacatca ataacttta 7981 atgctttat  
agggagtatt aatgtatgg tgcaatgta gattctgcag gagcataaga 8041 gtcatgtaa gcagctctg attgcttaa  
tatgcacaaa gaactatcaa aagtctcact 8101 ttcaaacac ccgacttact acaatacgtt gaagtgttg agcgtacgtg  
atttatctt 8161 tagatagatt tgaataacct cctctttta attgtatga tataaggata ggattcacag 8221 attgacata  
tgactaagtc atgactgaca cagctgtcat tgaaatccag gacacacagt 8281 cctggatgaa tttttatat tgacatgcat  
tgaaagagtt actcattgca tgtttgagta 8341 aacagagttg ctcaaatat tattgacctt aaagaaaaga aggaaggagc  
agaaattca 8401 agatctctt aaactctacc ttatttcaa aggtaaatga agtaggcagc ttctcagtga 8461  
aataaaacct gatgtcgtg aaggagagta acaagtgagg ggtggaaaga gggcctgaaa 8521 ggagtggctc  
tattcaggaa gatgagagga tcatatgggc catgctgaag acccagctgg 8581 ggctaggaac tgcagcttc  
tttatagtc ccctgacctg aacatttact gcactatacc 8641 cagcagtgt atgtgaacat agggtaggga ggacagatgg  
ctggattaat tcaggattgg 8701 cacttccag ggtcagtaca gctaaagaac tagagagtaa aggagtggg gttatggc

771 agcggtaccat gagatacaga ttggatcagg aagaagata tttaatgctt 7821 ggaagagaag  
gttaaaaagt ttaaccaac cccaaagtgt tttgtgtac taaaaaaaa 8881 atactgcatt cataatgta gagaacatg  
aatatttcc aagtcagagc cctaatttta 8941 ctaaaataga aaggagcaaa tacacctgt ttctttatgt acccaatcat  
tgggtcatgt 9001 caatccaaaa ataatcaatc aaaagtgggt aagtaaatag tcatatgcga gagcccataa 9061  
aatacaaaagg aaaggtaatg tcatgtcctt ctcatcaagc agttgatatc caagtcaagc 9121 ttttctcgg gtccagaaaa  
ggattgtgtt cattttcatg tatttgttat tcatgtagtc 9181 cttggattga gagaagaaat agtgccttag tttaacgag  
ctctggctga gatgaaagct 9241 ggatagtaga atgaaagtaa acaagagaca gtgtgctgag tcaacaaata tcattaaata  
9301 caactgatcc atgtgattgt gtcagtgaac accggaagc agatttggat aactggaaat 9361 atggacaatg  
tggactggc attctgtgtg tagaaactga tattgatgta catcttctct 9421 tatccatctg tgcataatca gtatgatctt  
gaagatgcag tatgtcttag agaaaggaag 9481 tataaaccaa cttaaccct gaagttcagc tagttcagct ctatcacttc  
ctattttgt 9541 gatatgtaga caagttgtgc aaccattttt agtccccatt tctggctgc aagtggaaat 9601 attaatagta  
tctaccttt ttgtgttaaa taaaaagata atgaataaaa agtataatgc 9661 atggcacata ccagattctt aatcactttt  
agatgctaatt attagtaaaa acagtcaaac 9721 ttacacaag actgttatgt cactgaatct tatgggaagg tgtaactta  
ataaagtct 9781 tagtaacacc ttccatattt ctccatgtct attttccaag acattctaag actcacttct 9841 ttgatcttaa  
ctgatctcaa cagttcatgt gacatctcca gtgtgtcacc tcatggaaa 9901 gataacatta atagtaagtc tattacctct  
gccacttctg catctgtgta ttgagtgaac 9961 ataactag tgcataaagt ttctctcta taaaagtagc acatggatt  
taagattgat 10021 ttgaaaaatg caaaatacat aaagttaag acagaagaag tcatccatac ttccaggact 10081  
attaacacat tggcatattt tcttccattt ttttctacat atttttaaag tccttattaa 10141 cattgtgctg cctgctattt  
ttacttagca ctaaagcatg agcatattct atattattag 10201 taatcttcca aacgtcatgt gtggtgacta aataatattc  
tgtttagata acagtgtgct 10261 agtatatgtt taatattcac ctactgaga aaaaaaaga cgtggatttg ttgctctgt  
10321 ttatttctgc agtaaaatac tctatagtaa aaaactctat tgtgtctgtg gccagtctca 10381 agctactatc  
aaataatgag cactgagttg ggaaatagca tgtgtagtag catcttcat 10441 atattattc taccacacag acacattaca  
gataacctca agaactata taataataaa 10501 atgtagttaa atcattggga atttcaagta ttaatacttt gttttaata  
tatttgatta 10561 taaatgtata caacttagtt ttaataatg attgtatata acaatcacct ctcaaaattc 10621 ctaaaaaatt  
accaagtggc tcttgcacac ctgcggaaga caaaactgt gtgcctcaat 10681 ctctccac ttgactacga ttaatagaat  
ttagtacaat tgatctgtt tctgcagtaa 10741 aagtcaccta tatgccttc tatatgtgag attatttct taggatagat  
tcccagagat 10801 gatgatgatg atgatgatga tattattatt atttagaga tagagtctg ctctgtcaca 10861  
caggctggag tacagaggtg caatcacagc tcaactgaaac ttgaactcc taggctcagt 10921 tgatctccc  
acctcagctt ctcccaagt agctgggatt acaaagtgtg tgccaccatg 10981 ccggctaatt tttaaattt tttagagat  
gtggtttctc tgtgtgtccc agcctggtct 11041 caaactccta ggctcaagt atcctccac ctgcgctca  
aaagtgtg gattacagac 11101 atgagccacc aaccacacc agcctgagat aaaatattaa cggataata catttgaatg  
11161 taataaagac aaggaaaaca atcaaacagc ctgggtttct ttttctaaat tatagaatca 11221 agtaacattt  
gcacagtgt ccatgtggac caaggacaat ttaaatggt ttccatttat 11281 ttattccttg tgacaagta tgtggaggct  
atacattatc tccgtctata gctgagacac 11341 tgagggttaag tgtgggttaag tgactgcag agtcggtaag tgatggagct  
gggatgtgaa 11401 ttcaagtcct gtgccacatt gcctctttt tttttttt tttttttg agacagagtc 11461 ttgactgtc  
gccaggctg gactgcagtg tgcgatctc agctcattac aagctccgc 11521 tccctggtc acgccattct  
cctgcctcag cctcccgagt tgctgggact acaggcaccc 11581 gccaccacgc ccggctaatt tttgtattt  
ttagtagaga tgggtttca cctgttagc 11641 caggatggc tcatctctt gacctctga tccgccgcc  
tcggcctctc aaagtgttag 11701 gattacaggc gtgagccacc gtgcctggc gctacattgc ctctaatgt gtagttgctc  
11761 aatagtctc cttttttt tttttttt ttttttggg actgagtctc actctgtgc 11821 ccaggctgga gtgcagcgg  
gctgtctcg cactgcaa tctccactc ctgggttcaa 11881 gtgattctc tgcctcagcc tccgagtag  
ctgggattac aggcctgcac caccacacc 11941 agctaattt tgtatttta gtagagatgg gattcacca tgtggccag  
gaatctctg 12001 aactgtggt cctccccgc tcggcctccc aaagtgtcg gattacaggc gtgagccacc 12061  
gcactggcc tagtcttct ttttaacag taaaagcatt caacatcatc aattaacct 12121 tgggctcatt gtaaccaca  
ctccacaagc ttaataaaat attgttttg ttcttatct 12181 ctcaatatct agatgattat actattaatt gcttattca  
ttcattcgtt gtttagaaaa 12241 taactttta ttgagattga ctttctcaa cttatgaat tataagttg cctccattgc 12301  
attttgaaa ttaacactc ttggcattc tatctgtac aatttttc tattatgaa 12361 gcaatagta ttcattttt  
taaaaaatcc tgtaagatac agaaaaacaa aatataaaa 12421 ttacacataa tgctcatagc aagggataag  
tgctcttagc atttgctat tcatcttc 12481 agtctcttc tctcatat gtgtgtgtgt atatgaagt gtatatgt  
tgtatatata 12541 cacatacaca cacatatatt atatattata tattatat gtgtgtgtat gtgtatgaa 12601 tttattttg  
taattttta gttccgggt acaagtgcag gatgtgcagt ttgttatc 12661 aggtaaacgt gtgcatggg ggttgctgc  
acctgcacc catcacctaa ataactggc 12721 tcagcatgta ttagctatt ttcaaatgc tctccctcc ccaatccac  
ctgctgacag 12781 gccccagtgt gtgtgttcc ctccctgt tccatgtgt ctcatgttc agttccact 12841

tataagtga aacgtgggtgt ttgtctttct gttctgcgat tagttgtctg aagagaatgg 12901 ctccagctc tatcatgtc  
cctgcaaagg acataatctc attccttttt atggctgcat 12961 agtattccat ggtgtatatg tatcacattt tctttatcca  
gtctatcatt gatggctact 13021 tgggttgctt ccatgtcttt gctattgtga atagtgtctgc agtgaacata ggtgtgcatg  
13081 tatctttaca aatttcagag gctgttattt cattgaggaa agagaagcat ttaaataaga 13141 agctctctct  
tcagctgcct accagcaaag gggaaaaacc tacctctctg catccatctt 13201 gtctctcttc tccctcactg tgctttaaga  
ggactttctc ttcctatccg tggtaaccc 13261 gtctttcttc ctctgagccc cacataaatc tgctttctca gggacctatt  
tccctcaatt 13321 atctctgtc ttctccaat gtctacatt ttgtctcta ctaggtgctt ccagtcagca 13381 tttaaaccca  
ctttgtcac catactcacc tccagcacca tgcagcccct ttctccctt 13441 ttattgttaa actctgtctc aaaaagatgt  
cttccctctc ctcttagttt ccacttctt 13501 atcacaacct aacccccacc actgcaatct ggcttccgcc aaatctgcaa  
gcacaaaat 13561 caacatgacc tctcatcag gaaactcagt gggcactttt aggtccttat ttaactaac 13621  
gtctcggcag catttgattc tccctctttt gtgaaacgtg tgctactctt gggctctgcc 13681 aatagcctcc actggcttgg  
cttacaactc tgatttctc ctctcagtct cttttctaaa 13741 ctcttcattc tcccacccat cttttataaa tgtttgtgtt  
ttcttcta at tggcttaggg 13801 caccagctc cctcctgtt caggctttca cgggtaccgt ttctctgcc tggaaactc  
13861 ttctctctcc actgcaccaa gccaaattg aatcatcctg tgaatgtgtg tgaatgtatt 13921 gtgtagttt  
ttttattcc tagttttatc aagttcagt gttgagaaac attattatc 13981 atgttaaaga aatactatta tattccgact  
ctactaatgg ttttcaagta gggaatggat 14041 agttaactct gttactgcct ttgtactgt gataggatc tttaaacta  
tgactatagt 14101 aaatcctgtt taaaggactt ttctattaaa ttatccttat attttgcaa ggatttttt 14161 tctgcctaaa  
tgcatagtaa taattttgaa atttatgatt taatttaatt tgcttttaa 14221 aattttactt tagggcttta catcctgctt  
gacttacatt agcattgtt tattccaaag 14281 attgatttga gaagctttct atactttata ttcctatag cttttgttg  
ttgtttttg 14341 agacaaggtc ttctctgtc acccaggctg gagtgcagt gtcgaatcac agctcactgc 14401  
agccttgacc tctggggctc aagtgtcct cctgcctcag gctcccaagt agctgggact 14461 acagatgtgt  
gccacctgta cccggcta at tttttatt ttgtatttt ttagagatg 14521 cagtcttgc atgttgcca ggctggctc  
aaaacacctg gatcctcag tggatcctc 14581 tgggctcaat ggatcatcct gcctcagcct cccaaagtgt  
tgagattaca ggtatgagcc 14641 actgcacctg gtccttgta gctttatgt aactggagac ttaattctt ctaagagtt  
14701 tttaaaaact tatctgaaa actttggggc attatattt ttccagaagt gttcttggct 14761 aatctaactt ttctctctg  
tgagtattgt tgatgattt accccacct ttactacatg 14821 tgaacaattt tgttttaaa attcttaatt cttagatt  
tcatcttaa atattcatta 14881 ctgttagct ctgtgaatt gtgtccaag aatgtgacat ataactgtt tttaaatt 14941  
atttaagctt taatttcat gggcatttga aaatatgtt catctatcag ggcttacagt 15001 tgatgtgcat atctgttaa  
ttaatttac taattctgt attctgttt actacatata 15061 taattatatt ttgtcttt gatctataaa caggattggg  
attttgtt ttttgctat 15121 cttttattg tctatttct acagattta ttatggtag aaaatataga ctatataaaa 15181  
tcaattctt gagctgggtt aaaatctct atgtagctt gtatatttc ttatgtttg 15241 aatgttcat ctatgcatc  
tttcaaaaat gtattctgta attgttcat tgtttataa 15301 atgtacatta tatctagtgt taattttgat gtttatatc  
tctatatct tactgtagt 15361 ctgttgata tattagtgc tgaaggagat ctctaaagg gttacactat gttaaaacat 15421  
ttctcatgt actctgtga taatttact ttgggttg agtccatatt tttaaataat 15481 taagtttcat gattgtcata  
tcttttagg gctgttctt ttatcatta agcaatgtt 15541 ctttttct tataaatgca tatgcccta tattacatt  
ttctatatt actattgcta 15601 tgcacttc ttgggatat cgttgctt atacatatt tccctccct ttattttaa 15661  
catttctgtt ttatttatt taagtgtgc tttgtgtt gatagcatc gtcatttcat 15721 aggtcagctt atacattgg  
cacttactgt gatttctgg atattggac ttgttctc 15781 catattatt tatgtctt gtaaccatg cttttctg  
gcttattat tccctctt 15841 ctctgttt gttttgct ttgttttga ttgataaagc ctcttgga cctctttt 15901  
tctctgtgt tttggaatt ttgaattta ttattttt agtagtaacc attaataagg 15961 tttaacata atcatthaac  
catagatgct tcttctgt tgaagtatt caatattct 16021 gtctctgt ttatggcaa gagcttagca tttttaatt  
acttagcatt ttaaacttct 16081 ttctgaact ttgatctat agttgttgt ctagaattta attcactct tttaaacac 16141  
aaaaattgt gatttttaa tattccatag tgtgtaaaa ttgcaatgg atttcaccac 16201 catttatgt attgtttt  
ataactcacc ctttcttc tggataaat tattcctag 16261 tgagttatt tactctagta actattcag agaaagtctg  
tgagtggtaa acactctcaa 16321 tattgttta taagtgttct gagtttaaaa ttattaccta agctagctgt gtaattctaa 16381  
gtaacagtt attttacgc agtcatgtaa aggtattagc ctattgcct ttggtatcaa 16441 ttgtgttg tgaataatc  
caggttacc aaaattggca ttctattaa ggaattaaac 16501 ttttcttc tggtagagt taagattta ttatctta  
attttacag tttaattca 16561 atgtgtcaa gtagaattt ctttcttt ttcttttt ttttcttc tgagacagag 16621  
tctccctcta tctcaggc tggagtgcag tggtcgatc tcagctact gcagcctcca 16681 cctcctggg  
tcaagcgatt atagtctc agcctccac atagtggga ctacaggtgt 16741 gcaccacat gtccagctaa atttttgta  
tttttagtag agacagggt tccatgtt 16801 agccaggct gcttgaact cctgagctca agtgatctgc cctcctggc  
ctccaaaagt 16861 gctgggatga caggtgtgag ccacatgcc cagctgtatt tcttttaa atctgtctg 16921  
tcattgggtg ggtacttcg acctaatat tccagggtt gttttcagt ttgaaaaat 16981 tatcagccat ttatctctt



atatattgct tctaggctgc tccctctctt tattttctct 17041 aaactccctat cagaggtgta ttatgacctg tcactgtata  
ctttatatct cctaactatt 17101 cttaatagt gtccatgtct gtatttcttt gtattatggt ctgtatatta taatgatcct 17161  
tatgatatat atatcatata tatgatatat ataatgatcc ttataatata ttatattata 17221 tataatatat attatatatt  
atatattata taatatatat tatatattat atatataata 17281 ttatatatat tatataatat atattatata atatatatta  
tatataatat atattatata 17341 tattataagg atcggtataa tatatattat aaaaattatt ataatatata ttataacaat 17401  
ccttataata tatattataa tgattattct gttgaaaagc tgggaagaaa gtggccctga 17461 tgactgtgta taagatgtca  
ttttacataa aaattctgct ttcttattc aactactatg 17521 ttcaacttt tttatttact ccttttgta aggccttata  
aatacagttt tgttcattta 17581 aacagtacat cagtcactgt gtcaccctg ggaattaaat gatgtctaaa acatgatccc  
17641 tgacctaaag ctcaagggtt taataattga gtgtgggtca aagacgtaaa cagatcattt 17701 taatagtatc  
tgtgtgacaa gtggcattat aagaatgaca ttccaggata acataagggt 17761 aaggaaagag gcatttgggt  
ctgcctagca tgtcagggga agtggaagga gatggatgct 17821 taaactgaat cgtaaaagac aaaataacat  
tagcaaggga gatatggggc aagtaaaacg 17881 ctcccactca ccatttttt tctactctag cagatgagct tgccttgac  
ttaccaaaa 17941 aataataata ataataaggt ttattcagaa agtggatgta tctttatgg ccaaacaacg 18001  
tgccagtctg ttctagatgc tctataagtc tgtcactgac ttttctctt ctaaatgtca 18061 atcatactac ttatttggct  
ttgatgtata ccttgccctt taactgaagg gaccatataa 18121 ttactgtat aaatgcagggt agccctcatt tcacagagga  
gtgagaaaaa agaaaggacg 18181 atgtctatag cctttcctcc tgtgtctta aaaaaataa aatagaacaa aacagctttg  
18241 agatctaatt cacataccgt gcgctttacc cattaaagtg tacaattcac aaagtgggtg 18301 ctcttcattt  
tctagtgtga tgcccaagtg aattctctat gaatctgatg aagcttaagc 18361 ttcagattct ctctattgca ggagccctt  
ctaagaccct cagtgggctt tagcaatgtg 18421 cttttatgag tgtctatttt tataaaatta ggggaaaatt gttcttaaaa  
aacaatttt 18481 taaattatta tcctttcca cctgacttc cttcagact cacttccctt tatgtgatg 18541 atattggggg  
ggacacagaa atttgtatt cataatttta ttttttct ttaaaaagta 18601 caaattgcac aaacttgggc ccataaaac  
ttgatctgc ctctcctctg atatcataa 18661 ctctaagccc tgctctctg agagacttct ctttgattt tcaaatgcct  
agtttgaag 18721 tagaacaac attctttaca taagctcttc ctttctttg gcaaatttct actctgggga 18781  
aacagaattc tcattcagggt atgtaatggc ttctgactgc ttaaggaagg gttagtaaac 18841 aaaattctag aatgttctct  
tttgatttct ctttctctt cagctcctgt catcaccact 18901 cctcttgaaa cagtggatgc ctagttgaa gaagtggcta  
ctttcatgtg tgcagtggaa 18961 tcctaccccc agcctgagat ttctggact agaaataaaa ttctcattaa gtaagtattc  
19021 cacattttaa ttttttaaa ttttgggg tatatagtag gtgtatatat atgtatatat 19081 ttatgaagta gatgagatg  
ttgatacag gcatgcaatg taaaataagt acctcatgga 19141 gaatggggta tccatccct caagcattaa tcatttgaat  
tacaacaat ccaattacac 19201 actttaagtt attttaaaat gtacaactaa gttattgtg actatagtca ctctgtgtc 19261  
ttatcaata gtaggacttt ttattcttt ctatttttt tgcacccact aaacatcccc 19321 tactcccccc gatccctgta  
ctacccttc cagcctctgg taaccatcct ttacgctcc 19381 atgtccatga gttcaattgt ttgatgttt agatcccaca  
aataagttag aacatgcaat 19441 gtttgtctt ctgtgcctgg ctaatttcat ttaacataat gatctccagt tccatccatg  
19501 tctttgcaa tgactggatc tcattcttt tatggctgaa tagtactcca ttgtgtatat 19561 gtaccacatt  
ttcttatcc attcatctgt taatgaacac atagggtgct ttcaaactt 19621 agttactgaa aacagtgtg caacaacat  
aggagtatag atatctctt gatatactga 19681 ttctcttca ttgcttata tatgcagcag tgggggtgct ggatcatatg  
gtagctcaat 19741 ttttagttt ttgaggaaac ttcaaactat tctccatagt ggtgtacca atttacattc 19801  
ccacatcaac agtgtacaag gattccctta tctacacatc ctgagagca ttgttattg 19861 cctgtcttt ggctctaagc  
catttctact gaggtgagat gatattctt ttagttttt 19921 atttgcattt ctctgatgat cagtgtgtt gagcatttt  
tcatatgcct gtttgccat 19981 tgcattgtct ctttcagaa attgttcaa ctttttgcc ttttttgat tggattaata 20041  
tatttttac tatagagttg ttgagctcc atatataatc tggttattaa tcctttgtca 20101 gatgggtagt ttgcaaata  
ttctcccat tctattgtt gtctcttcac ttgtttatt 20161 gtatccttg ctgtgcagaa ggcctttta cttgatgtga  
tccatttgt ccattttgt 20221 ttgggtgccc tatgcctgtg ggtatctctc aagaaattt tccccagacc aatgtcctgg 20281  
agagtttccc caatgtttc ttggagtagt ttcatagatt gaagcttag atttaaact 20341 ttaatccatt ttgatttga  
ttttgtatat ggagagagat aggggtctag tttattctt 20401 ctgtacatgg atatccagtt ttccacacat catttactga  
agagactgtc ttttcccag 20461 tgtatgttct tggtaacct gtcaaaaatg aatgagttc actgcagggt catgaattta  
20521 tttctgggtt ctctgtttt tcccattggt ctatgtgtct ctttgatga aagtactgtg 20581 ctgtttgggt tactctagct  
ctgtagtatg atttgaagta aggcaatgtg attcctccag 20641 ttttttctt ttttctttg gctattctgg gccttctg  
gtttcacata aatttttagga 20701 tttttttt ctatttctgt gaagaatgtc atcggtattt tgataggaat tgcattggaat 20761  
ctatagactg ctttggttag tatgaacatt ttaataatat tgattctcc aatccattaa 20821 tatggaatat tttccattt  
tttgggtgtc ctcatgaatt tctttcattg atgtcttaca 20881 gttttcatta tagagatctt tcaattctt gattaattcc  
tagctattta attttatgtg 20941 tggctattgt aaataggatt attttaaat ttattttca tattgttcat tgttggtata 21001  
tacaatgtt actgattttt gtacattgat ttgtatcct gcaactcat tgaattatc 21061 agttctaata gtttctgtg  
gagtatttaa gttttccaa atataagagc atatcattg 21121 taacaaaga taattctcc ctccaattt ggatggccct

taattctctg 21181 attgcttag gtaggactg caggactgtg tgaattaac agtgggtgaca gtgagcatcc  
21241 ttgttgcatt ccagactaga ggaaaggctt tcagttttc cccattcagt atgatactac 21301 tagctgtggg  
tctgtcatat atggctttta ttattttgag gcattttcca tctattttt 21361 gagggtttt atcaciaagg gatgtgta  
ttttcaaa tgcttttca gcatatattg 21421 aaataatcgt atgtttcta ccttcatct gttgatatga tgtatcat  
tgattgatt 21481 gcatatgtg aactatcct gtatccagg gataagttc acttggtgat gatatatgat 21541  
cttttaatg tattgtgaa ttgggttgc tagtatttg tgcagtctgg ataggccaat 21601 aatcccaat catcaagtc  
tggttcttt ttgcttagc agttttccc acttatctt 21661 tcctctgaa tttactata accagaaaa agaatgagg  
ccgcagctc gacacattc 21721 ttagaaatt cctcagctaa atatctgagt tcatattca caagcttgt ttccacata  
21781 actgcaggac accattcagc taagtctct gtctgcata acaaggatcc cctttctc 21841 tttccagt  
agcatgctcc tcatttccac tcaagtctc accagtagtg cttgaacat 21901 acatatttct acgaatagtc tgttcatg  
aatttaggta ttcttaaga tgatgatag 21961 ttctctacc atggaactct ctcttcca attcctcagg agcagaatca  
ttaacacag 22021 tatttctatt aacagtctc ttgaggaaat acaggcttt tctagcatgc tttcaaatt 22081 ttttcggt  
ctaactatt atcaattgca aagccacatc cacatgtta ggtattgtt 22141 gcagcagcac cacattcca ggtacaaaa  
cctgtattta ttattatcc ttgctgaac 22201 aaattaccac aaacttagtg gcctaaaaca acataaacgt actatgttac  
agtctggag 22261 ttacacgta tgaataaat ctctctgggc taaaatcaa gtgtggcag ggctgagtc 22321  
ctctggagg cttagggaa gaatctgatt tctgcctt ctagctct agaggccacc 22381 tgcgttctt ggccccctac  
tccattata agtctagca tggcactact ctgacctg 22441 cctccattgt catacctccc ttatcaatc tgcctctc  
ttcatctt taaggatact 22501 tattatcaca cagggacct tcgaatagtc cagaacact catttaaga ttctaacat  
22561 ctgcaaaata aggtaacata ttgacagatt ttggtgatta aaacaagaac ctctgtggga 22621 gtgtattct  
gcttaccaca cgcattggc ataaaaaac tcttattgg taaaagaaa 22681 ctctcttta tattgtgt tcttctca  
tttcttcta ctgccaat tccttctca 22741 acaatggt tgcataat taaataggta atatatgaa agcatatatt  
ttatagttg 22801 gaaattgtt tcctcctta tgcatacaa gtaactagaa gtgtgcctgg cactgttag 22861  
caatcagtaa gtaattgtt aatgaaagaa taaatattca actaatcatt agttactct 22921 ataagtaatt aacccttct  
gttcatcgta ttatacata tgcattgtt ttatctata 22981 atagctgcta ctccagaa ctattggga gaagacact  
atgtctggg ttatagct 23041 ttctgaata aagtaactt tacatttgt ctatcagtg ggcatcccc ttgaaagca 23101  
ttttgaagg actatgttac ttgactatt ggagcctaag aaagatgaga atataatgtt 23161 agctttatat tatcaagtaa  
ggttattcta ttattcagaa gtcactcaag ttctctca 23221 ctttattct acttctcat taacaagtca tcggttgat  
acattaatca tggcaaaaa 23281 atcacagagg aagcactaat ctgtcattt ttctgtgac ctgcagactc ttgacacc  
23341 ggtacagcat ccgggagaat gggcagctcc tcaccatct gagtgtgaa gacagtgat 23401 atggcattta  
ctgtcgacg gccaacaatg gtgtgggagg agctgtggag agttgtggag 23461 cctgcaagt gaagatgagt  
gagtgggaaa cagattcgtc tattgattg aaagttagt 23521 tggtagact agtttgtat ttattttta catttttt  
ttgagacaga gtctactct 23581 gttgctcagg ctggagtga gtggcatgat ctgggtcac tgcaactcc acctctggg  
23641 ttcaagtgat tctctgct caggctctg agtagctgg actacaggtg cgtgccacca 23701 agctcagcta  
attttctat ttccagaata tacagggtt cactatgtt gacaggctg 23761 tctgaactc ctgacctg gtgatccgc  
cacctggca tctgaagt ctggaattac 23821 aggcgtgag cactgtgcc ccgctgact ggtacattt  
aaaacagtca gtaaatagag 23881 atttctcag gcctgtgat tcagactga gacaagtca agtcaagca caacctgag  
23941 gccaatat cccacacct ttatgcctg tatcaaccac taccctaagg caagcctc 24001 aattctat  
ccttccat ttcttacct tactcatct ctgacttct tccacctga 24061 attcttca caggaaaact tctctgaa  
catttacct acacctgtga aacacaacca 24121 aacacattt ttattctaa ccttttga gacattttg cttattca  
aattgat 24181 tctctgagt gatttctgc ttagtggaa gctgttctat ttctccact tcatgtctac 24241 aagactgcca  
aacactagta ggtaatctc cagccctcag tgttcttt aaaccattct 24301 atttgtatt cctatacaa atcttctc  
tgatgagggc ttatgccatt ctgacctat 24361 ttctctaa ctgtattcat catgtcatct gcttctag gcactccc  
atattatta 24421 aaaacttga ttccaggct actatctt tatccatct tactctgca attacctaa 24481 gaaatttaa  
cagcatgaa atagaaccac tagccattta attctataa ttcttgacc 24541 tgcagaaatc cagtgatgt tgtctttt  
ttcaattt aaggctcata ctttaatt 24601 ctatgtac acgtatgag tcgttaagg aagtctgcca ctgtaggaa  
aggtagt 24661 attttatt ttactttc attttaggt cagggtgata tctgcagaat gtgcagtgt 24721 ttacatagg  
taaacatgt ccatggtgt atactgcaca gatcatcca tcacctagt 24781 attagccta gcatccatt tattctt  
gatgttctc ctccccac caaccccc 24841 gacaggcccc gtgtgtgtg ttccccca tgtgtcatg tgtcccat  
gttagctcc 24901 actctaagt gagaacatgc agtgttggg tatctgtcc tgcattagt tactaggat 24961  
aatggcttc aactccatc atgtcctgc aaaggacatg attcattcc atttatggc 25021 tctgtagtat tccatggtg  
ttaggtacca catttctt atccagcca tcattaatg 25081 gcatttaggt tgttgtgt aactgttta ttgtttt  
gttatata tttatatata 25141 aatatatgta aacatatatt taaatataa tacatacata ttttaaata tataaaaa 25201  
tatactaaa tataaaaa catatttaa tataaatag tataactata ttttaaata 25261 tataaatata tagctatag

tatatatagt cattatattta 25321 taatttttt atataaaacta cattaatattt ctatatattt  
 atataaaata taaataaact 25381 atatatttat ataaatatat catatatata ttcatatttt atataatata taatatataa 25441  
 atatataaat atataaacta tatatttata tattgtatag ttatatttat atataaatat 25501 atagctatat atttatattt  
 aaatatatat taaatatata tttaaataa aatatataaa 25561 tatatataaa tacatattta tatatatgta aaaaataata  
 aaatatgtga aaaatacata 25621 tttatatata atatatgtaa aaaatattaa aatatgtaa aaatacatat ttatatatat 25681  
 gtaaaaaata taaaaaatatg taaaaaatac atattttat ataaatatat acaactatat 25741 ataaatatat agttatatat  
 atttatatat tatatatatt tatatatttt ttactacata 25801 atatataaca tattatatat tttagtatat atatttatata  
 ttagtatata ttagtaatat 25861 accatataat atacatagta tattatatat aactatatat agttatatat aaatatataa 25921  
 ctatatatgt tatatatagt ttatatataa tattatatat tatatataaa ctatatatat 25981 cacatatagt ttatatattt  
 tttaatatat aatatataac tatatattta aatatataaa 26041 tatgtaacta tatatttata tataactata tatttaaata  
 taaatatata tttaaataa 26101 aattatataa atatacataa aaatacatat ttaaataata tatataaata tatatttaaa 26161  
 tataaatata tattttatata ttatattata aatattataa ttatatatta tatattataa 26221 atatataata tatatttatat  
 attaataata gtataaatat ataaatatat attatgtaag 26281 tataaatata taaatatata ttatataagt ataaatatag  
 aaatatatat tatataagta 26341 taaatataga aatatatatt taagtataaa tatataaata tataaatata tatttaagta 26401  
 tatataaata tatataaata tatatttaag tataaatata tatttaagta tatataaata 26461 tatataaata tatatttaag  
 taaaaatata taaatatata taaatatata tttaagtata 26521 aatatagaaa tatatattta aatataagta tatatatatt  
 taaatataag tatatacata 26581 aatatatata tttaaataa agtatatata taaatatata tatttaaata taaatatata 26641  
 ttcaatata agtatatata aatatatatt taaatataag tatatatata aatatatatt 26701 taaatataag tatatatata  
 aatatatatt taaatataag tatatatata aatatatatt 26761 taaatataag tatatatata aatatatata tttaaataa  
 agtatatata taaatatata 26821 tatttaaata taagtatata tataaatata tatatttaaa tataagtata tatataaata 26881  
 tatatattta aatataagta tatatataaa tatatatatt taaatataag tatatatata 26941 aatatatata tttaaataa  
 agtatatata taaatatata tatttaaata taagtatata 27001 tataaatata tatatttaaa tataagtata tatataaata  
 tatataaata taagtatata 27061 tataaatata tatatttaaa taaatatata tatatttttt gagacggagt ctgcctcagg 27121  
 ctggagtgca gtggcatgat catggctcac tgcaacctct gcctcctgag ttcaagcaat 27181 tctcctgcct  
 cagcctccca agtagctgag attacaggca tgtgccaccg gaccctgcta 27241 attttgtat ttttggtaga gtcagagttt  
 cgccaagttg gccaggccag tctcaaactc 27301 ctaacctga gtaatctgcc cactttggcc tcccaaagtt  
 ctgggattac aggcattgagc 27361 ctgtttgtgt taactcttta tcagcgtagc caatcgatga ctactcttg gcctgtcac  
 27421 ccactggaag tagtctgcat ttaaactctt cagcttcagt atgtcactct catcatggac 27481 atttttgtg  
 acagccttgt cagatgagca aaacagtttc ccatactcat gatttgcctc 27541 caagtagagt ttgtgggcac aaacttccat  
 tgtctccttc tcagctaaca acagtgtctc 27601 agtctctctc attctcctac tcttgctata caacctcaac atcaccagca  
 tcatcatgtt 27661 ctcttacctt gattcgtctc tgttctcctt tccattgatt cccaatggg gcttttatt 27721 ccttccatac  
 ttagttcttt ctctacctg gtgatgtatc atcaaact gccttaccag 27781 catctttaa tctcatggcc tctgtcctg  
 taagcatctg ctacttgcaa actgtcaatc 27841 ttacaatgat gtaaccttca tcttctcttc tctgacatgc ttataacct  
 acatacgggc 27901 accacacaaa ttagaggaat ttaggtctac ttgggacatt tatttttagt ttttgtgtg 27961  
 ttgtcttcc tcattatttc ttatcttttg ttattttgct ggaggaaatc attaggtact 28021 ttttcagag tggaagatg  
 taaaatattt cctgaatttg tgcacgattg gaagtcttca 28081 ttttgctgcg attgttgat aataatttg ctgcatgcag  
 aatgagagtt taaaatccc 28141 ttttcttag ttttagtaga tctctctgt tgcagatgag aagtctttt cttatttctt 28201  
 tacaagtaaa tctgatgtct ctcttaaaaa gtttaggatt ttctttttt ttctagagtt 28261 cataaatttc acaaattgac  
 aagaatatat taggtgtatt tttaagaatt attgtactc 28321 agtttaggt gggccttgtt ttttgttg tttggtgtg  
 tggttttgt tttgttttg 28381 ttttttgag acaagatctc actctgtaac tcaggctgta gtgcagttgt gtgaccatgg 28441  
 ctactgcag ccttgactgc ttgggctaaa gcaatctcc tgcttcagcc tcccaagtag 28501 ctaggactac  
 aggcattgagc caccatacca ggctactttt attatttat ttacttttt 28561 ttggtagaga taagtctca gtgtgttgca  
 catactgagt ctgaagtcc tgtgtctcaag 28621 tgatctccc acctggcct tccaaagat cgagattata ggagtgagcc  
 actgcacca 28681 gcctaggtgg gccttttga tctaaagacc aaagctttt agaaaggtac atttctcta 28741  
 ttttttct ttttcttc tctatgactt caaattttc ttctcatatt ttctgcatgt 28801 cttaatatc tactctcttg aagattcctt  
 ttacttttc ttcatattat gaatgtggtc 28861 tccagtatga ctattctgtc attctgagtg ttttggtctt aaaaactata  
 ttttaattt 28921 ctaagaattt ccttgatgtc tctgtgtca taacaaactc acttgatga tacaatttc 28981 acttaagctt  
 ctaaggatat cactagtga tcttttaaaa agacattttc tttttccc 29041 tgcattactt ttatttctt cagaaaaaaa  
 aaaattgatt ttgtttgggt tccatcttt 29101 tatgtttaca atttttctca aattgatctt ttatttttg atcataataa  
 atatacatgg 29161 agtggtcagt taattaggat aaaaagctgg tgggaatagc atgactttat ggaatactga 29221  
 tttggtactt actgtgagta agtaggtggg gatctgccta tatgcaggct tcccttcagt 29281 atgcagagaa gtaagaaatc  
 aaataaggaa gtgggaatgc tctcatttgc taaataatga 29341 agacttcatt ctgaggatga aacacattca agtatttct  
 tactttgtga cactacctt 29401 ctttgaata ttttgcata ttctctctgg cccaattgtt ctgatttgg gttctatact 29461

aaatccctt tcttttctt gctcttctt ttccactcc tcccttgag atctcatcca 29521 ttcatgtgga tataaccgg  
tgtggccatt ccaattgcta aaattttgga atgcttccat 29581 acttcttgga aagatccgtt ttataaggct cccgagatcc  
cccaaccct atcactactc 29641 cagctctctt aagccctccc ccaagagctc cctcccctaa attcctaag gtccatcagc  
29701 taaagtctca atgctggcac agcgggatac ttccagcatc ctgcttaag gtgaccagtt 29761 ctgattggtc  
agtacttatg actccaccct gaatcatgtt cccttacagt ggggatccat 29821 ggctatgcgt caatacccta gtcattccta  
gttgacttta cattcaattt cccaaaagg 29881 aattcctcac ccctcaccta acagatgacc aagacatcaa  
gtcactgaga agataggaga 29941 ttttgcttt aagcaaagg ctttaccta gacattatct gtgcctcagc ttaccatag  
30001 agatcttgtt cagggaacct atggaaggca tagataacac tttatttgac tgtcatagga 30061 atatcaagt  
ctcagctaag ttttcccag caactgtatg acaatacaac tcacaattga 30121 ggaacctggc cagtactgta ttacatgta  
gggtattaca gtttattaga aggagagttg 30181 tatgctatag atagcaggca aagtaataaa gttgtattt tctatattt  
taaagcctt 30241 ctgtattt tgctataaca cagggccgca ggaactctaa atgacagtga atgcttagat 30301  
taaaaaccaa caggctcac gcctgtaac ccggcactt gggaggccga ggcgggcaga 30361 acacgaggtc  
aggagatcaa gatcatcctg acaacagggt gaaacccgt ctccactaaa 30421 aatacaaaaa aaaaaaaaaa  
aaaaaattag ccgggtgtgg tgggtggcgc ctgtagccc 30481 agctactcgg gaagctgagg caggacaatg  
gcatgaacc gggaggcgga acttgacgtg 30541 ggccgagatc gcgccactgc actccagcct gggcgacaga  
gcgagactcc gtctcaaaaa 30601 aaaaaaaaaa aaaaaacaa aaacaaaac ccaacaggtc atgaaggctt  
tgcaagtatc 30661 tcttaccacc aacaacacca aagccccat tctctcct cacattgaag tagaagaaaa 30721  
caaagccat attcatgcg ttccttgc aaaataacaa attggttacg gcacatgtcc 30781 tgcaagaaat aaaaatgtgc  
cattgctcag tagtctctt tgcgaagtc ccctctgtat 30841 ctgtaacgta aaattcctaa ggacataaat gtagtttaa  
ctattttacg aatagtacta 30901 aaataactgg catcctgaac ttatcaattc tttgtatat tagattaat aactttctt 30961  
gaaagtttca tatttgagaa taaaaattaa ctggcataaa ctattcttc tgaagatta 31021 aaagtgttg aacagtaaat  
tacatgttg agtccccca aattgtatga cagaatttct 31081 tctgattgtt aatataataa tatctggtt actttctaga  
gaatgaatgt atttaattaa 31141 taatcataaa atttaatagt caaattaaga tggaagctaa agggaaaata ggtcataatt  
31201 tctaactagg taagaatata gttatatcaa aattttctt tcaaatgtt tatgtctatc 31261 agtatgaatt  
aaataatgtt gaattgctat ggtgacagtc tatgttaac agctttatt 31321 aactatctt taaaatgaag aatgctatgg  
taacttcaca ctgttaatat tttcataaa 31381 tttgtgtt gtagtaaga ttctaataa gcagagacaa ccaagtgtt  
ctaaactgat 31441 ttctgttga gatctactga ggaaaactgt cttgcattt ggtgaattt gtaatgtaac 31501  
atgcctcaaa tgatttcaa aacagatgtt tagaattaa tgaaagta gaaactctag 31561 gtttaataaa gccatattgc  
cttattatt ttgaatttc atttctttt agaacctaaa 31621 ataactgctc ctccataaa tgtgaaaata atagaggat  
taaaagcagt cctaccatgt 31681 actacaatgg gtaatccca accatcagtg tcttgataa agggagacag ccctctcagg  
31741 gtaagtgtt atgatgtta aacacatata taaaatgtat ttaaaatat aacatttct 31801 tacacactca  
gttacacact taaaacttc tagtataaag tagtttccat gtacatttta 31861 accaaatgta aatatttctg tttgcatata  
tgcaaactgc atggcatttc atttgggtct 31921 ggctagggaa aaaagagatg ggaaccaata atgttaaaga  
tagaaaagga ggcaatgaaa 31981 aagcaaacct ggaatcctt gtattgttg gctggctaaa tcatattt tttttaatg  
32041 ttgaatctga gacttagggg atgaaaaga aaactaaaa ccaggctt agaactgaca 32101 gtttctggaa  
ggaggggagg agacaagggt cggaagaaaa gaaatgat ctctggagag 32161 aagttaggcg aaaagactca  
agactcatc acaataacct tggcaatcc ctctgagtc 32221 atgaagagta gtcacgcctg taattccagc  
acttcaggat gccaaggcct gaggtcagaa 32281 gttcaagacc agcctggcca acatggcgaa atcctgtctc  
tactaaaaat acaaaaatta 32341 gctgggtgtg gtggtgtgtg cctataatcc cagctactca ggaggctgag gcaggagaat  
32401 aactgaacc cgagaggcag aggttgcaag tgagccaaga tctcaccact gcactccagc 32461 ctgggcaaca  
gaatgagact ccatctcaa aaaaaaaaaa gttattatcc atatgcttat 32521 ttgtactgc ctctgtatct tatccccaca  
ttattgata aattattatg aggcatcatt 32581 attgtcttc catctttata tcacctaaa gattacagac tatgttttc  
atttaacaat 32641 gcatagtata ttttaagagg aatacaagg tgcacttta tgtcaattaa ctgaactaag 32701  
gtataaaatt gctcagctt gctttattt aaataaaata aatattgcta attttaatg 32761 attaatatc tggcttctc  
cttggtataa atcttggtgc atttctaca atgacaaaca 32821 aggtgtgtg tacttatgtt actgaattta gggttcaaaa  
cagaaaagac agatgtaata 32881 tttaaactcc aaagagtaat ttaatatata tgtgtgaaat ttctagtat tcaaaaggac  
32941 atgtactct ctaaagatac catctagggt gcaaggtaaa cctgatagt aaaagcaatg 33001 tgtttatta  
ttcatatttc aatagctttt ggggtactag tggtttttg ttgcaaggat 33061 gaactgtata gtggccaagt ctgagattt  
agcgtgccta ttactgagt gctgtacatt 33121 ataccagta tatagtttg tatgtctac caccctctc tgcaacattt  
cccccttcta 33181 aaagcaatgc ttttaatcag atttagctgt gactttgggg aagcaaaata agccatata 33241  
catatatata ttatacatat acatattata tatataatat atatatac acactcatgg 33301 gatgaaagaa aataaaaaa  
aactatacct cataggaccc tggatgaagat taatttaggt 33361 actctgcac tatttcatt aatattgtat gttttacata  
ataagtgcc aataaaggtc 33421 aaagcagat ctgtgatgata gataatagt atgacaataa gttgatgata tttggcaat

33481 gtagcttga tagaccata aacattttg aattcacgtc ctagtctctg gcaggaaaat 33541 tccgaattg  
cagttcttga atctgggagc ttgaggattc ataacgtaca aaaggaagat 33601 gcaggacagt atcgatgtgt  
ggcaaaaaac agcctcgga cagcatattc caaagtgggtg 33661 aagctggaag ttgagggtaa ggagctgc  
ttctccctt gactgtgtga ccaggggcct 33721 cactgtctac tgtgaaggct gcacctgggc ttgggagaga  
agagatgtgg gcagcccact 33781 tccctcagtt gttccagata ttaggcata agttcaagcg tatgataaca gaaaaggaaa  
33841 actgaaaaa gaaagaaatt ttactagta taaaaggta tattccattg attactaca 33901 atcactggta  
attttacca aaacagacta aatttactgt aacagtaaaa taatagaaac 33961 ccattttaga atgccttctt gggttgaca  
attctccctt catttaaga ctgggcata 34021 ataattttaa tcttttaat catacagaac aactttaaaa agatgtgata  
aggaggaaaa 34081 agtagctatt ttcatagatg gttctatcac aaagctgaa aaaaaaaca ttaactcaa 34141  
tcgtaaagcc aaaaataatc ccagttctgt gagttatgtt atcaaaatcg ttttctttt 34201 ctttctgaaa atattttta  
atcagctaatt tcaataactt ggtgtgaaag gcttctactg 34261 agaaatcaga atccaaatag gtctaggtgt tctattgtct  
tgttagtcgg gtccttcttg 34321 acctaaaatt gcaccacatt ttgcttaaaa agaactatca gcacacctt attaggcgaa  
34381 taaactgagt acaaacctt ctagctctt cctgtgtat gccagagaat taacattttt 34441 ggctcctagc  
tttctacctt gtaagtggg gtttctctta ttaataag ttaggtgtg 34501 atagtgtta gcagagcatc tggctcttg  
tgcacctca ataaatgttg gctataagaa 34561 ttatcatcta ttttctgct tttcttat ctgattgata agtgttagag  
tatcacatac 34621 tggcacaat tacagttcaa tcaggaaaag actgaagag ttctccatat tttactttga 34681  
ttctgccta ctttcttag gccaaaatct atcttttct gcatatttcc ttctcattca 34741 tatagtttcc tattaactcc  
ttaagatta ttttatttct ctgatggac attctgtca 34801 cagctttaat gatctcgtt cccacgttg cctccaattg  
aggtaacatc ttattatgt 34861 cattgtacca attgtcata aaatttcat taattctca tggaaaataa tgagggtgtg 34921  
gggaatagt gctgtcagaa tataaaaata cattttcatc aagttgctgt aatttaatat 34981 ctctaaata atcagtgc  
ttgaagctc cgtattcaac aaccagtga tatgatttat 35041 tcagtaaaaa ctaaaataac ctacaaacc accagacac  
acattcagac tcatgaata 35101 tctgtctgcc tagatccagt gtttctgt tctgtctaag gaatgatgca gaattaatgc  
35161 tatccatttg tataaataat cacaagagt ttttcttt aagatattaa aaataagctt 35221 tctgtattat aatattaat  
actgatcatt taggtcacta gcttcataga tattaaaaca 35281 acttgctta ctttgacct agagaaaatt atcaccgaac  
tccattagt ggagttatta 35341 tacagtttg tttgtgtta ccatttaatt ttgtatcatg cctgtcagta acattgaata 35401  
ctgcctttt tctcgaacc tttaaatggg catgcttagt gctttaaag ttaatatatg 35461 ctagagatag tattaatt  
gctagaactg agagctcata atatcattta aagttattct 35521 aactgtaggt aagatgattt tcgcacacat ttgacacaca  
tgcctattt tacctcatc 35581 ttgtcccta taaaatagc caaatatgt gacatgctta gcacaattgc tggacataa  
35641 taagcattta ataatggaa tctactatac ttattatgat taaaacataa aattgaaca 35701 aattgctt  
ggctctggaa gctctgaaag gttgactcc actgaataa atagttagg 35761 tattttcata agatataatg tagacgtgac  
ctatttagag gtaaggctaa ctcaacctac 35821 aactcagaac aagttttt taaaaaaa gcaactgaga aatgactgga  
aaaacctcaa 35881 aagtacatgc agatgcctgc tagttggca atgatgagga ctgaagatga tgaggcaggg 35941  
ccatcgtcag ttggggcaga cgagcatatg tatgtatcaa gtcgtaactc tgcaaattag 36001 ttatgcagtg actatatcga  
atcagaactc tatggtgcca ttgatgctg ggctacatgt 36061 aacacagatg ggcatacagg aaaagataga  
gtttgtcat tgatagctc taataaagat 36121 aaacatgcca ggcatggat tgggtacct gtgttaacta aatcttgtt  
gttacaactg 36181 tgaagaaac accctaccac acagaagtaa agtccctt ccagattgcc attctcagac 36241  
tgctggacct ctgcaatgga aatgtaaagg tctctatac ttggtcttg cttaaaatg 36301 ttcaaagggt gacatacata  
attattgatg gaacctcta actcaagct ggtgcagcat 36361 ggatgtctt ctgaaaggat gtccaatggg  
aaggctaaca tttaaaaag ttccattgag 36421 gctaaatgt ttatgtggat tatctgtt aatttctact aaaagtctgt  
aacaagggcc 36481 ctatattctg ccatttagg aaacagagga atagagagga tagctaact acacaaggct 36541  
gcacagatag ctgtgtctaa gaatttagt caggctgaat actgtctgt ctattaaaga 36601 atgagatagt cctgtgtgac  
attgtcaaga gaagtatcta gatgaaatg aggggaaaaac 36661 cagaattctg caaatgaagg agaggatggg  
agctgaaaaa aaatagacag gaggtattga 36721 caaatttt gataattt tcagagaaaa gggaggagtc  
aaaaaaggaa gcagtagctg 36781 gagctatgtt tgggtgttag atcacgtgc attgcaagat ttctctcga aaaatattga  
36841 aatgtaaaaa aatttaaatg taaaatatt aatgacactg agctcagaga gaagaaaaat 36901 ttgaacatac  
ataagagaac aaataactca atgaaatgtg gtgtggata atgcacaagg 36961 gttgtattg ggggccaagt  
agaatgataa actgtataca gaggtgacc acatgtctg 37021 gtttcccag gacagtctg gttacacct gttgtcctgg  
aatcattatt aatagagtct 37081 ctctttact ttcaagaatg tccaagctc cagataaat tatatggta ctctccttag 37141  
acaggaagac agaattgctt tgtaatagga agaaaagaga agagggaagt tttagtata 37201 aatcagttca  
taagtatgat ggatggaatt tgagaaaatt ctgttctat ggtctctatt 37261 tctctagga aggagaaatt agggttatct  
ttgaaaaca ctttgttaa agggtcaggg 37321 aaggggtga ggatgaagt agttctaaa tagctgtgga  
atgggagaga tgactacaa 37381 agtaaccag gatttaggg cagcattaaa gtttagtag agagcaggac  
cgtgaatatg 37441 gagtagcatc aatccacatg gttgcagggt tttccctc agtgtgctc tgctgtacag 37501

gtgtaagttc agaaaatagc agaaaagctaa attcaaaggc aagacataaa tgttgagatt 37561 ttgtcaggaa  
ggaaaaatagg gcaaaggatt tgagactatt gcaaaaagaga gattgaagca 37621 tgaatcatgg aatctttagg  
taccaaatac acctataatt tctctttctt ttcttttctt 37681 tctttccgtc ttcttgttt gtttgtttt ttttggaca  
aagtctcact ctgttgctca 37741 ggctggagtg caatggcaca atcatagctt actatagcct caaactccta ggcttaagtg  
37801 attctccac ctcagcttct tgattagctg gggctacagg tgtgcactac tgtgctcagc 37861 tttttttt  
attttttta tttttttt tttactttac tttttttat tttttttat 37921 tttttttat tttttttat tttttttat tttttttat  
ttttttttat tttttttat 37981 tttttttat tttttttat tttttttat tttttttat tttttttat tttttttat 38041 tttttttat  
ttttttttat tttttttat tttttttat tttttttat tttttttat 38101 tttttttat tttttttat tttttttat ttttttcat  
agagacaggg tcttgctatg 38161 ttgccaggc tggctcaaa ctctcaagc aatctccag ccttgacct ccaaaatgtt  
38221 gggattatag gcatgagcta ccatgccag ccatacctat gatttaatat ccaaatatga 38281 aatatcctcg  
gatatgagcc taggattaaa cactatagct ccagcaatat aacagacaag 38341 ataatatgaa aatcttcaa  
ctagcccga aatgctgggc tagttgtata actgataaga 38401 ataaaatata aatctctgga agctcaaat  
ggacaggaac tgcaaaaacc ataagctcaa 38461 tgagctgggt tcttattgt ctaaaggtaa tgggacaggt  
gctcatctcc ataacctagg 38521 agattgggtt taagaccctt aaaggggcag gagacaggtt cttggcccat gtgaaatgga  
38581 ggtagcatt caaaccttg tataaagctg agaaccacaa aagtagaaag atgggccaga 38641 aattccatct  
tcaggcacia aacacacaa caatggctg tctgtctta gtcgtgaggg 38701 agaaaaaacc aggtcatctt  
aggagtgaat attcaact caggactata gcttccatag 38761 gcttgatatt gacttaatac catcagcaca gtctgggaat  
tctcagctgg aaaaatgaac 38821 atacaaactg gtttcaggct gggcacagt gctcaccct gtaatcccag cacattggga  
38881 ggctgatggc ttgagcactg gagaccaacc tgggcgacat ggcaaaact catctctaca 38941 aaaaatataa  
aaattagcca ggtgtgggtg tacatgcctc tagtctcaac tatttgggag 39001 cctgaagtgg gaggatggct  
tgaacctggg aggtggaggc tgcagtaagc caagattgtg 39061 ccactgcact tcagcctggg caacagagtg  
agaccctgtc tcaaaataaa aaaataataa 39121 taaaaaacct acatacat aaaacattgg ttccaggcca  
aaaaaccac acacacacaa 39181 aacattgggt ccaggccaaa aatttaacaa gaaaaaaaag ctaaaagaag  
aagcactta 39241 cccaagttac ataggcttt catggatata cctacactga ggatgagttc acaatgcaaa 39301  
attgtcacac ctacagaaaa caacctacct tgagtgaagtg ttgtccaaca taatataca 39361 agaaaattca  
gttaaccaca taacataca gaaattataa aataagtatg cttaaagtaa 39421 ttaaaaatgc aaaaggagga  
ataaggaaaa caaaaataca ttagggccag gcacagtgc 39481 tcacgcctgt aatcccagaa ctttgggagg  
ccaaggcagg cagattactt gaggtcagga 39541 gttcaagacc agcctggcca acattgtgaa accctgtctc  
tatacaaaaa ttgccgggc 39601 gtggtggtgc acgcctgtag ttccagctac tcagaaggct gagacaaaag gatctctaa  
39661 acccaggagg cagagggtgc agtgagccaa gattgcacca ctacactcca gcctgggcaa 39721 cagagtgaga  
ctttgtctaa aaaaaaaat taaataata aataaattag gaagacaggc 39781 ggttttgata aataataaa cacaattta  
acacataaaa atataattaa aattaaaatt 39841 caatggatga gtaatagtat attagagata aagagataat tcagccatta  
gaaatcagct 39901 cttcagaatt tagaattcag tgcagaaaga tttgaaagc atagaaaaga tgaaattgaa 39961  
ttaagaaat gataaaagat acattacaga aagagaaaat acagaaaata tgagaggcaa 40021 tactcaaaaa  
catgatgact aagaacttc cagcattgat gaaagactta aatctcaag 40081 tacgtgaagc ataccaagtc  
ccaatcgga aaaatgaaga gcagagaaat aagcatttca 40141 caccagtc aatcataagg aaacatcaaa  
gacaaagaga ttatcttaa atattgaaga 40201 cagattatt ataaggga acaattagga taacaataga  
gtgtggggaa actatcact 40261 tcatctatcc ttacaattg gtatagccgc atgaaggtt atgaaaaata aaaatcaaac  
40321 tttaaatgt atatagatt gtctcagcaa tttaacttct gacaattat ctaaaagaat 40381 attgcacaa  
gtgtatgtc aagattatt gttacaaagt tacttagtaa aaagttgtaa 40441 agaacttaa ttgcttcaa taggacacca  
tctaaatatg tgatgaatt ccatgcagcc 40501 attaaaaaga atgagatgga tttatata ttaacttca aaattatca  
ccgtatatgt 40561 gacttgggtc tgcttccat ctctgagcct cagcttctc ttcttaaaa tagagataaa 40621  
agcagaacct acctctagg atgcttgatt attagtatt atagacacat agtgtgact 40681 atataattat ttgctgttt  
attatttatt tcatgtatt aataagtact tgtatagtgc 40741 ttccatgtg caaggtactg ttctaagtgc ttagaatat  
taattcatta tcaatataat 40801 atgtcataa gtgaaaaagt aagtaaagaa cagtatatct tattattata tattagagta 40861  
catgtatatc gaactctaa gtcatcatct ctgcatagag aattatatgg ggggtcccgg 40921 cacgatggct cagcctata  
atccagcac ttgggaggc cgagggtggc gaatcacgag 40981 gtaggaggt tgagaccagc ctggccaaca  
tggtgaaacc ccatctctac taaaaataca 41041 aaaaattatc tgggcatggt ggcaggcacc tgaaattcta  
gtactcagg aggtcagggc 41101 aggaaaatca ctgaaccca ggaggcagag gttgcagtga gcagagattg  
tgccactgca 41161 ctccagccca ggcaacagt caagattcca tctcaaaaa aaaaaaaga aagaaagaaa 41221  
attatatggg gggttaactt tattttatc ttatgtagg cctatactt ttgcatctt 41281 ataaagagaa ctttataatt  
aggaagaatt aatacatgta ttatgctt ggaaaaaaa 41341 cacttctc aatattata ctattttga taaagtaaca  
tgaacttctc tgttcattag 41401 ttgatatt ttgcagttc gttgctcat tgatctcaa gacaaactca gggatgggaa

14611 aagttttgtc aaaggaattg gattctcatg ttgcttaggt ttggcaatt ctggatatt 41521 ggctgaagaa  
tttgaaggt ggaggttctg atgaacagga catagaacat gccatttctt 41581 tagggaagga atcaatccat  
aaagctgcta agcttgagac ctacaagagg aagctggcag 41641 agtcacctag atggaggaag tgaagggggg  
cagagaacag cagctgctgc tgaagtctcc 41701 actcatctga ctctcttt ctatgtatag atggaaatct gaaatttatg  
attttatagt 41761 ctggaatagt ttgcaggatc cagcacaaaa gttttgttag ggttctgatt tctcagtga 41821  
cattttccac actttgttgg gtgttactga cttacagcat aaagggaaaa gtaaaacaaa 41881 gggaagtcc  
tataggaaag ggaagcaccg ctaggtaaga actatttagg tatactgatt 41941 tgacattgac agggaaagcct  
cagtcactg ggaggcagaa gaaagtttc agtctcacia 42001 ctgtggaggc tcttctggaa aggttaagcc  
ctgtctcagg ccccatgtg ccaaagggt 42061 ctaggagagg attcacggca ggatgtgacc agggaaacatc  
ttattgtctg atgtcaccag 42121 agaaatctac atatcatatt tcatacattc taagatgctc attatttcat attttggcat 42181  
atctgggtta catctcatca ttaatccctt acaatcacia ttgaataaat ttagtttct 42241 ttgtgcaca tttaatatc  
tctgaaattg agatttttct tacagtgct aaaggcattc 42301 acaccagtt tgtggcttct gccctccagc taagatcgtt  
ccttagctgt ccccaatat 42361 gagaatgaat atacaatgat aaacacaaaa taaatcaacc atattggctc ataaagctt  
42421 cttattttt aactagaaat tttcttctg cttgagatca tttcattgt tctcacaga 42481 aatgaaagca  
ttattttcag tgagatgatg ccacctagcc ttttccctc aaacctttt 42541 attgctgcc tattcattt attaggtga  
aatagagact aagtggctt tcagggccat 42601 atagaggaaa ttatcttta agagacaatt ttgtctgct cttaatcca  
cttcacattc 42661 tactttaggt atggtgtgta gccaaagagt gatctatgt gttttctta tatatctgaa 42721 accattttc  
cctgagtacc tctaaaggac aggaagacag atactcaggg gcagagggat 42781 atggcagtgg aacatgctga  
ttgaaatggc agggctggaa tttcagtga gggtttgcta 42841 tcatgattgc ttgggacaac tttgaaatt ctgattttat  
ttcctgtt tgaccagtgg 42901 catatgccc cttaaaaacg ctagaccaga gggccaacca tagtggctca cacctgtcat  
42961 ctgggcactt tgggaggtcg aggcaggcgg atcacttgag gtcaggagt agagaccagc 43021 ctgggcaaca  
tggtgaagcc acgtctctac taaaaataca aaattagcc gggcatggtg 43081 gtgcacacct gtaatccag  
ctactcagga ggctgaggca ggagaactgc ttgagcctgg 43141 gaggtggagg ttgcagtga ctgagatgga  
gccactgaac tccagcctgg gcaacagatt 43201 gagaccctgt ctacacaaaa tagagagaga gagagagaaa  
caataaaga gagagagaga 43261 gagagaatta actcctctga ccagtgcagg ggctcatgcc tgtaatccca  
atacattgga 43321 aggccaaggt aggtgaacct ctgaatcca ggagtgcag acaagcctgg gtgacatggc 43381  
aaaaacctca tctctacact gaagtaaat aaagtaaat aaaaataaaa taccagacca 43441 tacaataca atctttaag  
gtgataacat aattactgt ttttatagct ggggggtgtc 43501 ttgttataa gatttttaa acattgcaa agactcatt  
aaaattata aatatctaat 43561 tttctttt cccctcacat tctctgctt aactaagatt tttaaaatg cactattta 43621  
ttgaggctg aatgtggctc ttactacatt ctgtgaatat cacattcaga tgaatactgc 43681 ttgtatata gaaactggct  
gaatgtagt tacttgagac ccaaatata atagatggat 43741 gctggagtgt atcaagctct tgtaattgc atttctatt  
attatctgt ttaccctga 43801 agcttaagc cattaaggaa aatattgggc agaagctgga atcaagagag ggctgtcagt  
43861 cagcaattgc tggtgggaag aggtgtctg gcaccaatac aaactgcaa ataagagcca 43921 gggagggtct  
agaagcagaa caaaaagaag agagtcctc tgggtacagg gttatttag 43981 ggctcctca tgttaaaca actccttatt  
tctcagggc ttgaaaagc agcctctgt 44041 caaacgtgg agaggcatt tggggagtag caagggaagg  
caagtcatat ggagaattta 44101 agtggctca gtgcagtgt ctccatcact tgcaggaca cctgcgtgct gccagcccag  
44161 tttcttgca atctgaaagg ctgcactatc tacccttaag gccacaaat ctattcagaa 44221 acttttatc  
tgaagatatt ttgcagaca tatgaaatag gtaagacaag tagaattcca 44281 aaagatgaaa ataaataatt cctatctatc  
tatctatcta tctatctatc tatctatcta 44341 tctatctatc atgtcacaga agcagatgtc aatagacata actataaaag  
atcagcattg 44401 tctcaaaat ttagacttc tggtgcctt cttcctaga gatcaaat attgttgca 44461  
tctacaaaag tggaagcaat catgtaattg ttataccaca ttgatttgc ttttctt 44521 gttatgctg cagctctta  
tatcacaat gccacagaga gaggtattta aaacccacc 44581 gtgtgctgtg ctctcagtga ttgcagttt aataaaatt  
gcagtggctc tgtcccggc 44641 atcagtccta attgttgat gccactaca ggttgattt gctgtcatga gtacattgtg  
44701 cattgaaa ccaacaaaag aaaaaaatca caaacctctg ataccctgg aggtatcat 44761 tgggaaaatt  
aatctgcat gatttaatag gatgcatgt ctaaaagagg agctgacc 44821 attgatttg acttagggg atattatgt  
atattatgt atggttcat ctaaaagt 44881 ctataaggct ttcagagaag aatggtaaag tggctctta gttgaacagt  
tgtcactgca 44941 tttcttaag aaaaagtcac ttgtataata atgatgcac tgaatagata atacataatg 45001  
ctcaagtca acacatagt aggcctctt aaagtgcagt gttaaagaaa atgtacttta 45061 aagtaattaa attgttagt  
ataatgtga cattatatta ttgaaatga aaagtatcg 45121 tgacctgaaa tacatatact ctaattggag tgagtttta  
atatcagttt tcagatatta 45181 aatgagatg cataagttca agcatacata cacagtaaag gaaaattgct ttctattca  
45241 tgcattagt catccaaca agacacactg agcaatgtc caggtgcgac atgagacaga 45301 gaaggccatg  
cctccactgg gcttaattc aaaatgtgac tatttgatt catgcaaga 45361 tatcatggaa agctattaga attctatggc  
aagaaggagt tcaagtaatt ttatattcag 45421 ttatttct cagatatcaa atacatgact ctgagactgt aattgtata

tttattccg 45481 tgaacaag gactatttt tggagaggac ttaatatag gggttaac 45541  
atgggtggtg ggtatcaag aaaactgcat gggctctaga gtctcaggta aacttctga 45601 gtccaaatcc  
tggttctacc acctatcaca tgtgtaact ccagtaggtt acttatctct 45661 ttgtgcttca gtttcctac ttgtaaaatt  
aggtaataa tactatctac ttcataaatt 45721 gaagaatgta gaagtagatg atatattat agctcttaca agagtgactg  
acacagagta 45781 aacactcaa tagaaattat caatgtagt tctagggcta atataacttc tgtgcaacag 45841  
aagcagtgat ttacgcactt gtgcagacaa ttatagctcc ctttccatg tgtcatctt 45901 atctctgagg tacaagcaat  
aaagtccaat ggcaaaaact aaattttat tttaatatg 45961 ttatttgat taatttggg tctagcaaaa gaataataac  
caactttaa tctgcaagga 46021 gaccccaaag tcatatagtt caattcctta gttttagat aaagaaatt gagactaggg  
46081 gcagtggctc acgcctgtaa tcccagccct ttgggaggct gaggcaggag gattgctga 46141 ggccaggagt  
tcgaggccag cctgggaaac atagttagac cccctctct aaaaaaagta 46201 tttatttaa aatatttaa aaaaataaat  
ttgagaccgg aaacatctt tattttatag 46261 ataaagacac ttgagacaa acaaattgtg actttgccca ggttggcaaa  
ggaacttgag 46321 tgtcttatt ctagtctagg acatgttcca ctaccttc cgattcttc ctcttttaa 46381 tatttatgtt  
gtgtagataa tactctgcag agttcacatg cttagtatc agacagacct 46441 ggggtgtaat cctgactgtg ctgcttaca  
gttatgtgag gtaggataat ttacttgacc 46501 tctgcaagtc ttttctca ttgtgaaat ggggggtaat attatctaga  
acacagagtt 46561 cttaaaatgg actcagatag catattcaca gtgtctatgc agtagctct tgataagtat 46621  
ttgctgtgtg tggattgt gtctgtgt tacattgta taaagctgga tgacatctat 46681 ccagagaata ccactagta  
agcttctga atttcataa tagaatgtca acattaacaa 46741 ctgctcatct ggtctccaaa gaacataaat ctacttcaa  
tcagcaatgc ttgtacctg 46801 cattctgtt acttgtaga gattataact ttggtgtggc ttcaccgtga caagtataa  
46861 aggggaagct atctaagaag ctgtgtaaag aggtgcctt aatggctaac aggagagagg 46921 ctatttgag  
tcaacctgtt aaaaaaaaa atagtacaac aacataaaag tgaaggcggc 46981 ctctgtgtg atcctgagct tatatcatat  
tttattcact atagaaatag atatttgcca 47041 aaaatctgt tgaataact gatccattct agcactcact gctcccaagt  
aaatccaag 47101 tgagaaatca cttaaaaat ttatgccaat aaaaatgat gagttcatgt cttttagg 47161  
gacatagatg aagctggaaa ccactattct cagcaacta ttgcaaggac aaaaaacaa 47221 acaccgcatg  
ttctactca taggtgggaa ttgaacaatg agaacttg gacacaggaa 47281 gggggacatc acacaccgga  
gcctgtgtg gggcggggg agaggggagg gatagatagc 47341 attaggagat atacctaag taaatgatg  
gtaatgggt gcagcacacc aacatggcac 47401 atgtatacat atgaacaaa cctgcacgtt gtgcacaggt  
accctagaac ttaaagtata 47461 ataataata aaaaaattta gtgcctggc gaagctctgt gaacaatggc tgcagaggag  
47521 ctctgcca gcctggggaa gccatagcct gcacatgatc tgtcccttt agtgaactaa 47581 ggttgacttg  
atggagccaa tgctggcaaa ggtctctgag gaaaactgac ctggattat 47641 acaaggtcca gcctgcagg  
ttgtaaggga ggtcacttc atggcaggcc aagatcctg 47701 agatgtttg aaaattgaa ggagaaagga  
attaggccaa aatgaataga tactgcagac 47761 gaaatctat ggagaaatt ccttgactt acatcctag cctcagcaca  
gcaaatat 47821 agaagctgc agaagacaa gctgagattt ctatagaga cctccagtgg aacaaactta 47881  
aagaaggccc atatggttaa cgttctgat gccatatgg ttaacattgt tgatgcacct 47941 gtgtaaagaa ccaggctaa  
tctaataagg ccatactac ttgtcgtca agaactttg 48001 agattcttt taatcaaaag tggggagact ataaggaaca  
atttgtgctt aatggaaaa 48061 ttgtgtgtg tcattctaga gcacacctgt gttgtgtgat tccaattctg tgggagctgt  
48121 ttaagctt tataaattgt agataactgg cagcaatgct aaatcgttct cctccataga 48181 ctgcaaatg  
aattctgtcc agtggaaaag caacaaaaa acccaatctg gctctgttg 48241 cacagtcatt ttaatttcc tgatctataa  
atgggtctgt cctgggatt ctctttcac 48301 ctggttgcaa cactcactg gttcctgt gaatgagta aataaacct  
ttaatcatg 48361 tttattctga aaaaaaaaa aaaaatcagt gcctgggtg gggagaaggg tctctgctga 48421  
gaaactgaca tttatccat tcctatagta agtactgtg actttattt ctttacttt 48481 atttttctg cggcctggca  
tgtatcttag aatccaatt gaagcttagt catagtatct 48541 gtacacaa accatccaga ggttttctc ctgactctaa  
tatattgta ttcattta 48601 ttatggccat atcaatatac ctcttaag atctctatgg aaagagaaag aaataactaa  
48661 gttgacgat tcatggaact tctctccaa gtggttctca aatgccagt cacatcagaa 48721 gcactggag  
atcttactaa atgacacagc ttcaggatgc attcccagt tattcatatt 48781 tgataggttt atgttagtgc ttttaacaa  
cacccaaag gatccttaat gcagtgaacc 48841 atgaaccaca cttgaaaaa cactgacttc aggttttcta  
cttagaggga ctttattcca 48901 gatgaatcta acaattcaa ggagaaagct tatctgcaa tagtaagata tcaatgtag  
48961 gatagctta aattcatcca ttgtggaat gcctactatg ttctatgcaa tgaggtaatt 49021 cttaaggata  
cagacgaaag agagatgtgg ttacttctt gaaaagtgt caattcagt 49081 gaggaagatg gatatgcaa  
caagtaaaat gcaatatatt tacaatgata gaagtgtg 49141 tagggtata tacacaggac agaggagata  
gggaaaggct agggaaatct tcagagaggt 49201 gaaggccaac agggcttga ttgatgaaga gtgaggagct  
cttggtagg atcatcac 49261 attgaggag gaaaaagaa atagaggaaa aaatcagat ttaccatgca  
agcacagcct 49321 gacactgact cataaccagg gagtaaaaga aggattagag agttgggac agtatctatt 49381  
agtgtgcta taaaacaga ataaacctg attgactca caggctaaca tggagatcat 49441 ctcttggtg tcttctctg



gacctttttt tctttttttt tttttttgag acagagtctc 49501 tctctgtcat tcaggctgaa gtgcagtggg gcaatctctg  
ctcactgcaa cctccgcctc 49561 ccagggttcaa gcgattctta tgcttcagcc tcttgagtag ctaggattac aggcatgtgc  
49621 caccatgccc agctaattct tgtattttta gtggagatgg ggcttcacca tgttggccag 49681 tctgctctca  
agctctggc ctcaagtgat ccacctgcct cagtctcca aagtgcagg 49741 attacagggtg tgagccacca  
tgcctagccc tctcttagac ataattttta acgggtagat 49801 acctaacatc ctgacaatgt gggaacctat ggtttggagg  
catatggcct tatctggcat 49861 ccagaattcc atctaaaagg ttacagaaat gtcccaacc caagccactt taggcaactg  
49921 ggatactgtg gtatgattta agattaagtt tatggcttct attttttt ccaactaaaa 49981 tttccggttg  
gctaaaaaa aaatcttatt cttaatagac ctacagctctg ttaacgcagt 50041 tcagagtgcagg ggcattctcc agagcttaga  
tcaaaaaagt tattttaaag taaactaaga 50101 ttttgataaa cgtaccatgg ttatacagga tgctaactt aggggaagtt  
gggtgaacag 50161 tacatggaaa ccttctatac tatctttgca actcttatgt aaatctaaaa ttatttcaaa 50221  
ataaaaaatgt tttaaaaagg taaactaaga aatacttctt tgtcctggta attaagcagt 50281 ttagcatctc ctcccatcaa  
aaacagaaaa tgaactttct ttaagaagaa aaaagtgaat 50341 caggaatgaa gtcacatatt ttattggctg atgattaaac  
ttctaataa tttcagaac 50401 cagttaaca aaagtgcggg tgctttatat acacctaaga ctgaaacaaa aacaagtaaa  
50461 ctttgttag ctctgtctg attacatgg taaacattc ttgctctgac ccactattca 50521 ccatccat  
ttacaagtga gaaaaacgtt accatctcaa aggccacaga aatgttcca 50581 acccaagcca tgggagggaa  
tcccacatca ttgaggcagg cagcccttatt tttgtcctgg 50641 agaagagagt cactgtatt gaggatgatg tgtatgttt  
ctaaaggagc ttgccttctg 50701 actccttcag agttggagcc acagtgggta aacctctca ggcattgccc tgcttcaag  
50761 cagacagaaa cgtaaacagt ggcagtacac caggatcggg tttcttctg ttagctacca 50821 agagtcagga  
aagagaaacc aggtatttat ttaggttgt cattattgct aggttttct 50881 ttaatgataa gggtttgaga aaagaagt  
ctgttcagaa acaaagtatc acagagcctc 50941 aataggatta cttttcaac caccagggc cactgtttt ttaagtcaa  
tataaaaaa 51001 atttaacca tttgttctt tgtagtctt gccttctaac aggcattctc aactcagtt 51061 ttcttaaaat  
atgatgctag atgagacaaa tagtctattt aagagcagat tcaataatc 51121 tgtatagatg agcatctatg tttaataac  
agggtcgaaa gaatttctct ctctacagag 51181 tgatttctct gtctcaaata attcagttta tgaaaggagt taaggatg  
cttttaaca 51241 ccggaagg gtacttaaca tgatcaatat ctaggataca gccagctaaa gcagattgac 51301  
gttcaaaaat aaaataaagc ctctccctt tgaagtcgc taaaggaaca gctttcatga 51361 ctcaagaaa  
tactctagag atcaaaaaag ctctggagaa agaaaaagaa ctagaagacc 51421 tggcttcaaa attacctt  
agtactccc agttatgagt tagctgctat attaattaat 51481 tgctttatat aaatcatgtc attaatctt ctccacaatt  
ctatgagttg aaagttaata 51541 actacgtttt ctggataaaa aacctgaagt tcagagaagt tgaacagcaa ctcaaaaaa  
51601 acagctagtg agagtgaagt gaggatcaa ttctaccacc tggattgctg ttaggttatt 51661 gtacatgagt  
gtaaggaaag tactctacta ctaagattt gacttccaa cctctgagtt 51721 tgcctttga aaaagccctg caatgggtt  
cttatttacc aaatggctag agattttctc 51781 aagatattga ctataaggaa aatgataaac aacttaataa aatggcacta  
tgaaaaataa 51841 ataactagg acaaatatt attttattt catagtcca ttcatataa ttgcagcact 51901  
attcacaata gcaaagactt ggaaccaacc taaaagccca tcaatgatag actggataaa 51961 gaaaatgtg  
tacatatatg ccatggaata ctatgcagcc ataaaaagga aagagatcat 52021 gcccttgaa gggacataga  
tggagctgga agccattatc ctacagaaac taacacagga 52081 acacaaaacc aaacaccaca tgtgtcact  
tataagtggg agctgaacga tgagaacaca 52141 tggacacatg gggggaacaa tacacactgg ggctgttg  
aggctgggag tgggaggaag 52201 gagagcttca ggaagagtag ctaacggatg ctaggcttat tacctaagt  
atgggctgat 52261 ctgtgcagca aaccaccgtg gcacacgtt acctatgtaa caaacctgca catctgcac 52321  
ttgtaccct gaacttaaaa tagaagttg gggaaaaaaa agaaaaaaga aaatattagc 52381 ttggtgcaaa  
agaaataatg gcaaaaactg caattactt tttgacta acctataaa 52441 gtgacttca gaaacagtc tacttttta  
aaaggcaaaa aacagagtgg tttatataat 52501 tggataatt ttacatctc ttttgatac acacttctta ttttcaaaa  
tttcacaaa 52561 tcatctaaa cattaatgct gtcacaaat aaattctac aaagtaatag aaagctcagg 52621  
aaattaatat ttgagaagta aatttagagg caaggataac ttaactgag aagcattat 52681 aattttccat ttgagaat  
actctgtagc attataaac attatattt aattttctat 52741 tcaataaat taatattgta ccagaatacc aaactgcatt  
tggaatcata ggcaactgtt 52801 atgtttgcc tttctgata ttgaaaaaa atgacctcc tttgaatgc tgcctcata 52861  
atttaaaatt ggccttctc ttacagggg acattcacga taaactctca ataggctta 52921 atttgagaa ttttagttt  
gccttagcag ctttcttat atcttctt aattctataa 52981 gtttaggctt tatatgttt gaaattatat tgttaagtgc  
atacacatta attattgtg 53041 taattcctc tctgcagatt gcattttta ccttggatg atgttctct tcatccctt 53101  
ttataatac ctttagcat aattctgtat tgttgatat taatcatt accacattt 53161 tctttgtt tgtgtttcc  
tgtctctt gtttggtatt ctctatccc ttttccaa 53221 cctcccaca atcttgaag cagaatatag ataaactt  
ttgaattca atcaaaaaga 53281 cttttttt agtagataag ttaggtctt tgtattatt ctgaaaattt atttctatta 53341  
ttcttagac gatttctat atgtattat ctgttctt tctctgtc ttttttaat 53401 tcttttctg ttttctgga  
gatcattata tatttttta attctcact ttaaccaca 53461 ccacaaccac ttgctgatt ttgaaattg ggatcacaat

gtttattttc agtgattact 53521 ttattatttt atattcataa tatgatgcta taattctaac agtttaagat catgtaggat 53581  
cttctccagt ctctttaact aaagcaagca tcttatcatt ctttaaaatc ttatctaaca 53641 gcacctccc tcatcctctg  
tcactttcct tggcattatc caaaatttta ttattcttaa 53701 aacactgaat tattttatgg tccataaata gttctatcaa  
tatatgccac caattgctgt 53761 gtatcatcatt caattttcat gtgcctttt tcttctgttt ccaatttctt atttctgaaa 53821  
catattatc attagttcat tcaattagat ctgtgagcag atatctttgt cttgtcttt 53881 gtatgtttga aaatgccact  
atttaccct gatcattcag gtgaacattg aaatctaagt 53941 tgacagatat tttccctcag tgttgccta tgtcttcta  
catcaattga tgagaagtgt 54001 tctgtcattg taactataat tcttggttag gtaacagagt tcttctatct ggtctttta 54061  
cctttgatta ccagtacttt taccataatt tgtcatagaa tctgtattag ttatctgttt 54121 cctgtaacg aattacacag  
aaactcaatg ttttaaaaca ataaacgatt atcacttcat 54181 agtttctata actcaggaag tacagagtga cttcccagg  
ccaatgtatg gattatgttt 54241 gcagtaaaga tgttgccac ttctgcagtc atctgaaagc ttgaatgggc tgaaggatct  
54301 aattcaaatg tggttgactc ataagtgggt ataaattgat gctggccagt gcagagcctc 54361 cctttgtccc  
catgtgggtc tctctcagg ctgcttgagt gtccccacac tatgggtgct 54421 tccttccta agagtagatg atctaataga  
gaacaaggag gagttagtaa tgttttcat 54481 ggtctagctt caaaagccac acacagtcac ttctgccaca tcctattgt  
tagaagtga 54541 tctaagtcca gcctacttc aaggagagca gaggaactat actctacttt tccaaggag 54601  
aatttggga caggtttta aactacaata gtgtcaatgc aaaatgcacc agaaagtctc 54661 agtaacagaa  
tcacacaagc agaagaaaga acttcagagc tgaagacaa ggctgaact 54721 aaccaaacc atcaaagaca  
aagaaaaat aattttaaa aatggacaaa gcctccaaga 54781 agtttaggac tatgttaaaa gtcaaacct aagaatagt  
ggaaggaaga agagaaagaa 54841 gataaatcta aaagtctgga aaacatattt gaggaataa tcaaggaaaa  
cttccctggc 54901 ctgctagag atctagacat ccgaatacaa gaagctcaaa gaacacctgg gaaattcatt 54961  
gcaaaaaat cattgcctag acacatagt atcagggtat ctagaatcaa gacaaagaa 55021 agaacttga  
gagctgtgag gcaaaagcat caggcatctt ataaaggaat atctatcaga 55081 gtaacagcag atttctcagc  
agaaacccta caagctagaa gaaattgggg tcctatttt 55141 agcctcctaa aacaaagcaa ttatcagcca agaatttgt  
atccagtaa actaagctc 55201 ataatgaag gaaagataca gtcttccag acaaatgctg aattagccac cacaaagcca  
55261 gcactacaat ctcaatgaa ctctaatct tgaacagat tctggaaata caccaaaata 55321 gaaccttt  
aaagttaca tctcacagga cctatataac agtaacacaa tgaaaacaac 55381 aacaacaaca acaacaaggt  
attcaggcaa caaatagcac aatgaataga atagtacct 55441 tcatctcaat actaacgtgg aatgtaaatg  
gcctaagtgc tccacttaaa agatacagaa 55501 tagcagaatg gataagaatt tcaccaacca agtttctact  
gtcttcaaga gactcaccta 55561 acacataagg actaacataa acttaaggta aaggggtaga aaaacatatt ccatacaaac  
55621 agacacaaa agcgagcagg agtcgctatt ctatatcag acaaaacaaa ctatagagca 55681 atagcagtt  
agaaagacaa agaggagat tatataatga taaaacact agttcaacag 55741 gaaaatatca caatcctaaa  
tatatatca ccttaacact ggagctcca aatttataa 55801 acaattatta ctgacctta aaaataagat agatggcaac  
acactaacag tgagggactt 55861 taatactaca ctgatagcac tagacagatc atcaggacag aaagtcaaca aataaacaat  
55921 ggaattaac tataccctac acaaatgga cctaacagat attacagaa cattctacc 55981 acaaatgca  
gaatatacat tgtaatcatc agcacatgga acatttcca agacagacca 56041 tatgataggc cacaaaacaa  
gtctcagtga atttgagaa atagaaatta tatcaaat 56101 tctctcacac cacagtgaat taaaactgga aatcaactcc  
aaaaggaacc ctcaaaacca 56161 tgaaaataca tggaaattaa atgacctgct cctgaatgat tgttggtca acaatgaagt  
56221 caagatggaa atttaaaaat tatttgact gaacgataat agtaacaaat agtgagacaa 56281 cctatcaaaa  
cctctgggat acagcaaaa cggactaag aggaaaattc atagcattat 56341 ctgaaaaagc acatatagac  
aatccaaggc cacacctca atttccatg caattggtga 56401 aacaagaaca atctaaacac aatgcagaa  
gaagaaaaga aatataaaag atgagagcag 56461 aactaaatga aattgaaatg gaaaaaata caaaagataa  
atgaaacaaa aagctgggtc 56521 ttgaaaaga taaataaaat cgatagacca ttagctagat taaccaagaa aagaagacag  
56581 aaaattcaa taagctttat tagaaatgaa atggaaggta ttacaactga tatcacagaa 56641 atatgaaca  
ttattcaagg ctaatatgaa caccttatg gacataaact agaaaaccta 56701 gaggagatgg ataaactcct  
ggaagtatac aacctccta gattaaacca ggaagatgta 56761 gaaactctga gcagaccaat acaagcaga  
aagattgaaa tggtaatttt aaaattgcca 56821 agaaaagca gtccaggacc agacagattc atagtgaat  
tgtatcagac attcaaagaa 56881 gaattggtac caatctatt gacactatc cacaagatag acaagaggg aatcctcct  
56941 aaattattct atgaaggcag tatcaccta atactaaacc aggaaagagc ataacaaaa 57001 aagaaaacta  
cagaccaata cacctgatga acacagatgc aaaaattctc acaaagtac 57061 tagtgaactg aatccaacaa  
catacaaaa atataatcta ccatgatcaa gtgggtttca 57121 taccaggat gcaggatgg ttaacatat gtaactcaat  
aatgtgata caccacataa 57181 acagaatcaa aaacaaaaat cacgatcatc ttagtagaca cagaaaaagc atttgacaaa  
57241 attagcatc ccattatgat taaaaccctc agcaaatca gcatagaaaa gacatacctt 57301 aaggtataa  
aagcatcta tgacaaacc acagccaacg ttactgaa tggggaaaag 57361 ctgaaagtgt taccctgag  
aactgaaaca agacaaggat gccacttc accacttcta 57421 ttacaatag tactggaagt ctagccaga

gcaatcagac aagagaaaga aataaagggc 57481 atccaatga gtaaagagga agtcagaatg tcattgtttg  
ctgatgatat aatcttatac 57541 ctagaaaacc ctaaagactc atccaaaaaa ctcttagaac tggtagatga attcagcaaa  
57601 gtttcaggat acaaaattaa tgtacacaaa tcagtagttc tcctatacag caacagtgc 57661 caagctgaaa  
atcaaatcaa gaactcaact gcttttacia tagctacaaa aataaaataa 57721 aatacttaag aatatatcta accaaggagg  
tgaaagacct ctacaaggaa aactacaaaa 57781 tactgctgaa agaaatcata gatggcacia agaaatggaa  
acacatcccc tgctcataga 57841 taggtagaat caatattgtg aaaatgacca tactgcctaa agcaatctat aattcaatgc  
57901 aattcccatg gaaataccac gattactctt tacagaacta gaaaaagcaa tcctaaaatt 57961 catatggaac  
ctaaaaagag cccacatggc caaagcaaga ctaagcaaaa agaacaaatc 58021 tggatgcatt acctaccca  
acttcaaacc atactacaac gccacagaca ccaaaacagc 58081 atggtagctg tataaaaatg ggcacagaga  
tcagtggaa tgaattgtga acccagaaat 58141 gaagccaaat acttacagt aaccgatctt tgacaaagca  
aacaaaagta taaagtgggg 58201 aaaggacacc ctattcaata aatggtgctg ggataattgg caagccacat  
gtagaagaat 58261 gaaactggat cctcacctct caccttttac aaaaatcaac tcaagataga tcaaggactt 58321  
aaattgaaga cctggaacca taaaattct agaagataac atcagaaaaa ctcttctaga 58381 cattggctta  
ggcaaagact tcataaccaa gaactaaaag caaatgcaac aaaaacaaag 58441 aaaaatagat gggacttggc  
cgggtgcatt ggctcatgcc tgtaatccct gcactttggg 58501 aggccaaaggc tggcagatca ctaagggtca  
ggagtgaag accagcctgg ccaatatggt 58561 gaaacccat ctctactaaa aatacaaaaa ttagctgggt  
gtggtgttac gtgcctgtag 58621 tctcagctgc cctggaggct gaggcagagg aatcactga aactgggagg  
tggaggttc 58681 agtgatccta gatagtcaa ctgcactcca gcctgggcaa cagagcgaga caccatcatg 58741  
ggaagaaaaa aaaaaacatg ggacttaatt aaactaaaaa gcttctgtac agcaaaagaa 58801 ataatcagca  
gagttaacag acaaccccc gagtgggaga aaattttgca aataatggat 58861 ctgaccaagg agtaatttc  
agaatctaca aagaactgaa acagcaagaa aaaaaaaatc 58921 ccatcaaaaa gtgggctaag gacatgaaca  
gacaatctca aaagaagata tacaatggc 58981 caacaagcat ggaaaaatgc tccacatcac taattatcag  
ggaaatgcaa atcaaaacca 59041 caacgtgata tcacttact cctgcaagaa tggctataat aaaaaataat agatgttggc  
59101 atgggatgtg gtgaaaaggg aacacttta tattgtgtt gggaacgtaa actagtaca 59161 ccactatgga  
aaacagtgtg gtgattctt aaagaactaa aagtagatct accattgat 59221 ccagcaatcc cactactagg catgtacca  
gaggaaaaga agtgattata caaaaagat 59281 acctgcacat gcattgtcat agcagcacia tttgcaattg  
caaaaatata gaaccagccc 59341 aatgtctcat caatcaacca gtggataaag aaaatgtgag acatataat acacacacat  
59401 acatacatat acacacacac catggaatac tactacatat acatacacac acacacacac 59461 acacacacac  
acatacatat catggaatac tacttatcca taaaaaggaa tgaaataatg 59521 gcattcacag caacctggt  
ggaattggag atcattatc taagtgaagt aactcaggaa 59581 tggaaaacca aacattgtat gtttcatgc ataagtggga  
gctaagataa tgaggatgca 59641 aaggcataag aacgacacat tagactttgg ggactcaggg gaaaagagt  
gaagggggat 59701 gagggataaa agactatata ttacgtacag ttaccctgc tcaggtgatg ggtgcaccaa 59761  
aatctcagaa atgaaaaaat tttaaaact acaacaatgt caaattgtt gtattaatcc 59821 tcctatgcaa tccagtgcc  
acttgaaagg cagtctcaa gtacttctga aaaatactca 59881 tccccaaaac acaggcaaaa aatttgatt cagtaacct  
aattgtgtgt ctggcattta 59941 attgttgtt tttgtcttg cttaacttc ataagtatt caatgaatt cgagtttaa 60001  
aagccaccac tttaactgat ctgggggttc atgtattgt tcaagcctag aaaatctca 60061 ccactatgtc ttcaatata  
acctctctgc tcttcttct ctctctact gctcacactc 60121 ctgtaagcat atattagagc tctaaatctg ttctcccat  
cttttagtta atcttcaca 60181 ttctgtcca tcttctctc tggcctcagg gctgtatgat ggcttaagt ccacttctg 60241  
attcattaat tcttacttg acctgtcca agcttgagt tatcatatct tttgtgtctc 60301 tgctgttat tatcaattc  
tagcattct actattatat gtattcaat ttgcctgtt 60361 tttttataa tttatttta tacatatact attatttag  
gttcttaaac tcttttgaa 60421 ctctttgtt ttctccaga gtaaattaat cccccagtt ctgaattcat taagtga 60481  
gtcaatttat tattgttag caattgttt cctaattgtc ttgaaatta tgattgcca 60541 ctgtaaatct tatcatcat  
tctctgaaat gattattcc ttctcagta atttggggg 60601 ttgccctca ctctctcat tcatataaga tattcaggg  
agcaatttta ggactctatt 60661 ctgtaattgt ttgacattca atccagacc agtcactaaa ccgtcaaaag cataacacat  
60721 gtctgacta cgatactat actgcttgg ttcaagcag cgagcctca atccccatc 60781 tcatatagta  
cacttctaga gaaatcaaac ttcaagcccc ttctctgtt tatagaattg 60841 gaactcagca gtgactact atctgtgtg  
ttttgtctac ttcttatac actgagatat 60901 tcatctgtt tttaatatg gcttgtctt ttaggtagc aaaaaattat  
atcttcatta 60961 ttgctatgta ctatattct acctagatga ctgaattga atatcataac accaactga 61021 gtagtactct  
ttgtgtata attattatat atcatcatat aaattctatc cagctgaata 61081 tataaaaaa aaaattata ttattgttg  
aaagagggtca aaagtattga tttttaaaag 61141 tgatatttt atccatctag aaaacacaag agtatcaact ccaagctac  
tttaactaat 61201 atgataatta atctattta caataaaat gcacttatgt acacatatat taacagttt 61261 cctatatagc  
agaaataacg cattagaaat taattgaaat aatggcattc acagcaacct 61321 gggtggaatt ggagatcatt attctaagt  
aagtaactca ggaatggaaa accaaacatt 61381 gtatgtttc atgcataagt gggagctaag ataagtagga

tgcaaggca taagaatgac 61441 acattagact ttggggactc aggggaaaag agtggaaggg ggatgagga  
taaaagacta 61501 catattacgt acagtttcat tcttgtagg tggatagaag tgggaaaagg gtcttataga 61561  
tagtaagtat aaagagattg gttttgggtt gattttgatt tacagatatt ctctctcctt 61621 tacaacacag ttgatcaaaa  
tggattgcta ctatgggtact gagtttctca taaataaaaac 61681 ttttcaagaa aattatggat tactatttac cttggatgtt  
gaagtgaagt gaataaatta 61741 tatctcagat tagtccaata agagcagtc tttgattattc taaataccct attggacagt  
61801 tccaacaaaa taggatgaaa atgccccact aatgcaactg gcaaataact tgtttaacaa 61861 taaatgtgtt  
cttctttcta caagagactg tgctggactt tagaggaaaa taaagcagca 61921 acaaaagtct gataactatc ccagtttaat  
ttagcccta acctccctaa agaagattac 61981 aatcaattt ggaagacaag aacaatgcat tacatataaa  
gcagttaaat aaaaatttag 62041 taattaaatg ggaataaaga ctatgaagca gaattttta aaaatgataa gtggtaaaac  
62101 aataagttca gaagtcaaga gtgacctag taggctaggc gagcaggata tgtggaaaaa 62161 ctaggactac  
tgtttgagct cgaaatgacc aaaaaagtca tacagcgaat aactatacct 62221 gagcttaaat aggccatag acttttctg  
cataattttc tctaatttaa agtaacctca 62281 attgtgtgtg catgcatga aatgtgtgta tgttaatgca taaacatata  
taaatttga 62341 tctataaaga ggtataatat atttgcatta gaaagaaatt ttgatagtct ataactgaaa 62401  
ctataatttc tggtagaact tctaagcttc ctcccaggaa aatgacaaat cttagacatt 62461 ctttcatgtc ttgagttcat  
ccactgttta cttacagtgg atgaaatagg tgtattcttt 62521 caaaattttg cactgctcc aatcccaaat aaggcaaaat  
gaacaatagt agcaacaata 62581 acatcaaact gaaaaatttc aaaggaaaat taatattatc taaaattgag cctacgctca  
62641 aagtagagtt caagtatagt cctgtataga tcatggagtg aaactgaaac gagactcaga 62701 attgacctgc  
agttgccctt gaacctgac aaagaacact ctaagagaag aaaatgacaa 62761 gtgaatataa ttctcaaata  
ttactaatgg aaaaagtta ctgatactct ttaactttag 62821 tggaataaag ttttgagat accacagttg cagaataaag  
acacttaata tccctataaa 62881 aacaccatgg ccatcccaac cactctaagt tacttggctg ataaaggaaa tagaaaaaga  
62941 gagagagggga gagagttttt gttttgtttt gttttgtttg tttgttttc caaacttaga 63001 aacaacaca  
ttgttctggg gctctagaaa gatgtgtcca gccgaaggc attcaaatgc 63061 aattttcaa gtctaactcg gccagtc  
ggaccttctt tcatttctcc tgattgaggt 63121 atgtatata gacagggaaat ctgcagttc ctaatgtcca gatgaccagt  
ttaaatatg 63181 aaagaaacta atatttatcc aatacctatg cttaccagg aaccgttacg aatattgtaa 63241  
aaaaagatt tcttcattg aaggtaact tgacagacga cctctaaatc tcttttaac 63301 gataaatata ttcaattcag  
aagttttaa tagttttga acttgatgct tataaacaaa 63361 aaccaagaat gtaccactga gttgatggag gtagggaaag  
ttcagacagt agaactctaa 63421 tgaggaatca caaattcact taaatgtaag gggattgggt gttaagtga aatatgagac  
63481 ctctcattg ggaagactca atgtctgaaa aggggggtga atttctggct ctgcacctgc 63541 agcaaatctc  
caagacttag atcctttgtc cggaaaatgg gctaattttg gcggggagga 63601 agtgaagggt ttactattt atttatgaca  
aatattcaac actcacaatt ctctccaatc 63661 agaagttctt tgagatgctg ttggtctga ccagtcagag aatggagtca  
tctgactcac 63721 ccattctgag aatggctcta cagacactat aggttttaa tggccatta aacctgccta 63781  
taacctgtc aacctggct aagttcatct ggatggatgc atggctctg gcacccatga 63841 tgcggtgtg  
ggcgaacat ttccactgca tgttcaggtc cacaactca ggctggataa 63901 tatcaattat gtcaattac  
agagacatgg ggagagtcaa atgagatcga gtaaaaaatg 63961 tgcataaaaa tatccacaat ctgtgaaaga  
ctatgcaagt gtattattgt cattgaatgt 64021 tgtagcaat agcatggcca tttttactt acaataaat attgcagttg  
acatattact 64081 aactctaaga aaggttcaaa ttacatgaa caataaaaac ttcaggaaag aaaactagag 64141  
ttccattgg ggactacgtc tgacatgggt atattaaaca ttttgaaca attaatgtg 64201 tttgtgtc tctcttag  
gatttttaa cattataaa ttctcaattc ttctattca 64261 atctaaacat ttacaatat cctgtggacc ttacttctt  
agtagattcc cagaaggtaa 64321 tgattgtctc ctttctgctc tccaagcagc ttctgtgtg gtgcagagtt gcagatctt  
64381 gttgggtgta ggttctattc tgcagaaacc cctaactct ctgtttacca caacatagt 64441 ctattgccat  
agaaatgata gctgagatcc cagattgaac accactgact tcacagcagg 64501 gcctggtgag aggagactct  
aagctacaag gggggaacgc aatgtatgag aatagtaggc 64561 actctgtagc cttgaaagaa agggtaactg  
tcaacattag aataaaaatt catgaaagag 64621 ctacattgtt aggtatgctg tagtttatt tctgtataat actgcctggc  
taaaagtaat 64681 cattctgaaa tcttatgtca ttaacagtt tgcttcaaa aggtctgcag ttttcttga 64741 ttgcattgt  
ttctattga aataagaac aagcagctc taattaatct tttgcacaa 64801 ctgatgttc tgtgtcaaa gatttccct  
ttcatgatgt gttgtttgt ttgctgttt 64861 attgtgtgtg tttgtttgt cttgtttta ttaacagaag aaagtgaacc  
cgaacaagat 64921 actaaaggta tttttttc ttctgcatg gcttctttt aattgttag ctctttcaa 64981 ttgttatt  
ttgtgacct tataacagc tctaagtgc atttttaaag aaataacaaa 65041 caatgtatgg ggaatattaa gtcacagcac  
ttaacggtgt tattagatag gcttctttat 65101 tatataatat gcttactgac catttgcatt tcttaagcaa gattgagta  
aaagtaatgt 65161 ttaatttgg tgtctctgga aatacaaca aatgaaatg aaataaatca gcatgagagt 65221  
ataaatcca catagattgg aaaagaaaga tacccttga ctaaaagact ttggtgggg 65281 gttggggggc  
ttacagtct ttggataat gtaggatgt caaggtgcca atttggttt 65341 tattgtgat attcaacaa gatcaggagt  
attatgcaat tgctccaat caataaaaat 65401 taagtattt taattgcaca gagacatag ttttagtgg aatagtta

gaggaaataa 65461 gctggaaatt aaatttgat gggaaaaatt cctacttttc cccaacagt ttctgtcaac 65521  
agtttctgtt ttctgtaaaa aaaaaaaaaa aaaagaaaaa agaaaaaaa aaaaggtacc 65581 ttgcattctg  
attaagcccc aaactttgtg ctcttctaac ctaaaatttg atatttgggg 65641 gatgaaattt gtgagttctc atgtaataga  
gttgactgta ggaattaatc tcaaactggt 65701 attatttaa acagtacctc cttatcttag tatctcatat aaagtacaga  
taatgttttc 65761 ttatttttaa ataccagggt gcttacaatt aaatacaggt aaaaaagcat ttacctgggt 65821  
cctatgtgaa tttttttct taatttattc ctatcagtca ttgctggttt gaatcatgta 65881 acctaaaaac cttttcaaa  
ggaagctaga aaataacaaa agaggaaggg aaaataaaat 65941 ccatgggagc tcctgtgtc ctttgaaata  
actgctcaga aatagaaatt gataagagac 66001 ttaagtattc ctctggcact gctcccttac caagaaaaga  
gaggtagttc atccagacc 66061 aaaccactca tttatttcag gacttaacat ggatgccctg tccctggggc ttttattac  
66121 actccagtgc aatttcagag tgaattatgc ctttatctt ttactatacc ttactccta 66181 agatgacaat  
caataataaa actgattaca tatctgaaag tgcttgaaa taaggagaga 66241 gagagaatat aatgtgggta tgttataaaa  
gattttagaa ttgctggcct ctgagccca 66301 attttgaata taggattctc cacttgcaat tagcctgcaa gtctgctcaa  
gagacattaa 66361 agcccaaac tcatgaatag atccatgag agaaaacca gagttaata tattaccttg 66421  
gtctattttc catgttgag atgcattgc ttaccacag gaaaccaagt ggtttagggc 66481 tcacagtga  
ttggagaagg atggataaga ctatgtacag aaagaggggt ttgatgatt 66541 tttgttta aaatccatat caaacagtt  
ataaatgctt tccaacttac taagtaatt 66601 aatgttcct ctattaagt gttaattgt ttatgaaca aaacacttt  
tatattctt 66661 tatgcagata aaacacaaaa tagggatatt ctatgccat ttatttaat aagaaacatg 66721  
tcatataact tttaaattg atgacctaga atgcatttc agattgtgac taccactgaa 66781 ataatgggat ttactgtga  
cttgtgtcca agtttgttat tgccgggtga ttattattca 66841 tggaggttaa tctggcattt atttttaatt gcaactgact  
ttattgtta caatgctga 66901 aaaacatgc aaaattccc tcatcactt ttaccttc atattgaaa aatggtaaat 66961  
ttgagtatta tgcaattgct cagatagagt tgggtaaaaa catatcagct ttattgctga 67021 taaggctgga atgaaaaata  
aagatttcta ttcatgtga ggattagact aacataact 67081 atgttctc atcctctcc tcccccccc actcttccc  
cttgactctt agttgtagga 67141 tgaagaagcc ctgacctgt aaacttact acacacatca accctatatc ctcttagat  
67201 gcaagagagc tgggagactg atagctcaga ataggattga gatacacata acatatcaa 67261 gtccctccc  
ccaacttac cagagaagtc atcatgtcg ttcatattt tattcgtca 67321 ctacgcaat attcattgag tgcctaccat  
atatatatac catgcagggt tctagaaata 67381 gagacagata tgtagataga tatatagatt gtatcagta gctcatgta  
aaaagcaaag 67441 caaacctgc ccttgatg ctacattct agagaggaga gactgacaaa aaacaaaca 67501  
gcaacaaat aaatcagtaa ttaccaaatg attcagatag tggatgatg atacaatata 67561 aacaagggta  
aggggaatgg ggatgagaaa gtactatgat aaggaaacat ttgagtagaa 67621 accagaaga catctgctat  
ctccttgag aaggaggag gactgggagg aagggtggaa 67681 actaacttc aatactgaaa aaaggggggt  
gagtttctat ttatcattt agagagcatg 67741 tgagagtga ggagaaagca gctccctt aatccctggc ctattgtcc  
tcttaacct 67801 atccactga cttaatgaaa cccatggtca gccatagcct atctgcccc ttcagggaga 67861  
agtttatcag cagtctcata ttcatgaagc tacctataat gtcagcagta ctctgtacc 67921 tgcctgtgcc aactggagc  
ccccagaaag tcccatgga gggcagagta ttacattagt 67981 taaattaatt ccaaagtcac gttgaattga ctctgttta  
ttaccatac cacactatgc 68041 ttagtgtgt tgtgcaatgt ggataatcag aggttcaca ataagccaa atgatattcc  
68101 aaatataata acagccaaa gaaaaaaac tgctataat taggacaaa taaaacctt 68161 ccaagaagaa  
ttaaagtcc ccaattaaa actctggct tcataaatta aagcagcaaa 68221 acataatga aattacatta ttccaatt  
tttattctg ctcatctca gccagaaggc 68281 ttcatcaa aaggcgttt tgattcaaaa agttcaaggg tatagtcaat  
gttactagaa 68341 cagtttcta gcacatgta ggttgaaatg tgtagattt tccaaatct tcaagatcc 68401  
tgctgtttc agattctcg gcaagggt ccatagatgg tcatgcagta gtccacact 68461 caaaaaatt  
aggaaacaca agcatagccc caaccctac aagagtatt tttagccagat 68521 gatgcacatg gactctaagt  
ctccattatt gtaaccagaa aacattagaa gactacctgg 68581 acgcaccctc actacgatgc ctgtcagtgt tagttgtcaa  
gagtctgtaa cgtgtgaatt 68641 tagattaagt tgggagaata agaatccaag cagaggcaca cattgcattt ggggtgatg  
68701 tctcttaagt ctctttaat ctataatgga tcaactttc tttttacc ctaatgcta 68761 atgatttcc ctgttaata  
tctgggttg attgaattgc atccatag tgttcttga 68821 aatgttctc aacctttaa tttttaga ttgttaattg  
gacccagga ctacttaaa 68881 atcaggctca atttgctc tgggggacag attcagctc atttaaaaca ttgatagca  
68941 ttcttgta tttttaata atctctttt gcctgaaga cagcaccctc ctgcattc 69001 ttttctctg gtttgggac  
ccacatttct atatctaaa tatcaatc aaaagatagg 69061 aagtcaaatt aatttaaact tgcaaaaagc cccaatagt  
caaacaaatc aatgttct 69121 taatctttt aaattatgca atgctttta agaggtactc aacaatgaga ccaactggaa  
69181 acactactct ggacgttc tatcattgtc ctgcgtatct cttatgtag cacatgtggt 69241 ctccatact  
ttagtttaga atccaatatt cacaaattc aatttaacta gaattaagt 69301 tcaaagcatt gtgctaattg gggcttcata  
ctctaatatt atattctgt ctaagtct 69361 agaaatcaa aagtaggagc ataaaatata cttacagtat aataggccat  
ccaaaagatt 69421 ccgtaatagt taaacaaac actgaattg aagtcagaag acttgagtc aggtttctca 69481

ctcattcatt ttgtttacaa gggaaccaa cttactcaa ttgtgtttc 69541 actgctataa gataagaaca  
ggaatctagc caatctctgg agtctcttcc aagtttaatg 69601 attctgtgaa tctaagtacc ctccaatttg taatgcattg  
tgagcctcaa tcccactgtt 69661 tagttaaagg taaaatttct tcctacatca aaataacctc ctcttactta atcagtgggg  
69721 attcaggggtc agaaaggaat agaaattact cattctgctg cctacacttt atctaaaaa 69781 tcctttttt  
ttttgcca atatatcatc tgaaaagttt gacacaattt gtctgccctc 69841 ccactatgat acagttgagg gtgtaaagt  
taattatttg attaattcaa taaaatacta 69901 tcctgtgctt gctctggta ggaactctgc ctgaaacaat acagcagtca  
acgaaaggca 69961 aggcttttgg ctcaaacaa tctaattggga aagggaata atagacaagt aaaaaataa 70021  
taaggtaatt tcagatagtt gtaaggctctg taaagacaat aatgtaggct gatgaaaagt 70081 gaatgggggg  
aggattacac ttgatgtgt gtgagtaaga aggaccttc tgagaaaatg 70141 tcacttaac agagacttga atgattcaag  
gaacctacta cttgaggatc tgggggatga 70201 gtggtctagg cagaggaaga acaagggcaa gtttccatgt  
taagaacaag ctcatgtgt 70261 ctttgagtgg tgagaaatat aggggtataa cataaagggc ttggaggctc ggccatggca  
70321 tgtggtatta tccttaaac agagcaaca ctgaagaact gcacacaggg gaacatggct 70381 taattgcat  
ttctaaaaga ccaccctagc ttgaccattt cctgcaggag cgtcactcac 70441 cacttctgc ttctaacag ttttgccag  
gatcctgcgg gctcctgaat cccacaatgt 70501 caccttggc tcctttgtga ccctgcactg tacagcaaca  
ggcattcctg tccccaccat 70561 cacctggatt gaaaacggaa atgctgtgag tgtcatgtgt gtggggactt gtctggggaa  
70621 gaccattgg tggtaactt caggatagac catatagttg tagttacca gatctctgc 70681 attggtctca  
cctacaccac tttcaaagc ctccaatat cttgtccta gaagccattg 70741 ccatagaaat caaactcaa gagtttgcct  
ccttccatgt atcatgagga atactagaaa 70801 accaatttct ttcttgcgc ctttgttaa atgggaagtg gtaataatat  
cttccatat 70861 aagtaaaata attttcata aactcatcac cgaaagatta gttccctgct agaggctact 70921  
ttgatggaaa gtaatccgga gttagaatca gtgtcagttc agcattctt tcttattt 70981 caatagtgg aataataact  
gatgtatatt aagtagttat ttcagccag gctctattcc 71041 aagcattta cctacataca tttatttatt tatttttca  
ttctacaaat atgtattgag 71101 ctctgaaca tcaaacata tttagggcc tgtggataca ggagtaaaca aaacaggcaa  
71161 agttctctgc cctcaagag cttaccttct catggggaaa tacgggaaa tatatgtgt 71221 atgtgtatgg  
tgtcaaatgc catgcagaaa aataaatcag gaaaaggaga cagaaagttc 71281 aaccttagga gaaatcagaa  
ctctctaca ctgttcatgg gaatgggaat tactacagtc 71341 actatggaaa acagtatggc ggttactcaa  
aaagctaaaa atggaattgc catatgatcc 71401 accaatccac tactgggtat acagtcaaaa gaaagaaaat  
cagtatatct aagaggatc 71461 tgcactcca tgtttatgc ggcactattc acaataacca agatatagaa tcaaactaag  
71521 tatccatcaa tggatgaatg gatacagaaa atgtgttaca tatacacaat gaaagaaata 71581 ttactaatcc  
ataagaagaa taaaatcctg ttattgcaa caacatggat ggaaccgcag 71641 gacattatgt taagtgaat  
aaaccagaca cagcaagaaa agtatttcat gttctcttc 71701 ataactaaa aaattgatct catggagata  
gagagtagaa tgatggatat cagaggctgg 71761 gaaaggtagt ggggaaggga ggataagag gggttcgtc  
atgggtacat aagttagaag 71821 gaacaatatt gagtgcttag tagctttatt agtcagttct cgcacgcga taaagaaata  
71881 cctgagactg ggtaattat aaagaaaaga ggttaattg gctcatggt ctgcaggcta 71941 ttcaggaagc  
ataatggctt ctgcttctgg ggaggcctcc agaaacttac aatcatggca 72001 gaaagcaaag tgggagcaag  
acatctcaca tggccagagc aggaaggaga ggaaggtgc 72061 cacacacgtt taacaacca gatctcaca  
ttcactcact cactatcatg agaacagcac 72121 tgaggggatg gtgttaacc attcatgaga cttctgtccc catgatcaa  
tcacccacg 72181 ccaggcccaa ctccaact gggaattaca attcgactg agatttggtg gggacacaga 72241  
tctaaacat agcaatagca caacaggaca actatacata gttcacgata ttgaactaca 72301 tagcacaata caatatttaa  
gtatttcaa ataatcaagaa gattggaatt ggaatgtcc 72361 tagcacaata aaatgacaaa ttacttaggt gatggatatc  
ccaattatcc taattgatc 72421 attacacatt gtatgctt atcaaaatt cacatgtacc ccataaatat gtacaactat 72481  
tatatatcca taaaatttta aattaagaaa cattttaaac agaaagttag acctcaggag 72541 gaagattata ttttaaaag  
aatgatcagt gaaggctcat ttggacaaag acatttgaac 72601 aaagatctga aggagtga ggggtgaagt  
acatagataa ctgggggaac ataactagac 72661 aaagtctctg agataatgg atacatggca tgtcagaaaa  
acagcaagga gaccaatgt 72721 gttagtggg agtaagcaa gggtaagag atgagaggca ggcattgtgg  
atcctatagg 72781 ccgtgtggtc atttagacaa ctttgcctt atttgagtga gatgaggtgc cactgtagg 72841  
ctgttctgt tgtctgtt cccactgatt cttgttcatt ttgtgtgt tcctgtgtg 72901 cctagctatc ttgattacc  
tgctgtgcat tgtttgtat aaaaatatca ggaactatt 72961 tgaggcttag atgaaggtat ttctccaa agagaattt  
gctgtttct gccagggaca 73021 agaggttact gctaatttg taccacctc aactaagctc aaggtatgaa gctccttggg  
73081 catccagat aattataaca tgaccagtaa ttcattatgt ggactattta actgtagt 73141 cacactgata  
gctccctgat atctagttct tttatatctt aatttattat atctcttatt 73201 agactcttaa gggcatgaag tttgattta  
tctctgact ccctaaggcc atcaaagga 73261 aagtcaa atttctgggt tggaaaactc tctaagggt aataagatt  
tcttagttg 73321 ttacatctgt taaaattt ttttcaaaa ttttaattt ctactgtgt agcttctgt 73381 gaataacct  
acatcaacat ctgagacaga aacctacat ggattttat tgtcattata 73441 tagacttaa ccacttgggt ttgcaccgag

tttttagtt ctgatactt ttatgaggtt 73501 aagaaaatgt atttttagt ttaattgat aatttaata tattttaaaa  
73561 tcaataaaac acttcatcat caattacatc ctcttttga tgtcatttt cactttaaat 73621 tgcaaagttt cccttatatt  
gaaccattct ttcatcttg aatacattgc tttttgtt 73681 aatttttaa ttgtgtgtt tcaattttct gtattttctt  
caggattatt tgcattctatt 73741 ttcaataaca gaaatgggtt tgtcttttag taggctatca tgatcaggct ttgttaatat 73801  
ttttccaatc ttatagaata gactgccaaag ttacatagt ttctttgat acagagcttg 73861 aggtgagaaa gttgagatgc  
aagtctttct tatactcaa gacattttcc tctactatac 73921 caataattac tgcttctctc ttctccacat cctttctatg  
tagactccat tgaaatgaat 73981 ttctttcaa acttcaatct ttcttctt tatgctctgc atatgtttgt ggaggaaata 74041  
ggggggcccta tttatctgt caggttattc tcaagctcta gtgtccacca tgattgtcaa 74101 ctataggaac ccacaacaga  
aaatctcatt cgcaatctct atctcacagg tagatgctc 74161 agcctgggtgc catatgcata cattatagct cccagagttc  
ttcaattact ttgctgactt 74221 tcttaaagtt ggctctgct tacagcccct gctatctgaa gtttgaaatt ttccatgact 74281  
ttgtagggaa aatgtatcca ttctctctc agtaaaccctc ttctttgtg ctaggttca 74341 gctacttagt tgatgttaat  
ttttctatct atcaaatcac ctctttttat ctccagaat 74401 ttgctggaaa tatctgatcc ttgtattata ataccattct  
tctatatatt tacttttctt 74461 aattttgtat ttatcttta ggatttcagg tccataaaca aggggttaaac atgtgagcta 74521  
agattattat tactgtaact ctgatgttaa tgaacatgac ttgcatagag cactatctta 74581 ttattttctt tgtcatttaa  
aaatattcag cagagcaagt tctttgcta ctatctaagc 74641 ctacctaag caggctctgt gattttctg gttactatta  
gatgattga aatcattaac 74701 attatccaa cttagtcatt taagtgtcta gtcctaagta ataaccaaag catccaatgg  
74761 cattcacagt tctcccttc tcagggatatt ttcagcttaa ctttcatata agaaaaaatt 74821 gcagttggct  
tcttaccta tgcactca ttctcccc atttctagc tgcctttat 74881 gacccagaa ggggtgggtg ggaggtaggg  
aggagcaata actgggtcaa gagagctcta 74941 attcaactga tgcacttgta agttggctt atacctctg tgcctgccag  
atatttaaa 75001 ctgactcta cctcataga cctattcatg attctcaga aatcaggga cattaagatg 75061  
ataccagtga tgcattttcc tcaggctatc catctttggc cacattagca agtccccaat 75121 ttgttagttg atggaaaagtc  
tctttgtgtt ggggtctaact cagtcccca aaaagtcac 75181 ttgggaggac tgaaaatgac tccaatcag atcttctata  
aaacctttt attgacaaac 75241 tctggaagcc cagaccattg gactctgtct tctttgttc ttccattgga gctgccagac  
75301 atctttaga tttacaggt gggaattaca tactgtcta atgtgtctcc aaattgcaag 75361 tgtgttagag  
tcccaagat cacattcatg tctgatgatt catgagaagg actcacagat 75421 tttagataag ctgttatgat tatggcttat  
tgcaggaaaa ggatatagat taaaatcac 75481 aaagaggcat cagtttctt ctctagtga agttgcatgg acagcacttc  
atttcccag 75541 caacaatgtg tgacagcatg catgaagtat tgtcaacaa ggaggctcac cctaacctg 75601  
gtgtccagag ttttactgg agctcagta catagatgtg gagtgctcac ataactagtc 75661 tttagtagtt tccagcccct  
ccaaaggta aactaatata acgtggccta ggattccaag 75721 tattactat cattcacatt attatcataa accatccagc  
attgcccaa atctcagata 75781 tataagata ttctattac acaggatatt ccaaggggca gaggtcatct ctgaggagcc  
75841 aaaggccaga ctttctttg gaatgttag gggttagca cctcgagccc attgagttag 75901 ccttcaact  
tttactgca cagcagtaaa acacatttat aactctccgg gtgggtccat 75961 ggaggatact tttatccctt aaggagatgg  
gtgcatgtcc aaccagtc tttgggtgga 76021 ttgagaatgg cttcaatat ggctgaacaa cccaaacctt tataactcat  
ctaactgggtg 76081 gctattttca gtttcatct cctccaggac aggtgtcca acttttgggt atcttggctg 76141  
tagtgaacat atattatcat attacaatat attaattgga ccatttgag atcaaagaag 76201 tgtcccaa atcgggacatt  
taatattcac atcatccaa attgtgtta atgcaagcat 76261 cacaacaaga aaatggggga cttctttta aggaaggcaa  
aaccttatgg tataattcaa 76321 atgatattaa gtataattc tacccaatcc aaggcacatt cttcatgga ctgaactat  
76381 ttcatgtct catgacttc tcttccag gattacatta gtattaggg ctgccataat 76441 agaataccac  
agataggggt tcttaaaaaa cagaatttt ttctctacag ttctaaaagc 76501 tggaagtcca aggtcaaggt gctatcaggg  
ttggttctg gtaaggcctc tcttctggc 76561 ttgcagatgg cttcacatgg ttatctcct gtattctac agggcttct  
ctcttgtgt 76621 gtgacttct ggtgtctgt cctacaatga tgagcgcaa aaatcccaga gtgttttc 76681  
ataacacagt tctattcca aaatagttt tattctctc tttatagac cattataagg 76741 ttctctc taaattaaat  
aacagtgact aaaactaagg caaatactct ggagcaaaat 76801 aaaaactaaa aaacagatag ccttaaagca  
ggaagtacc ctgtcactag ggcttggcat 76861 actgtaggct ttagaagcat ttcgcgcat gaaagaatgg  
taacctgag gcatctccat 76921 gtaataagtt aattgtata ctgctttta ataaagttaa acaacttaca gtttcagaaa  
76981 gatagaaggg aagagcattc ggaagactgg gagtgaagtt tcccgggct gaaccttat 77041 tcaaaggcgt  
ctgacatgg ataacctga gaacattatg ctaagtga aaagccagat 77101 acagaaaggc aaataccaaa  
tgatctcact tatatgtgga atcaagagt tgaactcata 77161 gaagcacaga atagaatagt ggctgtcagg  
gatgggagga tggggagatg atcatcaaag 77221 ggtacaaagt tttagtcatg caagatgaat taagtactgt  
agatgtaatg tacaatatgg 77281 tgactacagc taacaacact gtattgcga cttgaaatt gctaagaggg tagatctaa  
77341 gtgttctcaa aacacacaca caaaggtaac catgtgagat gatactcac tagcttgatt 77401 gcagtaatca  
ttcataata tacatatata tctcaaaaca tcacctgtt cacctaaat 77461 atatacaatt tctattgtg agttatacca  
ccaataagct aaaaaaatt aaaagtctaa 77521 attttttta aggagttca aaaactaat cttgtctta tactgtacc

tgcccccacc 77581 ctgtgtcttc taaagcaggg tgcccaggag agactgattg gctgtagccc caaagggtga 77641  
gaactaggac ataagataag aaagggaaga agggaaaggg agagaaggaa gtggggaaca 77701 aagtgcgtca  
atgtgtgaaa ttttagttgg atgttgtaaa acaggaaaaa aatgccaaa 77761 ttctatggct accccaataa caaagaatgt  
cttatggcaa tggcaccctc caagtcatat 77821 aattcattta ttattgtcac ttctactatt gttttcgctg aagcttttt  
tctgttactt 77881 gaacaaaatc attttttcg taatttgta ataaaattgt ttcattttat ctgtctatcc 77941 tacatccctt  
caaatacagt acacaaacaa atgaacgtgc tttccagct tgtaactga 78001 ggcatggtag aatgagaatt  
agatggggag ttggaagact gaggttgtaa atgcccctct 78061 ttagttaatg tgattttggg gtccgtttac aactcagaca  
ctgattttct catatctatc 78121 tacactaaca cagacgtcag gtggcgtgca aagatgatct ctaatggtat aattagagac  
78181 atcagggcta atgttctcta attttgtcca gttatgataa agtaacttgg agtgccctgt 78241 ctttacctct  
ctaagaacgt ttcaagtgtc atttaaaatt tgattcttat ttgtcaatgt 78301 gttttttggc tcctctgtgg aaactgttat  
agtcttaagc ctgtcaaggg agtataaaga 78361 catcctaaga aaatttggag actggggccgg gtgcggtgac  
tcactcctgt aatcccagca 78421 cttttggagg ccaaggtggg aggattatga ggtcaggatg gagaccatcc tggctaacac  
78481 ggtgaaaacc tcgtatctac taaaaataca aaaaatttag tcaggcgtgg tggcacatgt 78541 ctgtagtccc  
agctacttgg gaggctgagg cagaagaatc acttgaatcc aggaggtgga 78601 ggttacagtg agccaagatt  
gcgccactgc actccagtct gggcaacaga gagaaactcc 78661 atctcaaaaa ataaacaaaa taaaattggg  
agactgacaa tataacttca ctaatttgtc 78721 tatgtaaaaa tagtaataaa gaaaatggaa aggtatatac ttttaaatt  
tctagtattt 78781 tcaaagatt catatgaggt tataaatgga agataaatga ttattctctg tcgaagtta 78841  
ggaataacaa gagtaggata gttaagata gttgaggcct tattgagacc ccaacttatt 78901 cattcaacat gtgactcaca  
aaaagtgaaa ggcaaaatag atttatcacc tcagattcta 78961 aaacaggaat aaaacaaaca aagtgaattt  
catccaggaa gaaagcaaaa gtacatccgc 79021 agttcttacg gtcagagagt gtgtgctgct cttagagcca  
agtttagttc ttgtaattc 79081 tacccaagtc tgaaaggaaa tcaagatgac tgtccacatt gacgcaaact acaggacatg  
79141 gaggcaatgt caggcattta atgttgtaaa agttgcaaac cagaaatccc atggaggaga 79201 acacagagaa  
tcctatagtc ctgatatcat ttttggtgga atgaacaaag acgaacgcag 79261 agctgggaga tatttggcac  
agaatgaaac agagttgaa ctgtggctct tcactacta 79321 cgagttagta aactaatgcc atagcacgct  
gctcagtaca atgggtactc tgaaagaagt 79381 gagtgctccc ttctcccct gctgtgaacc tgccagtga  
ccaaaaccct taacagttag 79441 agccaaagag caggagaaag tccagcaacg tgtcccaaag tgattagaaa  
ctatcttgc 79501 ttctcctat ggaaatacca agcattttt gtggaaatct gaattcacag atgaagtca 79561  
gagtgaatag taacattcct tttgtttac aatcttgga atagtagttt ggcatggaaa 79621 gagcagagct tactttttaa  
aaagaaaatt atttgtattt ttataaccag atttattat 79681 agttatacca gtaatatctc tgtttttg gcatgcaact  
aaaaaatata gaaaaatttc 79741 atgtccctct tgctttgtcc aataaatata atttcaaaa tatttagaa gttgaataat  
79801 tttaacttgt tagaagaatt ttataaata aacagccaaa tcacctaggt tgaaggtgt 79861 ctttagaat  
tttcttaaag ggaggcatat ctatattag acatatttt aagaggcagt 79921 agttttgctt taaaatatat gacctgtgaa  
gtcctttat ctactagct gtgtaacca 79981 aaataattac atgaacaag tcttatgtgg aataattcag cagccagtt  
gaaaggagct 80041 aattaatatt tgggtctaca ttaatcagaa aaactatgga aatgtctctt ggttattat 80101  
cccttttct atgattcata aacagacatt attacaactg cataaacatg aacctactg 80161 ggcaacatcc tttttttt  
ttttatttt tccccaaga tggagtctg ctctgtcatg 80221 aggctggagt gcagtggcg gatctcagct cactgcaacc  
tccactcct gggttcaagc 80281 aatgctcctg cctcagcctc tggagtagct gggactacag gtgggtgcca  
tcaagcccag 80341 ctaactttt gtattcttag tagagacagg gttcaccat gtgagccagg atggtctga 80401  
tctcctaacc tcgtgatctg cctgccttgg tcttccaaag cgctgggatt acaggcatga 80461 gccactgcac  
ccggccctgg gccatattct aacagttcca caggatattt ccagccagct 80521 ggaactatct gcaagacagg  
gccattgagg ccagaatacc tttagaggt cttccctagc 80581 taaggtaaaa tcataaaatt atcggtat ccatagctgg  
gggtggattc tctcaagacc 80641 gcattagtaa tgtattaatg atacattaag aagtactcca caggtctata actgctcaat  
80701 cacctcaaa gagtttttac acacattatg tcaggcatga attattatgc ctatttaata 80761 gagcttcta  
tcctactgcc tctttttaga aaaaaagtt ttattgtgat cttatttga 80821 tacatttaag gtacaaaaca tgatgttag  
ataaacatat acagtgaat gattactata 80881 gtcaagcaaa ttaacaagtc catctctca catagttaca gtaacttag  
aaagacagaa 80941 catcacacc agagcaggga gctgtgtctc cagctccctc aggtccatat acctgagtga 81001  
cttgagaaa atcatgcatt tctgttaact accagacgta gtcacctcaa ttaagtaac 81061 tgttttgctt aggcatact  
tggtaaaagc tcacagtact aatctggacc caccctttg 81121 atctttgaaa cctgaggtgc gaaaaaat  
caaatggag ggcagaggga tttgtttta 81181 tttcagatc atcaaaaata cttaactgtt gatcagaacc atccatgaag  
aaagaaaaac 81241 aaattcaaac tatgactaat ggggcctgct gtgcgtgagt cacaactga atcaagcaag 81301  
gcctctggaa gcagggggaa aagcattcag gagtacttt gtactcaagc atgaacctcc 81361 taaagtgtg  
gtctctttgc tgaactattt caacacctgg atgaagtcca ggagaagaga 81421 cgtaggcag tttaaaaatt gcttcttt  
cctactaagg atgtttcag tgacctgag 81481 gaggtgtta agaagtactt tctaggtgt gaacatgaaa acagtgggac



ttagggcaac 81541 atttggggag ttccttctgt tcaaggtgt ttgcacattc ctactcttg 81601  
caggagggaa ctgtctttcc aaaggatttt gcaaactgtt ctgcttttgc ttatctaaac 81661 tggaagaga tatataaaca  
aaatataaaa taaaaataa cataaagtct gtgattgag 81721 catagaggct tggggctttt agctttttt cttattgttg  
ctttgtatta aaattcaagg 81781 gagtccaaat attttcagtc cccttgatct aactgggata ctatacaat gagacattgc  
81841 acttctgata aatatgataa tgatgagttt agtttgaatt cccaactgag tgcattgtctc 81901 ttaaaaacat  
ttttcttct actttgtaaa tttcttatag agtctagggt gctcatctgg 81961 ggaaaatgcc acaatacttg atctgacctg  
gaaagattcc cagtgaaggt aaattgatac 82021 tcacataagc cagttttat cataagaatt gagactagta ctgaaggtaa  
agaataaaaa 82081 gctagtggga caaacgttca ctgcatgatt gctacacagt gcttggtgcc agggatagcc 82141  
agccacctgg cagctaggaa gaaagctggc cttacctgag agctttcttc ttctggcta 82201 gtcaaactgt  
gaaaatcctt tctcatgcaa cacaataaaa taattggctc caaatgtct 82261 cattctcagc ctattccct aatactggac  
acaggaatct ctttcagcca agcagccaag 82321 ctgaggccaa catgggacgt acctccactc cttaagata  
aagtcaaagc ataaccag 82381 ctgattcctt aactgtcatt tcaactcagt ttccctcaat tggcatcatg ttccctgat  
82441 ataagcagcg ttaattaaag attagtattt gaaaagggtg tattgtgctc aagaaaacag 82501 tgaaaaaga  
accaccattt aaaaaaatg ccaccactt aacaatgaca ttgtcagat 82561 atgtattttg ttcatgggtg gttgattgt  
taaggtagtt gttactcttg ttttctaatg 82621 actgctcatt tgttctctt tctaggacta gggaaggcac tgtaacataa  
tgataaaaag 82681 cataggcttt ggtgtcagac acgctaggat gcaaattcta actatgcaac ctgtaaaat 82741  
gtgctgggca gctatcttc ctacagagtt ggagtaatgt tgactaatat atatgcatt 82801 gtataaatta agctgttaat  
tgtgtgtcaa tattgcattg atatcttggc tcttaagga 82861 catttgattt tctggttaa gtagtacctc ctgcatgaac  
ttctgacgt gttgaactat 82921 ttcaacacct ggatgaagtc caggagaaga gaggtcaggc agtttaaaaa ctgcttctgt  
82981 ttctactaa ggatgtttc ggtgacctg aggtattatg tatgtattat gtagtcatg 83041 cctcagagac  
agacttggt tcacaacct tttcctgac aacctccac ctatctgaca 83101 tgcatttatg gggaactgaa caggagttat  
gaaaataagt ccttaagtct gcaacctctc 83161 atacttaact gtcattctga ggacactgaa gacatatc agaggatcca  
caccgtatat 83221 aattcatgcc ttgtattgtt tatctatggt tgtatcaca atcagccaa agcttagtga 83281  
cttaaaccaa taactattag tgctcacaag tctgtggtc aactgggtgg tttgctgat 83341 ttggtttgc tgctgggcag  
gactgcctga tcttggtgg tcaagttct gtgatcgga 83401 gattgaaaag gtggtagttg gttcagaata  
gccttatgcg taccttgat ggtgtgtgt 83461 gggtccacc tggggcagag gggataaac ggccaggtg  
gtttcatct ctaccatgt 83521 ggctctgt tgtttatagg cagtcccagg ttccataac aagaaagcaa gccacaatgt  
83581 gcaagaacgt tagttctgc tattcattc caaacacat cacaaggcta atctagattc 83641 aaattatga  
ggaaaatgct acttcttgag ggaagagcta caaagtcaca ttgcaagggc 83701 atggacacag ggaggga  
tcttttggt atgtttgcag tgtaccacat gcactgatt 83761 ataacttaa tgctttccc ttcaaatcta ctgacatagt  
atagtgggaa atccttgact 83821 gagttcttt atttcttt actctgtcag gtttctctg ggtccattca agagagtgtg 83881  
aaagaccgag tgattgactc aagactgcag ctgtttatca ccaagccagg actctacaca 83941 tgcatagcta  
ccaataagca tggggagaag ttcagtactg ccaaggctgc agccaccatc 84001 agcatagcag gtaggatgcc  
ccttcacatt tgcgtgttc caggagagg gagagtgtat 84061 actattctac aatatcgagc attggagaaa atctccctt  
tctttatct cttattcag 84121 ttgcattgg gctattct ccccatggg gatactccg agtgacctc gatattgatt  
84181 ttggcagatt tgctgcctgg aaaactaaat cctcaatacc taccgaagt gtaggtaaca 84241 gcttcagga  
actcattct tcttcttc ttgttttct tatctttt cttttctc 84301 atttctctt cctccctccc tcttccctc  
cctcgctccc ttttctct ctttcttc 84361 tcttccct tcttccctc tcttccctc ccttctccc tcttccctc  
tcttctccc 84421 tcttccctc ttttcttt cttaatttc ctttcttt cccactct cgttctct 84481 ttggttgat  
caaactttc aagtctctca tggagaaagt tggcagacat tcaacatgg 84541 catgccaatt tctgcatggc tatttctgc  
gggcatttt acctgtgagc atgatccctg 84601 ttgtctttc cttccctgct tcagcaagc acagcaggtc ttacaggtgt  
ttcaagaaa 84661 aaggctgaca cacggattc taggatgtt gtgtgagtt ctaaaggttt attttaaaa 84721  
tgaaatgtc ccaaaggct ctgagaacat ttatagaatt ctagagatg gaaataatcc 84781 ctgtatcagg  
aaatgccagg catattagat tcatagcgt ctagggctc aagggtcagg 84841 agagaggtgc ttggcctgac  
atgtaaggca agcagggata gagctgtgc ctaggccaa 84901 ctccccacag cctgctgtt ctattacag  
tgccacctt ttgatcttc ctgatggga 84961 actttccagt aatgtctgt atttgaata tgaggtgaat aaaaaccaca  
gataaatgat 85021 aaggagcact ggacaaggct ggccctctg gactgcctat gaaggaaaag gaagactca 85081  
aaattaaggt tccctctct tctcccccc agtgatatct ctgcctacca tgtcttcaga 85141 caccatatca gttattctag  
catttcaca ggtgggaaat ttttctccc agaaaatgaa 85201 aagtcttcta aaagtaaatt caactcaatt taacaataa  
taataatc acataataag 85261 taatagtata atcatataat ataaatagta ataagaatta ctatttcat agcattttg  
85321 tgtttataa gcactttac atgcatttat caaactct agatgacgcc cattgtgtg 85381 ggtagagtaa  
gagatgaaa gtaatttaa aaatgggtc tgccttcag ggactctgca 85441 tctagaagga agtcagtcag  
tcacgtatat tatggcactg gctgtattct attgcagaag 85501 catacacia atacaacagc agaacaagag

aggcaggatg tcaggggaatc ctgggaaaag 85561 aggtatcat ggagcagaag atgtggatat gagatgacta  
gggtgaagtc aaacctttca 85621 aacctgttca aaaaacagca aatcagtggt caaggctaga ccacgagaga  
gacagcaggg 85681 aggtggaaaag tggaaacaaa agttgaaaca tgggctctag ccaggttatg aagagcctgc 85741  
ataggtttag tatattattt cattgatgag aagtcattta atgatttaga agaaataagt 85801 gcaatagata tatccttag  
caaattaaca gatgctgagg tgtaggagg ttgagaagtg 85861 cggcaagctg tcaggaggct ctccaggtg  
tctcaaaaag tcatgaaggt ctgaacagca 85921 gcagcagcat tggttcaaag ggaagaggag agatgcacag  
gacaaatcag gatagaaata 85981 aggtttgcaa atgcttgaag atggcagtg gctagaagga tgagttcaga tgtgtctgat  
86041 ttgaaaggt gccaggaca agcaataata tataacaca aagcatatga acaggagaag 86101 gtccaggaga  
taatagaata ctcaaaaatg ttgatgcctt tgaattacct ggaattattc 86161 tggctcact gctttgtat tattgacat  
ttgatcaaga cctactgtta aataacata 86221 tattataaa aatctatcaa tatatatta tataacatat atgtatgat  
gtgtgttat 86281 atacacacac atggagagag agagagaatc acatttaaat atgaatactc catccaagaa 86341  
aataaactga tctactttaa tttaacctgc actttcactg gcagaagaaa aatactaag 86401 ttactaatct taggagagtc  
tcatttcagg tcattattca gtcactcaa gataccctg 86461 ccagagctct ttctccctt tcttcttct ttcttttcc  
ctagatggca aaggagaaga 86521 ggatttgat ttaggcagtg gtgtctctg gacaccccc acaccactgc taacccccg  
86581 atctctagt aagtctgcag ctgaactgt gattttatct ctggcttg ttagggccca 86641 ggggacctcc  
ctggctggct tagcctgtt gagacatct ttggagcagc acagccctct 86701 gcactcagc caaatcttc atcatgcat  
tgtctacact ctgctctgca acctcagaag 86761 ctaggctcc ctgtctgtcc ctactgtggc cctgtggctg gcctgctgaa  
ttcaactca 86821 gctcctcag tactctcac agggcctgaa gcaactcta gatcatttc aaggcataca 86881  
gaattcagga gagatttggg ctgctaact cagtctgct gtctgccaa cctgtcatg 86941 ctaccattt cacattaatg  
ttgccatcca tgttgagta agggatccct gtgggtgtt 87001 ttacttatag catcctaat aagaagtag aaaaactcca  
tctgctttg gcttttct 87061 taattgatca atacacctct attctaggat ttgcattcag aaaagggatc tataaaatct 87121  
ataaaatc caaatttta atctcctac ctctcctt ttacagcat atgaagctg 87181 aagagcaggt ggtaggaat  
ctccccaac cttagtgca gtaatttta gagcctact 87241 atcataagta caaaggtgtg tgaaggca  
gtgctataac cactgagggg aacctaata 87301 aatgggtata tctactccac acaagggaag attcatcca  
tggacacaat cttaagatg 87361 ccgagaggac tacaggcat gattgccacc atactatg cagcaacatc atgactcat  
87421 tctgtccta gccagatga gaacctgac caactcata aacggaacac caacaggga 87481 atctgaacc  
ttaaaaaaac ggcacttcc agtggtagaa agagcctaaa ggtctgagac 87541 aggcagtata ggaaggccat  
gtcctagggt gtagggagag gtcacttag atatcagtg 87601 tgagaaagac cagaatgagg atggggacaa  
tcagcaatgg ccaccagga aaaataacag 87661 tggaattgc atgggggaag ggatggggg agcaatgcaa  
agattggcat gtggcagcag 87721 agagcaact gcaatctgct gcagcagcag aggtgagtgct ctatgaagag  
cagttatct 87781 ttaggaata atggttgtgt agactagaac cagctatgac ttctcatgag ctgacaatg 87841  
gcagtgcgat ggaggtcagc tttagagtg ggagaagtg gggaccctg aagtgaggct 87901 tgaagccact  
ctggacaggg gtatgttac agtagctacc caaggaactt ggttagaggt 87961 agagaaggca gcataaggag  
agggttaacc tataactggg acctgggact ttgcttct 88021 gaaccacaaa ggcaacaatt aaatctgacc  
ataacagaa tcatagtgt gcacgatgt 88081 cggagtcag taaagaaatg agagtgtta ctcgaaaact  
gaaaaatgga aaagactaaa 88141 aaggtctaga gtggatatga taaatgagaa acatgcctat taattaaaa attgctacac  
88201 atctagtgt attccctgga ataagacct ttgtccaac ccctgattg ttgtctggt 88261 tgattctcac  
tgattattag gggactgac actcctgac ttcccaaaa atttcccgag 88321 gcagacctaa taagggtgtg tcatgagtgt  
gattgaataa gacttctgaa ctcccatgag 88381 acaactcca ttctcttc ctcttgacc tgctctgtg agttagacct  
gctagaagcc 88441 ccatgaaggt ccctctgga tcatgagga aactacctc caactggg gtgctccgtg 88501  
gactgatatt ttagggaaat gaggctact cgatgaaaaa gggatcctg gagcctctt 88561 cattcagggt cattgaaag  
aagcatggcc ttatgtccc cagatctccc agaactcaag 88621 tatggtatct gcttttcca ttctgtctt tggccctct  
ctggcatcc gatgaggctg 88681 gccagaagtc cagaactca agtcagacat ggcgcctct ttgccattct ggcaatgctt  
88741 cttaatgcc aaactctgct gtctattta accatctcca tctccccta tgtgactagt 88801 acccctagta  
gtcaacagcc ccctctgca tgttctcgt gtttccctt gaaatttcta 88861 ctccatctgt ttattgtc ttccagcag  
gaaaactgga aatggaaaaa gctgatcta 88921 tgcttatgct taggattatg tctaagata ttctagtgt ttgaaggaca  
acaaaaata 88981 aagatcaggc ttcatcttc caaacctt ccatgtgtc gcccaatcc ttatgcattg 89041  
tttagaaat gtgatattt ttttctgac tcatttcat ttactgttag tcatcaaaag 89101 gactcagaaa aactttgga  
acctctcct atgaaccagg aagttgcatt tccctccag 89161 tcacaaccc ataaagctc aagttgcaa  
gtaactgtc caggatgctg ggcattggc 89221 aagatgctc tttgtcat cagaacctc agcctgtg  
aagaaagcaa gcagcctat 89281 gatacaata gtgagcatg tcctaaaaca gccggagacc atgaaaatg  
acacaggat 89341 tcagaagaga aaaatacagg cgggtgtg tgactcacac ctgaaccc aacatttg 89401  
gagtcagg tgggcagat acctgaagtc aggagtcca gaccagctg ggcaacatg 89461 tgaactcca

tctctctaa aaaatacaaa aattagccag gtatggtagc gcatgctgt 89521 aatccagct acttgggagg  
ccgaggcatg agagtcactt gcacctggga gatggaggct 89581 gcaatgagct gaaattgcac cactgcacca  
cggcactcca gcctgagcaa tagagtgaga 89641 ctctcatctca aaaaggaaaa aaaaaaaaa gagagagaga  
gagagagaga aataaaatac 89701 atatttgtat ttccattct caatggcacc aacaggctct tcatcagaga gtgcagtcca  
89761 tggttctatc catgtttatc cagtctcaga gtacaggagc gagcctatgg tcacacaccc 89821 ctctaata  
agccgctccc cattctacca acaaccccc ctttctatat tgccccctt 89881 ttgaatcgac ctgagggtct aagcctttg  
gtcactaaat ttaaaagtca catgaataca 89941 agtagtatca aaactgagca ggagggaata atctgatgtg  
gtaatactgg agtctcccaa 90001 actccccaga tgaaccacat ggttttatt ttctatttc aaaagagggtg atgtttcaca  
90061 ctactacaga aaaaaaaaaat ggaactttga aactatttc ataatacagta tagctgattg 90121 aatgtactga  
catgtttcat gctctttctc atgtctgata gccacactcc tgtttctcc 90181 caatgttga gataattct gagacttgg  
aacagagcag tagcacgtaa ttgctttac 90241 cactcagtgc ttcaaccatc ataggtaaag agtgttctta tcaacaaaac  
agacaccatc 90301 cctggcattc catgctggct ttctctgggt ttaataat taaagtcatt ttgttttgt 90361 tcttaataaa  
agggaagagg ataatgagt aacagccagt agccacatta aattgctacc 90421 agatgttctg cagttaggca  
taaaaggtaa gcatcctttt acaatcaggc agctttctta 90481 tattagaaca gttctgttc agaagagagc caatgtttt  
gctgacttct agataattt 90541 aaagatacta taatattgtt ggatatttta agaatttta aatactacaa atattgggtg 90601  
gatatttga gaattttta aaattgaatt ctgagcttaa agcactttat agttgcaagg 90661 ttctggacc cttctcat  
ctctagcca tacacccca caaaaataaa agaaaatgca 90721 agtggagaca ttctatag aagctcatta  
tcccctcca ggtactatgg ctggattctc 90781 ttgtcattg gcttatctc atgctcttc cacattacaa aatgagggt  
ctatcattta 90841 cataacctg gccccctgc tttcaatag atcttctgc tcagctgcta ttagaatctg 90901 ctttgtatt  
tcaaattat atgccattt ctctggaaga atttccagt gtccactgt 90961 ctttctccc actattgtat ttgtataatg  
gcagaactgc catgagattt gggggcatga 91021 aggcacttct ttctgaggt cagcagtgc atagagtct ctctattct  
ttcatagcc 91081 ttgggtcatt ttaattaaga gactctgca ggccttagc ccggttact aaaatttaa 91141  
ttctctctaa ttataattt gttgacatca ttggcatcac ctcttagatg atcaaatga 91201 caatctata accagcctg  
cctatctcag taaaacagaa agaattctact agatgtttt 91261 cagaatgaa atagatataa cattataat gatttctta  
ttgtccagca aattatctcg 91321 cagttggagt cctgcaaatg ttagagacat ctgatgtt cttcatagt cactccagag  
91381 tctgttagtt ctatgtata aagaaattc acaagaaat ccagctttc tactgctaa 91441 aaggatgtg  
cttctgtcc ctaagcaaag tgaccattt aggggaggga taaatttta 91501 gagcttatta ttggctaaa cctactctg  
gatcaaaagt ttgttttaa agtgcattgt 91561 agattgcaga acaactatga atcactcata aagagaggta acaagacct  
gaggctatat 91621 gtgtaaccag tgtattgaac aattaaacc tgacaggtag acagagaaaa ttgtgtttc 91681  
tcaaccaat ggggactgag gaattatgcc tttagaatc tcctgcct tctcaagagc 91741 aaaccttta caactttca  
ggcagattcc ataattcca ggtaattgtt agagattaaa 91801 aaccagcct gatctagtt aaaactctc tctacataa  
ttaaacctc atctgctca 91861 ctctctccac tgccagccaa tcttccattc aggaacatgg agagtagaca aaatgggtct  
91921 gctactatta tacaccttc ctttctccc ttctctctg ttctcttca tctctggcat 91981 atttaaggag  
aagaggattt acaaggaagg cggcaaatgt gtttcttaa atggaatag 92041 tttagttct ttctctgta attgtattg  
cttctctgac taataataat aatgtaaca 92101 attgcaaggt acattctcag tgccagtag catatatata tacatatata  
tatatatata 92161 cacatatata tacaatata tatatatata tatatatata tatatatata tttattaac 92221 acccacaact  
caatgaaatg gatacttta ttatcccat ttacagatg agcaactaa 92281 tgctcagaaa ggtgcccagt  
ctgacacagc tagtaaatgg cagaaccgtt attgaaacc 92341 agcaggtgca gcatccaggc tttaatgcc  
ttgatgggtt attaattgt ctctattgca 92401 ggtgtgacct gaatactgac tgtctctag gacattggg ttctttggag  
ggtccttcgg 92461 aagactgtgt attgcacagt gccctgatgt gggagattct ttactggtc aacctctcat 92521  
aatccccagt cctgatctc aatccctatt gaggtaacct gcaattgct atgactggg 92581 ttcttgtct ggtgtccagt  
cttctggta acttagctac ctcatagca tccactgaac 92641 acacaggaat gtccatgtc cctaccatcc caatgggtgg  
gagttctatt cctggacct 92701 ctactctgc cctcagattg ttgcaattct tttagacag taatattatt aaaaaaaaa  
92761 aaagacaaaa caatgctt cctgtctct gagtctagt ctctaattc ttaggcagtt 92821 gaaaaatgac  
tccatgagat gtgtgttac cattacatt gtatcattca agaatagaa 92881 gatctaggga aataattcat ccccttctc  
cttatattg ctgagatgcc ctcatctt 92941 actgaaggc tgagaacaa agctattgt ctggttatag ggcctacaaa  
ttgcaacaaa 93001 ggttgggtg attgtgcct ttagtaaat ccaaggaaaa atgtcaagtt gtatgtgtgt 93061  
gtgtgtctgt gtatgttac atatttcta cgtgtgtgt tctgtgtgt tgtgtttaca 93121 tgttctat aatcattgt  
cttgctttt gagggcattc caactactgg tggaataat 93181 aaataaatac aaggggtcc atgctgtgag tagttgaaat  
gaaaatactg gtgtttgat 93241 gggattaatt cagtacatt ataatagact aattcacca aaatcaact ctaaaaccag  
93301 ttgccttaa ctacttaac tcaattcag ttagcctgat gactattgca tctaattgt 93361 aaaattcaga  
ataaaaaatg aaatattggc tggatacagt ggctcatgcc tgatcccag 93421 cactttggga ggctgaggcg  
ggtggataat ttgaggttg gagttcgaga ctgacctggc 93481 caacatgggtg atacccatc tctactaaa

atatacaaaa tagccaggca gggcagcagg 93541 tgcctgtagt cccagctact caggaggctg aagcaggata  
atcgcttgaa cctgggaggc 93601 aaaggttaca gtgagccaag attgtgccac tgagctccag cctgggcaac  
agagttagac 93661 tctgtcttga aaaaaaaaaa aaagaaaaag aaagaaagaa acatttacca aataatatgg 93721  
ctgagtattt atgactaatt tttgtattgc taatacttta tcacatatag ggaatcatga 93781 gattgttaca tattgtgtg  
actgtctttt tctgttccag tcattttgaa cacttgcatt 93841 attctttagc caatttgca aaaaaaaaaa gtcttttct  
ttacaatttt gaatttctgc 93901 taaaaatatt tagtggaatg aaatttattc cattaaaaaa acgaaccttt tgattattat 93961  
tgtctccttg ctactttcct ttattataag agtctatgaa ctctacatgt atgtgtatat 94021 atatacatat gtatgcatta  
accaaattag catactctca gagctcattt ctgttttagt 94081 aggtattcgt attttaaaag aataaagaaa aatgggtccc  
tctttgatc accattccat 94141 gttatttatc aagagatgta attgataaag gttttatttt gttttgttt gagacagagt 94201  
ctctctctct tcttcccaag ttggaatgca gtgggtgtgtg atctcggctc attgcagcct 94261 ctgcctgagc tcaagagatc  
ctctgccac agccttccaa atagctggga ctacaggtgt 94321 gtgcataac gccagctaa ttttgtatt tttgtaaaag  
aaggagtttc accatgttgc 94381 tcagactggg ctgaattcc tgggctcaa tgatctcct gcctgggtct cccaaagtgc  
94441 tggaattaca ggcatgagcc accatgcctg gccctaattg ataaagtttt aaaatgcaaa 94501 atgtgcatca  
tttccaaatg aatttatagt gagaatcata acattttgaa aaacagtttt 94561 caaaatgcca ctggagtgtt aacaaattaa  
taccatctgt gatgactttt ccattctgcc 94621 aaaacctgat aaagctctgc tgaagtaaag aaattggttt cacagagcca  
gcacactgaa 94681 tgggcaaaag ctggaagtat tcccctgaa aaccagaata agacaaggat gccactctc 94741  
accactccta ttcaacatag tactagaagc cctggccata gcaatcagat aagggaagaa 94801 agtaaaaggc  
atccaaatag gaagagggga actcaaagta tcctgtttg cagataacat 94861 gattctatat ctagaaaacc  
ccatagtctc tgcccaaaag ctcttgagc tgtaagcaa 94921 catcagcaaa gtttcagggt acaaaattaa  
tgtacaaaag tcagtaaatt cctatatacc 94981 aacaatcacc aagccaaatc agaaacacaa tccattcac  
gattgccaca aaagaataaa 95041 taccgaggaa tacagctaac caggaagggt aaagatctct gcaataagaa  
ttacaaaaca 95101 ctgctcaatg tgctaaagc aatttataga ttcaatgcta ctgctatcaa acaaccaacg 95161  
acattcttca cagaactaga acaaaaacta ttctaaaatt catatagaat caaaaaagg 95221 cccaaacagc  
caaggcaacc ctaaacaaaa agaacaagc tggaggaatc atgctatctt 95281 actcaaact atactacagg  
actgcagtaa ccaaaacagc atggacttg taaaaaaca 95341 gacatataga ccactggaag agaatagaga  
gctcagaat aaaaccacac acttacaacc 95401 atctagtctt aggc aaagct ggcaaaaaca ggcaatgggg  
aaagaatccc tatttaataa 95461 atgggtgctgt gatagcaggc tagccatag taaaagattg aagctggatc ccttcctac  
95521 accatataca aaaatcaact caagatggat tatagaccta ataaaacct aaacagtaaa 95581 cctgaaagat  
aacttaggaa atacatttg gccataggaa ctggcaaaaa ttcatgatg 95641 aaaatgcaa aagcacttgc  
agccaaagca aatctgacaa atggaactta attaaactta 95701 agagcttcta catagcaaaa gaaactatca  
acagagtaaa caggcaactt acagagtga 95761 gaaaatattt acaaaccata catctgacaa aggtctaata  
tttcagaatc tacagggaaa 95821 ttatacatc aaggaaaaaa acaacaacc tcatttaaaa gtgagcaag gacataaaca  
95881 gacactttg aaaagaagac atacatgcag ccaacaagca tatgaaaaaa tgctcaatat 95941 cactaatcat  
tagagaaatg caaatcaaaa ccacatgag ataccatgtc actccagtt 96001 gagggttat tattaanaag  
tcaaacata acagatgctg tctgagacca gcctggacaa 96061 catggcaaaa cctcgtctct actagaatc  
caaaagttag ccaggtgtgg tggcacatgc 96121 ctgtaatccc agctgcttg gaggctgagg caggaaaata  
actgaaccc aggaggcaga 96181 ggctgcagtg agccaagatc acaccactgc actccctct gggccacaca  
gtgagactcc 96241 acctcaaaag aaataaaaaa ttaaaaaata acagacactg gcgaggtgc tgagaaaagg 96301  
gaactcttat acactgctgc tgggtgtgta aattagtta accactgtg aaagcagtgt 96361 ggtaagtctt  
aagataacaa aaacagaact accattcgac ccagcaatc cgctactgag 96421 tatatttca aaggaatata  
aatcagtcta ccataagac acatgcatgc aaatgttct 96481 tgcagcacta ttcataatag ccaagatgtg  
gaatcaacct aaatgcctat caatgacaga 96541 ttggacaaag gaaatgtggc acatatacac catggaatac  
tacgttgtca taaaaataa 96601 taagatcatg tctttgag gaacatgtat ggaactggag gccactatcc ttagcaaact  
96661 aatgcaggaa caggaaacta aatactgcat gtccactt ataagtggga gtaataaat 96721 gagaacacat  
ggacagaaag aggggaacaa cagacactgg gatctactg agggtagagg 96781 gttggagaaa ggagaggatt  
aggaaaaaaa aaaatagaac aacttctggg cactatggtt 96841 agtacgcggg tgatgaaata atctatacac  
caaactcgca agtcacaagt ttacctacac 96901 aacaaacctg aattatgtac cccgaacct aaaatcaaag  
ttaaaatatt cttcaggatc 96961 actgaataaa aagctcataa agattcaaaa aagtcataca ctcaaagtta taaaaacctt  
97021 ctagtacca accctacca atctcaaaga gaatgattag aaatacaagc tcattgtatt 97081 ttaagaagat  
tgaccttca gagaaattca tgttacagcc cttaaaaatc cccccaaaa 97141 taacaccaa atggatctaa  
aaccttcaa acggagttag acctcaacat taggagaaat 97201 ttaatatgg caaattgggt ttagacaaag catatgttt  
actgtttatt ttcgtaata 97261 ggggtgagag gacaggacga agtaaccata aagcacttg taaagagtgt gaagtttta  
97321 attacaaga aagaaaatgg aataattcag aaatgctgtt tatatcacac cctgcccggg 97381 attctatgc

cttggcagag tctgagtgg ggctgttgt cctgggaatc 97441 agaggagagg cgtattctcc  
tcagagccct gaggttttac atccgtgagc atgggcagct 97501 acataattg cagggctagg tgttccaaaa  
acggtaagga tttcaagga gggagagcag 97561 aacattaaat taagcccgag gcccttctga gtgcagatgc  
catgcagcta cccagggcac 97621 acagccttga ggcagccagg tctatgagaa caaccattgc ctactttctc ttctaccctc  
97681 tctcctctgc atgttctttt cttttctct tctccttctt ttttctttt ttccaagtct 97741 gctttatgca tcttctctgt  
taacctccac atcttgcttt tttttttt tttttttt 97801 tttgagacgg agtctcgctg tcgcccaggc tggagtgcac  
tggcgcgatc ttggttcact 97861 gcaggctccg cccccgggg gttcacgcca ttctctgcc tcagcctccc  
acgtagcggg 97921 attacaggcg cccgccacct cgcccggcta atttttgta ttttagtag agatgggggt 97981  
tcaccgtgtt agccaggatg gtctcgatct cctgacctca tgatccgcc acctcggcct 98041 tccaaagtgc  
tgggattaca ggcgtgagcc accgcgccc gcccacatct tgatttcta 98101 atgtaaagtc cctgggtagc  
taatggaggg aaattctgag cttagatatt gccttgggtg 98161 atgtacca tgattgactc agtttgaata gaacctgctt  
cctaaaagata ctcaatatt 98221 tcttcatttc ctccgaatct gccattaat gcagcatctg gcctcctagc agaagcggag  
98281 aacttttcag aaacttagag atcagtagta tcaaaacaat ctacgcaaaa gcataagatg 98341 aaaatgtact  
aacgttcttt cttttctct ttaattgac ttctgtggg aacttcctt 98401 cctgttaata gaatggagg aagaaactgt  
tattgtaaca attgtttcca atgtttgtt 98461 tttagggat ttcgttgtt tgttttgtc tgtgagaggg tctgtgtg  
cccaggctgg 98521 agtgcgggtg agtatgttt gttttgta ttgacatgc cattattga gtgttacta 98581  
tttgctgagc actgtaacat ttagaaaact ttctaattc taatccttt agtaagtatg 98641 atgaagtga agacaggtaa  
cctctactga atacttacta tggatcgggc actgtgctga 98701 gcttcacatg cattattta atctatctc aagacatccc  
catggaatgg gtattattgt 98761 tatctctatt ttgcagaaaa aaaaaataaa aaaacctaag aaagtttct tgaactggag  
98821 agttcaagt gcttacacag ccagtaaatg ataaagtag aatggaacc cagaactgcc 98881 aaactcccc  
ttatagctct aacatatata taagaagga tccttgcaa tataacctt 98941 tgcaacttac agtgtttat ttgcagtact  
ttaaaactg acctcataa aactctatgg 99001 agtgtaatta atttaagac agcattctta gcacatagcc tacgtttaa  
aacaggcagc 99061 aggatacaaa attttggtta gatagcaaaa ataagtcaa gagattaga gtacaataca 99121  
gtgactatca ttaataacaa tgtattgtat tctgacaac cactgagaat agatttaag 99181 tgttctcatc atcagaaaat  
ggtaagatg tgaggtaatg cattgttaa ttagctcaat 99241 ttagtcatcc cacaatgcgt acatgttta aaacatcatg  
tggtacacaa taaaaaaaaac 99301 agttttttt aactaaaaac acctttaaa gtttactgt taaaaggctc ttaagaaata  
99361 ccatttggat gtatatattg ctctgaaaag cagtgaat catgatacac attatatgaa 99421 aaattaaact  
agtttaagt atataggata gtgattgtc ataattgact gcattccagt 99481 ttgttaatgt ggtatcaaaa attctcagt  
caaaaaaag aaaaaattct gagtccatt 99541 ttaattctaa atattgctt aataatttt attacaatt ttggagctac  
tgccttagca 99601 gagtaaagt tatctaaact aaaattaata aaagtccat ttaataacc tcttctgaa 99661  
aaaaacaggc agcaggccaa attgtcctg tgggtgtac ttgctgacc ctgccttga 99721 gaataaata  
tatacaaga cactagacgc gaaagaatag aaacagttcc cgttgttt 99781 gaagggtgga agtagcacag  
aatctgtcat taccttgtt gggaatgtc aaggagagat 99841 aaggcagtg ctaaaaaagg gaagattgt  
ctgaagcaga ggagaggtac agctgtcaag 99901 tgtgcctgtg caggagggga gggaagtaag gtgtggagt  
tccactagag tctgggggt 99961 gtcataacac aaacatgcca tggctgtgca tctggaatgc cttgggaca aatattatg  
100021 tgtcaaagg gagtagacat ctccctcaga gaaactgaa gataacatt taaaatgtc 100081 tattgaatg  
gattcatgcg ttcaaagta gagagaaata ggagtaagag gtgcagtga 100141 aattctttac ctactccct  
tgaccacata ggggtgtctg ttataaaaga agtgaaaag 100201 gagatccgag atcaaatat cattattgcc  
tctacaagaa agggaactt tctgaaagag 100261 aagtcaactg agtttatatt gtaaggaggc aagagaggga  
ctgttccat gtgcaatatt 100321 aactagcatt attagaagct agtctggctg atgattccga aataaccagc attctgtgaa  
100381 tggatccctg tgacctgt cccacggtc taatagcaa caggaccagc tgctttagt 100441 gttgccccat  
cagcagtacc acgaactgca ggcagagaaa cacaactta gctggacatg 100501 gaggggtctt gtcacttaca  
aaagacaaca gaagacacca atggaaatta ttgcattta 100561 tctattccc cagtcttgc tgtgagctcc ttttaaaat  
gttgaaagt atagatttag 100621 gggttgagg gacaaaatgt tccagtggc ctctgtgtc tgcatctaga attgatcac  
100681 tgtgtaaat tgaaggctta ttttctgca caagaggaga ggaaaaggaa gtggtgaaa 100741 cactgaaact  
ataggtagt gatagataa caaattcaga tatatataa ttagataga 100801 tagatagata gattagatag atagatagat  
agatagatag atagataggt aggtagatca 100861 tcggtctgt gtgtgcctta cttttagag ctaatccaag  
cactgatata ataccaaagc 100921 caagtcctta attattccag gaacatcata gaaatgaaat gtagaaaact aataataatc  
100981 atatacttg tatgtgatg tttttcca gcacataag ggttgtata agctagtgt 101041 catcaagctg  
ttaggaagaa aaagcaaat taaaactaag atcttctcat ttctattca 101101 aacctattgt ctttttct tttcattt  
tatttgcatt tatatactta atgctgtaaa 101161 actaatgagg attcaatact agcagaaatt cagacagagg ggttcattat  
tagttgattg 101221 ttagtaatcc tatctctga agttatttc attaatttt cttttgtga cttttctta 101281 gtttcagtt  
tttaaaaaa gtgtgtttg atgtataatt aaaggaaaca tcatgaaatg 101341 tctattatt ttaaaaatac tcatggaaaa

tgagtaacag catcattgaa tagttaaac 101401 atgacagcaa aacctgaatg agctcggaga  
cactgagaaa tatttaattt 101461 ttacatggtg gagtttttc tgtaagcgt aaagagtcac acatgctctt attcatcccc  
101521 ctttatgccg agatattacg tcaacatgtg agaccatttc gtaaaccagt ttgagatatt 101581 tctggttact  
ccttattata tagtttctta aagcacagtg tagaagctgg ttagggatta 101641 attcctttcc ttccatcct aacagtcag  
gctgacacct atataacaat gacaggttaa 101701 caagagaaga gcataacaaa tatgttgat cacagtttta  
cataacatgg gacccttcag 101761 aataaagacc ccagatacag ggaaagcaat ccttttttc tgagacagag tctcgtctg  
101821 tcaccaggc cggagtgcag aggtgcaatc tcagctcact gcaacctctg cccccagat 101881 tcaagtatt  
ctctgcctc agcccctcga gtagctggga ttacagatgt ccgccaccac 101941 gcccggttaa ttttatgtt  
tttagtagag actgggttc tcgatgtcgg ccaggctggt 102001 ctcaaactcc tgacctcagg tgatccacc  
atctcggcct cccaaagtgc tgggattaca 102061 ggtgtgagcc accacactca gccaaagcaa tccattttta  
tgcttaggtt caatgaagta 102121 tgaacagctg tgtagaaata tgattagaca caaagggtat gatctaagc taacaggctg  
102181 agtggggaaa ctagcccatc ctgctgttc agattttct cagcccctct gtgcagcact 102241 cactcctccc  
aggcaagagg taggatccct ctggaatgag ggtctgaatt tctttatggc 102301 caggtgttac acagaaaagc  
tggggggtggg tagagtaaatt gtttaggtt tatggctggc 102361 cttgaggaaa aggcttctg gtgtctgatc  
tgacttgag aagagggtt ctagtgtcta 102421 aggtttgcct gaggggaagaa agagaggaga gacaggaggg  
cagaaggtct gttctgagg 102481 ctgcttcta ggcttcacc ttgggggtgc gtttactgag cctcaacaac agcatcctg  
102541 tttctgtcta attttctctg ggggtttct caccttacc ttgagaaagt tttgtggag 102601 tttgtgctt  
tcttattcaa ggccttcatt ttaaatttc ccaacaaca aagggataca 102661 gtaaaactca tgttggttaa ttagaaaaag  
gccagtatga attaaaggaa gactctatat 102721 taaaaatat tgttttaaag tatagctgtg tttctggaa gttcatcatt  
ttacctgaat 102781 gtattatc tcattccat gaattgctt taaagacctg ccagtgggtg tttgtaatta 102841  
tagtattaat ttttaaatt caattgggt cagtaacaa tttaaaatt tgacacaaat 102901 tctaattgt ttaattttt  
tactttaat tctttatata aagacaatga aaaactaaat 102961 tcgatagtgt tacaatcta aatgagaata taacttaaga  
gttttcttaa gtcattacta 103021 aactatgga agatctgata gaacacataa gaatatactg agaccatcac agtgcctaca  
103081 cataataagt attcaatata tgttgcag gtgagaatat gagttgtat aattcccagc 103141 attatattaa  
gggaacaagt agatgtgtga agagagtacc aatagcattt tccattctcc 103201 caattgtctt cagttattat  
agcagataag ttttaatcc tatgtttgtg ctgactag 103261 catttacagg ttctccctg atatatggcc cattaacaca  
caataatccg agttcagagt 103321 aattacttac atcattcaac agaataatc actgaggcac tgggtgacca gttgactttc  
103381 catgtgatga gacatgatga gaaaacagca aagctgaagg tgctacttg ctcctctgga 103441 agccatatt  
ctgctttct ctcctacat cactttctt ttcttaatg gaattctagg 103501 aagatgtgtg agtgggagaa tctgagtgtg  
gaaggtgtg caaagatga tatgtgtca 103561 aaaattaagg taaactatca taacacataa ataaactatg  
ttcctaaagc tgcaaactt 103621 ttaggtgaga gcaattatc ttatgtcaa ttattgtta accatcatga tgaatgtct  
103681 tccagatgca tcttgctta ttcagctta ttaactaaga gtagtcagat tctatttata 103741 atgtaaaata  
ttaaaaatac ccaatctat tcagtcctc atagttccca aagctttcca 103801 catctatcgt cacatttggc cttctcaata  
gccctgtgga gtagctagag atgatataat 103861 tgcagctgga aatgaagaca atattcaat ggagcgtgc  
aaccaattta ctagtacaat 103921 ttctcctat ttctgagaca cagatgtgaa aacaaaaaa aaaaagaaaa gcagaatgaa  
103981 tgccaagaaa tagcatgtga ttagaaatgt tgttcattc ttcttcagt aaaccacaga 104041 aagataacaa  
aggctactgc gcccagtaca gaggggagggt gtgtaatgca gtctggcaa 104101 aagatgtctt tgttttctc  
aacacctct atcgggacc tgaggaggcc caagagctac 104161 tgggtccacac ggcctggaat gaactgaaag  
tagtgagccc agtctgccgg ccagctgctg 104221 aggtttgtt gtgaaccac atctccagg agtgcagtc  
tgagtagtg cctactccta 104281 ttccatttg caggtaaaat ctcaaaaata agtcaaagga aaaattccat tttctatct  
104341 gcacaacaga aggagttttt gaaaaatgtt gtaatatgca acagtaaaag gaaaagctgg 104401 tttcatcca  
aaataggagg ttaatgcctg ggtgcagtgg ctcagcctg taatcccagc 104461 actcgggag gccgaagtgg  
gtggatcact tgaggtcagg agtttaacac cagcctgtcc 104521 aacatggtga aacccgtct ctactaaaca  
tacaaaaatt agccaggtgt ggtggtgcac 104581 ttgtaatccc agctactcgg gaggtgagg caggagaatc  
actgaactg gggaggcaga 104641 ggttcagtg agccgagatt gcaccactgc actccagcct gagtgtgag  
actctgtctc 104701 aaacaacaa acaaatagga ggtaattaat cagacaatat ttctaccata taaactacta 104761  
aagataacct aaaatacaag tacttagaac cttagaaaa taccataaat ggtgtaatat 104821 tccattactc ttgttattgt  
tcacattatt atcatatcca taaatatccc agatttctat 104881 cagatgaaag gagaaatctt aaacatggac ctcatagta  
agccaagata gagaaaataa 104941 aaactgtaca ttattgtca ataatgaga tcatgccag catctctgaa tgttatttta  
105001 aagtacatt catccaaaat tctaagtct gatgctgtg cctcatttg gtggttatag 105061 gaaggaatta  
gattataat agatattttg ttaaactccc atactttta aatattgaaa 105121 ttgataaatt tatgttcaat agaattatct  
tcatctttaa ttacttcta tgtagaaaaa 105181 aaagaatcta gttttgagc taaatagaac aaagttcaaa tactgttagt  
tctgctttct 105241 cgatgtgtgt ggtctggct aaactcagt ttctcatct gcacggtaga attgagagga 105301

ttaaaggaaa atggaatcct atggaaatcgc tcagaaatcgc gatagacatt gttattcctc 105361 aatttctgtg ttgaggaaacc  
ccatgacaac aaccaacaca gcacatttcc acttctatt 105421 tgataaaacc agaaactatt taaatattgc aataattga  
ggacactctc tatttagcat 105481 tcaataacaa cagtatggc attaaattag agttttgtat tcctcaattt actgcaaagt  
105541 ttgaggggtt ggagacacta taagagtaat ataattgtt tattcatcta agaagattgt 105601 attgtgatca  
ggcatgttat ctaaaaatct ctagggactt cagcattgac agaataagaa 105661 ggggaaagag aaggagagaa  
aaagtaaaat tactgcaaaa aaaaatggga agagtgggtg 105721 aggggcagta aaattgttt taatagaact  
taagaaatac tgatgctatt tcaactgtcc 105781 ttgcagttat ttgaaaaaat agtgtctctg ttaattatca ctctttagt  
ttagatttct 105841 ctttctggg ctctttata ggattctcca aaattgttta ttgacgtac tgctcaacag 105901  
tgaaaaatcct ttgctagaa agtagcacgt gtataataa cagaatgtaa ccagcaaaat 105961 aaagtgcag  
tagattctat cagcttttcc tttagtacta ctaacataat ttgtggtggc 106021 cacgggatag ttatcactac tacacagtga  
cactcaggca aatcagctca acaccatgga 106081 tagatgctg agagaaataa taattagatt agaaaaattc  
tctgtgtgtg tgacagccat 106141 tgtggtttc tgattacaaa acccacaaga ctccattgta taaaaaaga acacagtact  
106201 ttcatgcta aaaccagaa agttggcac tactgaggtg tgtgttact tatatttact 106261 tatatctata  
tttctgtact ctgaattcta ttcatggat ggtttctcta ttttgcatt 106321 agagactttg ggtttaatta ctgtctttat  
aattaattc aattgtgct acgaatttcg 106381 caggttttca tctttaaaa aattattgt tactcattat ataattatt  
ttattacatg 106441 ttgacattgg caaaatgtt ctaatttca ttttaaaaa taattatata agttatataa 106501  
tacaattata tattaacta acaataatta tcaataataa ttaataatta ttatattaat 106561 aataaataat acttaatat  
atataactaa ttataagcta tataattata tattatagta 106621 tataacttat ataattgata taatttaca ttatatata  
attatataac atataattaa 106681 tatataatta taattatagt ttataataat ataattatat attatagc tcactatata 106741  
attattttta aatataaaat ttagaaacat ttgccaatg tcacatgta aataccatt 106801 agaattgat cagaatgatg  
ctaagttat acaattaact tagggcacag agctatatt 106861 acattactga gtattctcat ttaggagat ggtatgccat  
tcttttatg tagatctgt 106921 attatgctg ctagtaaaat ttgatgatt ctcttact ttttttaat taaatttatg 106981  
actaggtgtg ttttatagtc attgctgtg ttgcaagagt attaatata atagattat 107041 tacaggaggc tagaatgtcc  
ataaaacata gagatgcaat taattccct gttccttatt 107101 ttaataaaac tgccattaat ttcttagaa ttgtacatt  
ttagagttga actatgtaat 107161 ttttggatc atattaatca gatttctaaa aatgtattct ttttttag gtagtagt 107221  
gatagaagta taatttatat acaagaaact gtgcccctt taaccatata gttcagagt 107281 tgacaaact atacaacat  
gtaaccacta cccaatcaa gacatagaat gtttcacca 107341 ccataaatt tctctatgc tcatttctt cttttttt  
tttttttt ttgtccctg 107401 ggttcaagca atttctctgt ctgagctcc caagtagctg ggactacagg cacctgtcac  
107461 caggtattt tgtatttta gtagagatg ggttcacct tgtggtcag gctggtctg 107521 aactctgac  
ctcaggtgat tcactgcct cgttctcca aagtctgag attacaggcg 107581 tgagccaccg cgccagccc  
tctatgctc atttctaac aacttccat tatctctaaa 107641 ggcacgtcg ttctgattc tctgacaact agtttgcct  
gttctgaat ctactactca 107701 tgaattgta taatatata tgcttctgt ctgacttct ttgttcaaca tgttttgat 107761  
attcatccac attgctacat gtaacagtgg ttgttctt ttcatgacg cttttattg 107821 tgtggttag atggaaatg  
ttatgtgaag aagtagtag ggtcaagctc ccttcatgc 107881 tgcctaagaa ttataagca attaatgta  
acaactgcag tatcaaaagg aaagtagta 107941 tagaaatgt aggccactca agatgacaga ctcatagcc  
acaacaaaa agtcagatac 108001 cagcttga cacaaggat caacaaata atttattct gcaattgta gttattcca  
108061 attttgtt gttattacc tcctaattat tgagaggaat caagtctcat caatcataa 108121 tcattaatcc  
tgccaacaa atgtgtatta ttttcattt tgtaacgag ttgttactac 108181 tatataata agccatttca tttattata  
tttatataca acaaccgct tacagtattc 108241 tattagatt ttgattgata gtctatggt cctctgatg aaaaatagg  
tctataaatt 108301 attatata gtttatat aatataaaac tataatctt aattagatt tacttctt 108361 taattgaaat  
ttcagaaatt ttactagaa ttaaaattaa attttatt catgtgctag 108421 cacaaaatac atttattaac ttccagcat  
ttatgtcca gatcagttta catgctgag 108481 ccacagatgt tcttctaatt ctgaaaata attcacctt ttgaaagaa  
aaaatccct 108541 tcattgaaat gttaaattta ttagaaaatc atagtattt cctaaatcta tgtcattcac 108601  
agtatacat taaattttt ttctaattc cattgtatt taaataagta gttttattg 108661 gaaaatgta tttttaaa  
tcctcatcat caaatattt gtcccatg aagtaagaaa 108721 atataatcta aaaatttta catttaata tttatagag  
gtttttctc tgatatata 108781 taataaaaat tggcattat aaagacttag tcttccat taacatacaa aattcatata  
108841 tttatgtca atcttctg ctctaaatg agtattagct atttggcca atagttaat 108901 agtgatgct  
caaaattttc acaattgtt ttccaagaat gtttcttgc aattctgact 108961 cctgctttt gcaccaagaa atattaaact  
aaaattgaat ttactgctga taactgtaa 109021 gttgatct cattttttg ttatatctt tgaaaaagtc tctacctta  
ttcatcaa 109081 tagttcagaa gttgtcaacc attttatatt ctactctac ttgcttga ttttttaa 109141  
agcgtgctat cactcatggt tttctaatta ttaggttgg acaaaagtaa ttgtgttt 109201 ttccattaa aagtaatggc  
aagaaccgca attactttg cccaacct acataagcag 109261 tcattcaatg atgtgtcct ctttcatga  
acgacatgga attttattg ctaacaaata 109321 ttattgatc tccttctgg ctccaagtac tactgagc atttgggata

tattaatgaa 109381 cataatgaa aacttatata taactttaga aggtgttaaa tgcattgaa aagaataaaa 109441  
ggaatgcttt aaggaagacc agaaataaca aacggagagg agaaagttgt aactttaaaa 109501 ataaggtgtt  
cagggtagac ttaattaagt tagcataatt gtactgaatc ttccacactt 109561 gtctttgaa actttacctg aaattatcaa  
ccgtatttgt attgttcaat tatattttat 109621 ttgcatatgc tcaatttttg gaacattatt cttagctttt acatttgatt  
tcataatcat 109681 gtataagtag atacttgag gagcttatac tatgttactt atcattgata ctcatgtca 109741  
ttcatttcaa ataaaatatt tcttttctt aaattcctaa tttaaattca ctctgttc 109801 attcatctca tctttactca  
tctctattc agctggagta ggtgttttc acatgtaaaa 109861 aaaaattctg tcattgtaca tatgtgtttt tgactgggta  
ttaagtctg tgtaacaca 109921 agtgttagct ttgctgttag ttctcctcac ttgtgttact tctcctcaa actgtggact  
109981 ctgaccaatt attttctggc catgttgtaa taaagaggaa gaagaaagca atctgactt 110041 ttgttcttt  
gtaaggaaca ttttctctc tccagattgt agaaagatta ttctttaat 110101 tgttgagatt caaaatattt gtaaaattca  
ttgggggata gatttattct cattgtttc 110161 ttcatgtaa tataaataat ataaaaataa tgggtaatat gccctaaaca  
ttgtgccctt 110221 ttcatcttaa aatgttttc ttataccaca tcttgatta ttcttattt ttatgtgct 110281 ctggttctct  
tgctaagaaa cactattatt tgatttgaa ctcttactt gctccactt 110341 atcagttatt tcacacatta ttctcatctg  
tttagccctt ctgcatca gtaggtcct 110401 ttctttctgc attcaattga atatttaatt caaatttgtt tatttctgc  
agtgccattt 110461 gttttctatt tcaatgaag attgttaagt gttggttta tttttgtgg ttctatttt 110521 ctgtagttac  
ttcatgttc aaattatcct acttttagt ctatagtca tcttgatttg 110581 tttttcttg tgaaaaactc tgctatagag  
ggcatgctt agtgcattggc aatgaaaaca 110641 aagcaaacca aaagccattc attaatgtgt tcttctgtt  
agaataaaaa aatttccag 110701 gtatttgctt ctctgccta atgtggagta tggagttgtt tcatatgtc ccatattgat  
110761 ttacacttta actatgctgt ctgctgcaa aaaaatgtgc ttatacaacc caggggtgga 110821 accaagctaa  
gcaactctcc tcaggtcctt tacctgtca gaagtctga aagccccatt 110881 atactcctt ctcccttacg  
cacaccaaga attataaatc ccattgttt ctctataaa 110941 gaatatatt gcattctatc acattcatat gcacagcctt  
ttattctatg catactcaat 111001 tagcacatat tggcaagta ggaaagtagg agtgtgggaa taagtatgaa aaaagacacc  
111061 attgtggcat atatatacac acacacacac acacacacac actcttaca tttctcctc 111121 tctgaatcct  
tcagatactg aataaaggac atctgctatt attatgtta attatttaa 111181 ttactttaa tttctctta ttattaacc  
caaatacctt aattgaaat taaccaggtt 111241 ttctatgc agttgtcct attttctatc aggctaaac aaataactat  
ctgcaaaatt 111301 ccaagtagtc caattagtgt ttctcagcc cttcactca taatacaaca tgtagatgaa 111361  
cataacagct tcatattcaa acagataata ctttgcttt ctcatagga agcagcaga 111421 gcaatgggac  
aggattccgt gcctcaaagt aagggtgag taaggacca gatgccctc 111481 tataagctgc caggagagtg  
gtggtgttct gtttcagagg acaaagcaca cagaggcca 111541 gactgtgtc ctgagccct acccattagc  
cccaagatca tagaaaaatc ttcaaagctg 111601 gaaactgggt gacaatgatc ctgacttca gtaggtgtgt ttttaaact  
ctgtatacct 111661 tttctctca cctgtgtgt tattgaata tgaagttggg agaagacata tcagagattc 111721  
ccaatctaact acgttttaaa ttgacgttt tttccctta gactagcatt aattgtgtt 111781 cacaacaaa cgagatagca  
ttcatctca cgggacagta cactagatt catgaggtct 111841 catattatt acagtaaaaa gtttcttca taaacgcgt  
ttttcaaga acaatttacc 111901 atgatgatgt ctgaaaaca cagaatttag gctctgccac aaatttgct taacatgtaa  
111961 tgattcatca agttttgtc tccatatact atttagaga gtactgctg gcagtaaagg 112021 agctcttctg  
cgcaaaagaa tggctggtta tggaagagaa gaccacaga ggactctaca 112081 gatccgagat gcattgctg  
tccgtgccag aatgcagcaa gttccagc atgcattggg 112141 accccacggc ctgtgccaga ctgccacatc  
taggtaacac agagttctcc caagactttg 112201 gaggttaaga gaaatttact atttgaaga aactaagggtg  
tgaacttaa gtttctaata 112261 ttctaggca ttctaattt tttttttg agttctgcct tcttagata cctactagcg 112321  
gaatcctaact gctatctaa ttgtacagat tagcgtaaag attatttca ttgctctaa 112381 aataaatgaa acagcacttt  
taattactgc ttgacattt agattcttc ataggaatc 112441 ttatgagagc ttgtaacatt ttctggagtg tgtagaaaaa  
tggctaagaa acatctata 112501 tttgtcagc agagtggat aaaggaataa agtcctttt cttagccaag aaagcatgct  
112561 aaaataagac acatgttgaa aatgctgat ctcaaaaac aaaattgaat tgcttcatgt 112621 tgctttaatg  
aactttgtt gtaaggaact atgtgttat ccctaacagc tggtttaatt 112681 tcaaagacc aattcttca cattcgaatg  
caaagaatgt ttccagttg tatataaaa 112741 agctgagaga gaactgcat ttctagcac tcaactctc acagaatag  
tgagatatct 112801 ggatgctcac taaaacaaa ttttctct ttcccttca gattataaca aagaaaacct 112861  
aaaaagtaag taattgtgt tgtgccctg aaaccttatg tgtatgtaatt tggattcatg 112921 catgtgtgtt tacacttata  
tttctgatg ccgagaacag aatgtacagc cgcttcaaa 112981 gtctctcac catactcatc cagggtataa  
catgagggaa aatcatggaa ggtctcagt 113041 tataactttt aattagaccg tagagagtac catatttagt  
gagtcataca aatgctatct 113101 ccacactcaa ggttttagt ctgtttatt tcttatatgg ctataagtaa gccaaattta  
113161 aatgtcacc tttgattt atattctga ttcagtataa tctaattatg tatagatgaa 113221 acccaacatt  
tatttctca ttgagccaat tcatgatctt cattgtgac aatagatccc 113281 tcttttgaa gtaggtatt ttttaagac  
agctgattc cagtataag tttataggat 113341 caaatcaat ggcttaaaa aggtcatcac aaaaactct



gggaagaagt113401 tgcttgaaa gggatgtcgt acaaaataac ttgtatcaga tagtgcctga acctgtcaga  
113461 atgcagaaat cctcaggatg aaattagaaa agcttttcat gtcaactaac ttctctggt 113521 ctacgcgttc  
taaggcttaa atcacactta cttctgttaa tacatatcc agccctaatac 113581 ttctctgcat ttgactaggt gccaggactt  
gattttacca gcttgcttaa aggaccaaca 113641 cttaaaagta taaaagcaa gaatgtact ggtcctagtt  
gaattactca gaggtattaa 113701 acaagaagag ttatggaaac cttaaaaatc tattattctg gtagcctgtc aaattgttat  
113761 tcccaaatcg aaggaataaa aaaaaattc aattctttgt tatatgagca gccaaagttt 113821 actttgattg  
gactttgaat tgattactgt gctctttgt atccatcgat tgctactca 113881 tccattcaaa cattcattga ggggttgctg  
tgtggaagga ccagaccatt catcttaaat 113941 tagacaggaa caatacacia aaaagcatcc acatttctgc  
cttcacact aattataaag 114001 gaattttgag cagcaciaac tagctacaat aataaatttt ctagtcttta aaaaacagct  
114061 ttatgaaatc ttcgatacat gtaagaaaat gagctcctaa tgcatgaac taaccattta 114121 aactgaaagt  
agggcaggga atatctgaaa gtatgtcct tgagttaagg caattattat 114181 taaaagagtt ggctttagca  
ggtcaatagt ggagcaaaga aaacatcctt attaggcagt 114241 gtccatatt ttataggggt gtgtaaagac  
cttaagtatt tccaaagag tgtcttgatt 114301 tctgagtaaa cttaaagaa taccaccagc tcattggag gggtcacaaa  
agagctgta 114361 atcatttgtt tatcttgca ttatttctt ctctctgag catagggact agaatttcag 114421 tagttttct  
ttttataat ttcttggct gaagtgaac atcttttga gcaggcaatg 114481 ccttgtgct atttactta ttgtaagca  
aggattacac tattctctc tccgtgaga 114541 cttcacatac ttattacag aaacactcag cagtgaatct gtcttctatt  
tcagagcttc 114601 tgtggagaaa aggttaattt gtcttaatac ttgaaataat tactttctc ttgaattctc 114661  
ttttcttc catcttgcct cttctatac atatacatgg agaataaagg acccaatgaa 114721 tgtacccaaa tccaaactga  
ctagtgtgat acatacatta tctctctaa tactcccaat 114781 agttctacia aattaagtac tatgaacgc ctccatttta  
ctacaacc aacatgagaa 114841 agagagatta agcaatgtgt ccaattttac ccatctagta aggtgataag ccagaatttg  
114901 aactgaaatc tatctgattc tggctctgtc ttacagacca gaatgtata cctgatgcata 114961 ttctgttatt  
actaatgttt cttaaaaaat tccaagacct catgtgtaat aaagcttaac 115021 tgattgttta actgattcat tctgaataa  
attccactac ctttcacat ttgtataat 115081 tgattattct taagaagctc taattgataa aaattttatt gttcacaatt  
ttaatcacc 115141 caggccactt gatgattga cttttgtta acatttaaat gaatacatgc ttgtgtccc 115201  
agaccatttt tccataatga tcagctacta tttgcccac gaatgaaatc atgaagcgtc 115261 agtgtctctg tgtgtgtgtg  
tgtgtgtgtg tgtctgtgta aaactcatga attatttcat 115321 aattgaaat gtgggttggg taattttgt ggtaatatta  
aagttacaag ttcttagaaa 115381 attggagttt aaagtaactt taacagttat ttaatctaaa gtctcccaca atgaagaat  
115441 cttttctaga gcactctga cagaaacatt ccattttccc tctgaattt atttctcaat 115501 tctttgtag  
aatacattaa ttattcaac aatttagcta ttagaacta aattctggtt 115561 ctctagaact gtcaacaact gatcttact  
ctatttctt gattatttta taatctgtat 115621 gatagtcctt aaaatatttg gagacaggca ctcaatctct ctgagtctt  
ctcttctca 115681 cattaaatat ctccaatttt taacttttc tttgcaact gacttcaaaa atctcacct 115741  
ccatgtttac ttttactgg ctgccacaag cttgagaata tccagaactg aacacaaaagc 115801 acagaacatg  
atctgatcag aattgcaatg caaccatatt ttctgtgata aggcttgtt 115861 cttttatgag tatagattaa actcatgcta  
gctgtctaata aatttcata cattaatagc 115921 cttctatac acatatgggt ttactgattt cttgatttt ctaataaatt  
ttctactaga 115981 ccaatccaat tcataattat ttattatac ttctctagc atttataata attgtactt 116041 tacatgttta  
gttactatgt tctatgaggc atagtatcc aagacactt tcttttata 116101 tgaagctctt taccaatgta aatgtcact  
ctgtcttgt tttagtgctt ttagctttaa 116161 atttctagta ttaataatgg taatttttc cttgtattta tgtaacctta  
gcacctttt 116221 gtctctttt tatttttctt ttctataaa caacatatac ctgggtttac tccaatcaga 116281 tagccattt  
ctattaatag gaggatttag cctgttcata tttatatca caactgatat 116341 actctatttt atccctacta tcttaactgt  
atattttcta ttcgctttac gttttgctt 116401 ctctttttc ttttcttta ctgttactg gttatgttt ctccactgct aagtgaaggt  
116461 cagacaccaa ttctttctac acatcgcagt gctctattta ttctcattt ctgccaccc 116521 catgggactt  
tcagaatctc caggagatcc tcagactgct tggatcttct tcttacctc 116581 cctgggtact cttaggttct tcttgcaga  
gtgatttca atattgagtc ttacctagcg 116641 aattagccaa gactccaccc atcacagccc cttcacatgt  
atctgaagt tattttctga 116701 ttcaattgtt attagagtc tctcatgta ttctctaga agggaaagtg tcttgggaga  
116761 cagaatccct gaagcctgt gtgttatcaa attgtttct tttattggg tagttgaaa 116821 gtgtattaac  
tggttatgga actcctgagt gacatttct tgggtggtt atagatgta 116881 ttctactctt tttagcttc tagtgtgga  
agcaggtagt ctggtgtgaa ttattttt 116941 tctgtaagt aatttattct ttctatctag gcagaaactt ttgatttt  
cccttatcc 117001 gtgatctg tatgataaaa attgtttaat catgtgctat tgaacatctc ttccaactc 117061  
catgataggg cttcatgttg ggagctgag ataagctat atgggaatct ttatccatt 117121 gaaatcagga  
tggtagacag accttctaa tgcaaaaagt tgatcatgct attccacctc 117181 gtaaaact cctataagac cctccattg  
ctgcagggca tagtccaaat tacttaaat 117241 ggtatacaag gactttatc actaaacctg atatctgcag cttacat  
agatactccc 117301 caactccaac aatgaaact ctaggtgcac tttagaaag gcatacatc tgcttagttc 117361  
agatcttggt atagtctatt acttctttat agaatactat ctctctacc tgactccatt 117421 ctactctt aattcccca

tccatcacac acgtttgtgt gtgtttttt gttttgttt 117481 gttttgttt gtttgagacg gagtctact  
ctgtcgccca ggctggagtg 117541 cagtggcaca atcttggtc actgcaagct ccgctcccc gggtcacgcc  
atcctcttg 117601 ctacgcctcc cgagtagctg ggactacagg cgcccaccac catgcccagc taatttttg 117661  
tatttttagt agagatgggg attcaccgtg ttagccagga tggctcgtat ctctgacct 117721 cgtgattcac  
ccgcttagc ctcccaaagt gctgggatta caggcgtgag ctactgtcc 117781 cagcccacac ctttctta  
gtctgttcag gttgtataa caaatgcc aagactgggt 117841 ggcttataca cagaaattta tttctcacag ttctggagtc  
caagaagtcc aagatcaagg 117901 tgccagcaga ttggtatct ggtgaggacc cattctcat agacatagct gtcttctcc  
117961 tgtgtctca catggcagaa cgggcgaggg agctttctg gacctttt ataaggcat 118021 taattccatt  
tatcaggact ctaccctat tcattcaac acatgaatgt gggggaaaga 118081 cacaagact cagatcatca  
taacctcaa ctggttactg gctactcacc atttatgtt 118141 aacttacagt tactcactct agaaaacct ctacgtatgt  
ctaaacctga gtagtgcca 118201 gccctgaacg agactcaca gcatcgtgt ctactactc ctataatgt tcttatatt  
118261 tgttttatt ctccattat tcttctgt ctcatgaca gcaaagact ctcatgttca 118321 ccacagtgt  
ctggatact aacagtcact attgattag tgaatgcatt tacatatgga 118381 tgaatgagtg tataaactcc cgtagtgtc  
agaggaaaag aatcaagaca gaaattgg 118441 gagagaaaag ataaaaagga aaaagaatga cgattcaaag  
tgatcttta gacccaaaga 118501 gatcattgat gtagttcaag ggaagatcag atcaaatcag aagcagtc  
caaggaataa 118561 caaaacaaa ctatctgaa ggaaagaaac atttaactcc ataaagcaa attattgtc 118621  
caactatgtc atttctgca ttttaaaaa actcactaaa tcatcataga ttttcttt 118681 aacatgacag taaattctac  
ttctgattc ttttagaaa aactaacct atattacca 118741 gtgaaattac actaccaact ttactaatta cattatattc  
cctcacatgt tatatatgg 118801 gtgagatgct ctgtaaactc caaatacaaa aatagtatt tctcctatc ttttaataat  
118861 tgtccaact ttattatag cagaaagcaa agctcgtcaa ttaagccac ccctaccac 118921 caccaccac  
ccatcttaga tcgagaaaac ttgggatgac tcagtccaaa gagaatcaga 118981 ctagctttca agtcagtcag  
agaggaaact ggtcagtcgt ttgagtcac cactcctgtg 119041 gtgccgatg aggcagtcgt tctatgact  
tgccagatg tttattgt gtgctgatg 119101 tctccagtt ccaggtgct gctgagtc cagtggtagc  
caggcctggc atccgcaggc 119161 ttcagaatca cttgcttagc cattgttact cagggcataa tctagggtc cactcatgt  
119221 atgactaaga agtcatacat gagcgtct ttagcctcc aatttgcaa gtgccctatt 119281 tcaatgct  
taggcatcta ctgccataa ggttttatt tgaattgt atattgata 119341 ttaatatgtc ccttctatt aatcattat  
tctctgacta tgatgtagc agtgctaat 119401 attcgttta ggtcttcta aactaggt gtataatcta tgtatgctt  
tttctctgt 119461 gctaacatt ccaggtgtg atattggtat tataataatt tctaaaataa tttgaaaga 119521  
tttctctta ctggaacata ttataaat ggaaattta tctcttcaa gactaaaaga 119581 atgtcttta taatgtgat  
acttaaaat ctagtctc gcctatgga atatttat 119641 ttctaagtc tcaaatgt gggattaata tttcctatc  
atttctta aggtgtgaaa 119701 tataataatt acacattatt ttaataact tgaatctgt tataacttt ttatcattc 119761  
taatttctg ttgtacct tctctttaa taaaattcc attgattaga ctactatag 119821 aatattata aaaccaacta  
ttgatcttt aattctatca ttgtgtac gtgtattcta 119881 actattaac ttctgctgt gtaggctgt tactttata  
cctattatc tttgtttc 119941 gtagttatt ttcttacc aaagtcgtg gttaaatt cagttcatt acttcattc 120001  
ttttatct agtggaggga gataacacta tgaattatc ttgagcaca acttggcta 120061 aataaaatc aactattaa  
gaggctgtg tctaactat aactatagt actctagt 120121 ttgtatcaa aaagtcatt atttttct ttttaaaat  
gtccattgg attttatta 120181 atctattatt aattgcact tggccataa gtagatatgc ataattctg ctttaaaat  
120241 ttattgat taatccaca atattgaaa ggaagggtta ttctattt ttgggtaca 120301 aggtcattct  
tagctattaa aacattgtg ctgattatt taaaactc tgaatcctg 120361 ttttgtct tactcaatc gtaagagga  
ttaaatgtg attaataagg tttttaat 120421 acatatacaa tggactgt actctacaaa tagtggtatg agtatggcat  
ctttgggt 120481 ccaacagtaa tgctgattt actttata tatcacatgc gcctttaaa ttgaagttg 120541  
acaggagtc agttttaga tgaattaact tctattgt ctctaatat tttatttt 120601 catctctt catgatttt  
cttctgttg taaactgaca gtaaatgt ataaaagctc 120661 agctctagc aatcctgat tcaagtgt ttagtgaaa  
atatttatt tgataattc 120721 catgattat gtcaggctat agataatag attcagtata aatggacca gcccaagatc  
120781 tacattatc tcagaaaaa aaacctatt tctctctc gactctatc tttaaaatt 120841 tattattcta  
taagctggat ttacttaca ctagacctta ctgaactta taaatatata 120901 accagggaga acctgataca taaatatatt  
attatcatga aatttttt actgattgt 120961 taaatacaaa aaattgctc taaagggtt gagaatgaat gaaataatta  
ttcttact 121021 acagcattcc caccaatgac gtctcaaag ccaagtgtg acattcaaa tctgcctcc 121081  
tctctctt ctctctc tgtctacct acatactca tgaatgaat aatctcatc 121141 atgtccagct ttgcaatatt  
tgtctctt accataacta ctcttattg ctgccgaaga 121201 agaaaacaat ggaaaaataa gaaaaggta  
gattctagt tcagctaacc atgttagta 121261 atatttaaa gcctgtgt ttatggagt ggtatgacgt gaggaatata  
tatgactg 121321 caactctta aatatccg tagcctgt taaaattaa gcaccccat catgatctt 121381  
acaaatgtca atgactttt ggcatggat caaatcaat gccctagggt tactgttca 121441 caaaggtaa

aatctaaataaatttggaggaaatggctattctgctcttctgtct121501tcttcaggccgtgtgcccgtgtggtg  
agagctaaacatttctgaga aaatgtgcct121561tttgactcta gaccaaaca aatattttat tgctctcaaa acgaaggatc  
ttggctgcc121621tagtataac ttgtttcat tactcttaaa tgccatatt cttagaatct aagtctaagt121681  
acaaagatct aacctgcttc tgagctcatt cctgatcttg cctgtcttgctgc ctgcagagaa121741tcagcagcag  
taacctcac cacactgcct tctgagctct tactagatag acttcatccc121801aaccccatgt accagaggat  
gccgctcctt ctgaacccca aattgctcag cctggagtat121861ccaaggaata acattgaata tgtgagagac  
atcgagagg gagcgtttg aagggtgtt121921caagcaagg aaagtacct atggaaaaa aaactccatt  
gaaatatgtt atgtctgaaa121981agctaccaa ctattagctt ggtatatata taatattagc tttatatata tatacacaca  
122041catatatata tatatatcaa gctaataata tagtacatat atatgtacac tgtgtgtgta122101tatatatata  
cacacacaca tatacatata tacacacagt gtaataata gtattatata122161gtattaatac aatattatat atgtattata  
tggtataat atactatata aaatagtttt122221tatcaagtta gtaattctg gccagggtgcg gtggctcgtg cctgtaatcc  
cagcactttg122281ggaggctgag gcgggaggat caccttagtc aggaattcaa gaccagcctg gccaacatgg122341  
cgaaaccccg tcttactaa aaatacaaaa ttgagccagg catggtggtg cacaactgta122401gtcctagcta  
ctcgggagtc tgaggcagaa gaattgcttg aagccggaag acagagggtg122461cagttagcca agatcgcgcc  
actgcactcc agcctgggtg acagagcaag actctgtctc122521aaaaaaaaa aaaaaagaa aagaaaaact  
agttaattct ttacatcatt aacctattt122581gtattgata atacactca aatctaatt tcccctctt gctggaaaac  
agtagcctat122641atggagataa tatattttac tgcacttaaa ataggtaatt tattggagat gtaaatgtgt122701  
cttacttct acgatttta aattataaga aattagtaat atagttaac aatatttct122761tttcaggaaa gaattacca  
tatatttta atcataatt ctacattgt tttaaataac122821tccttacatt ataataat gtatagatat taagtagatg  
ttcatgaaat gacaaacaga122881aaaggaataa aaaggcaaaa atttataaaa aatgagctca agaaaggagt  
atgtattagg122941gccaatatta gcctatgtat caccttgtg cgaattggaa taaaataccc tttctgtgc123001  
atggatatgg ctccacagac acacagctga gccagagaat atgaattgg ttttaatctc123061caactggcac  
ttcggcctgg tgctcttggg caagacaaa cttaatctc acccatggtg123121gccctggcgt agagggtaca  
tgaatagtga aaatcacaca caaacatgtc ttggaaacca123181aaattgcaa ggcaccact taggctcaat  
ggagggtaca aagatgagta agccatagt123241cctacgtcat ggaattaga ttctggacaa agattaaaag  
gttaggatgt ggctgggctc123301gatggctcac acctgtaac cccgcagtt gggaggccga ggtggctata  
tcacgaggtc123361aggagattga gaccatctg gtaacacag tgaaccctg tcttactaa aaatacaaaa123421  
aattagccag gtgtggtggc ggggtcctgt agaccagct actcaggagg ctgaggcagg123481agaatggtgt  
gaaccagta tgtggagctt gcagtgagcc tagatcatgc cactgcactc123541cagcctggat gacagagtga  
gactctgtc caaaaaaaaaa aaaaaaaaaa aagggttagga123601tggaatgat aatcctattg ggggtgtata  
ctcagaatt cctataatt gtaataatg123661catcttcaa acttcattgt tgaaattgt tgaataaac accagtatt  
tttattagt123721gacatcaagg agtttaagt atgtgtctt tcttgattc tgtggctctg ggaaaggctg123781  
cgtgagactt aaccagcctt ttacacagg gaggtgggag gatattgata aatgtgggta123841gtataaaga  
tatgatgtc atgatcttg gttctttt caataaatgt atctctcagg123901gcaccaggct tacttcccta tgaaccttc  
actatggtg cagtaaagat gctcaaagaa123961gaagcctcg cagatatgca agcggactt cagagggagg  
cagccctcat ggcagaatt124021gacaacct aattgtgaa gctattagg atgaaaatac aagtaggat atgtattca  
124081tcagaaaaca gaggcttcc aagttttct cccctgttc gtgcttttc ctttctct124141tgatcagtga  
gacgttcag ttcttttca aatttagctt cttcacctg gtctatcca124201accctatagg acattcatgg ctaatggat  
tatccctct taaattcat acttcaatt124261gtctgtct ttgctgcct ctattataa aatgtttta aatgtccca  
ttgtaaaaaa124321ttaactgc ttccatca caaaattat caatattgaa aagtctatat atttactta124381tttgttct  
ccttttct ccctaactag aatgtcatga gcagcattt gtatctttc124441tgttcattgt tgagttccag tttattcca  
gattcataa ttcaacaaa attttacaa124501tattagtt gtattaata cacagcaatt aataaaact ttcaaaatc  
tgtctctc124561gctgggagca gtggctcat cctataatc cagcactta ggaggccgag gcaggcagat124621  
cacttaggt caggagtgt acaccagct ggcaacaag gtgaaatccc atcttacta124681aaaatagaaa  
aattagctg gtgtggtgt gtggcctgt aatcctagct actcgggagg124741ctgaggcatg agaatcgct  
acaccggggg gcagaggtt gcagtaagcc aagattgcac124801cactgcacca cagcctgggt gacagagtga  
gattcatct ttaaaaaagg aagaaaaaa124861aatctgtc tctcatagag catacttca ctctatatga  
ggagacagat aataaaaaa124921aaacaaaaat atgggatgct ggatattaag ttctacagac ttttaaaagt gttaaagcag  
124981agaagtgg atgtgagcta caaagttga agactcagt gaaaatatta catttatata125041aagacctggc  
agaggcaagg gaataacagt gtggatatct tgggaaagaa cattccaaa125101agaatagaa gcatttgcaa  
aggtactgt gcaagagcag atgtggcatg cttgaggat125161agcaaggaga tgaatgtggc tggagcagag  
tgaaagatgg ggagagtat caaagatgag125221atcagagagg taatggggga ggtaggcagg tctgtcagg  
ccttataaa aacattggct125281ttaatctaa gttgggaaac aatggagag ttcagccaa gacatgacat gacacaactc

125341 atcattttt agatcttc ttgctgctt cttagcatt gcatgaagg aagcaatgaa 125401 atcaggaaga  
cagtaaacag gtattgcaat gatgcagcaa gagaagatga tggcatgggc 125461 caggtggtgg tagtgaagat  
cgtgagaagt gattctctc catgtgtaat gtgaaagtag 125521 agccaaataa ttgtctgaca gaccaaatat  
gagatgtgca aaaaagggaa aagtcaaaga 125581 tagtatcgaa gtatttggct gtgcagatga gtgaatggag  
gtgccattgg ctgagttgag 125641 gaatactcag aaggaacagg ttccttagt ggagagagtg ggaattcatt taaagatgtg  
125701 gttttgtcc aggcactgtg gctcacgcct gtaattcaa cactttgtga ggccgaggcg 125761 agcagatcac  
ctgaggtcag gaattcgaga ctgacctggc caacatgggtg aaaccccatc 125821 tctactaaaa atacaaaaat  
tagccgggtg tgggtggcaca cgcttgtaat cccagctgct 125881 tgagaggctg aagcaggaga attgcttgaa  
cctgggaggc ggaggttgca gtgagccgag 125941 attgtgcat tgcactccag cctgtgtgac agagtgagac  
tccatctggg aaaaaaaaaa 126001 gacgtgttt ttggcgatgc ttattcaaca tccacatgat ccacatgaag ttaaggatgc  
126061 atgtggatat ggaggcctag agttctggta aggatgatct ggtagacat gaatccaagg 126121 ctattgcagt  
acacagagta ttaaagcca tgaggttgag taagacacct aagtatggag 126181 aaagcaagcc agaacagaga  
agaggtccaa ggaccaaggc ctggagcatt ccagtattta 126241 gtgtgagaaa gaggagatga acaagaaaaa  
caactaaaa acgagcaacc aatgaaatag 126301 aagtaaata agagagtgtg gtgtctgga tgtcaaatga  
agtattttaa ataggtgaaa 126361 gtgagcatgt catatgcatt aagtcaagt agaggaggac tataaagtga ccttgaattt  
126421 gtaaacatgg atgttactg gtaacccga gaagagaggt ttctaggaa tgttgggggc 126481 agaggaaatg  
taagttagct caaaagaaga ggaagagaaa atctggagaa aaagtataa 126541 caactgttt tgccataaag  
gtgaaccaag gaacatggat agagctgaag ggggcagaaa 126601 gaagcatgct tctttcatg tggaaagtaat  
agcacattg taaattaatg agaatgatcc 126661 cgtaaagaga aaaattgatg acagggttg caaatagtgg  
aagtaacatc ttgaacagt 126721 gagagggaat ggaatcttg cactgttgga tggattggcc ttgtaaaga gaatgctcag  
126781 atcaaccata gtaataagag agaattggct ggagattgta gccagtctt tctgattgat 126841 ttgttttct  
ctgtgaggta ggaatcaaga tctcatctga ggggtaggaa tgggagaaga 126901 gttgaagatt tgaggaaaga  
gaagaaataa attgtcatct aagaaaatcc attttacat 126961 aaaatataa atggactaga gaaacataat  
atgattggca agaacattaa aagcttact 127021 gaaattagag attacacatt taacatgaga ctggtcagca  
tggttgta tttatcaaa 127081 tgctgccagc tgggcataga ctcgtaaaga ggagttaa tttaccagaa ttagcattt  
127141 gccacacaag taagtgaag tcaaattgag gcaaataaga gaggtgtatg caaaggagt 127201 attattatga  
ttgatcaagg aacttaagct gttaaaggaa ggaagacaaa acgtgaagaa 127261 agtagggatc attaaaagg  
ggtaggatca atagattaaa agtttcagg ggaggagcca 127321 agatggccga ataggaacag ctccggtcta  
cagctcccag cgtgagcgac gcagaagacg 127381 ggtgatttct gcatttccat ctgaggtacc ggggtcatct  
cactagggag tgccagacag 127441 tgggcgcagg ccagtgtgtg tgcgcaccgt gcgcgagccg aagcagggcg  
aggcattgcc 127501 tcacctggga agcgaagg gtcaggaggt tcccttctg agtcaaagaa aggggtgacg 127561  
gacgcactg gaaaatcggg tctctccac ccgaatttg cgctttcag accggcttaa 127621 gaaacggcg  
accacgagac tatatccac acctggctcg gagggctcta cgccacgga 127681 atctcgctga ttgctagcac  
agcagtctga gacaaactg caaggcgga acggggctgg 127741 ggagggggcg cccgccattg cccaggctg  
cttaggtaaa caaagcagcc aggaagctcg 127801 aactgggtg agccaccac agctcaagga ggctgcctg  
cctctgtag ctccactct 127861 gggggcagg cacagacaaa caaaaagaca gcagtaacct ctgcagactt  
aagtgtccct 127921 gtctgacagc ttgaagaga gcagtggct tcccagcacg cagctggaga tctgagaacg 127981  
ggcagactgc ctctcaagt gggctccctga cccctgaccc ccgagcagcc taactgggag 128041 gcacccccca  
gcaggggcac actgacacct cacacagcag ggtattccaa cagacctgca 128101 gctgagggtc ctgtctgtta  
gaaggaanaa taacaaccag aaaggacatc tacaccgaaa 128161 acctatctgt acatccat catcaaagac  
caaaagtaga taaaaccaca aagatgggga 128221 aaaaacagaa cagaaaaact ggaaactcta aaacgcagag  
cgctctct cctccaaagg 128281 aacgcagttc ctaccagca acagaacaaa gctggatgga gaatgattt  
gacgagctga 128341 gagaagaagg cttcagacga tcaattact ctgagctac ggaggacatt caaaccaaag 128401  
gcaaagaagt tgaanaactt gaaaaaatt tagaagaatg tataactaga ataaccaata 128461 cagagaagt  
cttaaggag ctgatggagc tgaanaacaa ggctcgagaa ctacgtgaag 128521 aatgcagaag ctcaggagc  
cgatgcgatc aactggaaga aagggtatca gcaatggaag 128581 atgaaatgaa tgaatgaag cgagaaggga  
agtttagaga aaaaagaata aaaagaaatg 128641 agcaaacct ccaagaaata tgggactatg tgaanaagac  
aaatctact ctgattggtg 128701 tacctgaaag tgatgtggag aatggaacca agttgaaaa cactctgcag gatattatc  
128761 aggagaact cccaatcta gcaaggcagg ccaacgttca gattcaggaa atacagagaa 128821  
tgccacaaag atactctcg agaagagcaa ctccaagaca cataattgtc agattacca 128881 aagtgaaat  
gaaggaanaa atgttaagg cagccagaga gaaaggctg gttacctca 128941 aaggaaagcc catcagacta  
acagcgatc tctggcaga aacctacaa gccagaagag 129001 agtgggggc aatattcaac attctaaag  
aaaagaatt tcaaccaga atttcatac 129061 cagccaaact aagctcata agtgaaggag aaataaata

ctttagagc aagcaaatgc 129121 tgagagattt tgtcaccagt aggcctgccc taaaagagct cctgaaggaa  
gcactaaaca 129181 tggaaaggaa caaccggtac cagccgctgc aaaatcatgc caaaatgtaa agaccatcga 129241  
gactaggaag aaactgcatc aactaatgag caaaatcacc agctaacatc ataatgacag 129301 gatcaaatc  
acacataaca atattaactt taaatataaa tggactaaat tctgcaatta 129361 aaagacacag actggcaagt  
tggataaaga gtcaagaccc atcagtgtgc tgtattcagg 129421 aaacccatct catgtgcaga gacacacata  
ggctcaaaat aaaaggatgg aggaagatct 129481 accaagccaa tggaaaacaa aaaaaggcag ggggtgcaat  
cctagtctct gataaaacag 129541 actttaaac aacaaagatc aaaagagaca aagaaggcca ttacataatg  
gtaaagggat 129601 caattcaaca agaggagcta actatcctaa atatttatgc acccaatata ggagcaccga 129661  
gattcataaa gcaagtctg agtgacctac aaagagactt agactccac acattaataa 129721 tgggagactt  
taacacccca ctgtcaacat tagacagatc aacaagacag aaagtcaaca 129781 aggataccca ggaattgaac  
tcagctctgc accaagcaga cctaatagac atctacagaa 129841 ctctccacc caaatcaaca gaatatacat  
tttttcagc accacaccac acctattcca 129901 aaattgacca catagttaga agtaaagctc tctcagcaa  
atgtaaaaga acagaaatta 129961 taacaaacta tctctcagac cacagtgcga tcaactaga actcaggatt aagaatctca  
130021 ctcaaagcca ctcaactaca tggaaactga acaacctgct cctgaatgac tactgggtat 130081 agaacgaaat  
gaaggcagaa ataaagatgt tctttgaaac caacgagaac aaagacacca 130141 cataccagaa tctctgggac  
gcattcaaag cagtgtgtag agggaaattt atagcactaa 130201 atgcctacaa gagaaagcag gaaagatcca  
aaattgacac cctaacatca caattaaag 130261 aactagaaaa gcaagagcaa acacattcaa aagctagcag  
aaggcaagaa ataactaaaa 130321 tcagagcaga actgaaggaa atagagacac aaaaaaccct tcaaaaaatc  
aatgaatcca 130381 ggagctgggt tttgaaagg atcaacaaaa ttgatagacc gctagcaaga ctaataaaga 130441  
aaaaaagaga gaagaatcaa atagacacaa taaaaaatga taaaggggat atcaccaccg 130501 atcccacaga  
aatacaaaact accatcagag aatactacaa acacctctac gcaataaac 130561 tagaaaatct agaagaaatg  
gatacattcc tcgacacata cactctcca agactaaacc 130621 aggaagaagt tgaatctctg aatagaccaa  
taacaggctc tgaaattgtg gcaataatca 130681 atagtttacc aacaaaaag agtccaggac cagatggatt  
cacagctgaa ttctaccaga 130741 ggtacaagga ggaactggtc ccattcctc tgaaactatt ccaatcaata  
gaaaaagagg 130801 gaatcctccc taactcattt tatgaggcca gcatcattct gataccaaag ccgggcagag 130861  
acacaaccaa aaaagagaat ttagaccaa tctcctgat gaacattgat gcaaaaatcc 130921 tcaataaaat  
actggcaaac cgaatccagc agcacatcaa aaagcttctc caccatgatc 130981 aagtgggctt catcctggg  
atgcaaggct ggttcaatat acgcaaatca ataaatgtaa 131041 tccagcatat aaacagagcc aaagacaaaa  
accacatgat tatctcaata gatgcagaaa 131101 aagccttga caaaattcaa caaccctca tgctaaaaac  
tctcaataaa ttaggtattg 131161 atgggacgta tttcaaaata ataagagcta tctatgacaa acccacagcc aatatcatac  
131221 tgaatgggca aaaactggaa gcattccctt tgaaaattgg cacaagacag ggatgccctc 131281 tctcaccgct  
cctattcaac atagtgttg aagtctggc cagggaatc aggcaggaga 131341 aggaataaaa gggatttcaa  
ttaggaaaag aggaagtcaa attgtccctg ttgcagacg 131401 acatgattgt ttatctagaa aaccccatcg  
tctcagccca aaatctcctt aagctgataa 131461 gcaacttcag caaagtctca ggatacaaaa tcaatgtaca  
aaaatcacia gcattcttat 131521 acaccaacia cagacaaaca gagagccaaa tcatgagtga actccattc acaattgctt  
131581 caaagagaat aaaataccta ggaatccaac ttacaaggga tgtgaaggac ctctcaagg 131641 agaactacia  
accatgctc aaggaaataa aagaggacac aaacaaatgg aagaacattc 131701 catgctcatg ggtaggaaga  
atcaatatcg tgaaaatggc catactgcc aaggtattt 131761 acagattcaa tgccatcccc atcaagctac  
caatgacttt cttcacagaa ttggaaaaaa 131821 ctactttaaa gttcatatgg aacaaaaaa gagcccgcat  
cgccaagtca atcctaagcc 131881 aaaagaacia agctggaggc atcacactac ctgactcaa actatactac  
aaggctacag 131941 taacaaaaac agcatggtag tggtaacaaa acagagatat agatcaatgg aagagaacag 132001  
agccctcaga aataatgccg catatctaca actatctgat ctttgacaaa cctgagaaaa 132061 acaagcaatg  
gggaaaggat tcctatttta ataatgggtg ctgggaaaac tggtagcca 132121 tatgtagaaa gctgaaactg  
gatcccttcc ttacacctta taaaaaatc aattcaagat 132181 ggattaaaga tttaaactg agacctaaa  
ccataaaaac ctagaagaa aacctaggca 132241 ttaccattca ggacataggc gtgggcaagg acttcatgtc  
caaaacacca aaagcaatgg 132301 caacaaaagc caaaattgac aaatgggagc taattaaact caagagctc  
tgcacagcaa 132361 aagaaactac catcagagtg aacaggcaac ctacaaaatg ggagaaaatt ttcgcaacct 132421  
actcatctga caaagggtta atatccagaa tctacaatga actcaacaa atttacaaga 132481 aaaaaacaaa  
caaccccatc aaaaagtggg cgaaggacat gaacagacac ttctaaaag 132541 aagacattta tgcagccaaa  
aaacacatga agaaatgctc atcatcactg gccatcagag 132601 aaatgcaaat caaaaccact atgagatatc  
atctcacacc agttagaatg gcaatcatta 132661 aaaagtcagg aaacaacagg tgctggagag gatgcggaga  
aataggaaca cttttact 132721 gttgggtggga ctgtaaacta gttcaacat tgtggaagtc agtgtggcga ttctcaggg  
132781 atctagaact agaaatacca ttgaccag ccatccatt actgggtata taccaaaag 132841 actataatc

atgtctgcat aaagacatcat ggcacatgat gtttattgcg gcactattca 132901 caatagcaaa gacttggaaac  
 caacccaaat gtccaacaat gatagactgg attaagaaaa 132961 tgtggcacat atacaccatg gaatactatg  
 cagccataaa aatgatgag ttcatgtcct 133021 ttgtaggggac atggatgaaa ttggaaacca tcattctcag  
 taaactatcg caagaacaaa 133081 aaaccaaaca ccgcatattc tcactcatag gtgggaattg aacaatgaga  
 tcacatggac 133141 acaggaaggg gaatatcaca ctctggggac tgtggtgggg tcaggggagg ggggagggat 133201  
 agcattggga gatataccta atgctagatg acacgttagt ggggtgcagcg caccagcatg 133261 gcacatgtat  
 acatatgtaa ctaacctgca caatgtgcac atgtacccta aaacttagag 133321 tataacaaaa aaataaaaaa  
 ataaaaata aaaaaataat gcatgaatac ccaaaaaaaaa 133381 aaaaaaaaaa aaaaaaaga aggcatttca  
 gcatgcaaac aagtaatact ttaggaatt 133441 aactgactt cattgtaatg cataggaaaa ataaataatt  
 cacaataaa aaacaaacaa 133501 acaaaaaaaaa agtttcagtg ggggtcaaagg atttttagag ttagggcagt  
 cgaggcagt 133561 aactagggtg aaaaaggagg gaagtatga acaacaggta gagtaactga aatgagatt 133621  
 atgggaggta tacaatgta tggaatgaca aagtcagggg tatgacaatg tgagtgatta 133681 gctgaagttg  
 ggcagaggtc taaggaaagg aagtaaagta atttagtgtt caggatattg 133741 gaaggaatct agataaatat  
 taaagcaag aatttctata gtagtatctc gaatagtctt 133801 tggcacattg taggcactct ataatattt gttcaataaa  
 tgaataaacg atattaagta 133861 cataacaatt catctgaaa acactcttc catttctca actcctaac attcattat  
 133921 tcattctca tcacacaaaa atctgaatct ggcttctgcc cctaccctc cttatttact 133981 ttctcaata  
 gtatacatt agtcattaaa caacatata tacatgcata tttcaagat 134041 tatcaagcaa ttctgtttc aactttctt  
 aaaatgtga ctctgtattc gtatacagtt 134101 tataacatcc tgaattcctg aaattgattc aaacagaaac tatgtacagt  
 ttccaattt 134161 aaccacagta gcatgcttat acatcactac ttggagttt ctctcattt tattgtccaa 134221  
 caagaactga aacttatgtt gccgtttgtt aaatgctata tctaaattcc atttgat 134281 ccaatgaaca caggttctat  
 ttttatcaa gtatacataa gcagtaatca ttcatgcaag 134341 tgattccact actctcatag ttcttgtaa gttaatcca  
 gtgaaataag atgacaatag 134401 tggaagaaag gggaattggg aaaatccata aaattcatt ctatcaataa  
 aagaaatcta 134461 cttgtttta tatattgat acatcagcca cttattgaac atgttcgtat cttaaaaatt 134521  
 gttccctt tattgaaatc ctagtggata atggtttgt agtcataat tgggaaaaat 134581 ggtataacta aagaaatg  
 cagaattta gaatgggagt aggcattgaa tattatagac 134641 tcttacggaa tattctggca gtggagcaaa  
 cagtagaaca atcagggtgag attattcatt 134701 gaagatgca tgctaaagt taaagacatg gcttgggcta  
 ggcagaggt tttcttatgc 134761 ccattcatct atgcattcat cttaaatct atccatgat ccacattgc attaatcat  
 134821 ccattccccc atcaacatat attgaaaacc catagtgc catgttagt attagacctg 134881 aggttacaag  
 gatgaataaa atacagtctt cctctcaata attattatat ttgaagtc 134941 cacctaagag ttgggttgga gtaattaca  
 tatagaaaac atttgaggt cttaataaa 135001 tgtatataca tatataattg taaattatat ctatacacat gtatatata  
 ttgtcataa 135061 taatcacaaa gtagaaatct ttgtatagt atttcttta tcagagtgga aaatttcatt 135121  
 aaatcaattt agttcaaac tttatttctc agagaaatat ttgtcattt ttccagta 135181 taagaaatta ttttaaatc  
 aactcaacca gcataacaat ggtaaagcca gttgatgaga 135241 taggtaagtc cctgttaact aaagattatc  
 caaaaaggat cccacagaag aaactctaa 135301 gtattatcca gttggattt cttattttt tcccttagt ttacagaaat  
 gtgctaattg 135361 aggtccttgg aattaaaaat taatgcaaaa ataaataagc caagatagca gtattctca 135421  
 ttctctct tttcaaaca gatacttta actttgctt gaaaaaacc aatagatcta 135481 ataattatt ttaagatga  
 tgtgaaatta tgccatctt atctaatt ccaagttctc 135541 cagtttccct ctcaaatata tcaagactt aagattgaa  
 aatgatctc tggtttaa 135601 ttaagactt tatttatatt aactttttg gtagcatgaa cattgtaaaa cctaaattc  
 135661 aaaatgttt actgcagcaa cttaataact tcatctaaga cactgaatt gtatttgta 135721 ttgttccaa  
 acttgataca ttttcttat taacatctt catagaagta aacagaaaca 135781 gacagcaatt acattacata ctacagagca  
 gcatccattc ataaattaac tcacaaaca 135841 ttataggga tctgctctgc cagacacgtg gtaggtgtg  
 ggaatttta aagaagaata 135901 aggttcaatc tctcttca aagtgtaaa acgttgggga gaaacctcaa atagtcaat  
 135961 gattataaaa taggatgga ggttctctgt gaaaggatga cagtaggaaa atctaacagt 136021 tactggaagg  
 atcaggagct gaggcacct agggagagtg ataaactgaa tctaaaggc 136081 aaagaggaga tgttaggca  
 gagaaatagg gtcagggtc aacctgggtg ttgcaacaa 136141 aaaaccaggg cctccagatt tcagagagaa  
 gagccactcc agagaactga tacacatgt 136201 acttatatgc accatgaact tgatgcacca tgtacgatg  
 acttatgaca agtggccagg 136261 acaacagcg tctgtggaa gtctcaaaa actttagcca agggacagaa  
 acccactac 136321 ccagagtga ttcctagt gagactcct ttgtgtgtg attaaaagga tacaatat 136381  
 aaaaaacaaa catacgaaa caacaacaaa aaacagggtc tcatatgtc tgacatggc 136441 gttgtctt  
 ggagtgtct ttccattgt tcatttaga aactgagact aacagggatg 136501 gtctttgt tccaggagt tgtgtgtc  
 ggaagccaat gtcctgtc tttgaataca 136561 tggcctatgg tgacctaat gattcctc gcagcatgc  
 cctcacacc gtgtgcagc 136621 tcatgcag tgactgtct atgagggtc aggtctccag cctggggcc  
 ccacctct 136681 cctgtgtga gcagcttgc attgccaggc aggtggcagc tggcatggct tacctcag 136741

aacgtaagtt tgtttaccga gatttagcca ccaggaaactg cctgggtgggc gagaacatgg 136801 tgggtgaaat  
tgccgacttt ggcctctcca ggaacatcta ctcagcagac tactacaaag 136861 ctaatgaaaa cgacgctatc  
cctatccgtt ggatgccacc agagtccatt ttttataacc 136921 gctacactac agagtctgat gtgtgggacct  
atggcggtgt cctctgggag atcttctct 136981 atggcctgca gccctactat gggatggccc atgaggaggt  
catttactac gtgcgagatg 137041 gcaacatcct ctctgccct gagaactgcc ccgtggagct gtacaatctc atgcgtctat  
137101 gttggagcaa gctgcctgca gacagacca gtttcaccag tattcaccga attctggaac 137161 gcatgtgtga  
gagggcgag ggaactgtga gtgtctaagg ttgaagacgt tcaaataaaa 137221 tgctgcagtt tcctctcaga  
ctctgtgagc caggggaatc ctacaccaga ggcccaacaa 137281 gaccacata ggaaagagta agagtaaaca  
tgagtagtgt gttgtttgct tcccaggag 137341 agcaaagaca gtgcaaaccc catgtgtag acggacccat  
tgaaagccag tgattggaaa 137401 cacaggctag gaaatgtgtc agataatgga gacaactatt cttctcatg aaggtttgta  
137461 atacactg cacagggaag aatgtcatcc tgttcagtt ccaaagtagc tggtcacaga 137521 gtaaagctct  
gctgtattaa attttaatat gaaatggat tcagagcttc atttttaat 137581 tgagttaatt cctgtccatt gtgaaagtag  
ctaatcgtc atgtaagaca cttaggtgaa 137641 gtacagaaaa ctaaaaagaa ggaaaagcca ctattctgt  
ctcccccaa agacgagtct 137701 tagtgttta ttaaacttt cttgcattta atgcataatt ttatattgt ttgtattctg 137761  
cagagttgtg gttacatttt attgatagag ggtttctaag gaatgaaaca gcaaatcagc 137821 aagcctgtaa  
ctctgagttc cttttctgt cctgtgcccc tcctttttc cttctgtgc 137881 attgtcatg aattaagtct gcttattta  
tcctccagt ttcttgaaa caagttttg 137941 tatcttactg atttacctt tccttataaa attgtattgg tatctttcc  
attgcttaa 138001 tccttattc tccttttc caggactct gccttttt agttattaag ctatttttt 138061 cttttattc  
attcatgtaa taaacactct ggcagaaata ataacattt aaataccatt 138121 gtatattgat atgtatatgc ctttgcaaa  
gtattactat ttttctgca ttgaccttg 138181 aagccacaca ttcaacatt ctacctatt aatattatta ctagagtcta  
ttaaatctc 138241 taaaccata atttataata tgagatttca caagatacac ttgtggctct gagttattc 138301  
aaaactgata tttctgtgca ttctgacatt ttattcttt tagaacaacaa ttcagttggc 138361 ttagaatta atactgtct  
gcttaacaac ttgtgcatg acatattaac tgattttgt 138421 gtattctatg atttaaaaaaaa aaagcagca gctctggaac  
tcagattcct ggggggtcag 138481 atttttctc agtggatcct cacacaatac atcttatct aagtcatac atgatctgag  
138541 tttattctg atagcagg aaccaaatt ctctgaaaa cgaacaggga agagaaaaa 138601 acagtctact  
ctataccagc ttatttaat tcagactaat tggtagttag ggcattggag 138661 gaattgtgtg aattctgaa agtagattt  
cgctgtctgc tggaaaactc tgcctgaaat 138721 cccaaatct gcctcatgta acagcttgac atcttgggtg  
ggaaacctgc catttctat 138781 tcatagtgtc tccaggcaac caagacaaaa atgtagaaat ttcttagac ttgacctct  
138841 ctttcatcat cagttttcta ttagtttac ttctaaaaat cctctgctg acatctctt 138901 ccttcaacc  
caagagccaa tgactcaacc tctaccgtt cccacctgt ctattagctg 138961 gccttctct catttcagac  
ctgaacagat tcttaggat acaacgacag taaggcggtc 139021 cttagtcaca gttctggtc ataatagcg  
aggtcagcat ttaggactga gacctaaaga 139081 agtgcttcag ataaaaatca tgagtctaag tccaaaattg  
atactgtaat ccaaatgact 139141 gaataaagaa taaagttgca gcgtgtgtct aaagcagaaa gtcaagatgc  
caacaaagca 139201 gaaaagttgg agagggccac cagcaagtct agaacttgag catagatct catggcttat 139261  
tttagatggt tcatgtatgc tctgcaaat tcaaagacag ctccgggctt tctccgctga 139321 taaagtttg ttgtaaaaga  
cagacataga agtcaggctg acagaaaata gtagaacgt 139381 aatcataaaa attataatat cagctagcat  
ttattgaaat ctaccatgt gtattctgag 139441 gcctttaaatt atatgaact aaacctcaca acatccctgt aatgttgga  
ctatcattat 139501 atacattta gtttgcttt gtttgttt gttttgaga cggagtctc ctctgtgcc 139561  
caggctggag tgcatggga cgatctggc tctgcaag ctcagcctc aacagtcaca 139621 gagagattgt  
gcaactggcc cgagtgcaca cagcaacaga gcctacttt tgacaaaaag 139681 aggccgaatt ctcaaccat  
atactgtaga gcctctgtac atgtagaag caataactga 139741 acctcagtaa ctctgtggaa gtgatttgta attgcatgt  
cgttcaagc acactctata 139801 tctatattt attctattaa ctcttaagt cttttaatg aatagcaaaa aaagtatt  
139861 tcagcattat caatttaagt taatcataac atctaataag tgacatgtt atttttcat 139921 gagtctaat  
tacatttca agttaagatc actgacttat tcctaagt ctcgatctaa 139981 tgttctgaat cacaggagta tagatgcatt  
attaccaat attgtttact ttttaata 140041 agatttttt tcatggtaga atcatcatat acattcaaaa aggtagacaa  
aagagagaca 140101 ctcagatgt cactgttacc aagtgccagg acagatatca gtaaggcacc agcagtcatt 140161  
tttagtgatc aaatacaaaa catggtaaga taccagagta ttttcatat gacacccaaa 140221 aacatattct ctgctatcgt  
ggtagagcag aaaaagaaca ctttctttc attttacagt 140281 atattacgaa cctgttccac gtcattaaat attctctaa  
aaaccaatt ttggaataat 140341 attctattt attcatatac tgtaatttag ctaatcaatc ttgtatttt gaacatttag 140401  
gtttttcca attttatca ttataaaaaa tgctgtaatt aacatcctta ttgttcatg 140461 tccacattc ttttatgaa  
aattcagaga aaggaaatgt ctggacaaaa tggcatgtac 140521 aatattaaca ctctgttat gtggtttcat attctgcaga  
aatattactg ccactctac 140581 attgtacaag agatctcata gccctaaaca tttgcttca tagataatt tctgtttt  
140641 agaaatctt tgtctcttg gttatagaaa aagagaacct cttttaatt ttattttta 140701 aattactagt

cagggtgaat ggttcttggt cctaggctat taacagtttt tatttggca 140761 attgtctaca gccctctgt ctgctgtgtt  
cattttctaa tcgaattatg ggatttatct 140821 tgtaaaaagc ctattaagcc ttttcatac ttacacaag agatcacatc  
tacttacttt 140881 accttaaaat aacatttact tttttctta taaaagtaat atattatggt tgaaaagaaa 140941  
aataatatgc aataatatac aataatatgt ataatacaca tagacaataa taaaaatgaa 141001 aaaacaccaa  
ccagaggtaa ttaacattaa catcataata ttcttcagg cttttcaga 141061 tagacaggta ggtaagtagg ttgtaggta  
aatagataga tagatgatac atagagagag 141121 atagatagat aatttaaaca aaaataagat catactgcta  
cattacttca agccttgctt 141181 ttactactta atatatctta aacatcttct acatgaacaa gtattcatgt gcaacattaa  
141241 ttttgatggg tgaatagtat tatacagatt tatcgttaatt gacataacta ttctactgtt 141301 agacatttgg  
tttatttcta ttttccatt ataaaatgta atgttggat catcctgttg 141361 ctaaaatttg taagcattta tcttaagtga  
ttcttttagc tataactcct agaagtgaaa 141421 tttctagatt aaaggataaa tgcactttta atacttttta aatatattaa  
aaaattacct 141481 tctgaatta tttattaac atgtacctct cctagtcaga taagacagcc catttatttc 141541  
agtctcacca atactgagta tagcatttta atcattgcc aataatagc taatagctta 141601 aagttatttc atagcttata  
ttacacttc tttaaatact aataaaattg aacattgttt 141661 aatgtttga ggatactga ttggtagatt gcctctact  
attattttc tactgggtat 141721 atcttttct tgttgcttg taagagcact ttatatatta aggagttaa tttgtgata 141781  
tatgtttcaa ctactttat catgttaaaa atagactt ctattgtct tttattgtag 141841 gtttatcaa tcagaaaaga  
atgtgactt ttccgtccat tcagatgatt gtggctttt 141901 tccaatgg attgttaat atgttcaatt gtagaattt  
atttctaat gtagcgatat 141961 cctgtcttc taggaataaa cttttgggc gaatcatatc aatcttctac ttaactacca  
142021 aattaattta catatattg catcaatatt aagttcataa aattaaagt ttatcattt 142081 catctctgtt  
agagtttgt attggcatta gcatttgat tagcattgta ttaggaaaaa 142141 ctaggagtt tttctata atcttggtta  
gttattttt aaataattgt tattatgaa 142201 agtaatacat aaaaatgttg tttaaaaaa ctacaagag ggtaaaaatt  
aaaaaataa 142261 taaaagtcc ctcttctt tcatctcta gtcccagct aagtgtaac cacttcccc 142321  
atttatgtg ttagtcttc tggtagtac cagtgcatt ctaacaaata ggttgcatt 142381 tcttttctg aattgatcaa  
tttttaaaa atatgcagca ctctgactca aactccctt 142441 cttttctg agatatgta acttcaatg ttattgtt  
tatcacaact ttcacaaata 142501 ttttaataa aaggtacct actgattctg gattgtgcta cataaatta gagcttcaa  
142561 atttccctc atacttctc cctgctctc actctcaca tcagtcaact atacacctat 142621 ttctacgtg  
tcaactatat gttcatttct atgaatctgt aatattgca tttgttctg 142681 gaacaaatta agatttaggt gcttgacta  
gattgattct aaacatcaaa aaacaaaaat 142741 aaaatatctg caattatgtg atcatgtatt tatgcattgc caaataatgg  
tattccatta 142801 tttaatttg ataagataaa ttaataatc attaatctt atttctcta tttatggaa 142861 gaaatattt  
taaaaatcac aaaacttta cattcgctc tcttctgat atttattt 142921 ctttttct ctgcctctc tcttctgctg  
cctttttcc gaaaattatt ttgatgatt 142981 ttttattca ccatacataa ttacaaatga agattgctc tggctcgat  
tggtagtaga 143041 agtggggctc cttgctgtt ttgttggtat attcaccag tgtgacctt ttccgtggg 143101  
atggctacct ctgggctctg attatgtggc tcataggga gtataggcag cctgagtcag 143161 aatccccaca  
gttccaaagt gatggaagac tgtactctga gatacaatat ttgacgtat 143221 ttactccca gggagagcta ctgctattc  
tttactgct tccattacc aaaagagtat 143281 gatattctc cattttctg tattgctca cacctaggac cttcaaacc  
cacaccaacg 143341 acctctcagg caaattgat tattcagata gcagtttaca gggatagaca tgaggcctt 143401  
tggccacct gctctataca caatctcta gtcgaccat ctgattgaca acccacagcc 143461 caccctgct  
tctgtatttg ctgactcaga gcatggagac ttatatactg tgaaatcaca 143521 tctccctc cctcacgctt ggcttgtgtg  
tattgcaaaa gctgcaatt agttttct 143581 gtgcctgtc ttaccatgg ataagaacac taagatact tccgctttt  
gaatatttgt 143641 caaagtgatg gcacttgat ttgttcagc atgtacatag attgattct attcatatac 143701  
attactgtc atattgggga aatcttgagg ggaaaagaaa agcctctac taccatgtt 143761 atcaagagtc  
ctctctggaa tagttgaat agtttaggag ttatcggtc actcctctg 143821 ctgtttgcc tccagattc ttttctt  
ctttctgt ttctaatgt tggaacagcc 143881 cacactcaa tcttgatg acatctcct tttatctga ttatcccta  
gtgatctt 143941 ctggtgcaa ggctataat gccatctgta tgctgagatt ttttattt tagttcaaac 144001  
ctctctccc aactttacac tcacatttct aactgtgtgt tatagatgat agcttagat 144061 tctctctc aggactaggc  
tttctgctg atctaggagc aaagctgaaa actgctatg 144121 agcttggtgt tgcctgata ccgaggagga  
gtctcagagc ctctccagt caaatacaca 144181 ctgcagtgt ctagtgctg ctgacttac tactattct  
aaagagggta gattgatcc 144241 atttaatat ctctcaatc cctgcccac tccattaca gctggcagaa attccccagc  
144301 tgcaaatggg ttgatttat ctgttacca ttctgattt gcagcacgat tgactgttc 144361 cttttctgcg  
tggctatgt gtcactccat gagaatctgg gagaggagaa ctgatatgg 144421 tgctattcc atattttaa ccatagtgt  
ctttattgt aagaggtatc ccggttagag 144481 tggagtcaaa gctttatagc aagtgtatt caggttaact tttttact  
tgttcagat 144541 ctattcagt agcacagcca ccaagataga acactataa gccctattt tggtagat 144601  
caccagagaa accactcacc actcgactt ggcctcagt actgagcat tacatattg 144661 aaggtcagaa  
actacatcaa caggaaagac ccatagggtt gggggtctga tatattgcc 144721 agtacattc ttatcattc



aaacaaagat ttatgtgtgt ttagatgt hu6-75; SEQ ID NO: 78 G\*G\*T A\*A\*G\*G \*G\*T\*G  
\*G\*T\*C \*T\*T\*T \*T\*A\*G \*A\*A\*A \*T\*G\*C \*A\* represents a phosphorothioate  
linkage, and each sugar of the oligonucleotides is a 2' -MOE modified sugar. hu6-  
69; SEQ ID NO: 79 G\*G\*T \*C\*A\*A \*G\*C\*T \*A\*G\*G \*G\*T\*G \*G\*T\*C \*T\*T\*T  
\*T\*A\*G \*A hu6-58; SEQ ID NO: 80 C\*T\*G \*C\*A\*G \*G\*A\*A \*A\*T\*G \*G\*T\*C  
\*A\*A\*G \*C\*T\*A \*G\*G\*G \*T hu6-39; SEQ ID NO: 81 G\*A\*A \*G\*T\*G \*G\*T\*G  
\*A\*G\*T \*G\*A\*C \*G\*C\*T \*C\*C\*T \*G\*C\*A \*G hu6-27; SEQ ID NO: 82 G\*T\*T  
\*A\*G\*G \*A\*A\*G \*A\*C\*A \*G\*A\*A \*G\*T\*G \*G\*T\*G \*A\*G\*T \*G hu6-12; SEQ ID  
NO: 83 A\*T\*C \*C\*T\*G \*G\*C\*A \*A\*A\*A \*A\*C\*T \*G\*T\*T \*A\*G\*G \*A\*A\*G \*A  
hu610; SEQ ID NO: 84 G\*T\*G \*G\*G\*A \*T\*T\*C \*A\*G\*G \*A\*G\*C \*C\*C\*G  
\*C\*A\*G \*G\*A\*T \*C hu619; SEQ ID NO: 85 G\*G\*T \*G\*A\*C \*A\*T\*T \*G\*T\*G  
\*G\*G\*A \*T\*T\*C \*A\*G\*G \*A\*G\*C \*C hu628; SEQ ID NO: 86 G\*G\*A \*G\*C\*C  
\*A\*A\*A \*G\*G\*T \*G\*A\*C \*A\*T\*T \*G\*T\*G \*G\*G\*A \*T hu637; SEQ ID NO: 87  
G\*G\*T \*C\*A\*C \*A\*A\*A \*G\*G\*A \*G\*C\*C \*A\*A\*A \*G\*G\*T \*G\*A\*C \*A hu646;  
SEQ ID NO: 88 A\*C\*A \*G\*T\*G \*C\*A\*G \*G\*G\*T \*C\*A\*C \*A\*A\*A \*G\*G\*A  
\*G\*C\*C \*A hu656; SEQ ID NO: 89 C\*T\*G \*T\*T\*G \*C\*T\*G \*T\*A\*C \*A\*G\*T  
\*G\*C\*A \*G\*G\*G \*T\*C\*A \*C hu669; SEQ ID NO: 90 G\*G\*G \*A\*C\*A \*G\*G\*A  
\*A\*T\*G \*C\*C\*T \*G\*T\*T \*G\*C\*T \*G\*T\*A \*C hu681; SEQ ID NO: 91 C\*A\*G  
\*G\*T\*G \*A\*T\*G \*G\*T\*G \*G\*G\*G \*A\*C\*A \*G\*G\*A \*A\*T\*G \*C hu693; SEQ ID  
NO: 92 C\*C\*G \*T\*T\*T \*T\*C\*A \*A\*T\*C \*C\*A\*G \*G\*T\*G \*A\*T\*G \*G\*T\*G \*G  
hu6110; SEQ ID NO: 93 T\*G\*A \*C\*A\*C \*T\*C\*A \*C\*A\*G \*C\*A\*T \*T\*T\*C  
\*C\*G\*T \*T\*T\*T \*C hu6125; SEQ ID NO: 94 A\*A\*G \*T\*C\*C \*C\*C\*A \*C\*A\*C  
\*A\*C\*A \*T\*G\*A \*C\*A\*C \*T\*C\*A \*C hu6139; SEQ ID NO: 95 G\*G\*T \*C\*T\*T  
\*C\*C\*C \*C\*A\*G \*A\*C\*A \*A\*G\*T \*C\*C\*C \*C\*A\*C \*A hu7-75; SEQ ID NO: 96  
A\*C\*T \*A\*T\*G \*T\*C\*A \*G\*T\*A \*G\*A\*T \*T\*T\*G \*A\*A\*G \*G\*G\*A \*A hu7-66;  
SEQ ID NO: 97 T\*C\*C \*C\*A\*C \*T\*A\*T \*A\*C\*T \*A\*T\*G \*T\*C\*A \*G\*T\*A  
\*G\*A\*T \*T hu7-53; SEQ ID NO: 98 T\*C\*A \*G\*T\*C \*A\*A\*G \*G\*A\*T \*T\*T\*C  
\*C\*C\*A \*C\*T\*A \*T\*A\*C \*T hu7-45; SEQ ID NO: 99 A\*A\*A \*A\*G\*A \*A\*C\*T  
\*C\*A\*G \*T\*C\*A \*A\*G\*G \*A\*T\*T \*T\*C\*C \*C hu7-33; SEQ ID NO: 100 G\*T\*A  
\*A\*A\*G \*G\*A\*A \*A\*A\*T \*A\*A\*A \*A\*G\*A \*A\*C\*T \*C\*A\*G \*T hu7-22; SEQ ID  
NO: 101 A\*A\*C \*C\*T\*G \*A\*C\*A \*G\*A\*G \*T\*A\*A \*A\*G\*G \*A\*A\*A \*A\*T\*A \*A  
hu7-10; SEQ ID NO: 102 G\*G\*A \*C\*C\*C \*A\*G\*A \*A\*G\*A \*A\*A\*C \*C\*T\*G  
\*A\*C\*A \*G\*A\*G \*T hu73; SEQ ID NO: 103 C\*A\*C \*T\*C\*T \*C\*T\*T \*G\*A\*A  
\*T\*G\*G \*A\*C\*C \*C\*A\*G \*A\*A\*G \*A hu717; SEQ ID NO: 104 C\*A\*C \*T\*C\*G  
\*G\*T\*C \*T\*T\*T \*C\*A\*C \*A\*C\*T \*C\*T\*C \*T\*T\*G \*A hu730; SEQ ID NO: 105  
G\*T\*C \*T\*T\*G \*A\*G\*T \*C\*A\*A \*T\*C\*A \*C\*T\*C \*G\*G\*T \*C\*T\*T \*T hu744;  
SEQ ID NO: 106 G\*A\*T \*A\*A\*A \*C\*A\*G \*C\*T\*G \*C\*A\*G \*T\*C\*T \*T\*G\*A  
\*G\*T\*C \*A hu758; SEQ ID NO: 107 A\*G\*T \*C\*C\*T \*G\*G\*C \*T\*T\*G \*G\*T\*G  
\*A\*T\*A \*A\*A\*C \*A\*G\*C \*T hu766; SEQ ID NO: 108 A\*T\*G \*T\*G\*T \*A\*G\*A  
\*G\*T\*C \*C\*T\*G \*G\*C\*T \*T\*G\*G \*T\*G\*A \*T hu776; SEQ ID NO: 109 G\*T\*A  
\*G\*C\*T \*A\*T\*G \*C\*A\*T \*G\*T\*G \*T\*A\*G \*A\*G\*T \*C\*C\*T \*G hu785; SEQ ID  
NO: 110 T\*G\*C \*T\*T\*A \*T\*T\*G \*G\*T\*A \*G\*C\*T \*A\*T\*G \*C\*A\*T \*G\*T\*G \*T  
hu796; SEQ ID NO: 111 A\*C\*T \*T\*C\*T \*C\*C\*C \*C\*A\*T \*G\*C\*T \*T\*A\*T  
\*T\*G\*G \*T\*A\*G \*C hu7111; SEQ ID NO: 112 C\*C\*T \*T\*G\*G \*C\*A\*G \*T\*A\*C  
\*T\*G\*A \*A\*C\*T \*T\*C\*T \*C\*C\*C \*C hu7136; SEQ ID NO: 113 C\*C\*T \*G\*C\*T  
\*A\*T\*G \*C\*T\*G \*A\*T\*G \*G\*T\*G \*G\*C\*T \*G\*C\*A \*G hu7146; SEQ ID NO: 114  
G\*G\*G \*C\*A\*T \*C\*C\*T \*A\*C\*C \*T\*G\*C \*T\*A\*T \*G\*C\*T \*G\*A\*T \*G hu7158;  
SEQ ID NO: 115 G\*C\*A \*A\*A\*T \*G\*T\*G \*A\*A\*G \*G\*G\*G \*C\*A\*T \*C\*C\*T  
\*A\*C\*C \*T MuSK HUMAN\_Ig3\_Domain (SEQ ID NO: 116)  
ARILRAPESHNVTFGSFVTLHCTATGIPVPTITWIENGNAVSSGSIQESVKDRVIDSRLQLFITKPGLYTCIAT  
NKHGEKFSTAKAAATIS MuSK MOUSE Ig3 Domain (SEQ ID NO: 117)  
ARILRAPESHNVTFGSFVTLRCTAIGIPVPTISWIENGNAVSSGSIQESVKDRVIDSRLQLFITKPGLYTCIAT  
NKHGEKEFTAKAAATVS MuSK 34 (spanning the exon/exon junction 3-4) Forward

CCTGCAAGTGAAGATGAAAGCTTAAA (SEQ ID NO: 118) MuSK 34 (spanning the exon/exon junction 3-4) Reverse ATGAATCCTCAAGCTCCCAGA (SEQ ID NO: 119) MuSK 67 (spanning the exon/exon junction 6-7) Forward GGCTCCTGAATCCCACAATG (SEQ ID NO: 120) MuSK 67 (spanning the exon/exon junction 6-7) Reverse GAATGGACCCAGAAGAAACAGCA (SEQ ID NO: 121) GAPDH (HKG) Forward CCTCAACGACCACTTTGTCA (SEQ ID NO: 122) GAPDH (HKG) Reverse TTACTCCTTGGAGGCCATGT (SEQ ID NO: 123) YWHAZ (HKG) Forward CGAAGCTGAAGCAGGAGAAG (SEQ ID NO: 124) YWHAZ (HKG) Reverse TTTGTGGGACAGCATGGATG (SEQ ID NO: 125) Region 1 - MuSK Exon 7 ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGACTCAAGAC (SEQ ID NO: 126) Oligonucleotide Bld51 (SEQ ID NO: 127) TTGAATGGACCCAGAAGAAA Oligonucleotide Bld52 (SEQ ID NO: 128) CTTGAATGGACCCAGAAGAA Oligonucleotide Bld53 (SEQ ID NO: 129) TCTTGAATGGACCCAGAAGA Oligonucleotide Bld54 (SEQ ID NO: 130) CTCTTGAATGGACCCAGAAG Oligonucleotide Bld55 (SEQ ID NO: 131) TCTCTTGAATGGACCCAGAA Oligonucleotide Bld56 (SEQ ID NO: 132) CTCTCTTGAATGGACCCAGA Oligonucleotide Bld57 (SEQ ID NO: 133) ACTCTCTTGAATGGACCCAG Oligonucleotide Bld58 (SEQ ID NO: 134) CACTCTCTTGAATGGACCCA Oligonucleotide Bld59 (SEQ ID NO: 135) AACTCTCTTGAATGGACCC Oligonucleotide Bld60 (SEQ ID NO: 136) CACTCTCTTGAATGGACC Oligonucleotide Bld61 (SEQ ID NO: 137) TCACACTCTCTTGAATGGAC Oligonucleotide Bld62 (SEQ ID NO: 138) TTCACACTCTCTTGAATGGA Oligonucleotide Bld63 (SEQ ID NO: 139) TTTCACACTCTCTTGAATGG Oligonucleotide Bld64 (SEQ ID NO: 140) CTTTCACACTCTCTTGAATG Oligonucleotide Bld65 (SEQ ID NO: 141) TCTTTCACACTCTCTTGAAT Oligonucleotide Bld66 (SEQ ID NO: 142) GTCTTTCACACTCTCTTGAA Bld51; SEQ ID NO: 143 T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A Bld52; SEQ ID NO: 144 C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A Bld53; SEQ ID NO: 145 T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A Bld54; SEQ ID NO: 146 C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G Bld55; SEQ ID NO: 147 T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A Bld56; SEQ ID NO: 148 C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A Bld57; SEQ ID NO: 149 A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G Bld58; SEQ ID NO: 150 C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A Bld59; SEQ ID NO: 151 A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C Bld60; SEQ ID NO: 152 C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C Bld61; SEQ ID NO: 153 T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C Bld62; SEQ ID NO: 154 T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A Bld63; SEQ ID NO: 155 T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G Bld64; SEQ ID NO: 156 C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C&T\*T\*G\*A\*A\*T\*G Bld65; SEQ ID NO: 157 T\*C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T Bld66; SEQ ID NO: 158 G\*T\*C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A Oligonucleotide Bld25-1 (SEQ ID NO: 159) CCAGAAGAAACCTGACAGAGTAAAG Oligonucleotide Bld25-2 (SEQ ID NO: 160) ACCCAGAAGAAACCTGACAGAGTAA Oligonucleotide Bld25-3 (SEQ ID NO: 161) ATGGACCCAGAAGAAACCTGACAGA Oligonucleotide Bld25-4 (SEQ ID NO: 162) GAATGGACCCAGAAGAAACCTGACA Oligonucleotide Bld25-5 (SEQ ID NO: 163) CTTGAATGGACCCAGAAGAAACCTG Oligonucleotide Bld26-1 (SEQ ID NO: 164) CTCTTGAATGGACCCAGAAGAAACC Oligonucleotide Bld26-2 (SEQ ID NO: 165) CTCTCTTGAATGGACCCAGAAGAAA Oligonucleotide Bld26-3 (SEQ ID NO: 166) CACTCTCTTGAATGGACCCAGAA Oligonucleotide Bld26-4 (SEQ ID NO: 167) TTCACACTCTCTTGAATGGACCCAG Bld25-1; SEQ ID NO: 168 C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T\*A\*A\*A\*G\* Bld25-2; SEQ ID NO:

[illegible]

NO: 226 ATTC AAGAGAGTGTGAAAGA SEQ ID NO: 227 TTCAAGAGAGTGTGAAAGAC  
 SEQ ID NO: 228 CTTTACTCTGTCAGGTTTCTTCTGG SEQ ID NO: 229  
 TTTACTCTGTCAGGTTTCTTCTGGGT SEQ ID NO: 230 TCTGTCAGGTTTCTTCTGGGTCCAT  
 SEQ ID NO: 231 TGTCAGGTTTCTTCTGGGTCCATT SEQ ID NO: 232  
 CAGGTTTCTTCTGGGTCCATTCAAG SEQ ID NO: 233  
 GGTTTCTTCTGGGTCCATTCAAGAG SEQ ID NO: 234  
 TTTCTTCTGGGTCCATTCAAGAGAG SEQ ID NO: 235  
 TTCTGGGTCCATTCAAGAGAGTGTG SEQ ID NO: 236  
 CTGGGTCCATTCAAGAGAGTGTGAA SEQ ID NO: 237 ACTCTGTCAGGTTTCTTCTGGGT  
 SEQ ID NO: 238 ACTCTGTCAGGTTTCTTCTGG SEQ ID NO: 239  
 TCTGTCAGGTTTCTTCTGGGTCC SEQ ID NO: 240 TCTGTCAGGTTTCTTCTGGGT SEQ  
 ID NO: 241 TGTCAGGTTTCTTCTGGGTCC SEQ ID NO: 242  
 TCAGGTTTCTTCTGGGTCCATT SEQ ID NO: 243 TCAGGTTTCTTCTGGGTCCAT SEQ  
 ID NO: 244 AGGTTTCTTCTGGGTCCATTCAA SEQ ID NO: 245  
 AGGTTTCTTCTGGGTCCATT SEQ ID NO: 246 GTTTCTTCTGGGTCCATTCAA SEQ ID  
 NO: 247 TTTCTTCTGGGTCCATTCAAGAG SEQ ID NO: 248  
 TTTCTTCTGGGTCCATTCAAG SEQ ID NO: 249 TCTTCTGGGTCCATTCAAGAGAG SEQ  
 ID NO: 250 TTCTGGGTCCATTCAAGAGAG SEQ ID NO: 251  
 TCTTCTGGGTCCATTCAAGAG SEQ ID NO: 252 TTCTGGGTCCATTCAAGAGAGTG SEQ  
 ID NO: 253 CTGGGTCCATTCAAGAGAGTG

## EQUIVALENTS

[0602] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above Description, but rather is as set forth in the following claims:

## Claims

1. An oligonucleotide composition, comprising plurality of oligonucleotides: the oligonucleotide composition being characterized in that, when it is contacted with a MuSK transcript in a transcript splicing system, relative amounts of transcripts that do not include Ig3 domain-encoding sequences are decreased as compared with such relative amounts observed under reference conditions selected from the group consisting of absence of the composition, presence of a reference composition, and combinations thereof; wherein the oligonucleotides mediate skipping of exon 6 and/or exon 7 of a MuSK gene and MuSK splicing is altered in that level of MuSK transcripts including exons 6 and 7 is decreased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is decreased, or both; and wherein the base sequence of the oligonucleotides comprise a sequence having no more than 5 mismatches from a 18-25 base long portion of the MuSK gene or its complement.
2. (canceled)
3. The composition of claim 1, wherein the exon skipping lowers levels of mRNAs encoding MuSK protein form that participate in BMP signaling compared with levels observed absent the exon skipping.
- 4-15. (canceled)
16. The composition of claim 1, wherein MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 remains substantially unchanged and level of MuSK transcripts including exons 6 and 7 is decreased.
17. (canceled)
18. The composition of claim 1, wherein MuSK splicing is altered in that total level of MuSK transcripts remained substantially unchanged and level of MuSK transcripts including exons 6 and 7 is decreased.
- 19-23. (canceled)
24. The composition of claim 1, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60%, greater than 70%, greater than 80%, or greater than 90% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and

4, or both, decreases by less than 40%, less than 30%, less than 20%, or less than 10%.

**25-31.** (canceled)

**32.** The composition of claim 1, wherein the oligonucleotides target a region on the MuSK genomic sequence corresponding to positions 83776-83800 and/or 83854-83878 of SEQ ID NO: 77.

**33.** The composition of claim 1, wherein the oligonucleotides target a region on the MuSK genomic sequence within or comprising at least a portion of sequence

ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGA  
CTCAAGAC (region 1, SEQ ID: 126).

**34-36.** (canceled)

**37.** The composition of claim 1, wherein the oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126.

**38.** The composition of claim 1, wherein the oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 19 21-25 consecutive bases of region 1, SEQ ID: 126.

**39-49.** (canceled)

**50.** The composition of claim 1, wherein the oligonucleotides target a region on the MUSK genomic sequence within or comprising at least a portion of sequence

GGGGAGAAGTTCAGTACTGCCAAGGCTGCAGCCACCATCAGCATAGCAGGTAGGAT  
GCCCCCTTCACATTTG (region 2, SEQ ID 211).

**51-53.** (canceled)

**54.** The composition of claim 1, wherein the oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 2, SEQ ID: 211.

**55-97.** (canceled)

**98.** The composition of claim 1, wherein the base sequence of the oligonucleotide comprises from 5' to 3':

TABLE-US-00021 SEQ Oligo ID ID 5' to 3' Sequence 1 Bld1

GCTAGGGTGGTCTTTTAGAAATGCA 2 Bld2 GGTCAAGCTAGGGTGGTCTTTTAGA 3 Bld3  
CTGCAGGAAATGGTCAAGCTAGGGT 4 Bld4 GAAGTGGTGAGTGACGCTCCTGCAG 5 Bld5  
GTTAGGAAGACAGAAGTGGTGAGTG 6 Bld6 ATCCTGGCAAAAAGTGTAGGAAGA 7 Bld7  
GTGGGATTCAGGAGCCCGCAGGATC 8 Bld8 GGTGACATTGTGGGATTCAGGAGCC 9 Bld9  
GGAGCCAAAGGTGACATTGTGGGAT 10 Bld10 GGTCACAAAGGAGCCAAAGGTGACA 11 Bld11  
ACAGTGCAGGGTCACAAAGGAGCCA 12 Bld12 CTGTTGCTGTACAGTGCAGGGTCAC 13 Bld13  
GGGACAGGAATGCCTGTTGCTGTAC 14 Bld14 CAGGTGATGGTGGGGACAGGAATGC 15 Bld15  
CCGTTTTCAATCCAGGTGATGGTGG 16 Bld16 TGACACTCACAGCATTTCCGTTTTTC 17 Bld17  
AAGTCCCCACACACATGACACTCAC 18 Bld18 GGTCTTCCCCAGACAAGTCCCCACA 19 Bld19  
ACTATGTCAGTAGATTTGAAGGGAA 20 Bld20 TCCCACTATACTATGTCAGTAGATT 21 Bld21  
TCAGTCAAGGATTTCCCACTATACT 22 Bld22 AAAAGAACTCAGTCAAGGATTTCCC 23 Bld23  
GTAAAGGAAAATAAAAGAACTCAGT 24 Bld24 AACCTGACAGAGTAAAGGAAAATAA 25 Bld25  
GGACCCAGAAGAAACCTGACAGAGT 26 Bld26 CACTCTCTTGAATGGACCCAGAAGA 27 Bld27  
CACTCGGTCTTTCACACTCTCTTGA 28 Bld28 GTCTTGAGTCAATCACTCGGTCTTT 29 Bld29  
GATAAACAGCTGCAGTCTTGAGTCA 30 Bld30 AGTCCTGGCTTGGTGATAAACAGCT 31 Bld31  
ATGTGTAGAGTCCTGGCTTGGTGAT 32 Bld32 GTAGCTATGCATGTGTAGAGTCCTG 33 Bld33  
TGCTTATTGGTAGCTATGCATGTGT 34 Bld34 ACTTCTCCCCATGCTTATTGGTAGC 35 Bld35  
CCTTGGCAGTACTGAACTTCTCCCC 36 Bld36 CTGCTATGCTGATGGTGGCTGCAG 37 Bld37  
GGGCATCCTACCTGCTATGCTGATG 38 Bld38 GCAAATGTGAAGGGGCATCCTACCT 127 Bld51  
TTGAATGGACCCAGAAGAAA 128 Bld52 CTTGAATGGACCCAGAAGAA 129 Bld53  
TCTTGAATGGACCCAGAAGA 130 Bld54 CTCTTGAATGGACCCAGAAG 131 Bld55  
TCTCTTGAATGGACCCAGA 132 Bld56 CTCTCTTGAATGGACCCAGA 133 Bld57  
ACTCTCTTGAATGGACCCAG 134 Bld58 CACTCTCTTGAATGGACCCA 135 Bld59  
ACACTCTCTTGAATGGACCC 136 Bld60 CACACTCTCTTGAATGGACC 137 Bld61  
TCACACTCTCTTGAATGGAC 138 Bld62 TTCACACTCTCTTGAATGGA 139 Bld63  
TTTCACACTCTCTTGAATGG 140 Bld64 CTTTCACACTCTCTTGAATG 141 Bld65  
TCTTTCACACTCTCTTGAAT 142 Bld66 GTCTTTCACACTCTCTTGA 159 Bld25-1

CCAGAAGAAACCTGACAGAGTAAAG 160 Bld25-2 ACCCAGAAGAAACCTGACAGAGTAA 161  
Bld25-3 ATGGACCCAGAAGAAACCTGACAGA 162 Bld25-4  
GAATGGACCCAGAAGAAACCTGACA 163 Bld25-5 CTTGAATGGACCCAGAAGAAACCTG 164  
Bld26-1 CTCTTGAATGGACCCAGAAGAAACC 165 Bld26-2  
CTCTCTTGAATGGACCCAGAAGAAA 166 Bld26-3 CACACTCTCTTGAATGGACCCAGAA 167  
Bld26-4 TTCACACTCTCTTGAATGGACCCAG 177 Bld25-A ACCCAGAAGAAACCTGACAGAGT  
178 Bld25-B CCAGAAGAAACCTGACAGAGT 179 Bld25-C GGACCCAGAAGAAACCTGACAGA  
180 Bld25-D ACCCAGAAGAAACCTGACAGA 181 Bld25-E GGACCCAGAAGAAACCTGACA 182  
Bld25-5-A GAATGGACCCAGAAGAAACCTGA 183 Bld25-5-B ATGGACCCAGAAGAAACCTGA  
184 Bld25-5-C TTGAATGGACCCAGAAGAAACCT 185 Bld25-5-D  
GAATGGACCCAGAAGAAACCT 186 Bld25-5-E TTGAATGGACCCAGAAGAAAC 187 Bld26-2-A  
CTCTTGAATGGACCCAGAAGAAA 188 Bld26-2-B CTTGAATGGACCCAGAAGAAA 189 Bld26-2-  
C CTCTCTTGAATGGACCCAGAAGA 190 Bld26-2-D CTCTCTTGAATGGACCCAGAA 191 Bld26-B  
CTCTTGAATGGACCCAGAAGA 192 Bld26-C CACTCTCTTGAATGGACCCAGAA, or 193 Bld26-  
D CACTCTCTTGAATGGACCCAG.

**99.** The composition of claim 1, wherein the oligonucleotide is complementary to a nucleotide sequence that is at least 90% identical to any one of SEQ ID NOs: 39-76 and 212-253.

**100.** The composition of claim 98, wherein the oligonucleotides comprise one or more types of base modifications, sugar modification, and internucleotidic linkage modifications.

**101-102.** (canceled)

**103.** The composition of claim 100, wherein the internucleotidic linkages of the oligonucleotide comprise natural phosphate, phosphorothioate, or phosphodithioate linkages.

**104.** The composition of claim 103, wherein each internucleotidic linkage of the oligonucleotide is a phosphorothioate linkage.

**105-108.** (canceled)

**109.** The composition of claim 100, wherein the oligonucleotides comprise one or more sugar modifications.

**110.** The composition of claim **105**, wherein the sugar modification is moiety has a 2'-modification.

**111-112.** (canceled)

**113.** The composition of claim 110, wherein the 2'-modification is 2'-MOE.

**114-118.** (canceled)

**119.** The composition of claim 113, wherein each sugar of the oligonucleotide is a 2'-MOE modified sugar.

**120-124.** (canceled)

**125.** The composition of claim 1, wherein the oligonucleotide has the structure from 5' to 3' of: TABLE-US-00022 Oligo SEQ ID NO: 5' to 3' Sequence Bld1 78

G\*C\*T\*A\*G\*G\*G\*T\*G\*G\*T\*C\*T\*T\*T\*T\*A\*G\*A\*A\*A\*T\*G\*C\*A Bld2 79  
G\*G\*T\*C\*A\*A\*G\*C\*T\*A\*G\*G\*G\*T\*G\*G\*T\*C\*T\*T\*T\*T\*A\*G\*A Bld3 80  
C\*T\*G\*C\*A\*G\*G\*A\*A\*A\*T\*G\*G\*T\*C\*A\*A\*G\*C\*T\*A\*G\*G\*G\*T Bld4 81  
G\*A\*A\*G\*T\*G\*G\*T\*G\*A\*G\*T\*G\*A\*C\*G\*C\*T\*C\*C\*T\*G\*C\*A\*G Bld5 82  
G\*T\*T\*A\*G\*G\*A\*A\*G\*A\*C\*A\*G\*A\*A\*G\*T\*G\*G\*T\*G\*A\*G\*T\*G Bld6 83  
A\*T\*C\*C\*T\*G\*G\*C\*A\*A\*A\*A\*A\*A\*C\*T\*G\*T\*T\*A\*G\*G\*A\*A\*G\*A Bld7 84  
G\*T\*G\*G\*G\*A\*T\*T\*C\*A\*G\*G\*A\*G\*C\*C\*C\*G\*C\*A\*G\*G\*A\*T\*C Bld8 85  
G\*G\*T\*G\*A\*C\*A\*T\*T\*G\*T\*G\*G\*G\*A\*T\*T\*C\*A\*G\*G\*A\*G\*C\*C Bld9 86  
G\*G\*A\*G\*C\*C\*A\*A\*A\*G\*G\*T\*G\*A\*C\*A\*T\*T\*G\*T\*G\*G\*G\*A\*T Bld10 87  
G\*G\*T\*C\*A\*C\*A\*A\*A\*G\*G\*A\*G\*C\*C\*A\*A\*A\*G\*G\*T\*G\*A\*C\*A Bld11 88  
A\*C\*A\*G\*T\*G\*C\*A\*G\*G\*G\*T\*C\*A\*C\*A\*A\*A\*G\*G\*A\*G\*C\*C\*A Bld12 89  
C\*T\*G\*T\*T\*G\*C\*T\*G\*T\*A\*C\*A\*G\*T\*G\*C\*A\*G\*G\*G\*T\*C\*A\*C Bld13 90  
G\*G\*G\*A\*C\*A\*G\*G\*A\*A\*T\*G\*C\*C\*T\*G\*T\*T\*G\*C\*T\*G\*T\*A\*C Bld14 91  
C\*A\*G\*G\*T\*G\*A\*T\*G\*G\*T\*G\*G\*G\*G\*A\*C\*A\*G\*G\*A\*A\*T\*G\*C Bld15 92  
C\*C\*G\*T\*T\*T\*T\*C\*A\*A\*T\*C\*C\*A\*G\*G\*T\*G\*A\*T\*G\*G\*T\*G\*G Bld16 93  
T\*G\*A\*C\*A\*C\*T\*C\*A\*A\*C\*A\*G\*C\*A\*T\*T\*T\*C\*C\*G\*T\*T\*T\*T\*C Bld17 94  
A\*A\*G\*T\*C\*C\*C\*A\*C\*A\*A\*C\*A\*A\*T\*G\*A\*C\*A\*C\*T\*C\*A\*C Bld18 95  
G\*G\*T\*C\*T\*T\*C\*C\*C\*A\*G\*A\*C\*A\*A\*G\*T\*C\*C\*C\*A\*C\*A Bld19 96

A\*C\*T\*A\*T\*G\*T\*A\*T\*G\*T\*A\*G\*T\*T\*T\*G\*A\*A\*G\*G\*A\*A\*Bld20 97  
T\*C\*C\*C\*A\*C\*T\*A\*T\*A\*C\*T\*A\*T\*G\*T\*C\*A\*G\*T\*A\*G\*A\*T\*T Bld21 98  
T\*C\*A\*G\*T\*C\*A\*A\*G\*G\*A\*T\*T\*T\*C\*C\*C\*A\*C\*T\*A\*T\*A\*C\*T Bld22 99  
A\*A\*A\*A\*G\*A\*A\*C\*T\*C\*A\*G\*T\*C\*A\*A\*G\*G\*A\*T\*T\*T\*C\*C\*C Bld23 100  
G\*T\*A\*A\*A\*G\*G\*A\*A\*A\*A\*T\*A\*A\*A\*A\*G\*A\*A\*C\*T\*C\*A\*G\*T Bld24 101  
A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T\*A\*A\*A\*G\*G\*A\*A\*A\*A\*T\*A\*A Bld25 102  
G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T Bld26 103  
C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A Bld27 104  
C\*A\*C\*T\*C\*G\*G\*T\*C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A Bld28 105  
G\*T\*C\*T\*T\*G\*A\*G\*T\*C\*A\*A\*T\*C\*A\*C\*T\*C\*G\*G\*T\*C\*T\*T\*T Bld29 106  
G\*A\*T\*A\*A\*A\*C\*A\*G\*C\*T\*G\*C\*A\*G\*T\*C\*T\*T\*G\*A\*G\*T\*C\*A Bld30 107  
A\*G\*T\*C\*C\*T\*G\*G\*C\*T\*T\*G\*G\*T\*G\*A\*T\*A\*A\*A\*C\*A\*G\*C\*T Bld31 108  
A\*T\*G\*T\*G\*T\*A\*G\*A\*G\*T\*C\*C\*T\*G\*G\*C\*T\*T\*G\*G\*T\*G\*A\*T Bld32 109  
G\*T\*A\*G\*C\*T\*A\*T\*G\*C\*A\*T\*G\*T\*G\*T\*A\*G\*A\*G\*T\*C\*C\*T\*G Bld33 110  
T\*G\*C\*T\*T\*A\*T\*T\*G\*G\*T\*A\*G\*C\*T\*A\*T\*G\*C\*A\*T\*G\*T\*G\*T Bld34 111  
A\*C\*T\*T\*C\*T\*C\*C\*C\*C\*A\*T\*G\*C\*T\*T\*A\*T\*T\*G\*G\*T\*A\*G\*C Bld35 112  
C\*C\*T\*T\*G\*G\*C\*A\*G\*T\*A\*C\*T\*G\*A\*A\*C\*T\*T\*C\*T\*C\*C\*C Cld36 113  
C\*C\*T\*G\*C\*T\*A\*T\*G\*C\*T\*G\*A\*T\*G\*G\*T\*G\*G\*C\*T\*G\*C\*A\*G Bld37 114  
G\*G\*G\*C\*A\*T\*C\*C\*T\*A\*C\*C\*T\*G\*C\*T\*A\*T\*G\*C\*T\*G\*A\*T\*G Bld38 115  
G\*C\*A\*A\*A\*T\*G\*T\*G\*A\*A\*G\*G\*G\*G\*C\*A\*T\*C\*C\*T\*A\*C\*C\*T, Bld51 143  
T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A Bld52 144  
C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A Bld53 145  
T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A Bld54 146  
C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G Bld55 147  
T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A Bld56 148  
C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A Bld57 149  
A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G Bld58 150  
C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A Bld59 151  
A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C Bld60 152  
C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C Bld61 153  
T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C Bld62 154  
T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A Bld63 155  
T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G Bld64 156  
C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G Bld65 157  
T\*C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T Bld66 158  
G\*T\*C\*T\*T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A Bld25-1 168  
C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T\*A\*A\*A\*G\* Bld25-2 169  
A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T\*A\*A\* Bld25-3 170  
A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\* Bld25-4 171  
G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\* Bld25-5 172  
C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\* Bld26-1 173  
C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\* Bld26-2 174  
C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\* Bld26-3 175  
C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\* Bld26-4 176  
T\*T\*C\*A\*C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\* Bld25-A 194  
A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T Bld25-B 195  
C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A\*G\*T Bld25-C 196  
G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A Bld25-D 197  
A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A\*G\*A Bld25-E 198  
G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A\*C\*A Bld25-5-A 199  
G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A Bld25-5-B 200  
A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T\*G\*A Bld25-5-C 201  
T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T Bld25-5-D 202

G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C\*C\*T Bld25-5-E 203

T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A\*C Bld26-2-A 204

C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A Bld26-2-B 205

C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A\*A\*A Bld26-2-C 206

C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A Bld26-2-D 207

C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A Bld26-B 208

C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A\*G\*A Bld26-C 209

C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G\*A\*A, or Bld26-D 210

C\*A\*C\*T\*C\*T\*C\*T\*T\*G\*A\*A\*T\*G\*G\*A\*C\*C\*C\*A\*G. wherein \* represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

**126.** An oligonucleotide composition comprising a mixture of two or more oligonucleotides according to claim 125.

**127.** (canceled)

**128.** A pharmaceutical composition comprising a therapeutically effective amount of an oligonucleotide, and at least one pharmaceutically acceptable inactive ingredient selected from pharmaceutically acceptable diluents, pharmaceutically acceptable excipients, and pharmaceutically acceptable carriers, wherein the oligonucleotide comprises an oligonucleotide of claim 1.

**129-142.** (canceled)

**143.** A method of treating a subject suffering from one or more features of neurodegenerative diseases, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of claim 1.

**144.** (canceled)

**145.** A method of treating a subject suffering from one or more features of neuromuscular dysfunction or a muscular dystrophy, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of claim 1.

**146.** (canceled)

**147.** A method of treating muscle fibrosis, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of claim 1.

**148-167.** (canceled)

---